0001558370-22-003022.txt : 20220308 0001558370-22-003022.hdr.sgml : 20220308 20220308073926 ACCESSION NUMBER: 0001558370-22-003022 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 121 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220308 DATE AS OF CHANGE: 20220308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XOMA Corp CENTRAL INDEX KEY: 0000791908 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522154066 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39801 FILM NUMBER: 22720338 BUSINESS ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-204-7239 MAIL ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: XOMA LTD /DE/ DATE OF NAME CHANGE: 19990107 FORMER COMPANY: FORMER CONFORMED NAME: XOMA CORP /DE/ DATE OF NAME CHANGE: 19920703 10-K 1 tmb-20211231x10k.htm 10-K
00007919082021FYfalse000098400098400000000050035003NoNoYesYes98400098400098400016000500350035003112287921131526315798000132980000.02370000000000000P3M0.718750.539060.558330.539060.523440.539060.523440000791908xoma:AronoraIncMemberxoma:SiliconValleyBankMemberxoma:RoyaltyPurchaseAgreementMember2019-04-072019-04-070000791908xoma:FederalOrphanCreditMember2021-01-012021-12-310000791908xoma:ThirdPartyConsultantMemberxoma:FiveYearWarrantsIssuedSecondRangeMember2021-02-012021-02-280000791908xoma:CommonStockWarrantExercisePrice14.71Memberxoma:SiliconValleyBankMember2021-01-012021-12-310000791908xoma:BioasisTechnologiesIncMember2020-01-012020-12-310000791908xoma:ViractaTherapeuticsInc.Member2021-01-012021-12-310000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember2021-01-012021-12-310000791908xoma:AffitechResearchAsMember2021-01-012021-12-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementRz358Member2017-12-062017-12-060000791908xoma:RezoluteIncMemberxoma:LicenseAgreementNonRz358ProductsMember2017-12-062017-12-060000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2015-09-012015-09-300000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:MezagitamabMemberxoma:CollaborationAgreementMember2006-11-012006-11-300000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2018-09-200000791908xoma:AgenusIncMemberxoma:IncyteImmunoOncologyAssetsMemberxoma:RoyaltyPurchaseAgreementMember2018-09-200000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2018-09-202018-09-200000791908xoma:NovartisPharmaAGMemberxoma:IL1TargetLicenseAgreementMember2017-08-242017-08-240000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:SecondRoyaltyInterestAcquisitionAgreementMember2016-12-212016-12-210000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:FirstRoyaltyInterestAcquisitionAgreementMember2016-12-212016-12-210000791908xoma:SeriesYConvertiblePreferredStockMember2018-12-310000791908xoma:SeriesXConvertiblePreferredStockMember2017-12-310000791908srt:MaximumMemberxoma:AtMarketIssuanceSalesAgreement2021Member2021-08-052021-08-050000791908srt:MaximumMemberxoma:TwoThousandEighteenAtMarketAgreementMember2018-12-182018-12-180000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2021-03-222021-03-220000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementTwoMember2020-11-022020-11-020000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2019-09-262019-09-260000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2018-09-202018-09-200000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2019-09-012019-09-300000791908xoma:LeasedFacilitiesEmeryvilleCaliforniaMember2021-01-012021-12-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementAndCommonStockPurchaseAgreementMember2020-01-012020-01-010000791908us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310000791908us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310000791908us-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2020-01-012020-12-310000791908xoma:AgenusIncMemberxoma:IncyteImmunoOncologyAssetsMemberxoma:RoyaltyPurchaseAgreementMember2018-09-202018-09-200000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementMember2019-02-252019-02-250000791908us-gaap:StateAndLocalJurisdictionMember2021-01-012021-12-310000791908us-gaap:DomesticCountryMember2021-01-012021-12-310000791908xoma:RezoluteIncMemberus-gaap:SubsequentEventMemberxoma:LicenseAgreementMember2022-01-012022-01-310000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2020-11-012020-11-300000791908xoma:AtMarketIssuanceSalesAgreement2021Member2021-08-052021-08-050000791908xoma:TwoThousandEighteenAtMarketAgreementMember2021-03-100000791908xoma:TwoThousandEighteenAtMarketAgreementMember2018-12-180000791908xoma:DeferredRevenueArrangementNameOfParty2Memberxoma:ArrangementWithGovernmentalAgency2DevelopmentTwoMember2011-10-310000791908xoma:DeferredRevenueArrangementNameOfParty2Memberxoma:ArrangementWithGovernmentalAgency2DevelopmentOneMember2008-09-300000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2019-08-012019-08-310000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2021-07-140000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementTwoMember2020-11-020000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2018-09-200000791908xoma:RezoluteIncMemberxoma:LicenseAgreementAndCommonStockPurchaseAgreementMember2018-04-012018-04-300000791908xoma:RezoluteIncMemberxoma:LicenseAgreementAndCommonStockPurchaseAgreementMember2017-12-062020-10-310000791908xoma:DeferredRevenueArrangementNameOfParty2Memberxoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member2021-12-012021-12-3100007919082021-12-012021-12-310000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2021-01-012021-12-310000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2021-01-012021-12-310000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2021-01-012021-12-310000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementTwoMember2021-01-012021-12-310000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2021-01-012021-12-310000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2021-01-012021-12-310000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2021-01-012021-12-310000791908xoma:SeriesXConvertiblePreferredStockMember2017-02-012017-02-280000791908xoma:CommonStockWarrantExercisePrice14.71Memberxoma:SiliconValleyBankMember2019-03-012019-03-310000791908xoma:TenYearWarrantsIssuedThirdRangeMemberxoma:SiliconValleyBankMember2018-05-012018-05-310000791908xoma:CommonStockWarrantExercisePrice23.69PerShareIssuedMay2018Memberxoma:SiliconValleyBankMember2018-03-072018-03-070000791908xoma:ThirdPartyConsultantMemberxoma:FiveYearWarrantsIssuedSecondRangeMember2016-02-012016-02-290000791908xoma:RezoluteIncMemberxoma:LicenseAgreementAndCommonStockPurchaseAgreementMember2020-01-010000791908xoma:RezoluteIncMember2020-10-310000791908xoma:RezoluteIncMember2020-09-300000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:FirstRoyaltyInterestAcquisitionAgreementMember2016-12-210000791908xoma:AffitechResearchAsMemberus-gaap:SubsequentEventMemberxoma:CommercialPaymentPurchaseAgreementMember2022-01-280000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2021-07-142021-07-140000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2021-10-200000791908xoma:RezoluteIncMemberxoma:LicenseAgreementRz358Member2017-12-060000791908xoma:NovartisPharmaAGMemberxoma:XOMA052LicenseAgreementMember2017-08-240000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2015-09-300000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:MezagitamabMemberxoma:CollaborationAgreementMember2006-11-300000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:OtherAntibodiesMemberxoma:CollaborationAgreementMember2009-02-012009-02-280000791908xoma:SiliconValleyBankMember2018-03-072018-03-070000791908xoma:SiliconValleyBankMember2021-06-300000791908xoma:NovartisNoteMember2020-10-210000791908xoma:NovartisNoteMember2015-09-300000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2019-04-072019-04-070000791908xoma:DeferredRevenueArrangementNameOfParty2Memberxoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member2008-09-012008-09-300000791908xoma:DeferredRevenueArrangementNameOfParty2Memberxoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member2017-01-012017-12-310000791908xoma:AronoraIncMemberxoma:BayerProductsMemberxoma:RoyaltyPurchaseAgreementMember2019-04-072019-04-070000791908xoma:BioasisTechnologiesIncMembersrt:MaximumMemberxoma:RoyaltyPurchaseAgreementMember2019-02-250000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementMember2021-12-310000791908xoma:AronoraKurosAndAffitechMemberxoma:RoyaltyPurchaseAgreementMember2021-12-310000791908xoma:AffitechResearchAsMemberxoma:RoyaltyPurchaseAgreementMember2021-12-310000791908xoma:AffitechResearchAsMemberxoma:RoyaltyPurchaseAgreementMember2021-10-060000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2021-10-060000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementMember2019-02-250000791908us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000791908xoma:AffitechResearchAsMemberus-gaap:SubsequentEventMemberxoma:CommercialPaymentPurchaseAgreementMember2022-01-282022-01-280000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2021-10-062021-10-060000791908xoma:NovartisNoteMember2005-03-012005-03-310000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementMember2021-01-012021-12-310000791908xoma:BioasisAffitechMemberxoma:RoyaltyPurchaseAgreementMember2021-01-012021-12-310000791908xoma:AffitechResearchAsMemberxoma:RoyaltyPurchaseAgreementMember2021-01-012021-12-310000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2020-11-012020-11-300000791908xoma:AgenusIncMember2020-01-012020-12-310000791908xoma:BiotechnologyValueFundLPMemberxoma:SeriesYConvertiblePreferredStockMember2020-02-290000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-08-242017-08-240000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2017-12-062017-12-060000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2015-09-302015-09-300000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2021-03-220000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2019-09-260000791908xoma:AronoraIncMemberxoma:NonBayerProductsMemberxoma:RoyaltyPurchaseAgreementMember2019-04-070000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2019-04-070000791908xoma:AronoraIncMemberxoma:BayerProductsMemberxoma:RoyaltyPurchaseAgreementMember2019-04-070000791908stpr:CAus-gaap:ResearchMember2021-12-310000791908xoma:FederalOrphanCreditMember2021-12-310000791908us-gaap:CommonStockMember2021-01-012021-12-310000791908dei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member2021-08-012021-12-310000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2021-01-012021-12-310000791908srt:DirectorMemberus-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-12-152020-12-150000791908srt:ChiefExecutiveOfficerMemberus-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-12-152020-12-150000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-12-152020-12-150000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-310000791908us-gaap:CommonStockMemberxoma:TwoThousandEighteenAtMarketAgreementMember2018-12-182021-12-310000791908xoma:SeriesYConvertiblePreferredStockMember2018-01-012018-12-310000791908xoma:NovartisPharmaAGMemberus-gaap:CommonStockMemberxoma:XOMA052LicenseAgreementMember2017-08-242017-08-240000791908xoma:SeriesXConvertiblePreferredStockMember2017-01-012017-12-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-310000791908us-gaap:CommonStockMember2020-01-012020-12-310000791908xoma:RezoluteIncMember2020-10-012020-10-310000791908us-gaap:RetainedEarningsMember2021-12-310000791908us-gaap:AdditionalPaidInCapitalMember2021-12-310000791908us-gaap:RetainedEarningsMember2020-12-310000791908us-gaap:AdditionalPaidInCapitalMember2020-12-310000791908us-gaap:RetainedEarningsMember2019-12-310000791908us-gaap:AdditionalPaidInCapitalMember2019-12-310000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2021-12-310000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2021-12-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-12-310000791908us-gaap:CommonStockMember2021-12-310000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-12-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-12-310000791908us-gaap:CommonStockMember2020-12-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-310000791908us-gaap:CommonStockMember2019-12-310000791908us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMemberdei:AdrMember2021-04-090000791908dei:AdrMember2021-04-090000791908srt:DirectorMemberus-gaap:SeriesAPreferredStockMember2020-12-150000791908srt:ChiefExecutiveOfficerMemberus-gaap:SeriesAPreferredStockMember2020-12-150000791908xoma:RezoluteIncMember2021-12-310000791908xoma:RezoluteIncMember2020-12-310000791908xoma:NovartisPharmaAGMemberus-gaap:CommonStockMemberxoma:XOMA052LicenseAgreementMember2017-08-240000791908xoma:TwoThousandFifteenEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2021-01-012021-12-310000791908xoma:TwoThousandFifteenEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2020-01-012020-12-310000791908xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember2021-01-012021-12-310000791908us-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2021-12-310000791908xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember2021-12-310000791908xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2021-12-310000791908xoma:TwoThousandFifteenEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2017-05-310000791908xoma:TwoThousandFifteenEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2017-04-300000791908xoma:TwoThousandFifteenEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2017-05-012017-05-310000791908us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000791908srt:MinimumMemberxoma:EmployeeTerminatedMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2021-01-012021-12-310000791908srt:MaximumMemberxoma:EmployeeTerminatedMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2021-01-012021-12-310000791908xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2021-01-012021-12-310000791908xoma:EmployeeMemberus-gaap:EmployeeStockOptionMember2021-01-012021-12-310000791908srt:DirectorMemberus-gaap:EmployeeStockOptionMember2021-01-012021-12-310000791908srt:EuropeMember2021-01-012021-12-310000791908srt:AsiaPacificMember2021-01-012021-12-310000791908country:US2021-01-012021-12-310000791908srt:EuropeMember2020-01-012020-12-310000791908srt:AsiaPacificMember2020-01-012020-12-310000791908country:US2020-01-012020-12-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2021-01-012021-12-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2020-01-012020-12-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2021-12-012021-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2021-10-202021-10-200000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2021-05-012021-05-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:LicenseAgreementMember2021-01-012021-12-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2021-01-012021-12-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2021-01-012021-12-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2021-01-012021-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2021-01-012021-12-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2021-01-012021-12-310000791908xoma:AffimedMemberxoma:LicenseAgreementMember2021-01-012021-12-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2020-11-162020-11-160000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2020-10-212020-10-210000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:LicenseAgreementMember2020-01-012020-12-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2020-01-012020-12-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2020-01-012020-12-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2020-01-012020-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2020-01-012020-12-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2020-01-012020-12-310000791908xoma:DeferredRevenueArrangementNameOfParty2Memberxoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member2020-01-012020-12-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2019-01-012019-12-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-01-012017-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2017-01-012017-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2015-01-012015-12-310000791908xoma:SiliconValleyBankMember2021-06-012021-06-300000791908xoma:SiliconValleyBankAndNovartisPharmaAgMember2021-06-012021-06-300000791908xoma:NovartisNoteMember2021-06-012021-06-300000791908us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMemberdei:AdrMember2021-04-092021-04-090000791908srt:DirectorMemberus-gaap:SeriesAPreferredStockMember2020-12-152020-12-150000791908srt:ChiefExecutiveOfficerMemberus-gaap:SeriesAPreferredStockMember2020-12-152020-12-150000791908xoma:SecondTermLoanMember2019-01-012019-12-310000791908xoma:FirstTermLoanMember2018-09-012018-09-300000791908xoma:NovartisPharmaAGMemberxoma:XOMA052LicenseAgreementMember2017-08-242017-08-240000791908xoma:SeriesYConvertiblePreferredStockMember2021-12-310000791908us-gaap:ConvertiblePreferredStockMember2021-12-310000791908us-gaap:ConvertiblePreferredStockMember2020-12-310000791908xoma:SeriesXConvertiblePreferredStockMember2021-12-310000791908xoma:SeriesXConvertiblePreferredStockMember2020-12-310000791908srt:ScenarioForecastMemberus-gaap:SeriesBPreferredStockMember2026-04-150000791908srt:ScenarioForecastMemberdei:AdrMember2026-04-150000791908srt:ScenarioForecastMemberus-gaap:SeriesAPreferredStockMember2025-12-150000791908srt:ScenarioForecastMemberus-gaap:SeriesBPreferredStockMember2025-04-150000791908srt:ScenarioForecastMemberdei:AdrMember2025-04-150000791908srt:ScenarioForecastMemberus-gaap:SeriesAPreferredStockMember2024-12-150000791908srt:ScenarioForecastMemberus-gaap:SeriesBPreferredStockMember2024-04-150000791908srt:ScenarioForecastMemberdei:AdrMember2024-04-150000791908srt:ScenarioForecastMemberus-gaap:SeriesAPreferredStockMember2023-12-150000791908srt:ScenarioForecastMemberus-gaap:SeriesBPreferredStockMember2023-04-150000791908srt:ScenarioForecastMemberdei:AdrMember2023-04-150000791908srt:ScenarioForecastMemberus-gaap:SeriesAPreferredStockMember2022-12-150000791908srt:ScenarioForecastMemberus-gaap:SeriesBPreferredStockMember2022-04-150000791908srt:ScenarioForecastMemberdei:AdrMember2022-04-150000791908us-gaap:SeriesAPreferredStockMember2021-12-150000791908us-gaap:SeriesBPreferredStockMember2021-12-310000791908us-gaap:SeriesAPreferredStockMember2021-12-310000791908us-gaap:SeriesBPreferredStockMember2020-12-310000791908us-gaap:SeriesAPreferredStockMember2020-12-310000791908us-gaap:SeriesBPreferredStockMember2021-04-090000791908us-gaap:SeriesAPreferredStockMember2020-12-150000791908us-gaap:SeriesAPreferredStockMember2021-10-202021-10-200000791908dei:AdrMember2021-10-202021-10-200000791908us-gaap:SeriesAPreferredStockMember2021-07-282021-07-280000791908dei:AdrMember2021-07-282021-07-280000791908us-gaap:SeriesAPreferredStockMember2021-05-212021-05-210000791908dei:AdrMember2021-05-212021-05-210000791908us-gaap:SeriesAPreferredStockMember2021-03-172021-03-170000791908us-gaap:SeriesAPreferredStockMemberus-gaap:SubsequentEventMember2022-01-182022-01-180000791908dei:AdrMemberus-gaap:SubsequentEventMember2022-01-182022-01-180000791908us-gaap:SeriesAPreferredStockMember2021-10-152021-10-150000791908dei:AdrMember2021-10-152021-10-150000791908us-gaap:SeriesAPreferredStockMember2021-07-152021-07-150000791908dei:AdrMember2021-07-152021-07-150000791908us-gaap:SeriesAPreferredStockMember2021-04-152021-04-150000791908us-gaap:SeriesBPreferredStockMember2021-04-092021-04-090000791908us-gaap:SeriesBPreferredStockMember2021-01-012021-12-310000791908us-gaap:SeriesBPreferredStockMember2020-01-012020-12-310000791908us-gaap:SeriesAPreferredStockMember2020-01-012020-12-310000791908dei:AdrMember2021-04-092021-04-090000791908us-gaap:SeriesAPreferredStockMember2020-12-152020-12-150000791908us-gaap:StateAndLocalJurisdictionMember2021-12-310000791908us-gaap:DomesticCountryMember2021-12-310000791908us-gaap:RetainedEarningsMember2021-01-012021-12-310000791908us-gaap:RetainedEarningsMember2020-01-012020-12-310000791908xoma:BiotechnologyValueFundLPMemberxoma:XomaCorporationMemberus-gaap:CommonStockMember2021-12-310000791908xoma:SiliconValleyBankMember2021-12-310000791908xoma:NovartisNoteMember2021-12-310000791908xoma:SiliconValleyBankMember2020-12-310000791908xoma:NovartisNoteMember2020-12-310000791908xoma:NovartisNoteMember2005-03-310000791908us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000791908us-gaap:FairValueMeasurementsRecurringMember2021-12-310000791908us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000791908us-gaap:FairValueMeasurementsRecurringMember2020-12-310000791908xoma:NovartisNoteMember2021-01-012021-12-310000791908xoma:OtherFinancingsMember2020-01-012020-12-310000791908xoma:NovartisNoteMember2020-01-012020-12-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2016-12-212016-12-210000791908xoma:RezoluteIncMember2021-01-012021-12-310000791908xoma:RezoluteIncMember2020-01-012020-12-310000791908xoma:RezoluteIncMember2021-12-310000791908xoma:RezoluteIncMember2020-12-310000791908us-gaap:MeasurementInputSharePriceMember2021-12-310000791908xoma:EquitySecuritiesTrancheTwoMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310000791908xoma:EquitySecuritiesTrancheTwoMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMember2020-12-310000791908xoma:EquitySecuritiesTrancheOneMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310000791908xoma:EquitySecuritiesTrancheOneMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMember2020-12-310000791908us-gaap:MeasurementInputSharePriceMember2020-12-310000791908us-gaap:EmployeeStockOptionMember2021-01-012021-12-3100007919082017-01-012017-12-310000791908xoma:EmployeeUnderAgeFiftyMember2021-01-012021-12-310000791908xoma:EmployeeAgeFiftyOrOverMember2021-01-012021-12-310000791908xoma:EmployeeUnderAgeFiftyMember2020-01-012020-12-310000791908xoma:EmployeeAgeFiftyOrOverMember2020-01-012020-12-310000791908srt:MaximumMember2021-01-012021-12-310000791908srt:MaximumMember2020-01-012020-12-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2021-12-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2020-12-310000791908xoma:SiliconValleyBankMember2018-03-070000791908xoma:SecondTermLoanMember2019-12-310000791908xoma:FirstTermLoanMember2018-09-300000791908srt:MinimumMemberxoma:SiliconValleyBankMember2018-03-070000791908xoma:NovartisNoteMember2020-10-212020-10-210000791908xoma:SiliconValleyBankMemberus-gaap:PrimeRateMember2018-03-072018-03-070000791908xoma:NovartisNoteMemberus-gaap:LondonInterbankOfferedRateLIBORMember2005-03-012005-03-310000791908xoma:SeriesXAndSeriesYConvertiblePreferredStockMember2018-12-310000791908xoma:SeriesXAndSeriesYConvertiblePreferredStockMember2017-12-3100007919082021-12-150000791908xoma:DeferredRevenueArrangementNameOfParty2Memberxoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member2021-12-310000791908xoma:DeferredRevenueArrangementNameOfParty2Memberxoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member2020-12-310000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310000791908xoma:Partner1Memberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2020-01-012020-12-310000791908xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember2015-05-310000791908xoma:FiveYearWarrantsIssuedSecondRangeMember2021-12-310000791908xoma:TenYearWarrantsIssuedThirdRangeMember2021-12-310000791908xoma:CommonStockWarrantExercisePrice14.71Member2021-12-310000791908xoma:TenYearWarrantsIssuedThirdRangeMember2020-12-310000791908xoma:FiveYearWarrantsIssuedSecondRangeMember2020-12-310000791908xoma:CommonStockWarrantExercisePrice14.71Member2020-12-310000791908xoma:CommonStockWarrantExercisePrice14.71Memberxoma:SiliconValleyBankMember2019-03-310000791908xoma:TenYearWarrantsIssuedThirdRangeMemberxoma:SiliconValleyBankMember2018-05-310000791908xoma:CommonStockWarrantExercisePrice23.69PerShareIssuedMay2018Memberxoma:SiliconValleyBankMember2018-03-070000791908xoma:ThirdPartyConsultantMemberxoma:FiveYearWarrantsIssuedSecondRangeMember2016-02-290000791908us-gaap:AccountingStandardsUpdate202006Member2021-01-010000791908us-gaap:AccountingStandardsUpdate202004Member2021-01-010000791908us-gaap:AccountingStandardsUpdate201912Member2021-01-0100007919082019-12-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2021-12-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementAndCommonStockPurchaseAgreementMember2021-12-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2021-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2021-12-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2021-12-310000791908xoma:AffimedMemberxoma:LicenseAgreementMember2021-12-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2020-12-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementAndCommonStockPurchaseAgreementMember2020-12-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2020-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2020-12-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2020-12-310000791908us-gaap:StockCompensationPlanMember2021-01-012021-12-310000791908us-gaap:WarrantMember2020-01-012020-12-310000791908us-gaap:StockCompensationPlanMember2020-01-012020-12-310000791908xoma:SiliconValleyBankMember2021-01-012021-12-310000791908xoma:SiliconValleyBankMember2020-01-012020-12-310000791908us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310000791908us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310000791908us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000791908us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-3100007919082020-01-012020-12-310000791908xoma:DeferredRevenueArrangementNameOfParty2Memberxoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member2014-12-3100007919082021-12-3100007919082020-12-310000791908us-gaap:SeriesAPreferredStockMember2021-01-012021-12-310000791908us-gaap:CommonStockMember2021-01-012021-12-310000791908dei:AdrMember2021-01-012021-12-3100007919082021-06-3000007919082022-03-0300007919082021-01-012021-12-31xoma:periodxoma:agreementxoma:customerxoma:facilityxoma:Dxoma:Mxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purexoma:Yxoma:segmentxoma:itemxoma:productiso4217:EUR

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

       ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

OR

      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM                      TO

Commission File Number 001-39801

XOMA CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

52-2154066

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

2200 Powell Street, Suite 310, Emeryville, California

94608

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (510204-7200

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0075 par value

 

XOMA

 

The Nasdaq Global Market

8.625% Series A Cumulative, Perpetual Preferred Stock, par value $0.05

XOMAP

The Nasdaq Global Market

Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)

XOMAO

The Nasdaq Global Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES  NO 

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES  NO 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES  NO 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES  NO 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES  NO 

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on the Nasdaq Global Market on June 30, 2021, was $240,018,070.

Number of shares of Registrant’s Common Stock outstanding as of March 3, 2022 was 11,319,124.

Portions of the Registrant’s Definitive Proxy Statement relating to the Company’s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Report.

XOMA Corporation

2021 FORM 10-K ANNUAL REPORT

TABLE OF CONTENTS

    

Glossary of Terms and Abbreviations

1

PART I

Item 1.

Business

5

Item 1A.

Risk Factors

16

Item 1B.

Unresolved Staff Comments

46

Item 2.

Properties

46

Item 3.

Legal Proceedings

46

Item 4.

Mine Safety Disclosures

46

PART II

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

47

Item 6.

Reserved

47

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

48

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

57

Item 8.

Financial Statements and Supplementary Data

57

Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

57

Item 9A.

Controls and Procedures

58

Item 9B.

Other Information

58

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

58

PART III

Item 10.

Directors, Executive Officers, and Corporate Governance

59

Item 11.

Executive Compensation

59

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

59

Item 13.

Certain Relationships and Related Transactions, and Director Independence

59

Item 14.

Principal Accountant Fees and Services

59

PART IV

Item 15.

Exhibits and Financial Statement Schedules

60

Item 16.

Form 10K Summary

67

SIGNATURES

68

This Annual Report on Form 10-K includes trademarks, service marks and trade names owned by us or others. “XOMA,” the XOMA logo and all other XOMA product and service names are registered or unregistered trademarks of XOMA Corporation or a subsidiary of XOMA Corporation in the United States and in other selected countries. All trademarks, service marks and trade names included or incorporated by reference in this annual report are the property of their respective owners.

i

GLOSSARY OF TERMS AND ABBREVIATIONS

Abbreviations

Definition

2010 Plan

the Company's 2010 Long Term Incentive and Stock Award Plan, as amended

2018 Common Stock ATM Agreement

At The Market Issuance Sales Agreement with HCW dated December 18, 2018

2021 Series B Preferred Stock ATM Agreement

At The Market Issuance Sales Agreement with B. Riley dated August 5, 2021

‘40 Act

Investment Company Act of 1940

ACA

The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010

Affimed

Affimed N.V.

Affitech

Affitech Research AS

Affitech CPPA

the Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021

Agenus

Agenus, Inc. and certain affiliates

Agenus RPA

the Company's Royalty Purchase Agreement with Agenus dated September 20, 2018

Anti-TGFβ Antibody License Agreement

the Company's License Agreement with Novartis dated September 30, 2015

Aronora

Aronora, Inc.

Aronora RPA

the Company's Royalty Purchase Agreement with Aronora dated April 7, 2019

AstraZeneca

AstraZeneca plc

ASC

Accounting Standards Codification

ASC 310

ASC Topic 310, Receivables

ASC 606

ASC Topic 606, Revenue from Contracts with Customers

Bayer

Bayer Pharma AG

Bioasis

Bioasis Technologies, Inc. and certain affiliates

Bioasis RPA

the Company's Royalty Purchase Agreement with Bioasis dated February 25, 2019

BLA

Biologic License Application

B. Riley

B. Riley Securities, Inc.

BVF

Biotechnology Value Fund, L.P.

CCPA

California Consumer Privacy Act of 2018, collectively the Act and its regulations

CARES

Coronavirus Aid, Relief, and Economic Security

cGMP

current Good Manufacturing Processes

Chiesi

Chiesi Farmaceutici S.p.A.

Chiron

Chiron Corporation

Chiron Collaboration Agreement

the Company's Collaboration Agreement with Chiron dated February 27, 2004, as amended in May 2005, July 2008 and September 2015

Compugen

Compugen Ltd.

CPPA

Commercial Payment Purchase Agreement

CPRA

California Privacy Rights Act

EMA

European Medicines Agency

ESPP

2015 Employee Stock Purchase Plan, as amended

EU

European Union

FCPA

U.S. Foreign Corrupt Practices Act of 1977, as amended

FDA

U.S. Food and Drug Administration

G&A

General and administrative

GDPR

General Data Protection Regulation

Gevokizumab License Agreement

the Company's License Agreement with Novartis dated August 24, 2017

HCRP

Healthcare Royalty Partners II, L.P.

1

HCW

H.C. Wainwright & Co., LLC

HIPAA

Federal Health Insurance Portability and Accountability Act of 1996

ICE®

Innate cell engager

Janssen

Janssen Biotech, Inc.

Kuros

Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC, collectively

Kuros RPA

the Company's Royalty Purchase Agreement with Kuros dated July 14, 2021

Merck

Merck Sharp & Dohme Corp

NDA

New Drug Application

NIAID

National Institute of Allergy and Infectious Diseases

NIH

National Institutes of Health

NOL

net operating loss

Novartis

Novartis Pharma AG, Novartis International Pharmaceutical Ltd., Novartis Institutes for Biomedical Research, Inc. and/or Novartis Vaccines and Diagnotics, Inc.

Novartis Note Agreement

the secured note agreement with Novartis (previously Chiron) dated May 26, 2005, as amended

Novartis Note

the note with Novartis pursuant to the Novartis Note Agreement

Ology Bioservices

Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)

Palo

Palobiofarma, S.L.

Palo RPA

the Company's Royalty Purchase Agreement with Palo dated September 26, 2019

Pfizer

Pfizer, Inc.

R&D

Research and development

Rezolute

Rezolute, Inc., formerly Antria Bio

Rezolute License Agreement

the Company's License Agreement with Rezolute dated December 6, 2017, as amended in March 2018, January 2019 and March 2020

RPA

Royalty Purchase Agreement

Roche

F. Hoffmann-La Roche AG

SEC

Securities and Exchange Commission

Second Bioasis RPA

the Company's Royalty Purchase Agreement with Bioasis dated November 2, 2020

Series A Preferred Stock

the 8.625% Series A cumulative, perpetual preferred stock issued in December 2020

Series B Preferred Stock

the 8.375% Series B cumulative, perpetual preferred stock issued in April 2021

Series B Depositary Shares

the depositary shares, each representing 1/1000th interest in a share of Series B Preferred Stock

SOX

Sarbanes-Oxley Act of 2002

SVB

Silicon Valley Bank

SVB Loan Agreement

the loan and security agreement with SVB dated May 7, 2018, as amended

SVB Loan

the loan with SVB pursuant to the SVB Loan Agreement

Takeda

Takeda Pharmaceutical Company Limited

Takeda Collaboration Agreement

the Company's Collaboration Agreement with Takeda dated November 1, 2006, as amended in February 2007 and February 2009

Viracta

Viracta Therapeutics, Inc.

Viracta RPA

the Company's Royalty Purchase Agreement with Viracta dated March 22, 2021

XOMA

XOMA Corporation, including subsidiaries

2

PART I

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995, which are subject to the “safe harbor” created by those sections. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to them. In some cases, you can identify forward-looking statements by words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “intend” and similar expressions intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: our future operating expenses, our future losses, the potential success of our strategy as a royalty aggregator, the extent to which our issued and pending patents may protect our products and technology, the potential of our existing product candidates to lead to the development of commercial products, our ability to receive potential milestone or royalty payments under license and collaboration agreements and the probability, amount and timing of receipt of those payments, and our continuing obligation to pay quarterly cash dividends on our Series A Preferred Stock and Series B Preferred Stock. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for our licensees engaged in the development of new products in a regulated market. Among other things: our product candidates subject to our out-license agreements are still being developed, and our licensees’ may require substantial funds to continue development which may not be available; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to market them; products or technologies of other companies may render some or all of our product candidates noncompetitive or obsolete; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; even once approved, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be voluntarily taken off the market; and we and our licensees are subject to various state and federal healthcare related laws and regulations that may impact the commercialization of our product candidates and could subject us to significant fines and penalties; and certain of our technologies are in-licensed from third parties, so our capabilities using them may be restricted and subject to additional risks. These and other risks, including those related to current economic and financial market conditions, are contained principally in Item 1, Business; Item 1A, Risk Factors; Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations; and other sections of this Annual Report on Form 10-K. Factors that could cause or contribute to these differences include those discussed in Item 1A, Risk Factors, as well as those discussed elsewhere in this Annual Report on Form 10-K.

Forward-looking statements are inherently uncertain and you should not place undue reliance on these statements, which speak only as of the date that they were made. These cautionary statements should be considered in connection with any written or oral forward-looking statements that we may issue in the future. We do not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Annual Report on Form 10-K to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

All references to “portfolio” in this Annual Report on Form 10-K are to milestone and/or royalty rights associated with a basket of drug products in development.

Risk Factors Summary

Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K. The below summary is qualified in its entirety

3

by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described under “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K as part of your evaluation of the risks associated with an investment in our securities.

The COVID-19 pandemic has adversely impacted and could materially and adversely impact in the future our licensees or royalty-agreement counterparties or their licensees, which could cause delays or elimination of our receipts of potential milestones and royalties under our licensing or royalty and milestone acquisition arrangements.
Our acquisitions of potential future royalty and/or milestone payments may not produce anticipated revenues and/or may be negatively affected by a default or bankruptcy of the licensor(s) or licensee(s), and if such transactions are secured by collateral, we may be, or may become, under-secured by the collateral or such collateral may lose value and we will not be able to recuperate our capital expenditures associated with the acquisition.
Many of our potential royalty acquisitions may be associated with drug products that are in clinical development and have not yet been commercialized. To the extent that such products are not successfully developed and commercialized, our financial condition and results of operations may be negatively impacted. Acquisitions of potential royalties associated with development stage biopharmaceutical product candidates are subject to a number of uncertainties.
We depend on our licensees and royalty-agreement counterparties for the determination of royalty and milestone payments. While we typically have primary or back-up rights to audit our licensees and royalty-agreement counterparties, the independent auditors may have difficulty determining the correct royalty calculation, errors, may be undetectable and payment calculations may call for retroactive adjustments. We may have to exercise legal remedies to resolve any disputes resulting from any such audit.
The lack of liquidity of our acquisitions of future potential milestones and royalties may adversely affect our business and, if we need to sell any of our acquired assets, we may not be able to do so at a favorable price, if at all. As a result, we may suffer losses. We have sustained losses in the past, and we expect to sustain losses in the foreseeable future.
Our royalty aggregator strategy may require that we register with the SEC as an “investment company” in accordance with the Investment Company Act of 1940. If we were to become an “investment company” and be subject to the restrictions of the 1940 Act, those restrictions would likely require significant changes in the way we do business and add significant administrative burdens to our operations.
Our royalty aggregator strategy may require us to raise additional funds to acquire milestone and royalty interests; we cannot be certain that funds will be available or available at an acceptable cost of capital, and if they are not available, we may be unsuccessful in acquiring milestone and royalty interests to sustain the business in the future.
Information available to us about the biopharmaceutical products underlying the potential royalties we buy may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited.
Our future income is dependent upon numerous potential milestone and royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our anticipated rates of returns. Reductions in potential milestone or royalty payments compared to expectations, or impairments in the value of potential milestones and royalties acquired could have a material adverse effect our financial condition and results of operations.

4

A large percentage of the calculated net present value of our portfolio is represented by a limited number of products. The failure of any one of these products to move forward in clinical development or commercialization may have a material adverse effect on our financial condition and results of operation.
We rely heavily on license and collaboration relationships, and any disputes or litigation with our licensees, collaborators and their partners or termination or breach of any of the related agreements could reduce the financial resources available to us. In the event of any disagreement that cannot be resolved satisfactorily to us, we may end up being paid less than anticipated on such product or involved in costly and time-consuming arbitration or litigation, which could materially adversely affect our financial condition, results of operation and future prospects.
Our potential milestone and royalty providers may rely on third parties to provide services in connection with their product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could adversely affect our potential milestone and royalty providers’ product candidate development.
We may not be able to successfully identify and acquire potential milestone and royalty streams on other products, product candidates, or programs, or other companies to grow and diversify our business, and, even if we are able to do so, we may not be able to successfully manage the risks associated with integrating any such products, product candidates, programs or companies into our business or we may otherwise fail to realize the anticipated benefits of these acquisitions.
Our potential milestone and royalty providers face uncertain results of clinical trials of product candidates. If our potential royalty providers’ therapeutic product candidates do not receive regulatory approval, our potential royalty providers will be unable to market them.
We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership, milestone or royalty interest.
If we and our potential royalty providers are unable to protect our intellectual property, in particular patent protection for principal products, product candidates and processes in which we have an ownership or royalty interest, and prevent the use of the covered subject matter by third parties, our potential royalty providers’ ability to compete in the market will be harmed, and we may not realize our profit potential.
We have a continuing obligation to pay quarterly dividends to holders of our Series A Preferred Stock and Series B Preferred Stock, which will be an on-going expenditure for us and may limit our ability to borrow additional funds. 

Item 1.   Business

Overview and Strategy

XOMA, a Delaware corporation, is a biotech royalty aggregator. We have a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Our portfolio was built through licensing our proprietary products and platforms from our legacy discovery and development business, combined with acquisitions of rights to future milestones and royalties that we have made since our royalty aggregator business model was implemented in 2017. We expect that most of our future revenue will be based on payments we may receive for milestones and royalties related to these programs.

Our strategy is to expand our pipeline by acquiring additional potential milestone and royalty revenue streams on drug product candidates from third parties. Expanding our pipeline through these acquisitions can allow for further diversification across therapeutic areas and development stages. Our ideal target acquisitions are in pre-commercial stages

5

of development, have an expected long duration of market exclusivity, high revenue potential, and are partnered with a large pharmaceutical or biopharmaceutical enterprise.

COVID-19

The COVID-19 pandemic continues to pose risks to our business as clinical trials industry-wide have slowed. Our business is dependent on the continued development and commercialization efforts of our licensees and our royalty agreement counterparties and their licensees. We have been monitoring and continue to monitor our portfolio programs for potential delays in underlying research programs and elections of our partners to continue or cease development. Delays in clinical trials and underlying research programs may lead to delayed revenue from milestones from our licensees and royalty agreement counterparties or, if certain research programs are discontinued, we may recognize impairment charges for our royalty receivables. COVID-19, the related variants, and the timing of vaccine distribution may impact our underlying programs in a variety of ways which are unknown in length and scope at this time.

Portfolio Highlights

The following table highlights key assets included in our portfolio of potential future milestone and royalty streams. This table does not include all assets because certain assets are subject to confidentiality agreements.

COMPANY

ASSET NAME

TARGET

ROYALTY RATE

Affimed

AFM13

CD30/CD16A

Confidential

Affimed

AFM24

EGRF/CD16A

Confidential

Aronora

AB002 (proCase/E-WE thrombin)

Protein kinase C

Low single-digit

Aronora

AB023 (xisomab, 3G3)

Factor XI

Low single-digit

Aronora

AB054

Factor XII

Low single-digit

AstraZeneca

AZD2936

TIGIT/PD-1

Low single-digit

AVEO Oncology

AV-299 (ficlatuzumab)

HGF

Low single-digit

Bayer (Aronora RPA)

BAY1213790 (osocimab)

Factor XIa

Low single-digit

Checkmate Pharmaceuticals

CMP-001 (vidutolimod)

TLR9

High single-digit to double-digit

Chiesi (Bioasis RPA)

Lysosomal Storage Disorders Enzymes

Enzyme replacement therapy

Low single-digit

Compugen

COM902

TIGIT

Low single-digit

Day One

DAY101

Pan-RAF

Mid single-digit

Denovo Biopharma

vosaroxin

Topoisomerase II

High single-digit

Incyte (Agenus RPA)

INCAGN1876

GITR

Mid single-digit

Incyte (Agenus RPA)

INCAGN1949

OX-40

Mid single-digit

Incyte (Agenus RPA)

INCAGN02390

TIM-3

Low to mid single-digit

Incyte (Agenus RPA)

INCAGN2385

LAG-3

Low to mid single-digit

Janssen Biotech

JNJ-63723283 (cetrelimab)

PD-1

0.75%

Janssen Biotech

JNJ-63709178

CD123xCD3

0.75%

Janssen Biotech

JNJ-63898081

PSMAxCD3

0.75%

Merck (Agenus RPA)

MK-4830

ILT-4

Low single-digit

6

Molecular Templates

MT-0169

CD-38

4%

Novartis

CFZ533 (iscalimab)

CD-40

Mid single-digit to low-teens

Novartis

VPM087 (gevokizumab)

IL-1ß

High single-digit to mid-teens

Novartis

NIS793

TGFß

Mid single-digit to low teens

Novartis (Palobiofarma RPA)

NIR178

Adenosine A2a receptor

Low single-digit

Ology Bioservices

G03-52-01

Botulinum neurotoxins

15%

Palo

PBF-680

Adenosine A1 receptor

Low single-digit

Palo

PBF-677

Adenosine A3 receptor

Low single-digit

Palo

PBF-999

Adenosine A2a / Phosphodiesterase 10 (PDE-10)

Low single-digit

Palo

PBF-1129

Adenosine A2b receptor

Low single-digit

Palo

PBF-1650

Adenosine A3 receptor

Low single-digit

Rezolute

RZ358

INSR

High single-digit to mid-teens

Rezolute

RZ402

Plasma kallikrein

Low single-digit

Roche

faricimab (faricimab-svoa)

Angiopoietin-2 and VEGF-A

0.5%

Sesen Bio

oportuzumab monatox-qqrs

EpCAM

0.875%

Takeda

TAK-079 (mezagitamab)

CD-38

4%

Zydus Cadila

IL-2/anti-IL-2 combination

IL-2

Single to double-digit

Acquisitions

Commercial Payment Purchase Agreement with Affitech

In October 2021, we entered into the Affitech CPPA, pursuant to which we purchased a future stream of commercial payment rights to Roche’s faricimab from Affitech for an upfront payment of $6.0 million. We are eligible to receive commercial payments from Roche consisting of 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction.

In January 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize faricimab (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. Pursuant to the Affitech CPPA, we paid Affitech a $5.0 million regulatory approval milestone tied to these U.S. marketing approvals. We may pay up to an additional $15.0 million to Affitech based upon the achievement of certain regulatory approval milestones and sales milestones representing a portion of the commercial payment receipts.

Kuros Royalty Purchase Agreement

In July 2021, we entered into the Kuros RPA, pursuant to which we acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals’ vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. We may pay additional sales-based milestones to Kuros of up to $142.5 million representing a portion of the future royalties on commercial sales.

7

Viracta Royalty Purchase Agreement

In March 2021, we entered into the Viracta RPA, pursuant to which we acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. We acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved.

Royalty Purchase Agreement with Agenus

In September 2018, we entered into the Agenus RPA, pursuant to which we acquired the right to receive 33% of the future royalties due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and sales milestones on sales of six Incyte immuno-oncology assets. In addition, we acquired the right to receive 33% of the future royalties due to Agenus from Merck and 10% of all future developmental, regulatory and sales milestones on sales of MK-4830, an immuno-oncology product currently in clinical development. Pursuant to the Agenus Royalty Purchase Agreement, our share in future potential development, regulatory and commercial milestones is up to $59.5 million and the royalties have no limit. Under the terms of the Agenus Royalty Purchase Agreement, we paid Agenus $15.0 million.

In November 2020, MK-4830 advanced to Phase 2 development stage. As a result of the advancement, Agenus earned a $10.0 million clinical development milestone pursuant to its license agreement with Merck, of which we received $1.0 million.

Royalty Purchase Agreement with Bioasis

In February 2019, we entered into the Bioasis RPA, pursuant to which we acquired future milestone, royalty and option fee payment rights from Bioasis for product candidates that are being developed pursuant to a License Agreement between Bioasis and Prothena Biosciences Limited. Under the terms of the Bioasis RPA, we paid Bioasis an upfront cash payment of $0.3 million and will be required to make contingent future cash payments of up to $0.2 million to Bioasis if and when the licensed product candidates reach certain development milestones. As of December 31, 2021, none of the development milestones had been achieved. In addition, we were granted an option to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties.

In November 2020, we entered into the Second Bioasis RPA, pursuant to which we acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. We paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights.

Royalty Purchase Agreement with Aronora

In April 2019, we entered into the Aronora RPA, pursuant to which we acquired the rights to potential royalties and a portion of upfront, milestone, and option payments associated with five anti-thrombotic hematology drug products in development: three candidates subject to Aronora’s collaboration Bayer (the “Bayer Products”) and two additional early stage candidates (the “non-Bayer Products”).

Under the terms of the Aronora RPA, we made a $6.0 million upfront payment to Aronora when the transaction closed on June 26, 2019, and in September 2019 we made an additional $3.0 million payment for the three Bayer Products that were active as of September 1, 2019. Pursuant to the Aronora RPA, if we receive $250.0 million in cumulative royalties on net sales per product, we will be required to pay associated tiered milestones payments to Aronora in an aggregate amount of up to $85.0 million per product. The tiered milestones will be paid based on various royalty tiers prior to

8

reaching $250.0 million in cumulative royalties on net sales per product. We will retain royalties per product in excess of $250.0 million. We will receive, on average, low single-digit royalties on future sales of the Bayer Products and 10% of all future developmental, regulatory and sales milestones related to the Bayer Products. In addition, we purchased from Aronora the right to receive low single-digit percentage of net sales of the non-Bayer Products and 10% of all future payments, including upfront payments, option payments and developmental, regulatory and sales milestone payments on potential future sales of the non-Bayer Products. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.

Royalty Purchase Agreement with Palobiofarma

In September 2019, we entered into the Palo RPA, pursuant to which we acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin’s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis, nonalcoholic steatohepatitis and other indications (the “Palo Licensed Products”) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. Under the terms of the Palo RPA, we paid Palo $10.0 million for the rights to potential royalty payments on future sales of the Palo Licensed Products.

Selected Programs Underlying Our Core Pipeline

Historically, we have licensed product candidates or provided research and development collaboration services to world-class organizations, such as Novartis and Takeda, in pursuit of new antibody products under which we are eligible to receive potential future milestone payments and royalties. The following is a summary of material license and collaboration agreements that represent a significant component of our core pipeline.

Novartis – Anti-TGFβ Antibody (NIS793)

In September 2015, we and Novartis entered into the Anti-TGFβ Antibody License Agreement under which we granted Novartis an exclusive, worldwide, royalty-bearing license to our anti-TGFβ antibody program (“NIS793”). Novartis is solely responsible for the development and commercialization of the antibodies and products containing the antibodies arising from this program.

Under the Anti-TGFβ Antibody License Agreement, we received a $37.0 million upfront fee, and were eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones. We also are eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and have percentage rates ranging from mid single-digits to low double-digits. Novartis’ obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country. This program is currently in clinical testing.

In October 2020, we earned a $25.0 million milestone upon the dosing of the first patient in Novartis’ first NIS793 Phase 2 clinical trial. As specified under the terms the Anti-TGFβ Antibody License Agreement, we received $17.7 million in cash and the remaining balance of $7.3 million was recognized as a reduction to our debt obligation to Novartis.

In July 2021, Novartis announced the FDA had granted Orphan Drug Designation to NIS793 in combination with standard of care chemotherapy for the treatment of pancreatic cancer.

In October 2021, we earned a $35.0 million milestone payment upon dosing of the first patient in Novartis’ first NIS793 Phase 3 clinical trial. We are eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGFβ Antibody License Agreement. Upon receipt of regulatory approval to commercialize NIS793, we will receive tiered royalties on net product sales that range from the mid single-digit to the low double-digits percentage rate.

9

Novartis – Anti-IL-1β Antibody (VPM087) and IL-1 Beta

In August 2017, we and Novartis entered into the Gevokizumab License Agreement, under which we granted Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (“VPM087”) (a clinical-stage anti-IL-1b product candidate) and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing such antibody.

Under the Gevokizumab License Agreement, we received total consideration of $30.0 million in 2017 for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis, on our behalf, to settle our loan with Les Laboratories Servier. In addition, Novartis extended the maturity date on our debt to Novartis to September 30, 2022. In June 2021, we repaid its entire outstanding debt balance to Novartis. We also received $5.0 million related to the sale of 539,131 shares of our common stock, at a price per share of $9.2742. Based on the achievement of pre-specified criteria, we are eligible to receive up to $438.0 million in development, regulatory and commercial milestones. We also are eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and have percentage rates ranging from mid-single digit to mid-teens. This program is in Phase 2 clinical testing.

Unless terminated earlier, the Gevokizumab License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The Gevokizumab License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety with six months’ prior written notice.

Novartis – Anti-CD40 Antibody

In February 2004, we entered into an exclusive, worldwide, multi-product collaboration agreement with Chiron to research, develop and commercialize multiple antibody products for the treatment of cancer, and such agreement was replaced with the Chiron Collaboration Agreement entered in May of 2005. The Chiron Collaboration Agreement was a risk-sharing arrangement whereby Chiron and XOMA shared expenses and revenues on a 70-30 basis, with XOMA’s share being 30%. Financial terms included a loan facility from Chiron to XOMA, secured by XOMA’s 30% ownership interest in the collaboration, of up to $50.0 million to fund up to 75% of our share of expenses beginning in 2005.

In October 2005, Chiron announced it had entered into a definitive merger agreement with Novartis under which Novartis acquired all of the shares of Chiron that it did not already own. This transaction closed in 2006 at which time Novartis acquired Chiron’s interest in the Chiron Collaboration Agreement. In July of 2008, Novartis and XOMA restructured the Chiron Collaboration Agreement, which involved six development programs including iscalimab, a fully human anti-CD40 antagonist antibody intended as a treatment for B-cell mediated diseases, including malignancies and autoimmune diseases. As part of the restructuring, Novartis, the successor to Chiron, was granted, among other things, control over the ongoing product development collaborations remaining thereunder, including iscalimab. In September 2015, the parties agreed to reduce the royalty-style payments that XOMA is eligible to receive on sales of Novartis’s clinical-stage anti-CD40 antibodies (such as iscalimab). These royalty-style payments are tiered based on sales levels and now have percentage rates ranging from mid single-digit to low teens.

In September 2021, Novartis announced its decision to discontinue its study of CFZ533 (iscalimab) in the prevention of organ rejection in patients receiving a kidney transplant after an interim analysis of data. Novartis is continuing its iscalimab studies in indications other than kidney transplant, for example, liver transplant, Sjögren’s Syndrome and Lupus Nephritis.

Our right to royalty-style payments expires on the later of the expiration of any licensed patent covering each product or 10 years from the first commercial sale of each product in each country.

10

Takeda

In November 2006, we entered into the Takeda Collaboration Agreement with Takeda under which we agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.

Under the Takeda Collaboration Agreement, we may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and a 4% royalty on future sales of all products subject to this license, including TAK-169, which entered a phase 1 study in February 2020. Our right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. Our right to royalties expires on the later of 13.5 years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).

In February 2009, we expanded our existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. We may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. Our right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. Our right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.

In November 2020, the first patient was dosed in Takeda’s Phase 2 study of mezagitamab and we earned a $2.0 million milestone payment from Takeda. We are eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement.

In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda.

Rezolute

In December 2017, we entered into a license agreement with Rezolute pursuant to which we granted an exclusive global license to Rezolute to develop and commercialize X358 (now “RZ358”) products for all indications. We and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to us, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.

Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to us of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, we are also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute’s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute’s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.

Pursuant to the license agreement, we are eligible to receive a low single-digit royalty on sales of Rezolute’s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical testing. Rezolute’s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from

11

the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee’s obligation to make payments to Rezolute based on sales of such product in such country.

The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days’ notice at any time. To the extent permitted by applicable laws, we have the right to terminate the license agreement if Rezolute challenges the licensed patents.

No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to us upon the occurrence of Rezolute’s financing activities.

The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, we received a total of $6.0 million upon Rezolute’s achievement of financing activities and $8.5 million in installment payments through October 2020. We also received 161,861 shares of common stock of Rezolute (on as adjusted post reverse-split basis).

In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to XOMA pursuant to our Rezolute License Agreement.

Janssen

We and Janssen were parties to a license agreement which was terminated in 2017. In August 2019, we and Janssen entered into a new agreement pursuant to which we granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under our patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to us. Additionally, for each drug candidate, we are entitled to receive milestone payments of up to $3.0 million upon Janssen’s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates, which are the subject of multiple clinical trials. Upon commercialization, we are eligible to receive 0.75% royalty on net sales of each product. Janssen’s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties.

In May 2021, we announced we earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets. In December 2021, we earned a $0.2 million milestone pursuant to our agreement with Janssen.

Affimed

In April 2021, we entered into a new agreement with Affimed, under which we are eligible to receive payments from Affimed on potential future commercial sales related to three ICE molecules and pre-loaded natural killer cells containing the ICE molecules. Additionally, we are eligible to receive a milestone upon the first product candidate in each program achieving marketing approval.

Compugen

In September 2021, we earned a $0.5 million milestone payment under our license agreement with Compugen triggered by the dosing of the first patient in a Phase 1/2 study of AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. AZD2936 is derived from COM902 and is being developed by AstraZeneca.

12

Competition

The biotechnology and pharmaceutical industries are subject to continuous and substantial technological change. Some of the drugs our licensees or royalty partners are developing may compete with existing therapies or other drugs in development by other companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our licensees’ or royalty partners’ competitors. There can be no assurance that developments by others, including, without limitation, the development of generics or biosimilars, will not render our, or our licensees’, products or technologies obsolete or uncompetitive.

Additionally, our royalty aggregator model faces competition on at least two fronts. First, there are other companies, funds and other investment vehicles seeking to aggregate royalties or provide alternative financing to development-stage biotechnology and pharmaceutical companies. The competitive companies, funds and other investment vehicles may have a lower target rate of return, a lower cost of capital or access to greater amounts of capital and thereby may be able to acquire assets that we are also targeting for acquisitions. Second, existing or potential competitors to our partners and licensees’ products, particularly large pharmaceutical companies, may have greater financial, technical and human resources than our licensees. Accordingly, these competitors may be better equipped to develop, manufacture and market products. Many of these companies also have extensive experience in preclinical testing and human clinical trials, obtaining FDA and other regulatory approvals and manufacturing and marketing pharmaceutical products.

For a discussion of the risks associated with competition, see below under “Item 1A. Risk Factors.”

Government Regulation and Environmental Matters

The research and development, manufacturing and marketing of pharmaceutical products are subject to regulation by numerous governmental authorities in the United States and other countries. We and our partners and licensees, depending on specific activities performed, are subject to these regulations. In the United States, pharmaceuticals are subject to regulation by both federal and various state authorities, including the FDA. The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of pharmaceutical products and there are often comparable regulations that apply at the state level. There are similar regulations in other countries as well. For both currently marketed and products in development, failure to comply with applicable regulatory requirements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. Development stage products in our portfolio require approval by the FDA before we will recognize any royalties from sales. In addition, changes in existing regulations could have a material adverse effect on us or our partners.

We believe there are no compliance issues with laws and regulations that have been enacted or adopted regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, that have adversely affected, or are reasonably expected to adversely affect, our business, financial condition and results of operations, and we currently do not anticipate material capital expenditures arising from environmental regulation. We believe climate change could present risks to our business. Some of the potential impacts of climate change to our business include increased operating costs due to additional regulatory requirements and the risk of disruptions to our business. We do not believe these risks are material to our business at this time.

For a discussion of the risks associated with government regulations, see below under “Item 1A. Risk Factors.”

Intellectual Property

Intellectual property is important to our business and our future income streams will depend in part on our, and our partners and licensees’, ability to obtain issued patents and to operate without infringing on the proprietary rights of others. We hold and have filed applications for a number of patents in the United States and internationally to protect our products and technology. We also have obtained or have the right to obtain licenses to, or income streams based on, certain patents and applications filed by others. However, the patent position of biotechnology companies generally is highly uncertain and consistent policy regarding the breadth of allowed claims has not emerged from the actions of the U.S. Patent

13

and Trademark Office with respect to biotechnology patents. Accordingly, no assurance can be given that our, or our partners or licensees’ patents will afford protection against competitors with similar products or others will not obtain patents claiming aspects similar to those covered by our, or our partners’ or licensees’ patent applications. Some of our agreements, or those of or our partners or licensees, contain “step-down” provisions where the royalty rate is reduced following patent expiry or revocation. Below is a list of representative patents and patent applications related to our licensed programs:

Licensee

Program

Representative
Patents/Applications

Subject matter

Expected last expiry in family

Novartis

Anti-IL-1b

US 7,531,166
US 7,582,742
EP 1 899 378

Gevokizumab (VPM087) and other antibodies and antibody fragments with similar binding properties for IL-1β

2027

US 7,695,718
US 8,101,166
US 8,586,036
US 9,163,082

Methods of treating Type 2 diabetes or Type 2 diabetes-induced diseases or conditions with high affinity antibodies and antibody fragments that bind to IL-1β

2027

US 8,637,029

Methods of treating gout with certain doses of IL-1β binding antibodies or binding fragments

2028

JP 5763625

US 10,611,832

Pharmaceutical compositions comprising anti-IL-1β binding antibodies or fragments for reducing acute coronary syndrome in a subject with a history of myocardial infarction.

2030

Novartis

Anti-TGFb

US 8,569,462
US 9,145,458
US 9,714,285

US 10,358,486

EP 2714735

EP 21186327

JP 6363948

TGFβ antibodies and methods of use thereof

2032

US 10,167,334

EP 3 277 716

JP 6901400

Combination therapy using an inhibitor of TGFb and an inhibitor of PD-1 for treating or preventing recurrence of cancer

2036

Rezolute

Anti-INSR

US 9,944,698
EP 2 480 254
JP 5849050

Insulin receptor-modulating antibodies having the functional properties of RZ358

2030

US 10,711,067

EP 3 265 491A1

Methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody to the insulin receptor

2036

Ology Bioservices

Anti-BoNT

US 8,821,879
EP 2 473 191

Coformulations of anti- botulinum neurotoxin antibodies

2030

14

Licensee

Program

Representative
Patents/Applications

Subject matter

Expected last expiry in family

Various

Phage display libraries

US 8,546,307
EP 2 344 686

US 7,094,579
EP 2 060 628

XOMA phage display library components

2032

2022

Zydus Cadila in India, Brazil, Mexico and other emerging markets

Anti-IL2

US 10,858,428*

EP 3 518 969A2*

Interleukin-2 Antibodies and Uses Thereof

2037

Seeking out license

Anti-PTH1R

US 10,519,250

EP 3 490 600A1

Parathyroid Hormone Receptor 1 Antibodies and Uses Thereof

2037

Seeking out license

Anti-PRLR

US 7,867,493 **
EP 2 059 535 **

Prolactin receptor antibodies

2027

* Jointly owned with Medical University of South Carolina Foundation for Research Development

** Jointly owned with Novartis Vaccines and Diagnostics, Inc.

If certain patents issued to others are upheld or if certain patent applications filed by others are issued and upheld, our partners and licensees may require certain licenses from others to develop and commercialize certain potential products incorporating our technology. There can be no assurance that such licenses, if required, will be available on acceptable terms. If such licenses are obtained, our partners and licensees may be able to deduct some or all of the costs from the royalties they owe to us.

We protect our proprietary information, in part, by confidentiality agreements with our employees, consultants and partners. These parties may breach these agreements, and we may not have adequate remedies for any breach. To the extent that we or our consultants or partners use intellectual property owned by others, we may have disputes with our consultants or partners or other third parties, as to the rights in related or resulting know-how and inventions.

Concentration of Risk

Our business model is dependent on third parties achieving specified development milestones and product sales. Our pipeline currently includes over 70 fully funded programs from which we could potentially receive royalties or other payments if the programs achieve marketability. Novartis is developing several of the programs in our pipeline. While we do not expect the discontinuation of any one program would have a material impact on our business, the discontinuation of all programs by Novartis could have a material effect on our business and financial condition.

Organization

We were incorporated in Delaware in 1981 and became a Bermuda-exempted company in December 1998. Effective December 31, 2011, we changed our jurisdiction of incorporation from Bermuda to Delaware and changed our name from XOMA Ltd. to XOMA Corporation. When referring to a time or period before December 31, 1998, or after December 31, 2011, the terms “Company” and “XOMA” refer to XOMA Corporation, a Delaware corporation; when referring to a time or period between December 31, 1998, and December 31, 2011, such terms refer to XOMA Ltd., a Bermuda company.

Our principal executive offices are located at 2200 Powell Street, Suite 310, Emeryville, California 94608. Our telephone number at our principal executive offices is (510) 204-7200. Our website address is www.xoma.com. The information found on our website is not part of this or any other report filed with or furnished to the SEC.

15

Human Capital Resources

We rely on a small number of skilled, experienced, and innovative employees to conduct the operations of our company. As of March 3, 2022, we employed 12 full-time employees primarily engaged in executive, business development, legal, finance and administrative positions. We also utilize independent contractors and consultants to supplement our workforce.

The success of our business is fundamentally connected to the well-being of our employees. We provide robust compensation and benefits programs to help meet the needs of our employees. In addition to salaries, these programs include potential annual discretionary bonuses, broad-based equity awards, a 401(k) plan, healthcare and insurance benefits, paid time off, family leave, and flexible work schedules, among others. These benefits provide our employees choices where possible so they can customize their benefits to meet their needs and the needs of their families, as well as access to tools and resources to help them improve or maintain their health status and encourage engagement in healthy behaviors to improve their physical and mental health.

In response to the COVID-19 pandemic, we have temporarily restricted access to our office in California, as well as suspended any non-essential business travel. Our employees are conducting their work remotely, and they otherwise have minimal presence in our offices for essential activities. The safety, health and well-being of our employees is paramount. As such, we will consider ongoing government regulations and local health conditions before allowing non-essential travel or allowing any gatherings at our offices.    

Item 1A. Risk Factors

The following risk factors and other information included in this Annual Report should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us also may impair our business operations. If any of the following risks occur, our business, financial condition, operating results and cash flows could be materially adversely affected.

Risks Related to our Royalty Aggregator Strategy

The COVID-19 pandemic has adversely impacted and could materially and adversely impact in the future our licensees or royalty-agreement counterparties or their licensees, which could cause delays or elimination of our receipts of potential milestones and royalties under our licensing or royalty and milestone acquisition arrangements.

The COVID-19 pandemic has severely affected global economic activity and resulted in the implementation of significant governmental measures, including lockdowns, closures, quarantines and travel bans, intended to control the spread of the virus.

The COVID-19 pandemic has adversely impacted and could materially and adversely impact in the future our licensees or royalty-agreement counterparties or their licensees, which has and could further cause delays, suspensions or cancellations of their drug development efforts including, without limitation, their clinical trials, which would correspondingly delay, suspend or negate the timing of our potential receipts of milestones and royalties under our out-licensing or royalty acquisition agreements. The disruptions to our licensees or RPA counterparties or their licensees could include, without limitation:

delays or difficulties in recruiting and enrolling new patients in their clinical trials;
delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;
diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as their clinical trial sites and hospital staff supporting the conduct of their clinical trials;

16

interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others;
limitations in employee resources that would otherwise be focused on the conduct of their clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;
interruption in global shipping that may affect the transport of clinical trial supplies and materials, such as the investigational drug product used in their clinical trials;
delays in receiving approval from the FDA, the EMA and other U.S. and foreign federal, state and local regulatory authorities to initiate their planned clinical trials or to market their products;
changes in FDA, state and local regulation (and those of their foreign counterparts if applicable) as part of a response to the COVID-19 pandemic which may change the ways in which clinical trials are conducted or discontinue clinical trials altogether;
delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;
delay in the timing of other interactions with the FDA due to absenteeism by federal employees or by the diversion of their efforts and attention to approval of other therapeutics or other activities related to COVID-19; and
refusal of the FDA to accept data from clinical trials in affected geographies outside the United States or of foreign regulatory authorities to accept data from clinical trials in affected areas outside their applicable countries.

The extent to which the COVID-19 pandemic continues to impact our business and prospects and the overall economies of the United States and other countries will depend on numerous evolving factors, which are highly uncertain and cannot be predicted with confidence, such as the duration and scope of the pandemic, mutations in the COVID-19 virus, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.

The COVID-19 pandemic continues to pose risks to our business, including at our headquarters in Emeryville, California, which has in the past been subject to local and statewide “stay-at-home” orders issued by Alameda County and the Governor of the State of California, as well as the business or operations of our partners and other third parties with whom we conduct business.

The COVID-19 pandemic has resulted in extended travel and other continued restrictions in order to reduce the spread of the disease, including California executive orders, San Francisco Bay Area orders and several other state and local orders across the United States, which, among other things, direct individuals to continue to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. The evolving effects of the COVID-19 pandemic and restrictive government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce, as significant reductions in business related activities have occurred, supply chains have been disrupted, and manufacturing and clinical development activities have been curtailed or suspended.

In response to these public health directives and orders, we previously implemented a work-from-home policy for all employees. We have been able to maintain our operations and productivity thus far; however, prolonged working remotely may negatively impact productivity, disrupt our business and delay our timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.

17

In addition, quarantines, stay-at-home, executive and similar government orders, shutdowns or other restrictions on the conduct of business operations continue to impact personnel at third-party clinical testing sites, manufacturing facilities, and the availability or cost of materials, which could disrupt our licensees’ and RPA counterparties and their licensees’ supply chains.

The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the evolving economic impacts brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has already significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.

The evolving effects of the COVID-19 pandemic have already resulted in significant disruption of global financial markets. While several of our partners have experienced delays due to the COVID-19 pandemic, we do not yet know the full extent of potential delays or impacts on our business, clinical trials, healthcare systems or the global economy as a whole. However, the effects could continue to have an impact on our operations and could have a material adverse effect on our business, financial condition, results of operations and prospects in future periods.

Our acquisitions of potential future royalty and/or milestone payments may not produce anticipated revenues and/or may be negatively affected by a default or bankruptcy of the licensor(s) or licensee(s) under the applicable license agreement(s) covering such potential royalties and/or milestones, and if such transactions are secured by collateral, we may be, or may become, under-secured by the collateral or such collateral may lose value and we will not be able to recuperate our capital expenditures associated with the acquisition.

We are engaged in a continual review of opportunities to acquire future royalties, milestones and other payments related to drug development and sales as part of our royalty aggregator strategy or to acquire companies that hold royalty assets. Generally, at any time, we seek to have acquisition opportunities in various stages of active review, including, for example, our engagement of consultants and advisors to analyze particular opportunities, technical, financial and other confidential information, submission of indications of interest and involvement as a bidder in competitive auctions. Many potential acquisition targets do not meet our criteria, and for those that do, we may face significant competition for these acquisitions from other royalty buyers and enterprises. Competition for future asset acquisition opportunities in our markets could increase the price we pay for such assets and could reduce the number of potential acquisition targets. The success of our acquisitions is based on our ability to make accurate assumptions regarding the valuation, probability, timing and amount of potential future royalty and milestone payments as well as the viability of the underlying technology and intellectual property. The failure of any of these acquisitions to produce anticipated revenues may materially and adversely affect our financial condition and results of operations.

Some of these acquisitions may expose us to credit risk in the event of a default by or bankruptcy of the licensor(s) or licensee(s) that are parties to the applicable license agreement(s) covering the potential milestone and royalty streams being acquired. In addition, recent volatility in on the capital markets may limit our licensees or royalty-agreement counterparties’ ability to access additional funding. While we generally try to structure our receipt of potential milestone and royalty payments to minimize the risk associated with such a default or bankruptcy, there can be no assurance that any such default or bankruptcy will not adversely affect our ability to receive future potential royalty and/or milestone payments. To mitigate this risk, on occasion, we may obtain a security interest as collateral in such royalty, milestone and other payments. Our credit risk in respect of such counterparty may be exacerbated when the collateral held by us cannot be realized upon or is liquidated at prices not sufficient to recover the full amount we are due pursuant to the terms of the agreements covering the particular assets. This could occur in circumstances where the original collateral was not sufficient to cover a complete loss (e.g., our interests were only partially secured) or may result from the deterioration in value of the collateral, so that, in either such case, we are unable to recuperate our full capital outlay. Any such losses resulting therefrom could materially and adversely affect our financial condition and results of operations.

18

Many of our potential royalty acquisitions may be associated with drug products that are in clinical development and have not yet been commercialized. To the extent that such products are not successfully developed and commercialized, our financial condition and results of operations may be negatively impacted. Acquisitions of potential royalties associated with development stage biopharmaceutical product candidates are subject to a number of uncertainties.

As part of our royalty aggregator strategy, we may continue to purchase future potential milestone and royalty streams associated with drug products which are in clinical development and have not yet received marketing approval by any regulatory authority or been commercialized. There can be no assurance that the FDA, the EMA or other regulatory authorities will approve such products or that such products will be brought to market timely or at all, or that the market will be receptive to such products. To the extent that any such drug products are not successfully developed and subsequently commercialized, the value of our acquired potential milestone and royalty streams will be negatively affected. The ultimate success of our royalty aggregator strategy will depend on our ability to properly identify and acquire high quality products and the ability of the applicable counterparty to innovate, develop and commercialize their products, in increasingly competitive and highly regulated markets. Their inability to do so would negatively affect our ability to receive royalty and/or milestone payments. In addition, we are dependent, to a large extent, on third parties to enforce certain rights for our benefit, such as protection of a patent estate, adequate reporting and other protections, and their failure to do so would presumably negatively impact our financial condition and results of operations.

If the FDA, the EMA or other regulatory authority approves a development-stage product candidate that generates our royalty, the labeling, packaging, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with the product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, and could include withdrawal of the product from the market.

In addition, the developers of these development-stage product candidates may not be able to raise additional capital to continue their discovery, development and commercialization activities, which may cause them to delay, reduce the scope of, or eliminate one or more of their clinical trials or research and development programs. If other product developers introduce and market products that are more effective, safer, less invasive or less expensive than the relevant products that generate our royalties, or if such developers introduce their products prior to the competing products underlying our royalties, such products may not achieve commercial success and thereby result in a loss for us.

Further, the developers of such products may not have sales, marketing or distribution capabilities. If no sales, marketing or distribution arrangements can be made on acceptable terms or at all, the affected product may not be able to be successfully commercialized, which will result in a loss for us. Losses from such assets could have a material adverse effect on our business, financial condition and results of operations.

We intend to continue, and may increase, this strategy of acquiring development-stage product candidates. While we believe that we can readily evaluate and gain conviction about the likelihood of a development-stage product candidate’s approval and achieving significant sales, there can be no assurance that our assumptions will prove correct, that regulatory authorities will approve such development-stage product candidates, that such development-stage product candidates will be brought to market timely or at all, or that such products will achieve commercial success.

Risks Related to our Industry

Biopharmaceutical products are subject to sales risks.

Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, obsolescence, loss of patent protection, government regulations, the impact of  COVID-19 or other factors, and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals, declining sales or litigation. As a result, payments of our future potential milestones and/or royalties may be reduced or cease. In addition, these potential payments may be delayed, causing our near-term financial performance to be weaker than expected.

19

Biopharmaceutical products are subject to substantial competition.

The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product’s commercial life cannot be predicted with certainty. There can be no assurance that one or more products on which we are entitled to a potential milestone or royalty will not be rendered obsolete or non-competitive by new products or improvements on which we are not entitled to a potential milestone or royalty, either by the current marketer of such products or by another marketer. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our potential milestones and royalties.

Competitive factors affecting the market position and success of each product include: 

effectiveness;
safety and side effect profile;
price, including third-party insurance reimbursement policies;
timing and introduction of the product;
effectiveness of marketing strategy and execution;
governmental regulation;
availability of lower-cost generics and/or biosimilars;
treatment innovations that eliminate or minimize the need for a product; and
product liability claims.

Biopharmaceutical products that have the potential to generate future milestones and royalties for us may be rendered obsolete or non-competitive by new products, including generics and/or biosimilars, improvements on existing products or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a milestone or royalty rights may become obsolete. These developments could have a material adverse effect on the sales of the biopharmaceutical products that have potential to generate our milestones and royalties, and consequently could materially adversely affect our business, financial condition and results of operations.

We depend on our licensees and royalty-agreement counterparties for the determination of royalty and milestone payments. While we typically have primary or back-up rights to audit our licensees and royalty-agreement counterparties, the independent auditors may have difficulty determining the correct royalty calculation, we may not be able to detect errors and payment calculations may call for retroactive adjustments. We may have to exercise legal remedies, if available, to resolve any disputes resulting from any such audit.

The royalty, milestone and other payments we may receive are dependent on our licensees and royalty agreement counterparties and their licensees’ achievement of regulatory and developmental milestones and product sales. Each licensee’s calculation of the royalty payments is subject to and dependent upon the adequacy and accuracy of its sales and accounting functions, and errors may occur from time to time in the calculations made by a licensee and/or a licensee may fail to report the achievement of royalties or milestones in whole or in part. Our license and royalty agreements typically provide us the primary or back-up right to audit the calculations and sales data for the associated royalty payments; however, such audits may occur many months following our recognition of the royalty revenue, may require us to adjust

20

our royalty revenues in later periods and may require expense on our part. Further, our licensees and royalty-agreement counterparties may be uncooperative or have insufficient records, which may complicate and delay the audit process.

Although we intend to regularly exercise our royalty audit rights as necessary and to the extent available, we rely in the first instance on our licensees and royalty-agreement counterparties to accurately report the achievement of milestones and royalty sales and calculate and pay applicable milestones and royalties and, upon exercise of such royalty and other audit rights, we rely on licensees’ and royalty-agreement counterparties’ cooperation in performing such audits. In the absence of such cooperation, we may be forced to incur expenses to exercise legal remedies, if available, to enforce our agreements.

The lack of liquidity of our acquisitions of future potential milestones and royalties may adversely affect our business and, if we need to sell any of our acquired assets, we may not be able to do so at a favorable price, if at all. As a result, we may suffer losses.

We generally acquire milestone and royalty rights that have limited secondary resale markets and may be subject to transfer restrictions. The illiquidity of most of our milestone and royalty receivable assets may make it difficult for us to dispose of them at a favorable price if at all and, as a result, we may suffer losses if we are required to dispose of any or all such assets in a forced liquidation or otherwise. In addition, if we liquidate all or a portion of our potential future milestone and/or purchased royalty stream interests quickly or relating to a forced liquidation, we may realize significantly less than the value at which we had previously recorded these interests.

Our royalty aggregator strategy may require that we register with the SEC as an “investment company” in accordance with the Investment Company Act of 1940.

The rules and interpretations of the SEC and the courts, relating to the definition of "investment company" are very complex. While we currently intend to conduct our operations so that we will not be an investment company under applicable SEC interpretations, we can provide no assurance that the SEC would not take the position that the Company would be required to register under the ‘40 Act and comply with the ‘40 Act’s registration and reporting requirements, capital structure requirements, affiliate transaction restrictions, conflict of interest rules, requirements for disinterested directors, and other substantive provisions. We monitor our assets and income for compliance under the ‘40 Act and seek to conduct our business activities to ensure that we do not fall within its definitions of “investment company” or that we qualify under one of the exemptions or exclusions provided by the ‘40 Act and corresponding SEC regulations. If we were to become an “investment company” and be subject to the restrictions of the ‘40 Act, those restrictions likely would require significant changes in the way we do business and add significant administrative costs and burdens to our operations. To ensure we do not fall within the ‘40 Act, we may need to take various actions which we might otherwise not pursue. These actions may include restructuring the Company and/or modifying our mixture of assets and income or a liquidation of certain of our assets.

Our licensees or royalty-agreement counterparties or their licensees could be subject to natural disasters, public health crises, political crises and other catastrophic events that could hinder or disrupt development efforts.

We depend on our licensees and royalty-agreement counterparties and their licensees to successfully develop and commercialize product candidates for which we may receive milestone, royalty and other payments in the future. Our licensees and royalty-agreement counterparties and their licensees operate research and development efforts in various locations in the United States and internationally. If any of their facilities is affected by natural disasters, such as earthquakes, tsunamis, power shortages or outages, floods or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability, labor disputes or strikes, other conflict, or other events outside of their control, their research and development efforts could be disrupted, which could result in the delay or discontinuation of development of one or more of the product candidates in which we have rights to future milestone and/or royalty payments which could have a material adverse effect on our business, results of operations and prospects.

21

Because many of the companies with which we do business also are in the biotechnology sector, the volatility of that sector can affect us indirectly as well as directly.

The same factors that affect us directly also can adversely affect us indirectly by affecting the ability of our partners and others with whom we do business to meet their obligations to us and reduce our ability to realize the value of the consideration provided to us by these other companies in connection with their licensing of our products.

Risks Related to our Financial Results and Capital Requirements

We have sustained losses in the past, and we expect to sustain losses in the foreseeable future.

We have incurred significant operating losses and negative cash flows from operations since our inception. Although we generated net income of $15.8 million and $13.3 million and positive cash flows from operations of $22.7 million and $10.1 million for the years ended December 31, 2021 and 2020, respectively, we had an accumulated deficit of $1.2 billion as of December 31, 2021. We do not know whether we will ever achieve sustained profitability or whether cash flow from future operations will be sufficient to meet our needs.

To date, we have financed our operations primarily through the sale of equity securities and debt and royalty interests, and payments received under our collaboration and licensing arrangements. The size of our future net losses will depend, in part, on the rate of our future expenditures and our and our partners’ ability to generate revenues. If our partners’ product candidates are not successfully developed or commercialized, or if revenues are insufficient following regulatory approval, we will not achieve profitability and our business may fail. Our ability to achieve profitability is dependent in large part on the success of our and our partners’ ability to license product candidates, and the success of our partners’ development programs, both of which are uncertain. Our success is also dependent on our partners obtaining regulatory approval to market product candidates which may not materialize or prove to be successful.

Our royalty aggregator strategy may require us to raise additional funds to acquire milestone and royalty interests; we cannot be certain that funds will be available or available at an acceptable cost of capital, and if they are not available, we may be unsuccessful in acquiring milestone and royalty interests to sustain the business in the future.

We may need to commit substantial funds to continue our business, and we may not be able to obtain sufficient funds on acceptable terms, if at all. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to us and/or result in dilution to our stockholders, including pursuant to our 2018 Common Stock At The Market Issuance Sales Agreement, as amended (the “2018 Common Stock ATM Agreement”) and to our 2021 Series B Preferred Stock At The Market Issuance Sales Agreement (the “2021 Series B Preferred Stock ATM Agreement”). Our Series A Preferred Stock and Series B Preferred Stock, while not dilutive, includes dividends and required that we establish a segregated cash account adequate to fund the dividends. If we raise additional funds through licensing arrangements with third parties, we may be required to relinquish some rights to our technologies or our product candidates, grant licenses on terms that are not favorable to us or enter into a license arrangement for a product candidate at an earlier stage of development or for a lesser amount than we might otherwise choose.

If adequate funds are not available on a timely basis, we may:

reduce or eliminate royalty aggregation efforts;
further reduce our capital or operating expenditures;
curtail our spending on protecting our intellectual property; or
take other actions which may adversely affect our financial condition or results of operations.

Changes in the potential royalty acquisition market, including its structure and participants, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire potential milestones

22

and royalties, fewer potential milestones and royalties (or potential milestones or royalties of significant scale) being available, or increased competition for potential royalties. Even if we continue to acquire potential royalties and they become actual royalties, they may not generate a meaningful return for a period of several years, if at all, due to the price we pay for such royalties or other factors relating to the underlying products. As a result, we may not be able to continue to acquire potential milestones and royalties as we have in the past, or at all.

We have a continuing obligation to pay quarterly dividends to holders of our Series A Preferred Stock and Series B Preferred Stock, which will be an on-going expenditure for us and may limit our ability to borrow additional funds.

Holders of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year). Dividends on the Series A Preferred Stock will accumulate and be cumulative from, and including, the date of original issue by us of the Series A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October beginning April 15, 2021. In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of shares of Series A Preferred Stock are entitled to be paid out of our assets legally available for distribution to our stockholders a liquidation preference of $25.00 per share, plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared), before any distribution or payment may be made to holders of shares of common stock or any other class or series of our equity stock ranking, as to liquidation rights, junior to the Series A Preferred Stock. The shares of Series A Preferred Stock are redeemable at our option, in whole or in part, at redemption prices ranging from $26.00 per share to $25.00 per share, plus any accrued and unpaid dividends, depending on the date of redemption.

Holders of depositary shares representing interests in our Series B Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share or $2.09375 per year per depositary share). Dividends on the Series B Preferred Stock will accumulate and be cumulative from, and including, the date of original issue by us of the Series B Preferred Stock. Dividends are payable in arrears on or about the 15th day of January, April, July and October beginning July 15, 2021. As of December 31, 2021, we held restricted cash of $2.0 million in a segregated account that may only be used to pay dividends on our Series A and Series B Preferred Stock.

The payment of cash dividends and share repurchases is subject to limitations under applicable laws and the discretion of our Board of Directors and is determined after considering current conditions, including earnings, other operating results and capital requirements. Decreases in asset values or increases in liabilities can reduce net earnings and stockholders’ equity. A deficit in stockholders’ equity could limit our ability to pay dividends and make share repurchases under Delaware law. On the other hand, our continued obligation to pay dividends to the holders of our Series A Preferred Stock and depositary shares representing interests in Series B Preferred Stock could restrict us from additional borrowings or make them more costly.

The holders of preferred stock have rights that are senior to those of our common stockholders.

At December 31, 2021, we had issued and outstanding 984,000 shares of Series A Preferred Stock with a liquidation preference of $25.00 per share, plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared). Additionally, as of December 31, 2021, we had issued and outstanding 1,600,000 depositary shares, each representing a 1/1000th fractional interest in a share of our Series B Preferred Stock with a liquidation preference of $25,000 per share of Series B Preferred Stock ($25.00 per depositary share), plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared). Our preferred stock is senior to our shares of common stock in right of payment of dividends and other distributions. In the event of our bankruptcy, dissolution or liquidation, the holders of our preferred stock must be satisfied before any distributions can be made to our common stockholders.

23

Information available to us about the biopharmaceutical products underlying the potential royalties we buy may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited.

We may have limited information concerning the products generating the future potential milestones and royalties we are evaluating for acquisition. Often following our acquisition, the information we have regarding products underlying a potential milestone or royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by sponsors of the products of others or the nature or number of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual potential cash flow from a potential royalty may be significantly lower than our estimates.

Our future income is dependent upon numerous potential milestone and royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns.

Our business model is based on multiple-year internal and external forecasts regarding potential product sales and numerous product-specific assumptions in connection with each potential milestone and royalty acquisition, including where we have limited information regarding the product. There can be no assurance that the assumptions underlying our financial models, including those regarding potential product sales or competition, patent expirations or license terminations for the products underlying our portfolio, are accurate. These assumptions involve a significant element of subjective judgment and may be and in the past have been adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product. Our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us potential royalties may also prove to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets may not generate our projected returns or in the time periods we expect. This could negatively impact our results of operation for a given period.

Reductions or declines in income from potential milestones and royalties, or significant reductions in potential milestone or royalty payments compared to expectations, or impairments in the value of potential milestones and royalties acquired could have a material adverse effect on our financial condition and results of operations.

The amount and duration of a royalty usually varies on a country-by-country basis and can be based on a number of factors, such as payments to third party licensors, whether the product is sold singly or in combination, patent expiration dates, regulatory exclusivity, years from first commercial sale of the applicable drug product, the entry of competing generic or biosimilar products, or other terms set out in the contracts governing the royalty. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, claims of patent misuse, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations. If an unexpected reduction in a royalty amount or shortening of a potential royalty term were to occur, it could result in a reduction in potential income from milestones and royalties, a significant reduction in potential milestones and royalty payments compared to expectations, or a permanent impairment of such potential milestones and royalty payments.

A large percentage of the calculated net present value of our portfolio is represented by a limited number of products. The failure of any one of these products to move forward in clinical development or commercialization may have a material adverse effect on our financial condition and results of operation.

Our asset portfolio may not be fully diversified by product, therapeutic area, geographic region or other criteria. Any significant deterioration in the amount or likelihood of receipt of potential cash flows from the top products in our asset portfolio could have a material adverse effect on our business, financial condition and results of operations. For example, in September 2021, Novartis announced its decision to discontinue its study of CFZ533 (iscalimab) in the prevention of organ rejection in patients receiving a kidney transplant after an interim analysis of data. In addition, should

24

the payor of any future potential milestones or royalties decline to pay such potential milestones and royalties for any reason, such failure may result in a material adverse effect on our financial condition and results of operation.

Risks Related to Our Reliance on Third Parties

We and our partners rely heavily on license and collaboration relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including our ability to receive milestone payments and future potential royalty and other revenues. License or collaboration agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our potential milestones, royalties and other payments.

License or collaboration agreements relating to the products generating our future potential milestones and royalties and other payment rights may be terminated, which may adversely affect sales of such products and therefore the potential payments we may receive. For example, under certain license or collaboration agreements, marketers may retain the right to unilaterally terminate the agreements. When the last patent covering a product expires or is otherwise invalidated in a country, a marketer may be economically motivated to terminate the applicable license or collaboration agreement, either in whole or with respect to such country, in order to terminate its payment and other obligations. In the event of such a termination, a licensor (which may be us in the case of our out-licensed products) or collaborator may no longer receive all of the payments it expected to receive from the applicable licensee or collaborator and may also be unable to find another company to continue developing and commercializing the product on the same or similar terms as those under the license or collaboration agreement that has been terminated.

In addition, license or collaboration agreements may fail to provide significant protection for the applicable licensor (which may be us in the case of our out-licensed products) or collaborator in case of the applicable licensee’s or collaborator’s failure to perform or in the event of disputes. License and collaboration agreements which relate to the products underlying our potential future milestones, royalties and other payment rights, are complex and certain provisions in such agreements may be susceptible to multiple interpretations. Disputes may arise regarding intellectual property, royalty terms, payment rights or other contractual terms subject to a license or collaboration agreement, including:

the scope or duration of rights granted under the license or collaboration agreement and other interpretative issues;
the amounts or timing of royalties, milestones or other payments due under the license or collaboration agreement;
the sublicensing of patent or other rights under our license or collaboration relationships;
the diligence obligations under the license or collaboration agreement and what activities satisfy such diligence obligations:
the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us or our partners; and
the priority of invention of patented technology.

The resolution of any contract interpretation disagreement that may arise could narrow what the licensor (which may be us in the case of our out-licensed products) or collaborator believes to be the scope of its rights to the relevant intellectual property or technology, or decrease the licensee’s or collaborator’s financial or other obligations under the relevant agreement, any of which could in turn impact the value of our potential royalties, milestones and other payments and have a material adverse effect on our business, financial condition, results of operations and prospects. If a marketer were to default on its obligations under a license or collaboration agreement, the licensor’s or collaborator’s remedy may be limited either to terminating certain licenses or collaborations related to certain countries or to generally terminate the license or collaboration agreement with respect to such country. In such cases, we may not have the right to seek to enforce

25

the rights of the licensor or collaborator (if not us) and we may be required to rely on the resources and willingness of the licensor or collaborator (if not us) to enforce its rights against the applicable licensee or collaborator. In any of these situations, if the expected upfront, milestone, royalty or other payments under the license or collaboration agreements do not materialize, this could result in a significant loss to us and materially adversely affect our business, financial condition and results of operations. At any given time, the Company may be engaged in discussions with its licensees or collaborators regarding the interpretation of the payment and other provisions relating to products as to which we have milestones and potential royalty or other payment rights. Should any such discussions result in a disagreement regarding a particular product that cannot be resolved satisfactorily to us, we may end up being paid less than anticipated on such product should it successfully progress through clinical development and be approved for commercialization. Should our milestone and future potential royalty or other payment interests be reduced or eliminated as result of any such disagreement, it could have an adverse effect on our business, financial condition, results of operation and prospects.

Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaborative arrangements to develop and commercialize our unpartnered assets. Generally, our current collaborative partners also have the right to terminate their collaborations at will or under specified circumstances. If any of our collaborative partners breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully (for example, by not making required payments when due, or at all or failing to engage in commercially reasonable efforts to develop products if required), our product development under these agreements will be delayed or terminated.

Our potential milestone and royalty providers may rely on third parties to provide services in connection with their product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could affect our potential milestone and royalty providers’ product candidate development.

Third parties provide services in connection with preclinical and clinical development programs, including in vitro and in vivo studies, assay and reagent development, immunohistochemistry, toxicology, pharmacokinetics, clinical trial support, manufacturing and other outsourced activities. If these service providers do not adequately perform the services for which our potential milestone and royalty providers have contracted, or cease to continue operations, and are not able to find a replacement provider quickly or lose information or items associated with their drug product candidates, our potential milestone and royalty providers’ development programs and receipt of any potential resulting income may be delayed.

Agreements with other third parties, many of which are material to our business, expose us to numerous risks and have caused us to incur additional liabilities.

Because our licensees, suppliers and contractors are independent third parties, they may be subject to different risks than we are and have significant discretion in, and different criteria for, determining the efforts and resources they will apply related to their agreements with us. If these licensees, suppliers and contractors do not successfully perform the functions for which they are responsible, we may not have the capabilities, resources or rights to do so on our own.

We do not know whether we or our licensees will successfully develop and market any of the products that are or may become the subject of any of our licensing arrangements. In addition, third-party arrangements such as ours also increase uncertainties in the related decision-making processes and resulting progress under the arrangements, as we and our licensees may reach different conclusions, or support different paths forward, based on the same information, particularly when large amounts of technical data are involved.

In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.

26

Failure of our potential milestone and royalty providers’ product candidates to meet current Good Manufacturing Practices standards may subject our licensees to delays in regulatory approval and penalties for noncompliance.

Our potential milestone and royalty providers may rely on third party manufacturers and such contract manufacturers are required to produce clinical product candidates under cGMP to meet acceptable standards for use in clinical trials and for commercial sale, as applicable. If such standards change, the ability of contract manufacturers to produce our potential milestone and royalty providers’ drug product candidates on the schedule required for clinical trials or to meet commercial requirements may be affected. In addition, contract manufacturers may not perform their obligations under their agreements with our potential milestone and royalty providers or may discontinue their business before the time required by us to successfully produce clinical and commercial supplies of our potential milestone and royalty providers’ product candidates.

Contract manufacturers are subject to pre-approval inspections and periodic unannounced inspections by the FDA and corresponding state and foreign authorities to ensure strict compliance with cGMP and other applicable government regulations and corresponding foreign standards. We do not have control over a third-party manufacturer’s compliance with these regulations and standards. Any difficulties or delays in contractors’ manufacturing and supply of our potential milestone and royalty providers’ product candidates or any failure of our potential milestone and royalty providers’ contractors to maintain compliance with the applicable regulations and standards could increase costs, reduce revenue, make our licensees postpone or cancel clinical trials, prevent or delay regulatory approval by the FDA and corresponding state and foreign authorities, prevent the import and/or export of our potential milestone and royalty providers’ product candidates, or cause any of our potential milestone and royalty providers’ products that may be approved for commercial sale to be recalled or withdrawn.

Certain of our technologies are in-licensed from third parties, so our and our licensees’ capabilities use of them may be restricted and subject to additional risks.

We have licensed technologies from third parties. These technologies include phage display technologies licensed to us in connection with our bacterial cell expression technology licensing program and antibody products. However, our and our licensees and collaborators’ use of these technologies is limited by certain contractual provisions in the licenses relating to them, and although we have obtained numerous licenses, intellectual property rights in the area of phage display are particularly complex. If we are unable to maintain our licenses, patents or other intellectual property, we could lose important protections that are material to continuing our operations and for future prospects. Our licensors also may seek to terminate our license, which could cause us and our licensees to lose the right to use the licensed intellectual property and adversely affect our and our licensees’ ability to commercialize our technologies, products or services.

Risks Related to Our Milestone Royalty Streams

We may not be able to successfully identify and acquire potential milestone and royalty streams on other products, product candidates, or programs, or other companies to grow and diversify our business, and, even if we are able to do so, we may not be able to successfully manage the risks associated with integrating any such products, product candidates, programs or companies into our business or we may otherwise fail to realize the anticipated benefits of these acquisitions.

To grow and diversify our business, we plan to continue our business development efforts to identify and seek to acquire and/or in-license potential milestone and royalty streams or companies. Future growth through acquisition or in-licensing will depend upon the availability of suitable products, product candidates, programs or companies for acquisition or in-licensing on acceptable prices, terms and conditions. Even if appropriate opportunities are available, we may not be able to acquire rights to them on acceptable terms, or at all. The competition to acquire or in-license rights to promising products, product candidates, programs and companies is fierce, and many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more financial, development and commercialization resources, personnel, and experience than we have. In order to compete successfully in the current business climate, we may have to pay higher prices for assets than may have been paid historically, which may make it more difficult for us to realize an adequate return on any acquisition.

27

Even if we are able to successfully identify and acquire or in-license new products, product candidates, programs or companies, we may not be able to successfully manage the risks associated with integrating any products, product candidates, programs or companies into our business or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate risks and liabilities of potential acquisitions through, among other things, due diligence, indemnification and risk allocation, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in identifying and managing these risks and uncertainties effectively would have a material adverse effect on our business. In any event, we may not be able to realize the anticipated benefits of any acquisition or in-licensing for a variety of reasons, including the possibility that a product candidate fails to advance to clinical development, proves not to be safe or effective in clinical trials, or that a product fails to reach its forecasted commercial potential or that the integration of a product, product candidate, program or company gives rise to unforeseen difficulties and expenditures. Any failure in identifying and managing these risks and uncertainties would have a material adverse effect on our business.

If our potential royalty providers’ therapeutic product candidates do not receive regulatory approval, our potential royalty providers will be unable to market them.

Our potential royalty providers’ product candidates cannot be manufactured and marketed in the United States or any other countries without required regulatory approvals. The U.S. government and governments of other countries extensively regulate many aspects of our product candidates, including:

clinical development and testing;
manufacturing;
labeling;
storage;
record keeping;
promotion and marketing; and
importing and exporting.

In the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act and other laws, including, in the case of biologics, the Public Health Service Act.

Initiation of clinical trials requires approval by health authorities. Clinical trials involve the administration of the investigational new drug to healthy volunteers or to patients under the supervision of a qualified principal investigator. Clinical trials must be conducted in accordance with FDA and International Conference on Harmonization Good Clinical Practices and the European Clinical Trials Directive, as applicable, under protocols that detail the objectives of the study, the parameters to be used to monitor safety and the efficacy criteria to be evaluated. Other national, foreign and local regulations also may apply. The developer of the drug must provide information relating to the characterization and controls of the product before administration to the patients participating in the clinical trials. This requires developing approved assays of the product to test before administration to the patient and during the conduct of the trial. In addition, developers of pharmaceutical products must provide periodic data regarding clinical trials to the FDA and other health authorities, and these health authorities may issue a clinical hold upon a trial if they do not believe, or cannot confirm, that the trial can be conducted without unreasonable risk to the trial participants.

The results of the preclinical studies and clinical testing, together with chemistry, manufacturing and controls information, are submitted to the FDA and other health authorities in the form of a NDA for a drug, and in the form of a BLA for a biological product, requesting approval to commence commercial sales. In responding to an NDA or BLA, the FDA or foreign health authorities may grant marketing approvals, request additional information or further research, or

28

deny the application if they determine the application does not satisfy regulatory approval criteria. Regulatory approval of an NDA, BLA, or supplement is never guaranteed. The approval process can take several years, is extremely expensive and can vary substantially based upon the type, complexity, and novelty of the products involved, as well as the target indications. Our potential royalty providers ultimately may not be able to obtain approval in a timely fashion or at all.

The FDA and foreign health authorities have substantial discretion in the drug and biologics approval processes. Despite the time and expense incurred, failure can occur at any stage, and our potential development partners could encounter problems that cause abandonment of clinical trials or cause them to repeat or perform additional preclinical, clinical or manufacturing-related studies.

Changes in the regulatory approval policy during the development period, changes in, or the enactment of additional regulations or statutes, or changes in regulatory review for a submitted product application may cause delays in the approval or rejection of an application.

The FDA and other regulatory agencies have substantial discretion in both the product approval process and manufacturing facility approval process, and as a result of this discretion and uncertainties about outcomes of testing, we cannot predict at what point, or whether, the FDA or other regulatory agencies will be satisfied with our licensees’ submissions or whether the FDA or other regulatory agencies will raise questions that may be material and delay or preclude product approval or manufacturing facility approval. In light of this discretion and the complexities of the scientific, medical and regulatory environment, our or our potential royalty providers’ interpretation or understanding of the FDA’s or other regulatory agencies’ requirements, guidelines or expectations may prove incorrect, which also could delay further or increase the cost of the approval process.

Our potential milestone and royalty providers face uncertain results of clinical trials of product candidates.

Drug development has inherent risk, and our potential milestone and royalty providers are required to demonstrate through adequate and well-controlled clinical trials that product candidates are effective, with a favorable benefit-risk profile for use in their target profiles before they can seek regulatory approvals for commercial use. It is possible our potential royalty providers may never receive regulatory approval for any licensed product candidates. Even if a product candidate receives regulatory approval, the resulting product may not gain market acceptance among physicians, patients, healthcare payors and the medical community.

Our potential milestone and royalty providers’ product candidates require significant additional research and development, extensive preclinical studies and clinical trials and regulatory approval prior to any commercial sales. This process is lengthy and expensive, often taking a number of years. As clinical results frequently are susceptible to varying interpretations that may delay, limit or prevent regulatory approvals, the length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly. As a result, it is uncertain whether:

our potential milestone and royalty providers’ future filings will be delayed;
our potential milestone and royalty providers’ preclinical studies will be successful;
our potential milestone and royalty providers will be successful in generating viable product candidates;
we will be successful in finding collaboration and licensing partners to advance our product candidates on our behalf;
our potential milestone and royalty providers will be able to provide necessary data;
results of future clinical trials by our potential milestone and royalty providers will justify further development; or

29

our potential milestone and royalty providers ultimately will achieve regulatory approval for product candidates in which we have an interest.

The timing of the commencement, continuation and completion of clinical trials by our potential milestone and royalty providers may be subject to significant delays relating to various causes, including failure to complete preclinical testing and earlier-stage clinical trials in a timely manner, inability to engage contract research organizations and other service providers, scheduling conflicts with participating clinicians and clinical institutions, changes in key personnel at clinical institutions, difficulties in identifying and enrolling patients who meet trial eligibility criteria and shortages of available drug supply. In addition, since we and our royalty agreement counterparties license our product candidates to others to fund and conduct clinical trials, we, and they, have limited control over how quickly and efficiently such licensees advance those trials. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the concentration of patients in specialist centers, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments. Regardless of the initial size or relative complexity of a clinical trial, the costs of such trial may be higher than expected due to increases in duration or size of the trial, changes in the protocol under which the trial is being conducted, additional or special requirements of one or more of the healthcare centers where the trial is being conducted, or changes in the regulatory requirements applicable to the trial or in the standards or guidelines for approval of the product candidate being tested or for other unforeseen reasons.

In addition, our potential milestone and royalty providers may conduct clinical trials in foreign countries, which may subject them to further delays and expenses as a result of increased drug shipment costs, additional regulatory requirements and the engagement of foreign clinical research organizations, and may expose our potential milestone and royalty providers to risks associated with foreign currency transactions to make contract payments denominated in the foreign currency where the trial is being conducted.

New products and technologies of other companies may render some or all of our potential milestone and royalty providers’ product candidates noncompetitive or obsolete.

New developments by others may render our potential milestone and royalty providers’ product candidates or technologies obsolete or uncompetitive. Technologies developed and utilized by the biotechnology and pharmaceutical industries are changing continuously and substantially. Competition in antibody-based technologies is intense and is expected to increase in the future as a number of established biotechnology firms and large chemical and pharmaceutical companies advance in these fields. Many of these competitors may be able to develop products and processes competitive with or superior to our potential milestone and royalty providers for many reasons, including that they may have:

significantly greater financial resources;
larger research and development staffs;
entered into arrangements with, or acquired, biotechnology companies to enhance their capabilities; or
extensive experience in preclinical testing and human clinical trials.

These factors may enable others to develop products and processes competitive with or superior to our own or those of our potential milestone and royalty providers. In addition, a significant amount of research in biotechnology is being carried out in universities and other non-profit research organizations. These entities are becoming increasingly interested in the commercial value of their work and may become more aggressive in seeking patent protection and licensing arrangements. Furthermore, many companies and universities tend not to announce or disclose important discoveries or development programs until their patent position is secure or, for other reasons, later. As a result, we and our potential milestone and royalty providers may not be able to track development of competitive products, particularly at the early stages.

Positive developments in connection with a potentially competing product may have an adverse impact on our future potential for receiving revenue derived from development milestones and royalties. For example, if another product

30

is perceived to have a competitive advantage, or another product’s failure is perceived to increase the likelihood that our licensed product will fail, our potential milestone and royalty providers may halt development of product candidates in which we have an interest.

Our potential royalty providers may be unable to price our products effectively or obtain coverage and adequate reimbursement for sales of our products, which would prevent our potential royalty providers’ products from becoming profitable and negatively affect the royalties we may receive.

If our potential royalty providers succeed in bringing our product candidates to the market, they may not be considered cost effective, and reimbursement to the patient may not be available or may not be sufficient to allow our potential royalty providers to sell the products on a competitive basis. In both the United States and elsewhere, sales of medical products and treatments are dependent, in part, on the availability of coverage and adequate reimbursement from third-party payors, such as government and private insurance plans. Significant uncertainty exists as to the coverage and reimbursement status of any products for which our potential royalty providers may obtain regulatory approval. Even if coverage is available, the associated reimbursement rate may not be adequate for our potential royalty providers to cover related marketing costs. Additionally, coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. Therefore, the process of obtaining coverage and reimbursement is often time-consuming and costly. Thus, even if our partners’ product candidates are approved by the FDA, our royalty partners may not be able to price the products effectively or obtain coverage and adequate reimbursement for their products, which could adversely affect the royalties we receive.

Third-party payors are increasingly challenging the prices charged for pharmaceutical products and services. Our business is affected by the efforts of government and third-party payors to contain or reduce the cost of healthcare through various means. In the United States, there have been and will continue to be a number of federal and state proposals to implement government controls on pricing.

In addition, the emphasis on managed care in the United States has increased and will continue to increase the pressure on the pricing of pharmaceutical products. We cannot predict whether any legislative or regulatory proposals will be adopted or the effect these proposals or managed care efforts may have on our or our potential milestone and royalty providers’ businesses.

We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership or royalty interest.

Even if product candidates in which we have an interest receive approval in the future, they may not be accepted in the marketplace. In addition, our potential royalty providers may experience difficulties in launching new products, many of which are novel and based on technologies that are unfamiliar to the healthcare community. We have no assurance healthcare providers and patients will accept such products, if developed. Similarly, physicians may not accept a product if they believe other products to be more effective or more cost effective or are more comfortable prescribing other products.

Furthermore, government agencies, as well as private organizations involved in healthcare, from time to time publish guidelines or recommendations to healthcare providers and patients. Such guidelines or recommendations can be very influential and may adversely affect product usage directly (for example, by recommending a decreased dosage of a product in conjunction with a concomitant therapy) or indirectly (for example, by recommending a competitive product over a product in which we have an ownership or royalty interest). Consequently, we do not know if physicians or patients will adopt or use products in which we have an ownership or royalty interest for their approved indications.

Even approved and marketed products are subject to risks relating to changes in the market for such products. Introduction or increased availability of generic or biosimilar versions of products can alter the market acceptance of branded products. In addition, unforeseen safety issues may arise at any time, regardless of the length of time a product has been on the market which may lead to litigation, increased costs and delays or removal of the product from the market.

31

We are exposed to an increased risk of product liability claims.

The testing, marketing and sales of medical products entails an inherent risk of allegations of product liability. In the past, we were party to product liability claims filed against Genentech Inc. and, even though Genentech agreed to indemnify us in connection with these matters and these matters have been settled, there can be no assurance other product liability lawsuits will not result in defense costs and/or liability to us or that our insurance or contractual arrangements will provide us with adequate protection against such liabilities. In the event of one or more large, unforeseen awards of damages against us, our product liability insurance may not provide adequate coverage. A significant product liability claim for which we were not adequately covered by insurance or indemnified by a third party would have to be paid from cash or other assets, which could have an adverse effect on our business, financial condition and the value of our common stock. To the extent we have sufficient insurance coverage, such a claim would presumably result in higher subsequent insurance rates. In addition, product liability claims can have various other ramifications, regardless of merit or eventual outcome, including loss of future sales opportunities, discontinuation of clinical trials, increased costs associated with replacing products, a negative impact on our goodwill and reputation, costs to defend litigation, and divert our management’s attention from our business, each of which could also adversely affect our business and operating results.

If we and our potential royalty providers are unable to protect our intellectual property, in particular patent protection for principal products, product candidates and processes in which we have an ownership or royalty interest, and prevent the use of the covered subject matter by third parties, our potential royalty providers’ ability to compete in the market will be harmed, and we may not realize our profit potential.

We and our potential royalty providers rely on patent protection, as well as a combination of copyright, trade secret, and trademark laws to protect our proprietary technology and prevent others from duplicating our products or product candidates. However, these means may afford only limited protection and may not:

prevent our competitors from duplicating our products and those of our potential royalty providers;
prevent our competitors from gaining access to our proprietary information and technology and that of our potential royalty providers; or
permit us or our potential royalty providers to gain or maintain a competitive advantage.

Because of the length of time and the expense associated with bringing new products to the marketplace, we and our potential royalty providers hold and are in the process of applying for a number of patents in the United States and abroad to protect product candidates and important processes and also have obtained or have the right to obtain exclusive licenses to certain patents and applications filed by others. However, the mere issuance of a patent is not conclusive as to its validity or its enforceability.

The U.S. Federal Courts, the U.S. Patent & Trademark Office or equivalent national courts or patent offices elsewhere may invalidate our patents or find them unenforceable. The America Invents Act introduced post-grant review procedures subjecting U.S. patents to post-grant review procedures similar to European oppositions. U.S. patents owned or licensed by us or our licensees may therefore be subject to post-grant review procedures, as well as other forms of review and re-examination. A decision in such proceedings adverse to our interests could result in the loss of valuable patent rights, which would have a material adverse effect on our business. In addition, the laws of foreign countries may not protect our intellectual property rights effectively or to the same extent as the laws of the United States.

If our, and our potential royalty providers intellectual property rights are not protected adequately, our potential royalty providers may not be able to commercialize technologies or products in which we have an ownership or royalty interest, and our competitors could commercialize such technologies or products, which could result in a decrease in our potential royalty providers’ sales and market share that would harm our business and operating results. Specifically, the patent position of biotechnology companies generally is highly uncertain and involves complex legal and factual questions.

32

The legal standards governing the validity of biotechnology patents are in transition, and current defenses as to issued biotechnology patents may not be adequate or available in the future. Accordingly, there is uncertainty as to:

whether any pending or future patent applications held by us or our potential royalty providers will result in an issued patent, or whether issued patents will provide meaningful protection against competitors or competitive technologies;
whether competitors will be able to design around our or our potential royalty providers’ patents or develop and obtain patent protection for technologies, designs or methods that are more effective than those covered by our or our potential royalty providers’ patents and patent applications; or
the extent to which our or our potential royalty providers’ product candidates could infringe on the intellectual property rights of others, which may lead to costly litigation, result in the payment of substantial damages or royalties, reduce the royalty rate due to us, and prevent our potential royalty providers from using our technology or product candidates.

If certain patents issued to others are upheld or if certain patent applications filed by others are issued and upheld, our potential royalty providers may require licenses from others to develop and commercialize certain potential products in which we have an ownership or royalty interest. These licenses, if required, may not be available on acceptable terms, or may trigger contractual royalty offset clauses in our license agreements, or those of our royalty-agreement counterparties. We may become involved in litigation to determine the proprietary rights of others, and any such litigation will presumably be costly, time consuming, may not be adequately covered by insurance and may have other adverse effects on our business, such as inhibiting our potential royalty providers’ ability to compete in the marketplace and absorbing significant management time.

Due to the uncertainties regarding biotechnology patents, we also have relied and will continue to rely upon trade secrets, know-how and continuing technological advancement to develop and maintain our competitive position. Our employees and contractors are typically required to sign confidentiality agreements under which they agree not to use or disclose any of our proprietary information. Research and development contracts and relationships between us and our scientific consultants and potential licensees provide access to aspects of our know-how that are protected generally under confidentiality agreements. These confidentiality agreements may be breached or may not be enforced by a court. To the extent proprietary information is divulged to competitors or to the public generally, such disclosure may adversely affect our licensees’ ability to develop or commercialize our products by giving others a competitive advantage or by undermining our patent position.

In addition, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and or applications will be due to the U.S. and various foreign patent offices at various points over the lifetime of our and our licensees’ patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the U.S. and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.

Litigation regarding intellectual property and/or the enforcement of our contractual rights against licensees and third parties can be costly and expose us to risks of counterclaims against us.

We may be required to engage in litigation or other proceedings to protect our intellectual property and/or enforce our contractual rights against former or current licensees or third parties, including third-party collaborators of such licensees. The cost to us of this litigation, even if resolved in our favor, could be substantial and parties to such litigation may be able to sustain the cost of such litigation and proceedings more effectively than we can if they have substantially greater resources than us. Such litigation and any negotiations leading up to it also may be time-consuming and could

33

divert management’s attention and resources. If this litigation is resolved against us, we may lose the value associated with contract rights contained in our arrangements with licensees and third parties, our patents may be declared invalid, and we could be held liable for significant damages. While it is our current plan to pursue, on a selective basis, potential material contractual breaches against licensees and third parties (including third-party collaborators of licensees) and/or infringement of our intellectual property rights or technology, there can be no assurance that any such enforcement actions will be successful, or if successful, the timing of such success or that we will have sufficient capital to prosecute any such actions to a successful conclusion.

In addition, we may be subject to claims that we, or our licensees, are infringing other parties’ patents. If such claims are resolved against us, we or our licensees may be enjoined from developing, manufacturing, selling or importing products, processes or services unless we obtain a license from the other party. Such license may not be available on reasonable terms or at all, thus preventing us, or our licensees, from using these products, processes or services and adversely affecting our potential future revenue.

Uncertainties resulting from our participation in intellectual property litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. There could also be public announcements of the results of hearings, motions or interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the perceived value of the drug product candidates as to which we hold future potential milestone or royalty interests, or intellectual property could be diminished. Accordingly, the market price of our common stock may decline. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could have a material adverse effect of our business, financial condition and results of operation.

Risks Related to Employees, Location, Data Integrity, and Litigation

The loss of, COVID-19 related absence of, or changes in any of our key personnel, could delay or prevent achieving our objectives.

Our business efforts could be adversely affected by the loss or COVID-19 related absence of one or more key members of our staff. We currently do not have key person insurance on any of our employees. In addition, given our minimal employee base, a COVID-19 outbreak in our employee population could significantly hinder our ability to meet our operating objectives. Furthermore, in December 2021, we announced James R. Neal notified us of his decision to retire as our Chief Executive Officer, effective at the earlier of (i) December 31, 2022, or (ii) the date we hire a new Chief Executive Officer.  Changes in management may cause disruption in our business, strategic and employee relationships, which may delay or prevent the achievement of our business objectives. During the transition periods, there may be uncertainty among investors, employees and others concerning our future direction and performance.

Because we are a small biopharmaceutical focused company with limited resources, we may not be able to attract and retain qualified personnel.

We had 12 employees as of March 3, 2022. We may require additional experienced executive, accounting, legal, administrative and other personnel from time to time in the future. We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. There is intense competition for the services of these personnel, especially in California.

Moreover, we expect the high cost of living in the San Francisco Bay Area, where our headquarters is located, may impair our ability to attract and retain employees in the future. If we do not succeed in attracting new personnel and retaining and motivating existing personnel, our business may suffer and we may be unable to implement our current initiatives or grow effectively.

While Mr. Neal has agreed to continue as the Chairman and Chief Executive Officer as per the terms of the separation agreement, there can be no assurance that a replacement will be found on a timely basis, or at all. Our inability to find a suitable replacement may have a detrimental impact on the organization and impede the progress of our research, development and commercialization objectives.

34

We rely and will continue to rely on outsourcing arrangements for many of our activities, including financial reporting and accounting and human resources.

Due to our small number of employees, we rely, and expect to continue to rely, on outsourcing arrangements for a significant portion of our activities, including financial reporting and accounting and human resources, as well as for certain of our functions as a public company. We may have limited control over these third parties and we cannot guarantee that they will perform their obligations in an effective and timely manner.

Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with applicable regulations, provide accurate information to regulatory authorities, comply with federal and state fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, the health care industry is subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.

Natural disasters, power shortages, power interruptions or other calamities at our Emeryville headquarters could disrupt our business and adversely affect our operations.

Our corporate headquarters is located in Emeryville, California. This location is in an area of seismic activity near active earthquake faults. Any earthquake, tsunami, terrorist attack, riot, fire, power shortage or other calamity affecting our facilities may disrupt our business and could have material adverse effect on our results of operations.

If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.

Our business and operations would suffer in the event of system failures.

Despite the implementation of security measures, our internal computer systems and those of our current and any future licensees, suppliers, contractors and consultants are vulnerable to damage from cyberattacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. We could experience failures in our information systems and computer servers, which could be the result of a cyberattacks and could result in an interruption of our normal business operations and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security breaches can cause interruptions in our operations and can result in a material disruption of our development programs and other business operations. The loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Similarly, we rely on third parties to manufacture our product candidates, and conduct clinical trials of our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of any of our product candidates could be delayed or otherwise adversely affected.

35

If our information technology systems or data are or were compromised by data breaches, cyberattacks, or other security incidents our intellectual property or other sensitive information could be exposed or stolen and we could experience adverse consequences, including regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.

Our business is increasingly dependent on critical, complex and interdependent information technology systems, including cloud-based systems, to support business processes as well as internal and external communications. Our computer systems, and those of our partners and contractors, are potentially vulnerable to breakdown, malicious intrusion and computer viruses that may result in the impairment of key business processes. Such disruptions and breaches of security could have a material adverse effect on our business, financial condition and results of operations.

In addition, our data security and information technology systems, as well as those of our partners and contractors, are potentially vulnerable to data security breaches, whether by employees or others, that may expose sensitive data or personal information to unauthorized persons.

In the ordinary course of our business, we maintain sensitive data on our networks, including our intellectual property and proprietary or confidential business information relating to our business and that of our customers and business partners. The secure maintenance and protection of this information is critical to our business and reputation. We believe companies have been increasingly subject to a wide variety of security incidents, cyberattacks and other attempts to gain unauthorized access. These threats can come from a variety of sources, all ranging in sophistication from a person with authorized access to our network, to an individual hacker, to a state-sponsored attack. Cyber threats may be intentional or accidental, generic or commodity in nature, or they may be custom-crafted against our information systems. Cyberattacks have become more prevalent and much harder to detect and defend against. Our network and storage applications may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions. It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose sensitive business information. A data security breach could also lead to public exposure of personal information of our clinical trial patients, customers and others which could expose us to liability under foreign, federal, or state privacy laws. Cyberattacks can result in the theft of proprietary information which could be used to compete against us and could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources. These incidents could also subject us to liability, expose us to significant expense and cause significant harm to our reputation and business.

Authorities worldwide have been warning businesses of increased cybersecurity threats from actors seeking to exploit the COVID-19 pandemic. Moreover, failure to maintain effective internal accounting controls related to data security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and could subject us to regulatory scrutiny. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures that are intended to protect our data security and information technology systems, such measures may not prevent such events.

We are subject to stringent and changing obligations related to data privacy and security. Significant disruptions of information technology systems, including cloud-based systems, or breaches of data security could adversely affect our business. Our actual or perceived failure to comply with any privacy or data security obligations could lead to regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.

We process sensitive and confidential information (including personal data), which subjects us to various obligations related to data privacy and security (e.g., U.S. and foreign law, regulations, guidance, industry standards, policies, contracts, and other obligations).  For example, the EU implemented in 2018 the GDPR a broad data protection

36

framework that expands the scope of current EU data protection law to non-European Union entities that process, or control the processing of, the personal information of EU subjects, including clinical trial data. The GDPR allows for the imposition of fines and/or corrective action on entities that improperly use or disclose the personal information of EU subjects, including through a data security breach.

In the U.S., the CCPA became effective on January 1, 2020. The CCPA establishes a privacy framework for covered businesses, including an expansive definition of personal information and data privacy rights for California residents. Additionally, although not effective until January 1, 2023, the CPRA, which expands upon the CCPA, was passed in the election on November 3, 2020. The CCPA gives (and the CPRA will give) California residents expanded privacy rights, including the right to request correction, access and deletion of their personal information, the right to opt out of certain personal information sharing, and the right to receive detailed information about how their information is processed. The CCPA and CPRA include a framework with potentially severe statutory damages and private rights of action and will likely impact our business activities, along with increasing our compliance costs and potential liability. If we fail to comply with the CCPA and CPRA, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Other states are beginning to pass similar laws. For example, on March 2, 2021, Virginia enacted the Virginia Consumer Data Protection Act, or CDPA, which becomes effective on January 1, 2023, and on June 8, 2021, Colorado enacted the Colorado Privacy Act, or CPA, which takes effect on July 1, 2023.  

Complying with the GDPR, CCPA, CPRA, CDPA, CPA, or other laws, regulations, amendments to or re-interpretations of existing laws and regulations, and contractual or other obligations relating to privacy, data protection, data transfers, data localization, or information security may require us to make changes to our business to enable us to meet new legal requirements, incur substantial operational costs, modify our data practices and policies, and restrict our business operations.  Further, data incidents experienced by us, our partners or contractors could lead to significant fines, required corrective action, the loss of trade secrets or other intellectual property, public disclosure of sensitive clinical or commercial data, and the exposure of personally identifiable information (including sensitive personal information) of our employees, partners, and others. A data security breach or privacy violation that leads to disclosure or modification of, or prevents access to, patient information, including personally identifiable information or protected health information, could result in fines, increased costs or loss of revenue as a result of:

harm to our reputation;
fines imposed on us by regulatory authorities;
additional compliance obligations under federal, state or foreign laws;
requirements for mandatory corrective action to be taken by us; and
requirements to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data.

In addition, cyber incidents can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Lastly, we cannot guarantee that we are in compliance with all applicable data protection laws and regulations as they are enforced now or as they evolve.

37

Risks Related to Government Regulation

Even after FDA approval, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be removed voluntarily from the market.

Even if our potential royalty providers receive regulatory approval for our product candidates, our licensees will be subject to ongoing regulatory oversight and review by the FDA and other regulatory entities. The FDA, the EMA, or another regulatory agency may impose, as a condition of the approval, ongoing requirements for post-approval studies or post-approval obligations, including additional research and development and clinical trials, and the FDA, EMA or other regulatory agency subsequently may withdraw approval based on these additional trials or obligations.

Even for approved products, the FDA, EMA or other regulatory agency may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and production of such product. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping for our products are subject to extensive regulatory requirements.

Furthermore, marketing approval of a product may be withdrawn by the FDA, the EMA or another regulatory agency or such product may be withdrawn voluntarily by our potential royalty providers based, for example, on subsequently arising safety concerns. The FDA, EMA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.

Healthcare reform measures and other statutory or regulatory changes could adversely affect our business.

The United States and some foreign jurisdictions have enacted or are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our potential royalty providers’ ability to sell products in which we have ownership or and royalty interests, if approved, profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. There have been judicial, Congressional and executive branch challenges to certain aspects of the ACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA.  Since January 2017, former President Trump signed several executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by ACA. Concurrently, Congress considered legislation that would repeal or repeal and replace all or part of ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January l, 2021, also eliminated the health insurer tax. The Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”. On, June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how other such challenges, and the healthcare reform measures will impact the ACA and our business.

38

Other legislative changes have also been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions in Medicare payments to providers of up to two percent per fiscal year, starting in 2013 and, due to subsequent legislative amendments to the statute, including the BBA and the Infrastructure Investment and Jobs Act, will remain in effect through 2031 unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. In addition, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Such laws, and others that may affect our business that have been recently enacted or may in the future be enacted, may result in additional reductions in Medicare and other healthcare funding.

Also, there has been heightened governmental scrutiny recently in the U.S. over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration’s proposals. The FDA concurrently released a final rule and guidance in September 2020, implementing a portion of the importation executive order providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services, or HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until January 1, 2023. On November 20, 2020, the Centers for Medicare & Medicaid Services, or CMS issued an interim final rule implementing former President Trump’s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation Model interim final rule. In July 2021, the Biden administration released an executive order, “Promoting Competition in the American Economy,” with multiple provisions aimed at prescription drugs. In response to Biden’s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering drug pricing as part of other reform initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, and restrictions on certain product access. In some cases, such legislation and regulations have been designed to encourage importation from other countries and bulk purchasing.

An expansion in the government’s role in the U.S. healthcare industry may cause general downward pressure on the prices of prescription drug products, lower reimbursements for providers, and reduced product utilization, any of which could adversely affect our business and results of operations. Moreover, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. We cannot know what form any such new legislation may take or the market’s perception of how such legislation would affect us. Any reduction in reimbursement from government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent our potential royalty

39

providers from being able to generate revenue, attain profitability, develop, or commercialize our current product candidates in which we have an ownership or royalty interest.

We and our potential milestone and royalty providers are subject to various state and federal healthcare-related laws and regulations that if violated may impact the commercialization of our product candidates for which we possess milestone or royalty rights or could subject us to significant fines and penalties.

Our operations may be directly or indirectly subject to various state and federal healthcare laws, including the federal Anti-Kickback Statute, the federal False Claims Act and state and federal data privacy and security laws. These laws may impact, among other things, the commercial operations for any of our product candidates that may be approved for commercial sale.

The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the furnishing or arranging for the purchase, lease, or order of a good or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The ACA modified the federal Anti-Kickback Statute’s intent requirement so that a person or entity no longer needs to have actual knowledge of the statute or the specific intent to violate it to have committed a violation. In addition, several courts have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry.

The federal false claims laws, including the False Claims Act, and civil monetary penalties laws prohibit, among other things, persons and entities from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from the federal government. Certain suits filed under the False Claims Act, known as “qui tam” actions, can be brought by any individual on behalf of the government and such individual, commonly known as a “whistleblower”, or “relator” may share in any amounts paid by the entity to the government in fines or settlement. The filing of qui tam actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend and/or settle a False Claims Act action.

HIPAA created new federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including a private payor, or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, health care benefits, items or services.

HIPAA, as amended by the Health Information Technology and Clinical Health Act, and its implementing regulations, also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information by entities subject to the law, such as certain healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform certain functions or activities that involve the use or disclosure of protected health information on their behalf.

Many states also have adopted laws similar to each of the federal laws described above, some of which apply to healthcare items or services reimbursed by any source, not only federal healthcare programs, such as the Medicare and Medicaid programs. In addition, some states have laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government. Additionally, certain state and local laws require the registration of pharmaceutical sales representatives, restrict payments that may be made to healthcare providers and other potential referral sources, and require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers. Further, some states have laws governing the privacy and security of health information in certain circumstances, many of which are not preempted by HIPAA and differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

40

Because of the breadth of these laws, and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our or our potential milestone and royalty providers’ business activities could be subject to challenge under one or more of such laws.

If we or our potential milestone and royalty providers are found to be in violation of any of the laws and regulations described above or other applicable state and federal healthcare laws, we or our potential milestone and royalty providers may be subject to penalties, including significant civil, criminal, and administrative penalties, damages, fines, disgorgement, imprisonment, integrity oversight and reporting obligations, reputational harm, exclusion from government healthcare reimbursement programs and the curtailment or restructuring of our or our potential milestone and royalty providers’ operations, any of which could have a material adverse effect on our business and results of operations. In addition, we and our licensees may be subject to certain analogous foreign laws and violations of such laws could result in significant penalties.

We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.

We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations. Our operations are subject to anti-corruption laws including the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. §201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. We and the royalty agreement counterparties and licensees who generate our royalties operate in a number of jurisdictions that pose a high risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anticorruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control laws by the United States or other authorities could also have an adverse impact on our reputation, our business, financial condition and results of operations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities or our business arrangements with third parties could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices or the business practices of the royalty agreement counterparties and licensees who generate our royalties may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations or the operations of the royalty agreement counterparties and licensees who generate our royalties are found to be in violation of any of these laws or any other governmental regulations, we or the royalty agreement counterparties and licensees who generate our may be subject to significant criminal, civil and administrative sanctions, including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we or the royalty agreement counterparties and licensees who generate our royalties become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we or marketers of products that generate our royalties may be required to curtail or restructure operations, any of which could adversely affect our ability to operate our business and our results of operations. The risk

41

of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.

As we or our potential milestone and royalty providers do more business internationally, we will be subject to additional political, economic and regulatory uncertainties.

We or our potential milestone and royalty providers may not be able to operate successfully in any foreign market. We believe that because the pharmaceutical industry is global in nature, international activities will be a significant part of future business activities and when and if we or our potential milestone and royalty providers are able to generate income, a substantial portion of that income will be derived from product sales and other activities outside the United States. Foreign regulatory agencies often establish standards different from those in the United States, and an inability to obtain foreign regulatory approvals on a timely basis could put us at a competitive disadvantage or make it uneconomical to proceed with a product or product candidate’s development. International sales may be limited or disrupted by many factors, including without limitation:

imposition of government controls;
export license requirements;
political or economic instability;
trade restrictions;
changes in tariffs;
restrictions on repatriating profits;
exchange rate fluctuations; and
withholding and other taxation.

General Risk Factors

Our share price may be volatile, and there may not be an active trading market for our common stock, Series A Preferred Stock or our Series B Preferred Stock.

There can be no assurance that the market price of our common stock will not decline below its present market price. Additionally, there may not be an active trading market for our common stock, Series A Preferred Stock or depositary shares representing interests in our Series B Preferred Stock. The market prices of biotechnology companies have been and are likely to continue to be highly volatile. Fluctuations in our operating results and general market conditions for biotechnology stocks could have a significant impact on the volatility of our stock price or the existence of an active trading market for our common stock, Series A Preferred Stock or depositary shares representing interests in our Series B Preferred Stock. We have experienced significant volatility in the price of our common stock. From January 1, 2021, through March 3, 2022, the share price of our common stock has ranged from a high of $44.50 to a low of $19.08. From January 1, 2021, through March 3, 2022, the share price of our Series A Preferred Stock has ranged from a high of $27.57 to a low of $24.88. From April 12, 2021, through March 3, 2022, the share price of our Series B Preferred Stock has ranged from a high of $27.95 to a low of $24.05. Additionally, we have two significant holders of our common stock that could

42

affect the liquidity of our stock and have a significant negative impact on our stock price if the holders were to quickly sell their ownership positions.

Our results of operations and liquidity needs could be materially negatively affected by market fluctuations or an economic downturn.

Our results of operations could be materially negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, the availability and cost of credit, and the U.S. financial markets have in the past contributed to, and may continue in the future contribute to, increased volatility and diminished expectations for the economy and the markets. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may decline.

We have issued equity securities and may issue additional equity securities from time to time, that materially and adversely affect the price of our common stock, including our Series X preferred stock, Series A Preferred Stock and depositary shares representing interests in our Series B Preferred Stock.

We expect significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in such a manner as we determine from time to time, including pursuant to our 2018 Common Stock ATM Agreement, as amended, and 2021 Series B Preferred Stock ATM Agreement. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. If we issue additional equity securities, the price of our existing securities may be materially and adversely affected.

As of December 31, 2021, there were 5,003 shares of Series X preferred stock issued and outstanding. Each share of Series X preferred stock is convertible into 1,000 shares of registered common stock. The total number of shares of common stock issuable upon conversion of all issued Series X preferred stock would be 5,003,000 shares. Each share is convertible at the option of the holder at any time, provided that the holder will be prohibited from converting into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares above a conversion blocker, which was initially set at 19.99% of our total common stock then issued and outstanding immediately following the conversion of such shares. A holder of Series X preferred shares may elect to increase or decrease the conversion blocker above or below 19.99% on 61 days’ notice, provided the conversion blocker does not exceed the limits under Nasdaq Marketplace Rule 5635(b), to the extent then applicable. If holders of our Series X convertible preferred stock elect to convert their preferred shares into common stock such conversion would dilute our currently outstanding common stock both in number and in earnings per share. BVF (and its affiliates), as current holders of all shares of our Series X preferred stock, would, if they converted all such shares to common stock, obtain majority voting control of the Company. As of December 31, 2021, BVF owned approximately 31.2% of our total outstanding shares of common stock, and if all of the Series X convertible preferred shares were converted, BVF would own 52.3% of our total outstanding shares of common stock. Additionally, as of April 9, 2021, we had issued and outstanding 984,000 shares of Series A Preferred Stock and 1,600,000 depositary shares, each representing a 1/1000th fractional interest in a share of our Series B Preferred Stock.

In addition, funding from collaboration partners and others has in the past and may in the future involve issuance by us of our common stock. We cannot be certain how the purchase price of such shares, the relevant market price or premium, if any, will be determined or when such determinations will be made.

Any issuance by us of equity securities, whether through an underwritten public offering, an at the market offering, a private placement, in connection with a collaboration or otherwise could result in dilution in the value of our issued and outstanding shares, and a decrease in the trading price of our securities.

43

We may sell additional equity or debt securities to fund our operations, which may result in dilution to our stockholders and impose restrictions on our business.

In order to raise additional funds to support our operations, we may sell additional equity or convertible debt securities, which would result in dilution to our stockholders and/or debt securities which may impose restrictive covenants that would adversely impact our business. The sale of additional equity or convertible debt securities could result in additional dilution or result in other rights or obligations that adversely affect our stockholders. For example, holders of shares of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year). Additionally, holders of depositary shares representing interests in our Series B Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share or $2.09375 per year per depositary share). The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.

Our organizational documents contain provisions that may prevent transactions that could be beneficial to our stockholders and may insulate our management from removal.

Our charter and by-laws:

require certain procedures to be followed and time periods to be met for any stockholder to propose matters to be considered at annual meetings of stockholders, including nominating directors for election at those meetings; and
authorize our Board of Directors to issue up to 1,000,000 shares of preferred stock without stockholder approval and to set the rights, preferences and other designations, including voting rights, of those shares as the Board of Directors may determine.

In addition, we are subject to the provisions of Section 203 of the Delaware General Corporation Law (the “DGCL”), that may prohibit large stockholders, in particular those owning 15% or more of our outstanding common stock, from merging or combining with us.

These provisions of our organizational documents and the DGCL, alone or in combination with each other, may discourage transactions involving actual or potential changes of control, including transactions that otherwise could involve payment of a premium over prevailing market prices to holders of common stock, could limit the ability of stockholders to approve transactions that they may deem to be in their best interests, and could make it considerably more difficult for a potential acquirer to replace management.

As a public company in the United States, we are subject to the Sarbanes-Oxley Act. We have determined our disclosure controls and procedures and our internal control over financial reporting are effective. We can provide no assurance that we will, at all times, in the future be able to report that our disclosure controls and internal controls over financial reporting are effective.

Companies that file reports with the SEC, including us, are subject to the requirements of Section 404 of the SOX. Section 404 requires management to establish and maintain a system of internal control over financial reporting, and annual reports on Form 10-K filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), must contain a report from management assessing the effectiveness of our internal control over financial reporting. Ensuring we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a time-consuming effort that needs to be re-evaluated frequently. Failure on our part to have effective internal financial and accounting controls would cause our financial reporting to be unreliable, could have a material

44

adverse effect on our business, operating results, and financial condition, and could cause the trading price of our common stock to fall.

Our ability to use our net operating loss carry-forwards and other tax attributes will be substantially limited by Section 382 of the U.S. Internal Revenue Code.

Under the federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the federal tax law. In addition, Section 382 of the U.S. Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, generally limit the ability of a corporation that undergoes an “ownership change” to utilize its net operating loss carry-forwards (“NOLs”) and certain other tax attributes against any taxable income in taxable periods after the ownership change. The amount of taxable income in each taxable year after the ownership change that may be offset by pre-change NOLs and certain other pre-change tax attributes is generally equal to the product of (a) the fair market value of the corporation’s outstanding shares (or, in the case of a foreign corporation, the fair market value of items treated as connected with the conduct of a trade or business in the United States) immediately prior to the ownership change and (b) the long-term tax exempt rate (i.e., a rate of interest established by the U.S. Internal Revenue Service that fluctuates from month to month). In general, an “ownership change” occurs whenever the percentage of the shares of a corporation owned, directly or indirectly, by “5-percent shareholders” (within the meaning of Section 382 of the Internal Revenue Code) increases by more than 50 percentage points over the lowest percentage of the shares of such corporation owned, directly or indirectly, by such “5-percent shareholders” at any time over the preceding three years.

Based on an analysis under Section 382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to an annual limitation), we experienced an ownership change in February 2017, when we completed an equity financing for net proceeds of $24.8 million that significantly impacted the availability of our tax attributes against future income. Further, due to the existence of a net unrealized built-in loss at the ownership change date, Section 382 further limits our ability to fully utilize the tax deductions associated with certain of our assets, including depreciation and amortization deductions recognized during the 60-month period following the ownership change ending in 2022. Although these deductions will occur in the post-change period, Section 382 treats the deductions as pre-change losses subject to the annual 382 limitation. As of December 31, 2021, we have excluded the NOLs and research and development credits that will expire as a result of the annual limitations. To the extent that we do not utilize our carry-forwards within the applicable statutory carry-forward periods, either because of Section 382 limitations or the lack of sufficient taxable income, the carry-forwards will also expire unused.

The 2017 tax reform law, as modified by 2020 tax legislation, and possible future changes in tax laws or regulations could adversely affect our business and financial condition.

On December 22, 2017, former President Trump signed into law comprehensive tax legislation (the “Tax Cuts and Jobs Act”) that significantly revised the Internal Revenue Code of 1986, as amended (the “Code”). Future guidance from the U.S. Internal Revenue Service and other tax authorities with respect to the Tax Cuts and Jobs Act may affect us, and certain aspects of the Tax Cuts and Jobs Act could be repealed or modified in future legislation. For example, on March 27, 2020, the CARES Act was enacted, which includes changes to the tax provisions that benefit business entities and makes certain technical corrections to the Tax Cuts and Jobs Act. On June 29, 2020, California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of California net operating losses and limits the use of California research tax credits for tax years beginning in 2020 and before 2023. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act, the CARES Act, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act, the CARES Act, or any newly enacted federal tax legislation.

45

Stockholder and private lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management’s time and attention from our business, and have a material adverse effect on our business, financial condition and results of operations.

Securities-related class action and stockholder derivative litigation has often been brought against companies, including many biotechnology companies, which experience volatility in the market price of their securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies often experience significant stock price volatility in connection with their product development programs.

It is possible that suits will be filed, or allegations received from stockholders, naming us and/or our officers and directors as defendants. These potential lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of these lawsuits is uncertain. We could be forced to expend significant time and resources in the defense of these suits, and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with these lawsuits. Although we carry insurance to protect us from such claims, our insurance may not provide adequate coverage. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests on these actions could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our cash flow, results of operations and financial position.

Monitoring, initiating and defending against legal actions, including any currently pending litigation, are time-consuming for our management, are likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business. In addition, the inherent uncertainty of any future litigation could lead to increased volatility in our stock price and a decrease in the value of an investment in our common stock.

Item 1B. Unresolved Staff Comments

None.

Item 2.   Properties

We currently lease space in one building that houses our corporate headquarters in Emeryville, California. The building lease expires in February 2023, and total net lease liability from January 2022 until expiration of the lease is $0.2 million. We believe our facilities are adequate to meet our requirements for the near term.

Item 3.   Legal Proceedings

From time to time, we may be involved in litigation relating to claims arising out of our operations. We are not currently involved in any material legal proceedings. We may, however, be involved in material legal proceedings in the future. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on our business, results of operations, financial position or cash flows.

Item 4.   Mine Safety Disclosures

Not applicable.

46

PART II

Item 5.   Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market for Registrant’s Common Equity

Our common stock trades on The Nasdaq Global Market tier of the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “XOMA.” On March 3, 2022, there were 196 stockholders of record of our common stock, one of which was Cede & Co., a nominee for Depository Trust Company (“DTC”). All of the shares of our common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore considered to be held of record by Cede & Co. as one stockholder.

Dividend Policy

We have not paid dividends on our common stock. Holders of shares of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year per share) per year. Holders of our Series B Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per year of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share or $2.09375 per year per depositary share). We do not anticipate paying cash dividends on our common stock in the foreseeable future.

Recent Sales of Unregistered Securities

None.

Item 6.   Reserved

47

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

XOMA, a Delaware corporation, is a biotech royalty aggregator. We have a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Our portfolio was built through licensing our proprietary products and platforms from our legacy discovery and development business, combined with the acquisition of rights to future milestones and royalties that we have made since our royalty aggregator business model was implemented in 2017. Our drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase 1 and 2, with significant commercial sales potential that are licensed to large-cap partners. We expect that most of our future revenue will be based on payments we may receive for milestones and royalties related to these programs.

The generation of future revenues related to licenses, milestones, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. Although we generated net income of $15.8 million and $13.3 million and positive cash flows from operations of $22.7 million and $10.1 million for the years ended December 31, 2021 and 2020, respectively, we do not expect these results to be indicative of future performance. The payments we received from Novartis pursuant to our Anti-TGFβ Antibody License Agreement in 2021 and 2020 of $35.0 million and $25.0 million, respectively, were one-time milestone payments that do not represent recurring revenue.

Significant Developments

Royalty and Commercial Payment Purchase Agreements

Commercial Payment Purchase Agreement with Affitech

In October 2021, we entered into the Affitech CPPA, pursuant to which we purchased a future stream of commercial payment rights to Roche’s faricimab from Affitech for an upfront payment of $6.0 million. We are eligible to receive commercial payments from Roche consisting of 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction.

In January 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize faricimab (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema.  Pursuant to the Affitech CPPA, we paid Affitech a $5.0 million regulatory approval milestone tied to these U.S. marketing approvals. We may pay up to an additional $15.0 million to Affitech based upon the achievement of certain regulatory approval milestones and sales milestones representing a portion of the commercial payment receipts.

Kuros Royalty Purchase Agreement

In July 2021, we entered into the Kuros RPA, pursuant to which we acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals’ vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. We may pay additional sales-based milestones to Kuros of up to $142.5 million representing a portion of the future royalties on commercial sales.

Viracta Royalty Purchase Agreement

In March 2021, we entered into the Viracta RPA, pursuant to which we acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. We acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related

48

to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved.  

License and Collaboration Agreements

Rezolute – RZ358 Antibody

In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to XOMA pursuant to our Rezolute License Agreement.

Novartis – Anti-TGFβ Antibody

In October 2021, we earned a $35.0 million milestone payment upon dosing of the first patient in Novartis’ first NIS793 Phase 3 clinical trial. We are eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGFβ Antibody License Agreement. Upon receipt of regulatory approval to commercialize NIS793, we will receive tiered royalties on any net product sales that range from the mid single-digit to the low double-digit percentage rates. In July 2021, Novartis announced the FDA had granted Orphan Drug Designation to NIS793 in combination with standard of care chemotherapy for the treatment of pancreatic cancer.

Novartis – Anti-CD40 Antibody

In September 2021, Novartis announced its decision to discontinue its study of CFZ533 (iscalimab) in the prevention of organ rejection in patients receiving a kidney transplant after an interim analysis of data. Novartis is continuing other iscalimab studies in indications other than kidney transplant, for example, liver transplant, Sjögren’s Syndrome and Lupus Nephritis.

Compugen

In September 2021, we earned a $0.5 million milestone payment under our license agreement with Compugen triggered by the dosing of the first patient in a Phase 1/2 study of AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. AZD2936 is derived from COM902 and is being developed by AstraZeneca.

Janssen

In May 2021, we announced we earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets.  In December 2021, we earned a $0.2 million milestone pursuant to our agreement with Janssen.

Affimed

In April 2021, we entered into a new agreement with Affimed under which we are eligible to receive payments from Affimed on potential future commercial sales related to three ICE molecules and pre-loaded natural killer cells containing the ICE molecules. Additionally, we are eligible to receive a milestone upon the first product candidate in each program achieving marketing approval.

Public Offering of Series B Depositary Shares Representing Interest in Series B Preferred Stock

In April 2021, we closed a public offering of 1,600,000 Series B Depositary Shares at the price of $25.00 per Series B Depositary Share. Total gross proceeds from the offering were $40.0 million. Total offering costs of $2.9 million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $37.1 million.

49

NIAID Contract Closeout

Prior to the sale of our biodefense business in 2016, we performed contract work for the U.S. government under multi-year contracts funded with federal funds from NIAID. The contract work was performed on a cost plus fixed fee basis and invoices were provisional until finalized. As such, we operated under provisional rates from 2010 through 2015, subject to adjustment based on final approved rates upon agreement with the government. In 2019, NIH engaged KPMG to perform an audit of our incurred cost submissions for 2013, 2014 and 2015, and, based on the results of KPMG’s procedures, which were completed in December 2020, we recognized an estimated refund liability representing amounts owed to NIH of $1.4 million on our consolidated balance sheet as of December 31, 2020. In December 2021, NIH completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and approved a finalized refund liability of $1.3 million. The $0.1 million reduction in the liability, from its previously recorded $1.4 million estimated amount, was recognized as an increase of revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the year ended December 31, 2021. In December 2021, we paid the final amount owed to NIH of $1.3 million and no balance of the contingent liability remained on the consolidated balance sheets as of December 31, 2021.

Debt Extinguishment

Novartis Note

In June 2021, we repaid our outstanding principal balance to Novartis of $9.1 million. No amount was recorded as an extinguishment gain or loss in other (expense) income, net of the consolidated statement of operations. No outstanding principal balance of the Novartis Note remained as of December 31, 2021.

SVB Loan

In June 2021, we repaid our principal balance of $6.5 million and paid the 8.5% final payment fee of $1.4 million to SVB. We recognized a non-cash loss on extinguishment of $0.3 million in other (expense) income, net of the consolidated statement of operations. No outstanding principal balance of the SVB Loan remained as of December 31, 2021.

COVID-19

The COVID-19 pandemic continues to pose risks to our business as clinical trials industry-wide have slowed. Our business is dependent on the continued development and commercialization efforts of our licensees and our royalty agreement counterparties and their licensees. We have been monitoring and continue to monitor our portfolio programs for potential delays in underlying research programs and elections of our partners to continue or cease development. Delays in clinical trials and underlying research programs have and may further lead to delayed revenue from milestones from our licensees and royalty agreement counterparties or, if certain research programs are discontinued, we may recognize impairment charges for our royalty receivables. COVID-19, the related variants, and the timing of vaccine distribution may impact our underlying programs in a variety of ways which are unknown in length and scope at this time.

Critical Accounting Estimates

A summary of the significant accounting policies is provided in Note 2 to our Consolidated Financial Statements. The preparation of financial statements in accordance with generally accepted accounting principles, or GAAP, requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions and conditions.

50

Management considers an accounting estimate to be critical if:

it requires a significant level of estimation uncertainty; and
changes in the estimate are reasonably likely to have a material effect on our financial condition or results of operations.

We believe the following critical accounting policies and estimates describe the more significant judgments and estimates used in the preparation of our consolidated financial statements.

Revenue Recognition

We recognize revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. We recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services.

We have certain license arrangements in the scope of ASC 606. The terms of these agreements may contain multiple performance obligations, which primarily include transfer of our licenses. Prior to recognizing revenue, we make estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include payments based upon the achievement of specified milestones, and royalty payments based on product sales derived from the license agreements. The royalty payments will be recognized as revenue when the related sales occur, as far as there are no unsatisfied performance obligations remaining. If there are multiple distinct performance obligations, we allocate the transaction price to each distinct performance obligation based on its relative standalone selling price. All licenses we grant to customers are unique, as each uses a specific technology of XOMA or is geared towards a specific unique product candidate. Thus, there is no observable evidence of standalone selling price for the licenses. The standalone selling price is generally determined using a valuation approach based on discounted cash flow analysis. For licenses that are bundled with other promises, we utilize judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under our license agreements, the nature of the combined performance obligation is the granting of licenses to the customers. As such, we recognize revenue related to the combined performance obligation upon transfer of the license to the customers or completion of the transfer of related materials and services (i.e., point in time).

Sale of Future Revenue Streams

In 2016, prior to the implementation of our royalty aggregator business model, we sold our rights to receive certain milestones and royalties on product sales pursuant to our agreement with HCRP. We defer recognition of the proceeds we received from HCRP and recognize such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment.

Estimating the total payments expected to be received by HCRP over the term of the arrangement requires management to use subjective estimates and assumptions. Changes to our estimate of the payments expected to be made to HCRP over the term of the arrangement could have a material effect on the amount of revenues recognized in any particular period.

Stock-based Compensation

Stock-based compensation expense for stock options and other stock awards is estimated at the grant date based on the award’s fair value-based measurement. The valuation of stock-based compensation awards is determined at the date of grant using the Black-Scholes option pricing model (the “Black-Scholes Model”). This model requires highly complex

51

and subjective inputs, such as the expected term of the option and expected volatility. These inputs are subjective and generally require significant analysis and judgment to develop. Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby increasing stock-based compensation cost recognized in future periods. To establish an estimate of expected term, we consider the vesting period and contractual period of the award and our historical experience of stock option exercises, post-vesting cancellations and volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues. Forfeitures are recognized as they occur.

We review our valuation assumptions quarterly and, as a result, we likely will update our valuation assumptions used to value stock-based awards granted in future periods utilizing current data. In the future, as additional empirical evidence regarding these input estimates becomes available, we may change or refine our approach of deriving these input estimates. These changes could impact our fair value-based measurement of stock options granted in the future. Changes in the fair value-based measurement of stock awards could materially impact our operating results.

Purchase of Rights to Future Milestones, Royalties and Commercial Payments

We have purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, and royalties on sales of products currently in clinical development. We acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables. We have accounted for the purchased rights as a financial asset in accordance with ASC 310.

We account for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. Except for faricimab, these developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The related receivable balances are classified as noncurrent since no payments are probable to be received in the near term. Faricimab (faricimab-svoa) received FDA approval in January 2022, and we do not yet have a foundation upon which to estimate receipts expected to be collected in the near term; therefore, they remain classified as noncurrent until such time an estimate can be made.  Under the cost recovery method, any milestone, royalty, or other payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected will be recognized as revenue.

We may be obligated to make contingent payments related to certain product development and regulatory approval milestones and sales-based milestones. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value at the end of each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive income.

We review these balances for impairment on a quarterly basis using updates from our partners, press releases and public information on clinical trials.  If we determine an impairment is necessary, the impairment recorded will be based on an estimate of discounted future cash flows, which will rely on assumptions including probability of technical success and discount rate.  Changes to these assumptions could have a material impact on our financial statements.  No impairment has been recorded as of December 31, 2021.

52

Results of Operations

Revenues

Total revenues for the years ended December 31, 2021 and 2020, were as follows (in thousands):

Year Ended

December 31, 

    

2021

    

2020

    

Change

Revenue from contracts with customers

$

36,518

$

27,941

$

8,577

Revenue recognized under units-of-revenue method

 

1,642

 

1,444

198

Total revenues

$

38,160

$

29,385

$

8,775

Revenue from Contracts with Customers

Revenue from contracts with customers includes upfront fees, annual licenses fees and milestone payments related to the out-licensing of our product candidates and technologies. The primary components of revenue from contracts with customers in 2021 was $35.0 million in milestone revenue earned under our Anti-TGFβ Antibody License Agreement with Novartis, $0.5 million of milestone revenue recognized in the third quarter of 2021 under our license agreement with Compugen and $0.5 million and $0.2 million of milestone revenue recognized in the second and fourth quarter of 2021, respectively, related to milestone events under our license agreement with Janssen. The primary components of revenue from contracts with customers in 2020 was $25.0 million in milestone revenue earned under our Anti-TGFβ Antibody License Agreement with Novartis and $2.0 million earned under our collaboration agreement with Takeda. The milestones received from Novartis in 2021 and 2020 are one-time payments and do not represent recurring revenue.

Revenue recognized under units-of-revenue method

Revenues recognized under the units-of-revenue method include the amortization of unearned revenue from the sale of royalty interests to HCRP in 2016. The increase in 2021 compared with 2020 was due to increased sales of products underlying the agreements with HCRP.

R&D Expenses

R&D expenses were consistent at $0.2 million in 2021 and 2020. We do not expect to incur substantial internal R&D expenses in 2022 due to the focus on our royalty aggregator business model.

G&A Expenses

G&A expenses include salaries and related personnel costs, professional fees, and facilities costs. In 2021, G&A expenses were $20.5 million compared with $16.8 million in 2020.

The increase of $3.7 million in 2021 as compared with 2020 was primarily due to a $2.2 million increase in stock-based compensation expense for stock options, $0.8 million increase in salary and related expenses, $0.4 million increase in legal and consulting costs and $0.2 million increase in insurance costs.

53

Other (Expense) Income

Interest Expense

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense is shown below for the years ended December 31, 2021 and 2020 (in thousands):

Year Ended

December 31, 

    

2021

    

2020

    

Change

SVB Loan

$

373

$

1,365

$

(992)

Novartis Note

 

88

 

477

 

(389)

Other

 

 

2

 

(2)

Total interest expense

$

461

$

1,844

$

(1,383)

The decrease in interest expense compared with 2020 is due to the repayment of our SVB and Novartis loans in June 2021. We expect our interest expense to further decrease in 2022 as we have no outstanding loan balances, however if we elect to obtain new debt financing, our interest expense may increase.

Other (Expense) Income, Net

The following table shows the activity in other (expense) income, net for the years ended December 31, 2021 and 2020 (in thousands):

    

Year Ended

    

December 31, 

2021

    

2020

Change

Other (expense) income, net

 

Change in fair value of equity securities

$

(919)

$

1,012

$

(1,931)

Investment income

35

159

(124)

Other

 

5

 

54

 

(49)

Total other (expense) income, net

$

(879)

$

1,225

$

(2,104)

The fluctuation in other (expense) income, net for 2021 as compared to 2020, is primarily due to the change in fair value of equity securities which consist of shares of Rezolute’s common stock.

We own equity securities consisting of shares of Rezolute’s common stock which are remeasured at fair value at each reporting period. During the years ended December 31, 2021 and 2020, we remeasured the fair value of the equity securities and recognized a loss of $0.9 million and a gain of $1.0 million, respectively.

The decrease in investment income for 2021 as compared to the same period of 2020 is due to lower rates of return on our cash deposits.

Provision for Income Taxes

We recorded a $1.5 million income tax benefit for the year ended December 31, 2020, as a result of the CARES Act, which was enacted on March 27, 2020. The CARES Act permits us to carry back losses from 2018 to offset income in 2017 resulting in an income tax receivable. During the second quarter of 2021, we received $1.5 million in cash for our income tax receivable. We recorded a $0.1 million income tax expense for the year ended December 31, 2021.

We continue to maintain a full valuation allowance against our deferred tax assets. We had a total of $5.9 million of gross unrecognized tax benefits, none of which would impact our effective tax rate to the extent that we continue to maintain a full valuation allowance against our deferred tax assets. We do not expect our unrecognized tax benefits to change significantly over the next twelve months.

54

Liquidity and Capital Resources

The following table summarizes our unrestricted cash, our working capital and our cash flow activities as of and for each of the periods presented (in thousands):

December 31, 

December 31,

    

2021

    

2020

    

Change

Cash

$

93,328

$

84,222

$

9,106

Working capital

$

84,006

$

75,763

$

8,243

Year Ended December 31, 

    

2021

    

2020

    

Change

Net cash provided by operating activities

$

22,678

$

10,092

$

12,586

Net cash used in investing activities

 

(26,500)

(209)

 

(26,291)

Net cash provided by financing activities

 

12,835

 

19,793

 

(6,958)

Net increase in cash

$

9,013

$

29,676

$

(20,663)

Our primary source of cash provided by operating activities in 2021 was the $35.0 million milestone payment received from Novartis, partially offset by our operating expenses of $20.6 million excluding non-cash expenses including stock-based compensation of $6.2 million. Our primary source of cash provided by operating activities in 2020 was the $17.7 million cash portion of the $25.0 million milestone received from Novartis, partially offset by our operating expenses of $17.0 million, less non-cash expenses including stock-based compensation of $4.0 million.

Net cash used in investing activities for the year ended December 31, 2021, of $26.5 million was due to our acquisitions under RPAs and a CPPA, including a $13.5 million payment pursuant to the Viracta RPA, a $7.0 million payment pursuant to the Kuros RPA and a $6.0 million payment pursuant to the Affitech CPPA. Net cash used in investing activities for the year ended December 31, 2020 of $0.2 million was due to the purchase of milestone and royalty rights of $1.2 million in connection with the Second Bioasis RPA in November 2020, partially offset by $1.0 million milestone payment received in connection with the Agenus RPA.

Net cash provided by financing activities for the year ended December 31, 2021 of $12.8 million was primarily due to the receipt of net cash proceeds of $37.1 million from our public offering of Series B Preferred Stock, $1.1 million net cash provided from the exercise of stock options after related tax payments, partially offset by $4.3 million cash used in the principal payments of debt, $17.1 million cash used to extinguish outstanding loans and $3.5 million payment of dividends on our Series A Preferred Stock and Series B Preferred Stock. Net cash provided by financing activities for the year ended December 31, 2020, of $19.8 million was primarily due to the receipt of net cash proceeds of $22.6 million from the public offering of Series A Preferred Stock and $2.4 million net cash provided from the exercise of stock options after related tax payments, partially offset by $5.3 million cash used in the principal payments of debt.

Capital Resources

As of December 31, 2021, we had $93.3 million and $2.0 million in unrestricted and restricted cash, respectively. Based on our current cash balance and our ability to control discretionary spending, such as royalty acquisitions, we have evaluated and concluded our financial condition is sufficient to fund our planned operations, commitments, and contractual obligations for a period of at least one year following the filing date of this report.

Our planned spending includes increased personnel related costs to hire a new CEO and fund our employee retention efforts.  To support our royalty aggregator business model, we engage third parties to assist in our evaluation of potential acquisitions of milestone and royalty streams. Additional operating expenses, including consulting and legal costs, may increase in 2022 in response to an anticipated increase in the volume of acquisition targets evaluated or completed.

55

We have primarily financed our operations and acquisitions through the issuance of our common stock, Series A and Series B Preferred Stock, and amounts received as milestone payments under our license agreements.  The generation of future revenues related to licenses, milestones, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. Milestone payments earned in 2021 and 2020 are not indicative of anticipated milestones in future periods. We may seek additional capital through use of our 2018 Common Stock ATM Agreement or 2021 Series B Preferred Stock ATM Agreement (see Note 12 of the Consolidated Financial Statements), or through other public or private debt or equity transactions. Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common and preferred stock, which are subject to a number of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us.  If we are unable to raise additional funds when we need them, our business and operations may be adversely affected.

Our recent financing activities are summarized below and described in more detail in Note 12 of our Consolidated Financial Statements:

Public Offering of Series A Preferred Stock: In December 2020, we sold 984,000 shares of 8.625% Series A Preferred Stock at the price of $25.00 per share, through a public offering for aggregate gross proceeds of $24.6 million. Total offering costs of $2.0 million were offset against the proceeds from the sale of Series A Preferred Stock, for net proceeds of $22.6 million.
Public Offering of Depositary Shares Representing Interest in Series B Preferred Stock: In April 2021, we closed a public offering of 1,600,000 Series B Depositary Shares at the price of $25.00 per depositary share. Total gross proceeds from the offering were $40.0 million. Total offering costs of $2.9 million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $37.1 million.
Novartis Note Extinguishment: In June 2021, we repaid our outstanding principal balance to Novartis of $9.1 million. No amount was recorded as an extinguishment gain or loss in other (expense) income, net of the consolidated statement of operations. No outstanding principal balance of the Novartis Note remained as of December 31, 2021.
SVB Loan Extinguishment: In June 2021, we repaid our principal balance of $6.5 million and paid the 8.5% final payment fee of $1.4 million to SVB. We recognized a non-cash loss on extinguishment of $0.3 million in other (expense) income, net of the consolidated statement of operations. No outstanding principal balance of the SVB Loan remained as of December 31, 2021.

Material Cash Requirements

Our material cash requirements in the short and long term consist of the following expenditures:

Operating expenditures: Our primary uses of cash and operating expenses relate to employee and related costs, consultants to support our administrative and business development efforts, legal and accounting services, insurance, investor relations and IT services. Our headquarters lease expires in February 2023, and we are currently evaluating our office space needs, however, due to our small staff and minimal operating space requirements, we do not expect to incur material incremental costs associated with our current or future building leases.  

RPAs and CPPAs: A significant component of our business model is to acquire rights to potential future milestone and royalty streams.  We expect to continue deploying capital toward these acquisitions in the near and long term.  

We also have potential contingent consideration of $8.1 million recorded on our consolidated balance sheets as of December 31, 2021, for development and regulatory approval milestones due under our agreements with Affitech and Bioasis.  We paid $5.0 million in regulatory approval milestones to Affitech in January 2022 and expect the remaining $3.1 million contingent payments may become due in the near term.  We have evaluated and concluded our existing capital resources are adequate to meet those needs.

56

We also have potential sales-based milestones that may become due under our agreements with Aronora, Kuros and Affitech. All of these sales-based milestones represent a portion of the funds we may receive in the future pursuant to these agreements, and therefore will be fully funded by the related royalty or commercial payment receipts.

Collaborative Agreements, Royalties and Milestone Payments: We have committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by our licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million have not been recorded on our consolidated balance sheet as of December 31, 2021. We are unable to determine precisely when and if our payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.  All payments due will be funded by a portion of the related milestone or royalty revenue we receive or will be reimbursed by our licensees.

Dividends: Holders of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per share of Series A Preferred Stock per year). Holders of Series B Depositary Shares are entitled to receive, when and as declared by our Board of Directors, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year, which is equivalent to $2,093.75 per year per share of Series B Preferred Stock ($2.09375 per year per depositary share).  Dividends on the Series A and Series B Preferred Stock are payable in arrears on or about the 15th day of January, April, July and October of each year.  Since original issuance, all dividends have been paid as scheduled.  We expect to continue making these dividend payments as scheduled using our existing capital resources.

Recent Accounting Pronouncements

See Note 2 to the Consolidated Financial Statements for information regarding new accounting pronouncements.

Item 7A.       Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.

Item 8.   Financial Statements and Supplementary Data

The following consolidated financial statements of the registrant, related notes and report of independent registered public accounting firm are set forth beginning on page F-1 of this report.

Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34)

F-1

Consolidated Balance Sheets

F-3

Consolidated Statements of Comprehensive Income

F-4

Consolidated Statements of Stockholders’ Equity

F-5

Consolidated Statements of Cash Flows

F-6

Notes to the Consolidated Financial Statements

F-7

Item 9.   Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

57

Item 9A.       Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Senior Vice President, Finance and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15 promulgated under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this report. Our disclosure controls and procedures are intended to ensure that the information we are required to disclose in the reports that we file or submit under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Senior Vice President, Finance and Chief Financial Officer, as the principal executive and financial officers, respectively, to allow timely decisions regarding required disclosures. Based on this evaluation, our Chief Executive Officer and our Senior Vice President, Finance and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Management’s Report on Internal Control over Financial Reporting

Management, including our Chief Executive Officer and our Senior Vice President, Finance and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Exchange Act Rules 13a-15(f)). The Company’s internal control system was designed to provide reasonable assurance to the Company’s management and board of directors regarding the preparation and fair presentation of published financial statements in accordance with accounting principles generally accepted in the United States.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control—Integrated Framework (2013 Framework). Based on our assessment we believe that, as of December 31, 2021, our internal control over financial reporting is effective based on those criteria.

This Annual Report does not include an attestation report by our registered public accounting firm regarding internal control over financial reporting. Management's report is not subject to attestation by our registered public accounting firm under Section 404(b) of the Sarbanes-Oxley Act pursuant to the rules established by the Securities and Exchange Commission, which permit us to provide only our management report in this Annual Report.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal controls over financial reporting as defined in Rule 13a-15(f) under the Exchange Act during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. While COVID-19 resulted in our staff operating remotely, our established internal control structure is not impacted. As we continue to monitor and adapt to the changing environment due to COVID-19, we will continue to evaluate our internal controls over financial reporting.

Item 9B.       Other Information

None.

Item 9C.       Disclosure Regarding Foreign Jurisdiction that Prevents Inspections

None.

58

PART III

Item 10. Directors, Executive Officers, Corporate Governance

Information required by this Item will be included in the Company’s proxy statement for the 2022 Annual Meeting of Stockholders (“2022 Proxy Statement”), under the sections labeled “Proposal 1—Election of Directors,” “Information about our Executive Officers” and “Delinquent Section 16(a) Reports” and is incorporated by reference. The 2022 Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year to which this report relates.

Code of Ethics

The Company’s Code of Ethics applies to all employees, officers and directors including the Chief Executive Officer (principal executive officer) and the Senior Vice President, Finance and Chief Financial Officer (principal financial and principal accounting officer) and is posted on the Company’s website at https://investors.xoma.com/corporate-governance. We intend to satisfy the applicable disclosure requirements regarding amendments to, or waivers from, provisions of our Code of Ethics by posting such information on our website.

Item 11. Executive Compensation

Information required by this Item will be included in the sections labeled “Compensation of Executive Officers,” “Summary Compensation Table,” “Outstanding Equity Awards as of December 31, 2021,” “Pension Benefits,” “Non-Qualified Deferred Compensation” and “Compensation of Directors” appearing in our 2022 Proxy Statement and is incorporated by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Information required by this Item will be included in the sections labeled “Common Stock of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” appearing in our 2022 Proxy Statement and is incorporated by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Information required by this Item will be included in the section labeled “Transactions with Related Persons” appearing in our 2022 Proxy Statement and is incorporated by reference.

Item 14. Principal Accountant Fees and Services

Information required by this Item will be included in the section labeled “Proposal 3 – Ratification of Appointment of Independent Registered Public Accounting Firm” appearing in our 2022 Proxy Statement and is incorporated by reference.

59

PART IV

Item 15. Exhibits and Financial Statement Schedules

(a)The following documents are included as part of this Annual Report on Form 10-K:
(1)Financial Statements:

All financial statements of the registrant referred to in Item 8 of this Report on Form 10-K.

(2)Financial Statement Schedules:

All financial statements schedules have been omitted because the required information is included in the consolidated financial statements or the notes thereto or is not applicable or required.

(3)Exhibits:

Incorporation By Reference

Exhibit

Number

    

Exhibit Description

    

Form

    

SEC File No.

    

Exhibit

    

Filing Date

3.1

Certificate of Incorporation of XOMA Corporation

8-K12G3

000-14710

3.1

01/03/2012

3.2

Certificate of Amendment of Certificate of Incorporation of XOMA Corporation

8-K

000-14710

3.1

05/31/2012

3.3

Certificate of Amendment to the Amended Certificate of Incorporation of XOMA Corporation

8-K

000-14710

3.1

05/28/2014

3.4

Certificate of Amendment to the Amended Certificate of Incorporation of XOMA Corporation

8-K

000-14710

3.1

10/18/2016

3.5

Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock

8-K

000-14710

3.1

02/16/2017

3.6

Certificate of Designation of 8.625% Series A Cumulative Perpetual Preferred Stock

8-K

000-14710

3.1

12/11/2020

3.7

Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock

8-K

001-39801

3.1

04/08/2021

3.8

Certificate of Correction of the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock

10-Q

001-39801

3.8

08/05/2021

3.9

Certificate of Amendment to the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock of XOMA Corporation.

8-K

001-39801

3.1

08/05/2021

3.10

By-laws of XOMA Corporation

8-K12G3

000-14710

3.2

01/03/2012

60

Incorporation By Reference

Exhibit

Number

    

Exhibit Description

    

Form

    

SEC File No.

    

Exhibit

    

Filing Date

4.1

Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9 and 3.10

4.2

Specimen of Common Stock Certificate

8-K

000-14710

4.1

01/03/2012

4.3

Deposit Agreement, effective as of April 9, 2021, by and among XOMA Corporation, American Stock Transfer & Trust Company, LLC, as depositary, and the holders of the depositary receipts issued thereunder

8-K

001-39801

4.1

04/08/2021

4.4

Form of Warrants (May 2018 Warrants)

10-Q

000-14710

4.6

08/07/2018

4.5

Form of Warrants (March 2019 Warrants)

10-Q

000-14710

4.7

05/06/2019

4.6+

Description of Registrant’s Securities

10.1*

Amended and Restated 2010 Long Term Incentive and Stock Award Plan

DEF 14A

000-14710

Appendix A

04/05/2019

10.2*

Form of Stock Option Agreement for Amended and Restated 2010 Long Term Incentive and Stock Award Plan

10-K

000-14710

10.6A

03/14/2012

10.3*

2016 Incentive Compensation Plan

10-Q

000-14710

10.1

05/04/2016

10.4*

Amended 2015 Employee Share Purchase Plan

8-K

000-14710

10.2

05/24/2017

10.5*

Form of Subscription Agreement and Authorization of Deduction under the 2015 Employee Stock Purchase Plan

S-8

333-204367

99.2

05/21/2015

10.6†

License Agreement by and between XOMA Ireland Limited and MorphoSys AG, dated as of February 1, 2002

10-Q/A

000-14710

10.43

12/04/2002

10.7†

Amended and Restated Research, Development and Commercialization Agreement, executed November 7, 2008, by and between Novartis Vaccines and Diagnostics, Inc. (formerly Chiron Corporation) and XOMA (US) LLC

10-K

000-14710

10.24C

03/11/2009

10.8†

Amendment No. 1 to Amended and Restated Research, Development and Commercialization Agreement, effective as of April 30, 2010, by and between Novartis Vaccines and Diagnostics, Inc. (formerly Chiron Corporation) and XOMA (US) LLC

10-K

000-14710

10.25B

03/14/2012

61

Incorporation By Reference

Exhibit

Number

    

Exhibit Description

    

Form

    

SEC File No.

    

Exhibit

    

Filing Date

10.9†

Amendment to Amended and Restated Research, Development and Commercialization Agreement, dated September 30, 2015, by and between XOMA (US) LLC and Novartis Vaccines and Diagnostics, Inc. (formerly Chiron Corporation)

10-Q

000-14710

10.4

11/06/2015

10.10†

Collaboration Agreement, dated as of November 1, 2006, between Takeda Pharmaceutical Company Limited and XOMA (US) LLC

10-K

000-14710

10.46

03/08/2007

10.11

First Amendment to Collaboration Agreement, effective as of February 28, 2007, between Takeda Pharmaceutical Company Limited and XOMA (US) LLC

10-Q

000-14710

10.48

05/10/2007

10.12

Second Amendment to Collaboration Agreement, effective as of February 9, 2009, among Takeda Pharmaceutical Company Limited and XOMA (US) LLC

10-K

000-14710

10.31B

03/11/2009

10.13†

Discovery Collaboration Agreement dated September 9, 2009, by and between XOMA Development Corporation and Arana Therapeutics Limited

10-Q/A

000-14710

10.35

03/05/2010

10.14

Letter Agreement, dated June 19, 2015, by and between XOMA (US) LLC and Novartis Vaccines and Diagnostics, Inc.

10-Q

000-14710

10.1

08/10/2015

10.15†

License Agreement, dated September 30, 2015, by and between XOMA (US) LLC and Novartis Institutes for Biomedical Research, Inc.

10-Q

000-14710

10.2

11/06/2015

10.16

Protective Rights Agreement dated December 21, 2016 by and between XOMA (US) LLC and HealthCare Royalty Partners II, L.P. relating to the Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P. and the Amended and Restated License Agreement, dated effective as of October 27, 2006, between XOMA (US) LLC and DYAX, Corp.

10-K

000-14710

10.60

03/16/2017

10.17

Protective Rights Agreements dated December 21, 2016 by and between XOMA (US) LLC and HealthCare Royalty Partners II, L.P. relating to the Royalty Interest Acquisition Agreement dated

10-K

000-14710

10.61

03/16/2017

62

Incorporation By Reference

Exhibit

Number

    

Exhibit Description

    

Form

    

SEC File No.

    

Exhibit

    

Filing Date

December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P. and the License Agreement, dated effective as of August 18, 2005, between XOMA (US) LLC and Wyeth Pharmaceuticals

10.18

Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P., relating to the Amended and Restated License Agreement, dated effective as of October 27, 2006, between XOMA (US) LLC and DYAX, Corp.

10-K

000-14710

10.62

03/16/2017

10.19

Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P., relating to the License Agreement, dated effective as of August 18, 2005, between XOMA (US) LLC and Wyeth Pharmaceuticals

10-K

000-14710

10.63

03/16/2017

10.20

Amendment of Section 6.10(a) and (b), dated March 8, 2017, to Royalty Interest Acquisition Agreements dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P.

10-K

000-14710

10.64

03/16/2017

10.21†

IL-1b Target License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG

10-Q

000-14710

10.2

11/06/2017

10.22†

License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG

10-Q

000-14710

10.3

11/06/2017

10.23

Asset Purchase Agreement, dated November 4, 2015, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)

10-Q

000-14710

10.4

11/06/2017

10.24†

License Agreement, dated March 23, 2016, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.))

10-Q

000-14710

10.5

11/06/2017

63

Incorporation By Reference

Exhibit

Number

    

Exhibit Description

    

Form

    

SEC File No.

    

Exhibit

    

Filing Date

10.25†

Amendment and Restatement, dated February 2, 2017, to the Asset Purchase Agreement, dated November 4, 2015, and License Agreement, dated March 23, 2016, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.))

10-Q

000-14710

10.6

11/06/2017

10.26+*

Amended and Restated Employment Agreement, dated December 15, 2021, between XOMA Corporation and James R. Neal

10.27*

Officer Employment Agreement, dated August 7, 2017, between XOMA Corporation and Thomas Burns

10-Q

000-14710

10.8

11/06/2017

10.28*

Amended and Restated Change of Control Severance Agreement, dated August 7, 2017, to the Change of Control Severance Agreement, dated January 3, 2011, between XOMA Corporation and James R. Neal

10-Q

000-14710

10.9

11/06/2017

10.29*

Amended and Restated Change of Control Severance Agreement, dated August 7, 2017, to the Change of Control Severance Agreement, dated October 28, 2015, between XOMA Corporation and Thomas Burns

10-Q

000-14710

10.10

11/06/2017

10.30†

Royalty Purchase Agreement dated September 20, 2018, between XOMA Corporation and Agenus Inc.

10-Q

000-14710

10.9

11/07/2018

10.31†

License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio)

10-K

000-14710

10.66

03/07/2018

10.32†

Amendment No. 1, dated March 30, 2018, to the License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio, Inc.)

10-Q

000-14710

10.1

05/09/2018

10.33†

Amendment No. 2, dated January 7, 2019, to the License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio)

10-K

000-14710

10.71

03/07/2019

64

Incorporation By Reference

Exhibit

Number

    

Exhibit Description

    

Form

    

SEC File No.

    

Exhibit

    

Filing Date

10.34

Common Stock Sales Agreement, dated December 18, 2018, by and between XOMA Corporation and H.C. Wainwright & Co., LLC

8-K

000-14710

10.1

12/18/2018

10.35#

Royalty Purchase Agreement dated April 7, 2019, between XOMA (US) LLC and Aronora, Inc.

10-Q

000-14710

10.1

08/06/2019

10.36#

Royalty Purchase Agreement dated September 26, 2019, between XOMA (US) LLC and Palobiofarma, S.L

10-Q

000-14710

10.1

11/05/2019

10.37#

License Agreement between the Company and Novartis International Pharmaceutical Ltd., dated September 30, 2015 (this exhibit was previously filed under confidential treatment request as Exhibit 10.2 to Form 10-Q filed November 6, 2015)

10-Q

000-14710

10.1

11/05/2020

10.38#

Amendment to Amended and Restated Research, Development and Commercialization Agreement, between the Company and Novartis Vaccine and Diagnostics, Inc., dated September 30, 2015 (this exhibit was previously filed under confidential treatment request as Exhibit 10.4 to Form 10-Q filed November 6, 2015)

10-Q

000-14710

10.2

11/05/2020

10.39#

Collaboration and License Agreement, dated as of March 5, 2020, by and between XOMA (US) LLC and Cadila Healthcare Limited

10-Q

000-14710

10.1

05/05/2020

10.40

Form of Amended and Restated Indemnification Agreement for Directors and Officers

10-K

001-39801

10.56

03/10/2021

10.41

Non-Exclusive License Agreement, dated November 30, 2001, between XOMA Ireland Limited ("XOMA") Sesen Bio, Inc. and (formerly Viventia Biotech Inc.)

10-K

001-39801

10.57

03/10/2021

10.42

Amendment No. 1, dated July 24, 2020, to the Non-Exclusive License Agreement, dated November 30, 2001, between XOMA Ireland Limited ("XOMA") and Sesen Bio, Inc.

10-K

001-39801

10.58

03/10/2021

10.43

Amendment No. 1, dated March 10, 2021, to the Common Stock Sales Agreement, dated December 18, 2018, by and between XOMA Corporation and H.C. Wainwright & Co., LLC

10-K

001-39801

10.59

03/10/2021

65

Incorporation By Reference

Exhibit

Number

    

Exhibit Description

    

Form

    

SEC File No.

    

Exhibit

    

Filing Date

10.44#

Royalty Purchase Agreement dated March 22, 2021 between XOMA (US) LLC and Viracta Therapeutics, Inc.

10-Q

001-39801

10.1

05/06/2021

10.45#

Settlement and Release Agreement, dated April 15, 2021, by and among XOMA (US) LLC and Affimed N.V., Affimed GmbH Affimed

10-Q

001-39801

10.1

08/05/2021

10.46#

Royalty Purchase Agreement, dated July 14, 2021, by and among XOMA (US) LLC and Kuros Royalty Fund (US) LLC

10-Q

001-39801

10.2

11/04/2021

10.47#

At Market Issuance Sales Agreement, dated August 5, 2021, by and between XOMA Corporation and B. Riley Securities, Inc.

8-K

001-39801

10.1

08/05/2021

10.48 + #

Commercial Payment Purchase Agreement, dated October 6, 2021, by and among XOMA (US) LLC and Affitech Research AS

21.1+

Subsidiaries of the Company

23.1+

Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm

24.1+

Power of Attorney (included on the signature pages hereto)

31.1+

Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)

31.2+

Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)

32.1+

Certification of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)(1)

101.INS+

Inline XBRL Instance Document

101.SCH+

Inline XBRL Taxonomy Extension Schema Document

101.CAL+

Inline XBRL Taxonomy Extension Calculation Linkbase Document

66

Incorporation By Reference

Exhibit

Number

    

Exhibit Description

    

Form

    

SEC File No.

    

Exhibit

    

Filing Date

101.DEF+

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB+

Inline XBRL Taxonomy Extension Labels Linkbase Document

101.PRE+

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

†     Confidential treatment has been granted with respect to certain portions of this exhibit. This exhibit omits the information subject to this confidentiality request. Omitted portions have been filed separately with the SEC.

*     Indicates a management contract or compensation plan or arrangement.

+      Filed herewith.

#     Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential.

(1)    This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Annual Report on Form 10-K.

Item 16. Form 10-K Summary

None.

67

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 8th day of March 2022.

XOMA Corporation

By:

/s/ JAMES R. NEAL

James R. Neal

Chief Executive Officer and Chairman

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints James Neal and Thomas Burns, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature

    

Title

    

Date

/s/ James R. Neal

Chief Executive Officer (Principal Executive Officer) and Chairman of the Board of Directors

March 8, 2022

(James R. Neal)

/s/ Thomas Burns

Senior Vice President, Finance and Chief Financial Officer

March 8, 2022

(Thomas Burns)

(Principal Financial and Principal Accounting Officer)

/s/ W. Denman Van Ness

Director

March 8, 2022

(W. Denman Van Ness)

/s/ Joseph M. Limber

Director

March 8, 2022

(Joseph M. Limber)

/s/ Jack L. Wyszomierski

Director

March 8, 2022

(Jack L. Wyszomierski)

/s/ Matthew Perry

Director

March 8, 2022

(Matthew Perry)

/s/ Barbara Kosacz

Director

March 8, 2022

(Barbara Kosacz)

/s/ Natasha Hernday

Director

March 8, 2022

(Natasha Hernday)

/s/ Heather L. Franklin

Director

March 8, 2022

(Heather L. Franklin)

68

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of XOMA Corporation

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of XOMA Corporation and subsidiaries (the "Company") as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive income, stockholders' equity, and cash flows, for the each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Long-Term Royalty and Commercial Payment Receivables — Refer to Notes 2 and 5 to the financial statements

Critical Audit Matter Description

The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties, and option fees on sales of products currently in clinical development.  As of December 31, 2021, the carrying value of the long-term royalty and commercial payment receivables (“milestone and royalty rights”) is $69.1 million. The Company accounts for milestone and royalty rights on a non-accrual basis using the cost recovery method. The milestone and royalty rights relate to developmental pipeline products which are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Management assesses any impairment indicators and changes in expected recoverability of the long-term receivable asset regularly.

F-1

The determination of impairment indicators requires obtaining and assessing all available information regarding the developmental pipeline products as of the Company’s financial reporting dates. The Company obtains information through available sources including: 1) updates from the selling party of the milestone and royalty rights, 2) publicly available clinical trial data and news, and 3) public disclosures provided by the research companies developing the products.

We identified the accounting evaluation of impairment indicators as a critical audit matter, primarily due to the Company’s reliance on third parties to disclose updates to the Company timely for the Company's required financial reporting deadlines.  The timing of disclosure to the Company of a change in the use, or intent for future use, of the licenses related to the milestone and royalty rights could have a significant impact on the fair value of milestone and royalty rights and a significant change in fair value could cause a significant impairment. Performing audit procedures to evaluate whether management had appropriately identified impairment indicators involved challenging and complex auditor judgment, including the need to involve more experienced auditors in assessing the completeness of available information and if any available public information represents an impairment indicator as of the Company’s financial reporting date.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the evaluation of assumptions used in the impairment assessment of the long-term royalty receivables included, but were not limited to, the following:

Considering the impact of changes in the regulatory environment on management’s impairment indicator conclusions.

We evaluated the Company’s assessment of impairment indicators by developing an independent expectation of impairment indicators through research of third-party disclosures and clinical trial news for programs associated with the milestone and royalty rights and comparing such expectation to those included in the impairment analysis.

We inspected the Company’s documentation of inquiries and written correspondence to obtain program updates from the selling parties of the milestone and royalty rights throughout the year and through the Company’s reporting date.  

Confirmed with the selling parties of the milestone and royalty rights that complete information known to the selling party regarding the associated research programs was provided timely, completely, and accurately to the Company.

/s/ DELOITTE & TOUCHE LLP

San Francisco, California  

March 8, 2022  

We have served as the Company's auditor since 2018.

F-2

XOMA Corporation

CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

December 31, 

December 31, 

    

2021

    

2020

ASSETS

Current assets:

Cash

$

93,328

$

84,222

Restricted cash

2,049

1,611

Short-term equity securities

774

Trade and other receivables, net

 

209

 

263

Income tax receivable

1,526

Prepaid expenses and other current assets

 

613

 

443

Total current assets

 

96,973

 

88,065

Long-term restricted cash

531

Property and equipment, net

 

13

 

21

Operating lease right-of-use assets

200

359

Long-term royalty and commercial payment receivables

 

69,075

 

34,575

Long-term equity securities

 

 

1,693

Other assets - long term

 

301

 

41

Total assets

$

166,562

$

125,285

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

1,072

$

456

Accrued and other liabilities

 

525

 

642

Income taxes payable

 

91

 

Contingent consideration under RPAs and CPPAs

8,075

75

Operating lease liabilities

195

179

Unearned revenue recognized under units-of-revenue method

 

1,641

 

1,452

Contingent liabilities

 

 

1,410

Current portion of long-term debt

 

 

8,088

Preferred stock dividend accrual

1,368

Total current liabilities

 

12,967

 

12,302

Unearned revenue recognized under units-of-revenue method – long-term

 

11,685

 

13,516

Long-term debt

 

 

12,764

Long-term operating lease liabilities

34

229

Other liabilities - long term

 

 

50

Total liabilities

 

24,686

 

38,861

Commitments and Contingencies (Note 13)

Stockholders’ equity:

Preferred Stock, $0.05 par value, 1,000,000 shares authorized:

8.625% Series A cumulative, perpetual preferred stock, 984,000 shares issued and outstanding at December 31, 2021 and December 31, 2020

49

49

8.375% Series B cumulative, perpetual preferred stock, 1,600 and zero shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively

 

Convertible preferred stock, 5,003 shares issued and outstanding at December 31, 2021 and December 31, 2020

 

 

Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,315,263 and 11,228,792 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively

 

85

 

84

Additional paid-in capital

 

1,307,030

 

1,267,377

Accumulated deficit

 

(1,165,288)

 

(1,181,086)

Total stockholders’ equity

 

141,876

 

86,424

Total liabilities and stockholders’ equity

$

166,562

$

125,285

The accompanying notes are an integral part of these consolidated financial statements.

F-3

XOMA Corporation

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(in thousands, except per share amounts)

Year Ended

December 31, 

    

2021

    

2020

Revenues:

Revenue from contracts with customers

$

36,518

$

27,941

Revenue recognized under units-of-revenue method

 

1,642

 

1,444

Total revenues

 

38,160

 

29,385

Operating expenses:

 

 

Research and development

 

171

 

170

General and administrative

 

20,460

 

16,799

Total operating expenses

 

20,631

 

16,969

Income from operations

 

17,529

 

12,416

Other (expense) income, net:

 

 

Interest expense

 

(461)

 

(1,844)

Loss on extinguishment of debt

 

(300)

Other (expense) income, net

 

(879)

 

1,225

Income before income tax

 

15,889

 

11,797

Income tax (expense) benefit

 

(91)

 

1,501

Net income and comprehensive income

$

15,798

$

13,298

Net income and comprehensive income available to common stockholders (Note 11), basic

$

7,787

$

8,793

Net income and comprehensive income available to common stockholders (Note 11), diluted

$

7,968

$

9,010

Basic net income per share available to common stockholders

$

0.69

$

0.82

Diluted net income per share available to common stockholders

$

0.65

$

0.78

Weighted average shares used in computing basic net income per share available to common stockholders

 

11,288

10,674

Weighted average shares used in computing diluted net income per share available to common stockholders

12,192

11,503

The accompanying notes are an integral part of these consolidated financial statements.

F-4

XOMA Corporation

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands)

Series A 

Series B

Convertible

Additional

Total

Preferred Stock

Preferred Stock

Preferred Stock

Common Stock

Paid-In

Accumulated

Stockholders’

Shares

  

Amount

  

Shares

  

Amount

  

Shares

  

Amount

     

Shares

  

Amount

 

Capital

   

Deficit

  

Equity

Balance, December 31, 2020

984

$

49

$

5

$

 

11,229

$

84

$

1,267,377

$

(1,181,086)

$

86,424

Issuance of preferred stock

 

2

 

 

37,140

37,140

Preferred stock dividends

 

 

 

 

 

 

(4,867)

 

 

(4,867)

Stock-based compensation expense

 

 

 

 

 

 

6,195

 

 

6,195

Exercise of stock options

 

 

 

 

77

 

1

 

1,052

 

 

1,053

Exercise of common stock warrants

 

 

 

 

5

 

 

 

 

Issuance of common stock related to 401(k) contribution and ESPP

 

 

 

 

4

 

 

133

 

 

133

Net income and comprehensive income

 

 

 

 

 

 

 

15,798

 

15,798

Balance, December 31, 2021

984

$

49

2

$

5

$

 

11,315

$

85

$

1,307,030

$

(1,165,288)

$

141,876

Series A 

Series B

Convertible

Additional

Total

Preferred Stock

Preferred Stock

Preferred Stock

Common Stock

Paid-In

Accumulated

Stockholders’

Shares

  

Amount

  

Shares

  

Amount

  

Shares

  

Amount

     

Shares

  

Amount

 

Capital

   

Deficit

  

Equity

Balance, December 31, 2019

$

$

6

$

 

9,759

$

73

$

1,238,299

$

(1,194,384)

$

43,988

Issuance of preferred stock

984

49

22,572

22,621

Issuance of common stock related to Series Y preferred stock conversion

(1)

1,253

10

(10)

Stock-based compensation expense

 

 

 

 

 

 

3,961

 

 

3,961

Exercise of stock options

 

 

211

1

2,406

2,407

Issuance of common stock related to 401(k) contribution and ESPP

 

 

 

 

6

 

 

136

 

 

136

Disgorgement of stockholder's short-swing profits

 

 

 

 

 

 

13

 

 

13

Net income and comprehensive income

 

 

 

 

 

 

 

13,298

 

13,298

Balance, December 31, 2020

984

$

49

$

5

$

 

11,229

$

84

$

1,267,377

$

(1,181,086)

$

86,424

The accompanying notes are an integral part of these consolidated financial statements.

F-5

XOMA Corporation

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Year Ended December 31, 

    

2021

    

2020

Cash flows from operating activities:

Net income

$

15,798

$

13,298

Adjustments to reconcile net income to net cash provided by operating activities:

Stock-based compensation expense

 

6,195

 

3,961

Common stock contribution to 401(k)

 

90

 

88

Depreciation

 

7

 

22

Amortization of debt issuance costs, debt discount and final payment on debt

 

200

 

698

Non-cash portion of Novartis Milestone Payment

(7,300)

Reduction of contingent NIH refund liability

(105)

Non-cash lease expense

 

160

 

150

Loss on extinguishment of debt

 

300

Change in fair value of equity securities

 

919

 

(1,012)

Changes in assets and liabilities:

Trade and other receivables, net

 

54

 

2,670

Income tax receivable

1,526

(1,526)

Prepaid expenses and other assets

 

(169)

 

83

Accounts payable and accrued liabilities

 

765

 

(542)

Income taxes payable

91

Operating lease liabilities

(179)

(163)

Unearned revenue recognized under units-of-revenue method

 

(1,642)

 

(1,444)

Contingent NIH refund liability

 

(1,305)

 

612

Other liabilities

 

(27)

 

497

Net cash provided by operating activities

 

22,678

 

10,092

Cash flows from investing activities:

Payments related to purchase of royalty rights and other commercial payment rights

 

(26,500)

 

(1,200)

Receipts related to purchased royalty rights

1,000

Purchase of property and equipment

 

(9)

Net cash used in investing activities

 

(26,500)

 

(209)

Cash flows from financing activities:

Proceeds from issuance of preferred stock

 

40,000

 

24,600

Payment of preferred and common stock issuance costs

(3,385)

(1,945)

Proceeds from exercise of options and other share-based compensation

 

1,584

 

4,850

Principal payments – debt

 

(4,250)

 

(5,313)

Payment for extinguishment of debt

(17,103)

Payment for preferred stock dividends

(3,499)

Taxes paid related to net share settlement of equity awards

 

(488)

 

(2,395)

Other

(24)

(4)

Net cash provided by financing activities

 

12,835

 

19,793

Net increase in cash and restricted cash

 

9,013

 

29,676

Cash and restricted cash at the beginning of the period

 

86,364

 

56,688

Cash and restricted cash at the end of the period

$

95,377

$

86,364

Supplemental Cash Flow Information:

  

Cash paid for interest

$

311

$

692

Non-cash investing and financing activities:

 

  

  

Estimated fair value of contingent consideration under the Affitech CPPA

$

8,000

$

Preferred stock dividend accrual

$

1,368

$

Interest added to principal balance on long-term debt

$

$

490

Accrued cost related to issuance of capital stock

$

$

264

The accompanying notes are an integral part of these consolidated financial statements.

F-6

XOMA Corporation

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Description of Business

XOMA (referred to as “XOMA” or the “Company”), a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. The Company’s portfolio was built through licensing its proprietary products and platforms from its legacy discovery and development business, combined with the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs.

Liquidity and Financial Condition

The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December 31, 2021, the Company had unrestricted and restricted cash of $93.3 million and $2.0 million, respectively. The restricted cash balance may only be used to pay dividends on the outstanding Series A Preferred Stock and the outstanding Series B Preferred Stock (Note 12).

In June 2021, the Company repaid its outstanding debt obligations to SVB and Novartis, for a total of $17.1 million (Note 8). Based on the Company’s current cash balance and its ability to control discretionary spending, such as royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these consolidated financial statements are issued.

2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X. 

Use of Estimates

The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts and amortization of the payments received from HCRP. Under the Company’s contracts with the NIAID, a part of the NIH, the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. As of December 31, 2020, the audit procedures were completed, and the Company adjusted its estimated liability owed to NIH to $1.4 million. In December 2021, the NIH

F-7

completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and the Company adjusted its liability owed to NIH to $1.3 million. In December 2021, the Company paid the final approved refund liability of $1.3 million. As such, no contingent liability remained on the Company’s consolidated balance sheets as of December 31, 2021.

In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.

The COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.

Cash and Restricted Cash

Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2021 and 2020, the Company did not have any cash equivalent balances, defined as highly liquid financial instruments purchased with original maturities of three months or less.

Restricted cash consists of bank deposits held to pay dividends on the Company’s Series A Preferred Stock and Series B Preferred Stock.

The Company maintains cash and restricted cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash and restricted cash.

The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):

Year Ended December 31, 

2021

2020

Cash

$

93,328

$

84,222

Restricted cash

2,049

2,142

Total cash and restricted cash

$

95,377

$

86,364

Revenue Recognition

The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.

To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once

F-8

the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.

The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.

License of intellectual property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).

Milestone payments

At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments.

If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract

F-9

inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.

Sale of Future Revenue Streams

The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment.

Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.

Stock-Based Compensation

The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.

Equity Securities

The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive income in the period of sale.

In October 2020, Rezolute completed a 1:50 reverse stock split of its common shares (the “Rezolute Reverse Stock Split”) and started trading on the Nasdaq Stock Market. As a result, the Company’s number of shares of Rezolute common stock was reduced from 8,093,010 shares (pre reverse-split shares) to 161,861 shares (post reverse-split shares). All subsequent disclosures of Rezolute share numbers will be presented post reverse-split.

Purchase of Rights to Future Milestones, Royalties and Commercial Payments

The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product

F-10

development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive income.

The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.

The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2021 and December 31, 2020.

Leases

The Company leases its headquarters office space in Emeryville, California.

The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.

Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive income.

The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.

Income Taxes

The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.

F-11

The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Prior Period Reclassifications

Within the consolidated statement of cash flows, the Company presented principal payments on its finance lease and proceeds from disgorgement of stockholder's short-swing profits together in order for the prior period to conform with current period presentation.

Net Income per Share Attributable to Common Stockholders

The Company calculates basic and diluted income per share attributable to common stockholders using the two-class method. The Company’s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.

Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period and any deemed dividends related to beneficial conversion features on convertible preferred stock, if applicable, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income per share attributable to common stockholders is then calculated by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.

Diluted net income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock. The calculation of diluted net income per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options or warrants, the presumed exercise of such securities are dilutive to net income per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and therefore, are not included in the diluted shares until the contingency is resolved.

Comprehensive Income

Comprehensive income is comprised of two components: net income and other comprehensive income. Other comprehensive income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net income. The Company did not record any transactions within other comprehensive income in the periods presented and, therefore, the net income and comprehensive income were the same for all periods presented.

Accounting Pronouncements Recently Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company on January 1, 2021. The Company adopted ASU 2019-12, on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the Company’s consolidated financial statements.

F-12

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. These amendments provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The ASU provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. It is intended to help stakeholders during the global market-wide reference rate transition period. The guidance is effective for all entities as of March 12, 2020 through December 31, 2022 and can be adopted as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company adopted ASU 2020-04 as of January 1, 2021. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusion. In addition, this ASU improves and amends the related EPS guidance. These amendments are effective for the Company for fiscal years beginning after December 15, 2023, including interim period within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The Company adopted ASU 2020-06 on January 1, 2021. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for all entities except public companies that are not smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted. The Company plans to adopt ASU 2016-13 and related updates as of January 1, 2023. The Company is currently evaluating the impact of adopting this new accounting guidance on its consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations – Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. Early adoption is permitted. The Company is currently evaluating the impacts of the provisions of ASU 2021-08 and the Company does not expect this ASU to have a material impact on its consolidated financial statements.

F-13

3. Consolidated Financial Statement Detail

Equity Securities

As of December 31, 2021 and December 31, 2020, equity securities consisted of an investment in Rezolute’s common stock of $0.8 million and $1.7 million, respectively (Note 4). For the years ended December 31, 2021 and December 31, 2020, the Company recognized a loss of $0.9 million and a gain of $1.0 million, respectively, due to the change in fair value of its investment in Rezolute’s common stock in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income.

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

December 31, 

December 31, 

    

2021

    

2020

Accrued legal and accounting fees

295

351

Accrued payroll and benefits

 

135

 

136

Accrued incentive compensation

55

71

Other accrued liabilities

40

84

Total

$

525

$

642

4. Licensing and Other Arrangements

Novartis – Anti-TGFβ Antibody (NIS793)

On September 30, 2015, the Company and Novartis entered into the Anti-TGFβ Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company’s anti-transforming growth factor beta (“TGFβ”) antibody program (now “NIS793”). Under the terms of the Anti-TGFβ Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGFβ Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’s royalty obligations end. The Anti-TGFβ Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGFβ Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days’ notice.

The Company concluded that there were multiple promised goods and services under the Anti-TGFβ Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December 31, 2015.

The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGFβ Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGFβ Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment which was recognized as license fees in the consolidated statement of operations and comprehensive income.

The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when

F-14

the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid single-digit percentage rate to up to a low double-digit percentage rate. Novartis’s obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.

On October 21, 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis’ first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGFβ Antibody License Agreement, the Company received $17.7 million in cash and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis.

On October 20, 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis’ first NIS793 Phase 3 clinical trial. The Company is eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGFβ Antibody License Agreement.

As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company recognized $35.0 million and $25.0 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the years ended December 31, 2021 and 2020, respectively.

Novartis – Anti-IL-1β Antibody (VPM087) and IL-1 Beta

On August 24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (“VPM087”), a novel anti-Interleukin-1 (“IL-1”) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087.

On August 24, 2017, pursuant to a separate agreement (the “IL-1 Target License Agreement”), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the “Exclusivity Option”) to such intellectual property for the treatment and prevention of cardiovascular disease.

Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company’s outstanding debt with Les Laboratories Servier (“Servier”) (the “Servier Loan”). In addition, Novartis extended the maturity date on the Company’s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company’s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August 24, 2017, resulting in a $0.2 million premium paid to the Company.

Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications

F-15

covered by the Company’s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid single-digits.

Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months’ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice.

The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.

At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the year ended December 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.

The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2021 and 2020.

Takeda

On November 1, 2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.

Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and TAK-169, and low single-digit royalties on future sales of all products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all

F-16

research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 13.5 years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).

In February 2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.

As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. During the years ended December 31, 2021 and 2020, the Company recognized annual license fee revenue of $0.1 million from Takeda. On November 16, 2020, the first patient was dosed in Takeda’s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda. The Company is eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement. During the years ended December 31, 2021 and 2020, the Company recognized $0.1 million and $2.1 million, respectively, as revenue from contracts with customers in the consolidated statement of operations and comprehensive income.  

Rezolute

On December 6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now “RZ358”) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.

Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute’s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute’s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.

Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute’s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical testing. Rezolute’s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee’s obligation to make payments to Rezolute based on sales of such product in such country

The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days’ notice at any time. To the extent

F-17

permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.

No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute’s financing activities.

The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute’s achievement of financing activities and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute’s common stock.

As of December 31, 2021 and December 31, 2020, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2021 and 2020.

The Company reassessed the development and regulatory milestones and concluded that such variable consideration is fully constrained and excluded from the transaction price as of December 31, 2021 and 2020.   

Janssen Biotech

The Company and Janssen were parties to a license agreement which was terminated in 2017. In August 2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen’s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen’s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties.

The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019 as it had completed its performance obligation.

The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen’s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

In May 2021, the Company earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets. In December 2021, the Company earned a $0.2 million milestone pursuant to its agreement with Janssen.

As of December 31, 2021 and December 31, 2020, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. Milestone revenue of $0.7 million and $0.4 million was recognized for the years ended December 31, 2021 and 2020, respectively.

F-18

Affimed

In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE molecules and preloaded natural killer cells containing the ICE molecules. Additionally, the Company is eligible to receive a milestone upon the first product candidate in each program achieving marketing approval.

The Company concluded that the commercial milestone payments are solely dependent on Affimed’s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

As of December 31, 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the year ended December 31, 2021.

NIAID

Prior to the sale of the Company’s biodefense business in 2016, the Company performed services under contracts funded with federal funds from NIAID including under a $64.8 million multiple-year contract (Contract No. HHSN272200800028C), for development of anti-botulinum antibody product candidates and a $28.0 million multiple-year contract (Contract No. HHSN272201100031C) for development of broad-spectrum antitoxins for the treatment of human botulism poisoning. The contract work was being performed on a cost plus fixed fee basis over a three-year period. The Company recognized revenue under the arrangement as the services were performed on a proportional performance basis. Consistent with the Company’s other contracts with the U.S. government, invoices were provisional until finalized. The Company operated under provisional rates from 2010 through 2015, subject to adjustment based on actual rates upon agreement with the government. In 2014, upon completion of NIAID’s review of hours and external expenses, XOMA agreed to exclude certain hours and external expenses resulting in a $0.4 million receivable and $0.8 million deferred revenue balances. As of December 31, 2017, the Company wrote off the $0.4 million receivable from NIAID as the likelihood of collection was remote. In October of 2019, NIH, which includes NIAID, notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. The KPMG testing procedures were completed in December 2020. As a result, the Company recognized $1.4 million as estimated refund liabilities owed to NIH on the consolidated balance sheet as of December 31, 2020. The additional $0.6 million liability was recognized as a reduction of revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the year ended December 31, 2020. In December 2021, NIH completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and approved a finalized refund liability of $1.3 million. The $0.1 million reduction in the liability, from its previously recorded $1.4 million estimate, was recognized as revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the year ended December 31, 2021. In December 2021, the Company paid the finalized refund liability owed to NIH of $1.3 million and no balance of the contingent liability remained on the consolidated balance sheets as of December 31, 2021.

Sale of Future Revenue Streams

On December 21, 2016, the Company entered into two royalty interest sale agreements (together, the “Royalty Sale Agreements”) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale

F-19

Agreement entered into in December 2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.

The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under units-of-revenue method over the life of the license agreements because of the Company’s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company’s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period’s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.

The Company recognized $1.6 million and $1.4 million as revenue under units-of-revenue method under these arrangements during the years ended December 31, 2021 and December 31, 2020, respectively. As of December 31, 2020, the current and non-current portion of the remaining unearned revenue recognized under units-of-revenue method was $1.5 million and $13.5 million, respectively. As of December 31, 2021, the Company classified $1.6 million and $11.7 million as current and non-current unearned revenue recognized under units-of-revenue method, respectively.

5. Royalty and Commercial Payment Purchase Agreements

Royalty Purchase Agreement with Agenus

On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (“Incyte”) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentage of applicable net sales.

In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company’s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.

Under the terms of the Agenus RPA, the Company paid Agenus $15.0 million.

At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets.

In November 2020, MK-4830 advanced into Phase 2 development and Agenus earned a $10.0 million clinical development milestone under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.

F-20

The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

Royalty Purchase Agreement with Bioasis

On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product.

Under the terms of the Bioasis RPA, the Company paid $0.3 million and will make contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the “Bioasis Contingent Consideration”).

At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $0.1 million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income. As of December 31, 2021, there was no change in the fair value of the contingent consideration from its initial value and no amounts were paid during the year ended December 31, 2021. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights.

At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under the Second Bioasis RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

Royalty Purchase Agreement with Aronora

On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the “Non-Royalties”) related to five anti-thrombotic hematology drug candidates. Three candidates were subject to Aronora’s collaboration with Bayer (the “Bayer Products”), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the “non-Bayer Products”) for which the Company will receive low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will

F-21

be reduced from 10% to 5% upon the Company’s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.

Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB (Note 8). The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the “Aronora Contingent Consideration”). Pursuant to the Aronora RPA, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the “Royalty Milestones”). The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product. Royalties per product in excess of $250.0 million are retained by the Company.

At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term.

Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. 

Royalty Purchase Agreement with Palobiofarma

On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin’s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the “Palo Licensed Products”) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis.

Under the terms of the Palo RPA, the Company paid Palo a $10.0 million payment at the close of the transaction which occurred simultaneously upon parties’ entry into the Palo RPA on September 26, 2019.

At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

Royalty Purchase Agreement with Viracta

On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0

F-22

million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved.

At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

Royalty Purchase Agreement with Kuros

On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals’ vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestones.

At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

Commercial Payment Purchase Agreement with Affitech

On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche’s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones (Note 15). At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which includes the $6.0 million upfront payment and $8.0 million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million meet the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.

Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the investment has been fully collected.  The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

F-23

The following table summarizes the long-term royalty receivable activities including acquisitions of royalty rights, commercial payment rights and cash receipts for achievement of contractual milestones during the years ended December 31, 2021 and 2020 (in thousands):

Balance at January 1, 2020

    

$

34,375

Acquisition of royalty rights:

Bioasis

1,200

Cash receipts for achievement of contractual milestones:

Agenus

(1,000)

Balance at December 31, 2020

    

34,575

Acquisition of royalty and commercial payment rights:

Viracta

 

13,500

Kuros

 

7,000

Affitech

14,000

Balance at December 31, 2021

$

69,075

6. Fair Value Measurements

The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company’s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

Fair Value Measurements at December 31, 2021 Using

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

Total

Assets:

Equity securities

$

774

$

$

$

774

Liabilities:

Contingent consideration under RPAs and CPPAs

$

$

$

8,075

$

8,075

F-24

Fair Value Measurements at December 31, 2020 Using

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

Total

Assets:

  

  

  

  

Equity securities

$

$

$

1,693

$

1,693

Liabilities:

Contingent consideration

$

$

$

75

$

75

Transfers to and from Levels 1, 2, and 3 are recognized at the end of the reporting period. On June 30, 2021, the Company’s equity investment in Rezolute’s common stock transferred from Level 3 to Level 1. In reporting periods prior to June 30, 2021, the Company applied an illiquidity discount to the fair value of Rezolute’s common stock due to the lack of trading volume, resulting in classification as Level 3. Since June 30, 2021, there has been sufficient and consistent trading volume on the Nasdaq Stock Market to provide an estimate of fair value utilizing quoted prices in an active market for the identical securities as of the reporting date, resulting in classification as Level 1. There were no transfers between levels during 2020.

Equity Securities

The following table reconciles the beginning and ending balance for the Level 3 financial assets recurring fair value measurement for the year ended December 31, 2021 (in thousands):

Year Ended

December 31, 2021

Balance at December 31, 2019

$

681

Change in fair value

1,012

Balance at December 31, 2020

$

1,693

Change in fair value

 

617

Transfer out of Level 3 as of June 30, 2021

(2,310)

Balance at December 31, 2021

$

The equity securities consisted of an investment in Rezolute’s common stock and are classified on the consolidated balance sheets as current assets as of December 31, 2021, and long-term assets as of December 31, 2020. The reclassification from noncurrent to current assets was due to the equity securities achieving sufficient and consistent trading volume on the Nasdaq Stock Market during the second quarter of 2021. The equity securities are revalued each reporting period with changes in fair value recorded in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income.

As of December 31, 2020, the Company and its valuation specialist, valued the equity securities using the closing price for Rezolute’s common stock traded on the Nasdaq Stock Market and adjusted for an illiquidity discount. The inputs that were used to calculate the illiquidity discount were based on observable and unobservable estimates and judgments and therefore were classified as a Level 3 fair value measurement. As the Company has the right and option to sell up to 100,000 shares of Rezolute’s common stock back to Rezolute after December 31, 2019 (Note 4), the fair value of the equity securities was determined by dividing the total shares of Rezolute’s common stock held by the Company into two tranches based on the estimated time to a potential liquidity event.

As of December 31, 2021, the Company valued the equity securities using the closing price for Rezolute’s common stock traded on the Nasdaq Stock Market. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement.

F-25

The closing price of Rezolute’s common stock as per the Nasdaq Stock Market was $4.78 and $11.99 as of December 31, 2021 and December 31, 2020, respectively. The estimated fair value of the equity securities as of December 31, 2020 was calculated based on the following assumptions:

December 31, 

December 31, 

2021

2020

 

Closing common stock price

$

4.78

$

11.99

Tranche 1:

Discount for lack of marketability

 

N/A(1)

%  

12

%

Estimated time to liquidity of shares

 

0.25 year

Tranche 2:

Discount for lack of marketability

N/A(1)

%

14

%

Estimated time to liquidity of shares

0.67 years

(1)Due to sufficient and consistent trading volume, the equity investment will be measured at the closing price per the Nasdaq Stock Market. The assumptions related to the unobservable inputs identified above, and any changes in those assumptions thereto, will no longer be considered in determining the fair value of the equity securities.

Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the equity securities.

Contingent Consideration

The estimated fair value of the contingent consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate.

The estimated fair value of the contingent consideration liability at the inception of the Affitech CPPA represents the future consideration that is contingent upon the achievement of specified regulatory milestones. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving regulatory milestones.

Changes in the fair value of the liability for contingent consideration will be recorded in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income until settlement. As of December 31, 2021, there were no changes in the estimated fair value of the contingent consideration recorded pursuant to the Bioasis RPA and Affitech CPPA from the initial values of $0.1 million and $8.0 million, respectively.

7. Lease Agreement

The Company leases one facility in Emeryville, California under an operating lease that expires in February 2023. The Emeryville lease contains an option to extend the lease for an additional term, however, the Company is not reasonably certain to exercise this option.

F-26

The following table summarizes maturity of the Company’s operating lease liabilities as of December 31, 2021 (in thousands):

Operating

Undiscounted lease payments

    

Leases

2022

 

202

2023

 

34

2024

 

Total undiscounted lease payments

 

236

Present value adjustment

 

(7)

Total net lease liabilities

 

$

229

The following table summarizes the cost components of the Company’s operating lease for the years ended December 31, 2021 and 2020, respectively (in thousands):

    

Year Ended December 31, 

    

2021

    

2020

Lease costs:

Operating lease cost

$

177

 

$

177

Variable lease cost (1)

8

 

7

Total lease costs

$

185

$

184

(1)Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.

The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):

    

Year Ended December 31, 

    

2021

2020

Cash paid for amounts included in the measurement of lease liabilities

 

 

Operating cash flows under operating leases

$

196

$

189

The present value assumptions used in calculating the present value of the lease payments for the Company’s operating lease as of December 31, 2021 and December 31, 2020 were as follows:

    

December 31, 

December 31, 

    

2021

2020

Weighted-average remaining lease term

1.17 years

2.17 years

Weighted-average discount rate

5.51

%

5.51

%

8. Long-Term Debt and Other Financings

SVB Loan

On May 7, 2018 (the “Effective Date”), the Company executed the SVB Loan Agreement with SVB. Under the Loan Agreement, upon the Company’s request, SVB made advances (each, a “Term Loan Advance”) available to the Company up to $20.0 million (the “Term Loan”). The Company was allowed to borrow advances under the Term Loan from the Effective Date until the earlier of March 31, 2019 or an event of default (the “Draw Period”). The interest rate was calculated at a rate equal to the greater of (i) 4.75%, or (ii) 0.25% plus the prime rate as reported from time to time in The Wall Street Journal.

F-27

Payments under the Loan Agreement were interest only until the first anniversary of the funding date of each Term Loan Advance. The interest-only period was followed by equal monthly payments of principal and interest over 24 months. Each Term Loan Advance was scheduled to mature at the earlier of (i) the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii) March 1, 2023, or (iii) 30 days prior to the earliest maturity of any portion of the Company’s loan with Novartis (the “Loan Maturity Date”). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed. The entire principal balance, including a final payment fee equal to 8.5% of the original principal, was due and payable on the Loan Maturity Date.

In June 2021, the Company repaid its principal balance of $6.5 million and paid the 8.5% final payment fee of $1.4 million to SVB. The Company also paid SVB a prepayment fee of 1% of the outstanding principal balance.

In connection with the Loan Agreement, the Company issued a warrant to SVB which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share (the “Warrant”). The Warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the Warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. In addition, the Company incurred debt issuance costs of $0.2 million in connection with the Loan Agreement.

On March 4, 2019, the Loan Agreement was amended to extend the Draw Period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million.

Both warrants may be exercised on a cashless basis and are exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. As of December 31, 2021, both warrants are outstanding.

In September 2018, the Company borrowed advances of $7.5 million under the Loan Agreement in connection with the Agenus RPA (Note 5). The Company recorded a discount of $0.3 million against the debt, which was being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.

During the year ended December 31, 2019, the Company borrowed advances totaling $9.5 million under the Loan Agreement in connection with the Aronora RPA, Palo RPA and payment of the Aronora Contingent Consideration (Note 5). The Company recorded a discount of $45,000 against the debt, which was being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.

The Company recorded $0.2 million of non-cash interest expense resulting from the amortization of the discount and accretion of the final payment before the loan was extinguished in June 2021 and $0.6 million for the year ended December 31, 2020.  

As of December 31, 2020, the carrying value of the debt under the Loan Agreement was $11.8 million. Of this amount, $8.1 million was classified as current portion of long-term debt and $3.7 million was classified as long-term debt on the consolidated balance sheet. In June 2021, the Company paid off its entire outstanding principal balance to SVB. Upon repayment of the principal balance, the Company recognized a loss on extinguishment of $0.3 million in other (expense) income, net of the consolidated statement of operations for the year ended December 31, 2021. As of December 31, 2021, there was no carrying value of the debt under the Loan Agreement.

Novartis Note

In May 2005, the Company executed the Novartis Note Agreement with Novartis, which was due and payable in full in June 2015. Under the Novartis Note Agreement, the Company borrowed semi-annually to fund up to 75% of the Company’s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50.0 million in aggregate principal amount. Interest on the principal amount of the loan accrued at six-month LIBOR plus 2% and the interest rate reset in June and December annually. Accrued interest was payable semi-annually in

F-28

June and December of each year or, at the Company’s election, the semi-annual interest payments could be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount did not exceed $50.0 million. The Company made this election for all interest payments. Loans under the Novartis Note Agreement were secured by the Company’s interest in its collaboration with Novartis, including any payments owed to it thereunder. In June 2021, the Company repaid its outstanding principal balance to Novartis of $9.1 million and extinguished its debt obligation.

On September 30, 2015, concurrent with the execution of a license agreement with Novartis as discussed in Note 4, XOMA and Novartis, who assumed the rights to the note from Novartis Vaccines Diagnostics, Inc. executed an amendment to the Novartis Note Agreement (the “Secured Novartis Note Amendment”) under which the parties extended the maturity date of the note from September 30, 2015 to September 30, 2020, and eliminated the mandatory prepayment previously required to be made with certain proceeds of pre-tax profits and royalties. In addition, upon achievement of a specified development and regulatory milestone, the then-outstanding principal amount of the note was to be reduced by $7.3 million rather than the Company receiving such amount as a cash payment.

On September 22, 2017, in connection with the Gevokizumab License Agreement with Novartis, the Company and Novartis executed an amendment to the Novartis Secured Note Amendment under which the parties further extended the maturity date of the Novartis Secured Note Amendment from September 30, 2020 to September 30, 2022.

On October 21, 2020, the first patient was dosed in Novartis’s first NIS793 Phase 2 clinical trial and the Company earned a $25.0 million milestone pursuant to the Anti-TGFβ Antibody License Agreement, of which $17.7 million was received in cash and $7.3 million was recognized as a reduction to the debt obligation to Novartis.

As of December 31, 2020, the outstanding principal balance under the Novartis Secured Note Amendment was $9.1 million and was included in long-term debt in the accompanying consolidated balance sheet. In June 2021, the Company repaid its entire outstanding debt balance to Novartis. The repayment of principal did not result in any gain or loss on extinguishment. As of December 31, 2021, there was no carrying value of the debt under the Novartis Note Agreement.

Interest Expense

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive income for the years ended December 31, 2021 and 2020, relates to the following debt instruments (in thousands):

Year Ended December 31, 

    

2021

    

2020

SVB Loan

$

373

$

1,365

Novartis Note

 

88

 

477

Other

 

 

2

Total interest expense

$

461

$

1,844

9. Income Taxes

The Company has pre-tax book income of $15.9 million and $11.8 million for the year ended December 31, 2021 and 2020, respectively.  The Company has $0.1 million income tax expense and $1.5 million income tax benefit for the years ended December 31, 2021 and 2020, respectively.  

F-29

The provision (benefit) for income taxes, all classified as current, consists of the following (in thousands):

Year Ended December 31, 

    

2021

    

2020

Federal

$

91

$

(1,501)

State

 

 

Total

$

91

$

(1,501)

Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company’s actual effective income tax rate is as follows:

Year Ended December 31, 

 

    

2021

    

2020

 

Federal tax at statutory rate

 

21

%  

21

%

Stock compensation and other permanent differences

 

9

%  

(6)

%

Federal orphan drug credit

 

(2)

%  

%

Tax benefit related to CARES Act

 

%  

(13)

%

Tax benefit related to net operating loss carryforward utilization

 

(11)

%  

%

Valuation allowance

 

(16)

%  

(15)

%

Total

 

1

%  

(13)

%

On March 27, 2020, the CARES Act was enacted, which includes a five-year NOL carryback provision which enabled the Company to benefit from certain losses at the former federal tax rate of 34%. In 2020, the Company recorded tax benefits of $1.5 million related to the NOL carryback provision. During the year ended December 31, 2021, the Company received $1.5 million in cash for its income tax receivable.

The significant components of net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):

December 31, 

    

2021

    

2020

Capitalized research and development expenses

$

7,822

$

11,500

Net operating loss carryforwards

 

17,657

 

17,638

Research and development and other tax credit carryforwards

 

13,125

 

13,454

Stock compensation

 

4,778

 

5,158

Unearned revenue

 

2,817

 

3,462

Other

 

807

 

401

Total deferred tax assets

 

47,006

 

51,613

Valuation allowance

 

(47,006)

 

(51,613)

Net deferred tax assets

$

$

The net decrease in the valuation allowance was $4.6 million and $3.9 million, for the years ended December 31, 2021 and 2020, respectively.

Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company’s four sources of taxable income including historical operating performance and the repeal of NOL carryback, the Company has determined that total deferred tax assets should be fully offset by a valuation allowance.

Based on an analysis under Section 382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to annual limitations), the Company experienced an ownership change in February 2017 which substantially limits the future use of its pre-change NOLs and certain other pre-change tax attributes per year. The Company has excluded the related tax attributes that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2021 and December 31, 2020. To the extent that the Company

F-30

does not utilize its carryforwards within the applicable statutory carryforward periods, either because of Section 382 limitations or the lack of sufficient taxable income, the carryforwards will expire unused.

As of December 31, 2021, the Company had federal NOL carry-forwards of approximately $78.8 million and state NOL carry-forwards of approximately $38.1 million to offset future taxable income. $13.6 million of federal NOL carryforwards will begin to expire in 2036 and the remainder may be carried forward indefinitely. The state NOL carryforwards will begin to expire in 2033. The Company had federal orphan credit of $2.0 million which if not utilized will expire in 2037. The Company also had $19.8 million of California research and development tax credits which have no expiration date.

Under the 2017 federal income tax law, as modified by the federal tax law changes enacted in March 2020, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but, for taxable years beginning after December 31, 2020, the deductibility of such federal NOLs may only be utilized to offset 80% of taxable income annually.  

The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company’s federal income tax returns for tax years 2018 and beyond remain subject to examination by the Internal Revenue Service. The Company’s state income tax returns for tax years 2017 and beyond remain subject to examination by state tax authorities. In addition, all of the NOLs and research and development credit carryforwards that may be used in future years are still subject to adjustment.

The following table summarizes the Company’s activity related to its unrecognized tax benefits (in thousands):

Year Ended December 31, 

    

2021

    

2020

Balance at January 1

$

5,938

$

5,517

Increase related to current year tax position

 

 

Increase related to prior year tax position

 

 

421

Balance at December 31

$

5,938

$

5,938

As of December 31, 2021, the Company had a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as the Company currently has a full valuation allowance against its deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.

The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through December 31, 2021, the Company has not accrued interest or penalties related to uncertain tax positions.

10. Stock Based Compensation

The Company may grant qualified and non-qualified stock options, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company’s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period.

Employee Stock Purchase Plan

In May 2015, the Company’s stockholders approved the 2015 Employee Stock Purchase Plan (the “2015 ESPP”), which replaced the Company’s legacy 1998 ESPP. Under the 2015 ESPP, the Company reserved 15,000 shares of common stock for issuance as of its effective date of July 1, 2015, subject to adjustment in the event of a stock split, stock dividend,

F-31

combination or reclassification or similar event. The 2015 ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2015 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period.

In February 2017, the Compensation Committee and the Board of Directors adopted, and in May 2017, the Company’s stockholders approved, an amendment to the Company’s 2015 ESPP. The amendment (a) increased by 250,000 the shares of common stock (from 15,000 shares to a total of 265,000 shares) available for issuance under the 2015 ESPP; and (b) increased the maximum number of shares of common stock an employee may purchase in any offering period to 2,500. As of December 31, 2021, the Company had 237,072 remaining authorized shares available for purchase under the ESPP.

During the years ended December 31, 2021 and 2020, employees purchased 2,225 and 2,746 shares of common stock, respectively, under the 2015 ESPP.

Deferred Savings Plan

Under section 401(k) of the Internal Revenue Code of 1986, the Board of Directors adopted, effective June 1, 1987, a tax-qualified deferred compensation plan for employees of the Company. Participants may make contributions which defer up to 50%of their eligible compensation per payroll period, up to a maximum for 2021 and 2020 of $19,500 (or $26,000 for employees over 50 years of age). The Company may, at its sole discretion, make contributions each plan year, in cash or in shares of the Company’s common stock, in amounts which match up to 50% of the salary deferred by the participants. The expense related to these contributions was $0.1 million for the years ended December 31, 2021 and December 31, 2020, and 100% was paid in common stock for each year. The Company applies shares from plan forfeitures of terminated employees toward the Company’s matching contribution.  

Stock Option Plans

In May 2010, the Compensation Committee and Board of Directors adopted, and in July 2010 the Company’s stockholders approved the 2010 Plan. The 2010 Plan was amended in 2016, 2017 and 2019 to (a) increase the number of shares of common stock issuable under the 2010 Plan; (b) increase the number of shares of common stock issuable under the 2010 Plan as incentive stock options; and (c) extend the term of the 2010 Plan to April 1, 2029. As of December 31, 2021, the number of shares of common stock reserved for issuance under the 2010 Plan is 3,029,062 shares.

From the 2010 Plan, the Company grants stock options to eligible employees, consultants and directors. Stock-based awards granted under the 2010 Plan may be exercised when vested and generally expire ten years from the date of the grant or three to six months from the date of termination of employment (longer in case of death or certain retirements).

As of December 31, 2021, the Company had 161,140 shares available for grant under the 2010 Plan. As of December 31, 2021, options to purchase 1,911,177 shares of common stock were outstanding under the 2010 Plan.

Stock Options

Stock options generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement.

F-32

Stock Option Plans Summary

The following table summarizes the Company’s stock option activity for the year ended December 31, 2021.

As of December 31, 2021

Weighted

    

Weighted

Average

Average

Aggregate

Exercise

Contractual 

Intrinsic

Number of

Price

Term

Value

shares

Per Share

(in years)

(in thousands)

Outstanding at January 1, 2021

1,827,906

$

20.66

 

6.31

 

$

51,401

Granted

 

325,211

 

32.02

 

  

 

  

Exercised

 

(77,305)

 

13.61

 

  

 

  

Forfeited, expired or cancelled

(164,635)

 

46.59

 

  

 

  

Outstanding at December 31, 2021

1,911,177

$

20.64

 

6.33

$

15,103

Exercisable at December 31, 2021

1,553,696

$

18.75

 

5.69

$

14,894

The aggregate intrinsic value of stock options exercised in 2021 and 2020 was $1.6 million and $5.4 million, respectively.

The weighted-average grant-date fair value per share of the options granted in 2021 and 2020 was $22.23 and $18.41, respectively.

As of December 31, 2021, $4.1 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.21 years.

Stock-based Compensation Expense

The fair value of stock options granted during the years ended December 31, 2021 and 2020, was estimated based on the following weighted average assumptions for:

Year Ended December 31, 

 

    

2021

    

2020

 

Dividend yield

 

0

%  

0

%

Expected volatility

 

83

%  

100

%

Risk-free interest rate

 

0.95

%  

0.72

%

Expected term

 

5.66 years

5.64 years

The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive income (in thousands):

Year Ended December 31, 

    

2021

    

2020

Research and development

$

$

General and administrative

 

6,195

 

3,961

Total stock-based compensation expense

$

6,195

$

3,961

11. Net Income Per Share Attributable to Common Stockholders

Potentially dilutive securities are excluded from the calculation of diluted net income per share attributable to common stockholders if their inclusion is anti-dilutive.

F-33

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income per share attributable to common stockholders (in thousands):

Year Ended December 31, 

    

2021

    

2020

Convertible preferred stock

Common stock options

 

479

616

Warrants for common stock

 

6

Total

 

479

 

622

The following is a reconciliation of the numerator (net income) and denominator (number of shares) used in the calculation of basic and diluted net income per share attributable to common stockholders (in thousands):

Year Ended December 31, 

    

2021

    

2020

Numerator

 

  

 

  

Net income

$

15,798

$

13,298

Less: Series A accumulated dividends

 

(2,122)

 

(88)

Less: Series B accumulated dividends

(2,438)

Less: Allocation of undistributed earnings to participating securities

 

(3,451)

 

(4,417)

Net income available to common stockholders, basic

$

7,787

$

8,793

Add: Adjustments to undistributed earnings allocated to participating securities

 

181

217

Net income available to common stockholders, diluted

$

7,968

$

9,010

 

Denominator

 

 

Weighted average shares used in computing basic net income per share available to common stockholders

 

11,288

 

10,674

Effect of dilutive stock options

 

900

824

Effect of dilutive warrants

 

4

5

Weighted average shares used in computing diluted net income per share available to common stockholders

 

12,192

 

11,503

Basic net income per share available to common stockholders

$

0.69

$

0.82

Diluted net income per share of common stock

$

0.65

$

0.78

12. Capital Stock

Series X and Series Y Convertible Preferred Stock

The Company sold directly to BVF 5,003 shares of Series X convertible preferred stock in 2017 and 1,252.772 shares of Series Y convertible preferred stock in 2018. There were no shares of Series Y convertible preferred stock outstanding as of December 31, 2021, after BVF converted all Series Y preferred stock into common stock on April 15, 2020.

As of December 31, 2021 and 2020, there were 5,003 shares authorized and issued of Series X convertible preferred stock.

The Series X and Series Y convertible preferred stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.

Dividends— Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock.

F-34

Liquidation Rights— In the event of the Company’s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.

Conversion— Each share of Series X and Series Y is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share and $13.00 per share of common stock respectively.

Voting Rights— Convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.

Classification— The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the convertible preferred stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.

Beneficial Conversion Feature— The fair value of the common stock into which the Series X convertible preferred stock is convertible exceeded the allocated purchase price of the Series X convertible preferred stock by $5.6 million on the date of issuance, as such the Company recorded a deemed dividend. The Company recognized the resulting beneficial conversion feature as a deemed dividend equal to the number of shares of Series X convertible preferred stock sold on February 16, 2017 multiplied by the difference between the fair value of the common stock and the Series X convertible preferred stock effective conversion price per share on that date. The dividend was reflected as a one-time, non-cash, deemed dividend to the holders of Series X convertible preferred stock on the date of issuance, which is the date the stock first became convertible. There was no beneficial conversion feature associated with the issuance of Series Y convertible preferred stock.

Series A Preferred Stock

On December 15, 2020, the Company sold 984,000 shares of its 8.625% Series A cumulative, perpetual preferred stock at the price of $25.00 per share, through a public offering for aggregate gross proceeds of $24.6 million. Total offering costs of $2.0 million were offset against the proceeds from the sale of Series A Preferred Stock, for total net proceeds of $22.6 million.

Mr. Matthew Perry, a member of the Company’s Board of Directors and President of BVF, purchased 200,000 shares of Series A Preferred Stock in the public offering at the public offering price of $25.00 per share for an aggregate amount of $5.0 million. The spouse of James Neal, the Company’s Chief Executive Officer and Chairman of the Board of Directors, purchased 8,000 shares of the Series A Preferred Stock in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million.

As of December 31, 2021 and 2020, there were 984,000 shares authorized and issued of Series A Preferred Stock.

The Series A preferred stock have the following characteristics, which are set forth in the Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.

Dividends— Holders of the Series A Preferred Stock shall be entitled to receive, when, and if authorized by the Board of Directors and declared by the Corporation, cumulative cash dividends at the rate of 8.625% per annum of the $25.00 liquidation preference per share of the Series A Preferred Stock. Such dividends will accumulate and be cumulative from, and including, the date of original issue of the Series A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October of each year beginning on or about April 15, 2021. The amount of

F-35

any dividend payable on the Series A Preferred Stock for any period greater or less than a full Dividend Period shall be prorated and computed on the basis of a 360-day year consisting of twelve 30-day months. 

Liquidation Rights— In the event of the Company’s liquidation, dissolution or winding up, holders of Series A Preferred Stock will rank senior to all classes or series of common stock as to dividend rights and rights upon liquidation, dissolution or winding-up and on parity with respect to the distribution of assets with the Company’s Series X Preferred Stock. The Series A Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25.00 per share plus any accrued and unpaid dividends.

Redemption and Special Optional Redemption— The Company, at its option, may redeem the Series A Preferred Stock, in whole or in part, at any time for a cash redemption price, plus any accrued and unpaid dividends, as follows: (i) $26.00 per share between December 15, 2021 and December 15, 2022, (ii) $25.75 per share between December 15, 2022 and December 15, 2023, (iii) $25.50 per share between December 15, 2023 and December 15, 2024 (iv) $25.25 per share between December 15, 2024 and December 15, 2025 and $25.00 per share on or after December 15, 2025. The Company also has a special optional redemption option whereby, upon the occurrence of a delisting event or change of control event, the Company may redeem outstanding Series A Preferred Stock at an amount of $25.00 per share.

Conversion— The shares of Series A Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company except upon the occurrence of a delisting event or change in control event and the Company has not, on or before the date of such an event, provided the required notice of its election to redeem the Series A Preferred Stock pursuant to its redemption right or special optional redemption right. In this case, the holder of shares of Series A Preferred Stock can convert some or all of their Series A Preferred Stock into a number of shares of common stock per share equal to the lesser of (A) (i) the sum of the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus (y) the amount of any accrued and unpaid dividends to, but not including, the event date, as applicable by (ii) the common stock price and (B) 1.46071 (the “Share Cap”). The common stock price to be used in the latter noted calculation for a delisting event will be the average of the closing price per share of the Company’s common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the delisting event. The common stock price used in the event of a change in control event will, alternatively, be based on market price according to the definition in the Certificate of Designation.

Voting Rights— Holders of the Series A Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.

Classification—The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.

Depositary Shares Representing Interest in Series B Preferred Stock

On April 9, 2021, the Company sold 1,600,000 Series B Depositary Shares, at the price of $25.00 per Series B Depositary Share, through a public offering for aggregate gross proceeds of $40.0 million. Total offering costs of $2.9 million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $37.1 million.

The spouse of James Neal, the Chief Executive Officer and Chairman of the Board of Directors, purchased 8,000 shares of the Series B Depositary Shares in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million.

As of December 31, 2021, there were 3,600 shares authorized and 1,600 issued of Series B Preferred Stock.

The Series B Preferred Stock has the following characteristics, which are set forth in the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock, as corrected, filed with the Delaware Secretary of State.

Dividends— Holders of Series B Preferred Stock shall be entitled to receive cash dividends, when and if declared by the Board of Directors at the rate of 8.375% per annum of the $25,000.00 liquidation preference per share, which equals

F-36

$2,093.75 per share each year. Such dividends shall be payable quarterly in arrears on or about the 15th calendar day of each January, April, July and October commencing on or about July 15, 2021. The dividends will accumulate and be cumulative from, and including, the date of original issue of the Series B Preferred Stock, on the basis of a 360-day year consisting of twelve 30-day months. Dividends will be payable to holders of record as they appear in the stockholder records of the Company (or the depositary in the case of Series B Depositary Shares representing underlying Series B Preferred Stock) at the close of business on the applicable dividend record date.

Liquidation Preference - Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Company ranking junior to the Series B Preferred Stock, the holders of shares of Series B Preferred Stock shall be paid out of the assets of the Company, after payment of or provision for the debts and other liabilities and any class or series of capital stock, as to rights upon any voluntary or involuntary liquidation, dissolution or winding up, senior to the Series B Preferred Stock. The Series B Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25,000.00 per share plus any accrued and unpaid dividends.

Redemption and Special Redemption - On and after April 15, 2022, the Company, at its option, may redeem the Series B Preferred Stock, for cash, in whole or in part, at any time or from time to time, as follows: (i) between April 15, 2022 to April 15, 2023, at a redemption price of $26,000.00 per share ($26.00 per depositary share), (ii) between April 15, 2023 to April 15, 2024, at a redemption price of $25,750.00 per share ($25.75 per depositary share), (iii) between April 15, 2024 to April 15, 2025, at a redemption price of $25,500.00 per share ($25.50 per depositary share), (iv) between April 15, 2025 to April 15, 2026, at a redemption price of $25,250.00 per share ($25.25 per depositary share), and (v) after April 15, 2026, at a redemption price of $25,000.00 per share ($25.00 per depositary share), and in each case, plus any accrued and unpaid dividends thereon up to but not including the date fixed for redemption, without interest. If fewer than all of the outstanding shares of Series B Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata or by lot. Upon the occurrence of a delisting event or change of control the Company will have the option to redeem the Series B Preferred Stock, in whole or in part, for cash at $25,000.00 per share plus accrued and unpaid dividends.

Conversion - The shares of Series B Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company, except upon the occurrence of a delisting event or a change of control, each holder Series B Preferred Stock will have the right (unless the Company has elected to redeem the Series B Preferred Stock) to convert some or all of the shares of Series B Preferred Stock held by such holder on the delisting event conversion date or change of control conversion date into a number of shares of the common stock (or equivalent value of alternative consideration) per share of Series B Preferred Stock, equal to the lesser of (A) the quotient obtained by dividing (1) the sum of the $25,000.00 per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the delisting event conversion date or change of control conversion date, as applicable (unless the delisting event conversion date or change of control conversion date, is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and then remaining unpaid dividend will be included in this sum) by (2) the common stock price (such quotient, the “Conversion Rate”); and (B) 1,253.13 (1.25313 per depositary share) (i.e., the “Share Cap”), subject to certain adjustments described in the Series B Preferred Stock Certificate of Designation.

Voting Rights— Holders of the Series B Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.

Classification—The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.

F-37

Dividends

During the year ended December 31, 2021, the Company’s Board of Directors declared and paid cash dividends on the Company’s Series A Preferred Stock and Series B Depositary shares as follows.

Series A Preferred Stock

Series B Depositary Share

Cash Dividend Declared

Cash Dividend Declared

Dividend Declaration Date

    

($ per share)

    

($ per share)

    

Dividend Payment Date

March 17, 2021

$

0.71875

    

$

N/A (1)

April 15, 2021

May 21, 2021

$

0.53906

$

0.55833

July 15, 2021

July 28, 2021

$

0.53906

$

0.52344

October 15, 2021

October 20, 2021

$

0.53906

$

0.52344

January 18, 2022

(1)The Company sold 1,600,000 Series B Depositary Shares on April 9, 2021. As such, the first dividend was declared on May 21, 2021.

As of December 31, 2021, the Company held restricted cash of $2.0 million in a segregated account that may only be used to pay dividends on the Series A and Series B Preferred Stock.

BVF Ownership

In February 2020, BVF elected to increase the beneficial ownership limitation of the Series Y preferred stock to 50%, which became effective on April 11, 2020. On April 15, 2020, BVF converted all of its shares of Series Y preferred stock into common stock. As of December 31, 2021, BVF owned approximately 31.2% of the Company’s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own 52.3% of the Company’s total outstanding shares of common stock. The Company’s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of December 31, 2021, the contingency was not met, therefore the Series A Preferred Stock is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.

2018 Common Stock ATM Agreement

On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.

2021 Series B Preferred Stock ATM Agreement

On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed.

F-38

Common Stock Warrants

As of December 31, 2021 and 2020, the following common stock warrants were outstanding:

    

    

    

Exercise Price

    

December 31, 

    

December 31,

Issuance Date

Expiration Date

Balance Sheet Classification

per Share

2021

2020

February 2016

 

February 2021

 

Stockholders’ equity

$

15.40

 

 

8,249

May 2018

 

May 2028

 

Stockholders’ equity

$

23.69

 

6,332

 

6,332

March 2019

March 2029

Stockholders’ equity

$

14.71

4,845

4,845

 

  

 

  

 

  

 

11,177

 

19,426

In February 2016, in conjunction with services provided by a third-party consultant, the Company issued a warrant to purchase up to an aggregate of 8,249 unregistered shares of the Company’s common stock at an exercise price equal to $15.40 per share. The warrant was exercisable immediately and had a five-year term expiring in February 2021. As of December 31, 2020, the estimated fair value of the warrant of $0.1 million was calculated using the Black-Scholes Model and was classified in stockholders’ equity on the consolidated balance sheet. In February 2021, the Company issued 4,917 shares of common stock upon a cashless exercise of the common stock warrants held by Torreya Partners LLC. There is no balance of these warrants on the consolidated balance sheet as of December 31, 2021.

In May 2018, the Company issued SVB a warrant in connection with the SVB Loan Agreement (Note 8) which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share. The warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. The warrant is classified in stockholders’ equity on the consolidated balance sheets.

In March 2019, the Loan Agreement was amended to extend the Draw Period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The second warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. As of December 31, 2021, both warrants are outstanding and no shares have been issued upon exercise of the warrants.

13. Commitments and Contingencies

Collaborative Agreements, Royalties and Milestone Payments

The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company’s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.

Contingent Consideration

Pursuant to the Company’s royalty and commercial payment purchase agreements with Bioasis, Aronora, Kuros and Affitech, the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones and the Affitech regulatory and sales milestones. The Company recorded $0.1 million and $8.0 million for the Bioasis Contingent Consideration and the Affitech Regulatory Milestones, respectively, which, represents the estimated fair value of these potential future payments at the inception of the respective agreements. The contingent

F-39

consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other (expense) income, net. As of December 31, 2021, there were no changes in the estimated fair value of the Bioasis Contingent Consideration and the Affitech Sales Milestones from the initial value. The liability for future Aronora Royalty Milestones, Kuros Sales Milestones and Affitech Sales Milestones will be recorded when the amounts, by product, are estimable and probable. As of December 31, 2021, none of these Aronora Royalty Milestones, Kuros Sales Milestones or Affitech Sales Milestones were assessed to be probable and as such, no liability was recorded on the consolidated balance sheet.

14. Concentration of Risk, Segment and Geographic Information

Concentration of Risk

Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.  

The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the year ended December 31, 2021, one partner represented 92% of total revenues. For the year ended December 31, 2020, one partner represented 85% of total revenues. As of December 31, 2021 and 2020, one partner represented 100% of the trade receivables balance.

Segment Information

The Company has determined that it operates in one business segment as it only reports operating results on an aggregate basis to the chief operating decision maker of the Company.

Geographic Information

Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:

Year Ended December 31, 

    

2021

    

2020

Europe

$

35,000

$

25,010

United States

 

2,610

 

1,275

Asia Pacific

 

550

 

3,100

Total

$

38,160

$

29,385

The Company’s property and equipment is held in the United States.

15. Subsequent Events

On January 28, 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize faricimab (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. Upon approval, the Company became eligible to receive a 0.5% commercial payment stream on net sales associated with faricimab for a ten-year period following its first commercial sale in the United States.  The Company acquired this interest under the Affitech CPPA, pursuant to which, the Company paid Affitech a $5.0 million milestone tied to these U.S. marketing approvals. The Company may pay up to an additional $15.0 million to Affitech based on the achievement of certain regulatory approval and sales milestones.

In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to XOMA pursuant to the Company’s Rezolute License Agreement.

F-40

EX-4.6 2 tmb-20211231xex4d6.htm EX-4.6

Exhibit 4.6

DESCRIPTION OF XOMA CORPORATION CAPITAL STOCK

The following is a description of the Common Stock, $0.0075 par value (the “Common Stock”), Preferred Stock, $0.05 par value (the “Preferred Stock”) and depositary shares of XOMA Corporation (the “Company”). The Common Stock, 8.625% Series A Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock”) and the depositary shares (the “Series B Depositary Shares”) representing the 8.375% Series B Cumulative Perpetual Preferred Stock (the “Series B Preferred Stock”) are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Common Stock

General. The Company is authorized to issue up to 277,333,332 shares of Common Stock. The following description is based on (i) the Company’s Certificate of Incorporation, as currently in effect (the “Certificate of Incorporation”), (ii) the Company’s By-laws, as currently in effect (the “By-laws”), and (iii) the Delaware General Corporation Law (the “DGCL”). The following summary description of the Common Stock of the Company is qualified in its entirety by reference to the provisions of the Certificate of Incorporation and By-laws, copies of which have been filed as exhibits to the Company’s Annual Report on Form 10-K filed herewith, and the applicable provisions of the DGCL.

Dividend Rights. The holders of our Common Stock have the right to receive dividends and distributions, whether payable in cash or otherwise, as may be declared from time to time by our board of directors, from legally available funds.

Voting Rights. Each holder of our Common Stock is generally entitled to one vote for each share of Common Stock owned of record on all matters submitted to a vote of our stockholders. Except as otherwise required by law, holders of Common Stock (as well as holders of any Preferred Stock entitled to vote with the common stockholders) will generally vote together as a single class on all matters presented to the stockholders for their vote or approval, including the election of directors. Any matter brought before the stockholders for a vote, other than the election of directors, will generally be decided by a majority of the votes cast on the matter, unless the matter is one in which an express provision of the DGCL, the Certificate of Incorporation, the By-laws, the rules or regulations of any stock exchange applicable to us, applicable law or pursuant to any regulation applicable to us or our securities requires a different vote, in which case the express provision will govern and control the decision of the matter. Directors will be elected by a plurality of the votes cast and entitled to vote generally on the election of directors. There are no cumulative voting rights with respect to the election of directors or any other matters.

No Preemptive or Similar Rights. Holders of our Common Stock have no redemption rights, conversion rights or preemptive rights to purchase or subscribe for our securities.

Right to Receive Liquidation Distributions. In the event of our liquidation, dissolution or winding-up, holders of our Common Stock will be entitled to share equally in the assets available for distribution after payment of all creditors and the liquidation preferences of our Preferred Stock (if any).

The rights of the holders of our Common Stock are subject to, and may be adversely affected by, the rights of holders of shares of any Preferred Stock that we may designate and issue in the future.

Preferred Stock

General. Under our Certificate of Incorporation, our board of directors is authorized to issue up to 1,000,000 shares of Preferred Stock, and, by resolution, to divide the Preferred Stock into series and, with respect to each series,


to determine the designations and the powers, preferences and rights, and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights, redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. Our board of directors can, without stockholder approval but subject to the terms of the Certificate of Incorporation and to any resolution of the stockholders approved by at least 75% of all issued shares entitled to vote in respect thereof, issue Preferred Stock with voting and other rights that could adversely affect the voting power of the holders of our Common Stock and which could have certain anti-takeover effects. Before we may issue any series of Preferred Stock, our board of directors will be required to adopt resolutions creating and designating such series of Preferred Stock.

The following summary description of the Preferred Stock of the Company, including the Series B Depositary Shares, is qualified in its entirety by reference to the provisions of the Certificate of Incorporation, By-laws and the certificates of designation of preferences, rights and limitations of each series of the Preferred Stock, copies of which have been filed as exhibits to the Company’s Annual Report on Form 10-K, and the applicable provisions of the DGCL. As of December 31, 2021, 5,003 shares of Series X Preferred Stock, 984,000 shares of Series A Preferred Stock and 1,600 shares of Series B Depositary Shares were issued and outstanding.

The 8.625% Series A Cumulative Perpetual Preferred Stock. We have designated 984,000 shares of our Preferred Stock as Series A Preferred Stock.

The Series A Preferred Stock will rank, as to dividend rights and rights upon our liquidation, dissolution or winding up:

senior to all classes or series of our Common Stock and to all other equity securities issued by us expressly designated as ranking junior to the Series A Preferred Stock;

senior with respect to the payment of dividends and on parity with respect to the distribution of assets upon our liquidation, dissolution or winding up with our Series X Preferred Stock and on parity with any future class or series of our equity securities expressly designated as ranking on parity with the Series A Preferred Stock;

junior to all equity securities issued by us with terms specifically providing that those equity securities rank senior to the Series A Preferred Stock with respect to the payment of dividends and the distribution of assets upon our liquidation, dissolution or winding up, none of which exists on the date hereof; and;

effectively junior to all our existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) and to the indebtedness and other liabilities of (as well as any preferred equity interests held by others in) our existing or future subsidiaries.

Dividends. We will pay cumulative cash dividends on the Series A Preferred Stock, when and as declared by our board of directors, at the rate of 8.625% of the $25.00 liquidation preference per share per year (equivalent to $2.15625 per year). Dividends will be payable quarterly in arrears, on or about the 15th day of January, April, July and October; provided that if any dividend payment date is not a business day, then the dividend which would otherwise have been payable on that dividend payment date may be paid on the next succeeding business day, and no interest, additional dividends or other sums will accumulate. Dividends will accumulate and be cumulative from, and including, the date of original issuance. The first dividend, which was paid on April 15, 2021 in the amount of $0.71875 per share of Series A Preferred Stock, was for more than a full quarter and covered the period from, and including, the first date we issued and sold the Series A Preferred Stock through, but not including, April 15, 2021. Dividends on the Series A Preferred Stock will continue to accumulate whether or not (i) any of our agreements prohibit the current payment of dividends, (ii) we have earnings or funds legally available to pay the dividends, or (iii) our board of directors does not declare the payment of the dividends.

Liquidation Preference. The liquidation preference of each share of Series A Preferred Stock is $25.00. Upon liquidation, holders of our Series A Preferred Stock will be entitled to receive the liquidation preference with respect to their shares of Series A Preferred Stock plus an amount equal to accumulated but unpaid dividends with respect to such shares.


Optional Redemption. On and after December 15, 2021, the first anniversary of December 15, 2020, to but excluding the second anniversary, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $26.00 per share, plus any accrued and unpaid dividends. On and after December 15, 2022, the second anniversary of December 15, 2020, to but excluding the third anniversary, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.75 per share, plus any accrued and unpaid dividends. On and after December 15, 2023, the third anniversary of December 15, 2020, to but excluding the fourth anniversary, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.50 per share, plus any accrued and unpaid dividends. On and after December 15, 2024, the fourth anniversary of December 15, 2020, to but excluding the fifth anniversary, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.25 per share, plus any accrued and unpaid dividends. On and after December 15, 2025, the fifth anniversary of December 15, 2020, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.00 per share, plus any accrued and unpaid dividends.

Special Optional Redemption Upon a Change of Control or Delisting Event. Upon the occurrence of a Delisting Event (as defined below), we may, at our option, redeem the Series A Preferred Stock, in whole or in part, within 90 days after the first date on which such Delisting Event occurred, for cash, at a redemption price of $25.00 per share, plus any accrued and unpaid dividends up to, but not including, the date of redemption.

With respect to the Series A Preferred Stock, a “Delisting Event” occurs when, after the original issuance of Series A Preferred Stock, both (i) the shares of Series A Preferred Stock are no longer listed on Nasdaq, the New York Stock Exchange (the “NYSE”) or the NYSE American LLC (“NYSE AMER”), or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER, and (ii) we are not subject to the reporting requirements of the Exchange Act, but any Series A Preferred Stock is still outstanding.

Upon the occurrence of a Change of Control (as defined below), we may, at our option, redeem the Series A Preferred Stock, in whole or in part within 120 days after the first date on which such Change of Control occurred, for cash, at a redemption price of $25.00 per share, plus any accrued and unpaid dividends up to, but not including, the date of redemption.

With respect to the Series A Preferred Stock, a “Change of Control” occurs when, after the original issuance of the Series A Preferred Stock, the following have occurred and are continuing:

the acquisition by any person, including any syndicate or group deemed to be a “person” under Section 13(d)(3) of the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition transaction or series of purchases, mergers or other acquisition transactions of shares of our company entitling that person to exercise more than 50% of the total voting power of all shares of our company entitled to vote generally in elections of directors (except that such person will be deemed to have beneficial ownership of all securities that such person has the right to acquire, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and

following the closing of any transaction referred to in the bullet point above, neither we nor any acquiring or surviving entity (or if, in connection with such transaction shares of our Common Stock are converted into or exchanged for (in whole or in part) common equity securities of another entity), has a class of common securities (or ADRs representing such securities) listed on Nasdaq, the NYSE or the NYSE AMER, or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER.

We refer to redemption following a Delisting Event or Change of Control as a “special optional redemption.” If, prior to the Delisting Event Conversion Date (as defined below) or the Change of Control Conversion Date (as defined below), as applicable, we have provided or provide notice of exercise of any of our redemption rights relating to the Series A Preferred Stock (whether our optional redemption right or our special optional redemption right), the holders of the Series A Preferred Stock will not have the conversion right described below.


Conversion. Upon the occurrence of a Delisting Event or a Change of Control, as applicable, each holder of Series A Preferred Stock will have the right (unless, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide notice of our election to redeem the Series A Preferred Stock) to convert some or all of the Series A Preferred Stock held by such holder on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, into a number of shares of our Common Stock (or equivalent value of alternative consideration) per share of Series A Preferred Stock equal to the lesser of:

the quotient obtained by dividing (1) the sum of the $25.00 per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable (unless the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable is after a record date for a Series A Preferred Stock dividend payment and prior to the corresponding Series A Preferred Stock dividend payment date, in which case no additional amount for such accumulated and unpaid dividend will be included in this sum) by (2) the Common Stock Price (as defined below); and

1.46071 (i.e., the Share Cap), subject to certain adjustments; and subject, in each case, to certain conditions, including, under specified circumstances, an aggregate cap on the total number of shares of our Common Stock issuable upon conversion and to provisions for the receipt of alternative consideration.

If, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide a redemption notice, whether pursuant to our special optional redemption right or our optional redemption right, holders of Series A Preferred Stock will not have any right to convert the Series A Preferred Stock, and any Series A Preferred Stock subsequently selected for redemption that has been tendered for conversion will be redeemed on the related date of redemption instead of converted on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable.


In the event that the conversion would result in the issuance of fractional shares of Common Stock, we will pay the holder of Series A Preferred Stock cash in lieu of such fractional shares.


Except as provided above in connection with a Delisting Event or Change of Control, shares of the Series A Preferred Stock are not convertible into or exchangeable for any other securities or property.

For purposes of this description of the Series A Preferred Stock, “Change of Control Conversion Date” means a business day fixed by our board of directors that is not fewer than 20 days nor more than 35 days after the date on which we provide notice to the holders of the Series A Preferred Stock of a Change of Control.

For purposes of this description of the Series A Preferred Stock, “Common Stock Price” for any Change of Control will be: (1) if the consideration to be received in the Change of Control by the holders of our Common Stock is solely cash, the amount of cash consideration per share of Common Stock; and (2) if the consideration to be received in the Change of Control by holders of our Common Stock is other than solely cash (x) the average of the closing prices for our Common Stock on the principal U.S. securities exchange on which our Common Stock is then traded (or, if no closing sale price is reported, the average of the closing bid and ask prices per share or, if more than one in either case, the average of the average closing bid and the average closing ask prices per share) for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred as reported on the principal U.S. securities exchange on which our Common Stock is then traded, or (y) the average of the last quoted bid prices for our Common Stock in the over-the-counter market as reported by OTC Markets Group Inc. or similar organization for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred, if our Common Stock is not then listed for trading on a U.S. securities exchange. The “Common Stock Price” for any Delisting Event will be the average of the closing price per share of our Common Stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the Delisting Event.

For purposes of this description of the Series A Preferred Stock, “Delisting Event Conversion Date” means a business day fixed by our board of directors that is not fewer than 20 days nor more than 35 days after the date on which we provide notice to the holders of the Series A Preferred Stock of a Delisting Event.


Voting Rights. Holders of Series A Preferred Stock generally will have no voting rights. However, if we do not pay dividends on any outstanding shares of Series A Preferred Stock for six or more quarterly dividend periods (whether or not declared or consecutive), holders of Series A Preferred Stock (voting separately as a class with all other outstanding series of preferred stock upon which like voting rights have been conferred and are exercisable) will be entitled to elect two additional directors to our board of directors to serve until all unpaid dividends have been fully paid or declared and set apart for payment. In addition, certain material and adverse changes to the terms of the Series A Preferred Stock cannot be made without the affirmative vote of holders of at least 66 2/3% of the outstanding shares of Series A Preferred Stock, voting as a separate class. In any matter in which the Series A Preferred Stock may vote, each share of Series A Preferred Stock shall be entitled to one vote.

The 8.375% Series B Cumulative Perpetual Preferred Stock and the Series B Depositary Shares. We have designated 3,600 shares of our Preferred Stock as Series B Preferred Stock.

The Series B Preferred Stock underlying the Series B Depositary Shares will rank, as to dividend rights and rights upon our liquidation, dissolution or winding up:

senior to all classes or series of our Common Stock and to all other equity securities issued by us expressly designated as ranking junior to the Series B Preferred Stock;

senior with respect to the payment of dividends and on parity with respect to the distribution of assets upon our liquidation, dissolution or winding up with our Series X Preferred Stock;

on parity with our Series A Preferred Stock, and with any future class or series of our equity securities expressly designated as ranking on parity with the Series B Preferred Stock;

junior to all equity securities issued by us with terms specifically providing that those equity securities rank senior to the Series B Preferred Stock with respect to the payment of dividends and the distribution of assets upon our liquidation, dissolution or winding up, none of which exists on the date hereof; and

effectively junior to all our existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) and to the indebtedness and other liabilities of (as well as any preferred equity interests held by others in) our existing or future subsidiaries.

Dividends. We will pay cumulative cash dividends on the Series B Preferred Stock, when and as declared by our board of directors, at the rate of 8.375% of the $25,000.00 liquidation preference ($25.00 per depositary share) per year (equivalent to $2,093.75 per share or $2.09375 per depositary share per year). Dividends will be payable quarterly in arrears, on or about the 15th day of January, April, July and October; provided that if any dividend payment date is not a business day, then the dividend which would otherwise have been payable on that dividend payment date may be paid on the next succeeding business day, and no interest, additional dividends or other sums will accumulate. Dividends will accumulate and be cumulative from, and including, the date of original issuance. Dividends on the Series B Preferred Stock underlying the Series B Depositary Shares will continue to accumulate whether or not (i) any of our agreements prohibit the current payment of dividends, (ii) we have earnings or funds legally available to pay the dividends, or (iii) our board of directors does not declare the payment of the dividends.

Liquidation Preference. The liquidation preference of each share of Series B Preferred Stock is $25,000.00 ($25.00 per depositary share). Upon liquidation, holders of our Series B Preferred Stock will be entitled to receive the liquidation preference with respect to their shares of Series B Preferred Stock plus an amount equal to accumulated but unpaid dividends with respect to such shares.

Optional Redemption. On and after April 15, 2022, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $26,000.00 per share ($26.00 per depositary share), plus any accrued and unpaid dividends. On and after April 15, 2023, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,750.00 per share ($25.75 per depositary share), plus any accrued and unpaid dividends. On and after April 15, 2024, the shares of Series B Preferred


Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,500.00 per share ($25.50 per depositary share), plus any accrued and unpaid dividends. On and after April 15, 2025, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,250.00 per share ($25.25 per depositary share), plus any accrued and unpaid dividends. On and after April 15, 2026, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,000.00 per share ($25.00 per depositary share), plus any accrued and unpaid dividends. On or after the date fixed for redemption of shares of Series B Preferred Stock, each holder of Series B Depositary Shares to be redeemed must present and surrender the depositary receipts evidencing the Series B Depositary Shares to the depositary at the place designated in the notice of redemption. The redemption price of such Series B Depositary Shares will then be paid to or on the order of the person whose name appears on such depositary receipts as the owner thereof.

Special Optional Redemption Upon a Change of Control or Delisting Event. Upon the occurrence of a Delisting Event (as defined below), we may, at our option, redeem the Series B Preferred Stock, in whole or in part, within 90 days after the first date on which such Delisting Event occurred, for cash, at a redemption price of $25,000.00 per share (equivalent to $25.00 per depositary share), plus any accrued and unpaid dividends up to, but not including, the date of redemption, and the depositary will redeem a proportional number of Series B Depositary Shares representing the shares redeemed.

With respect to the Series B Preferred Stock, a “Delisting Event” occurs when, after the original issuance of Series B Preferred Stock, both (i) the shares of Series B Preferred Stock (or the Series B Depositary Shares) are no longer listed on Nasdaq, the NYSE or the NYSE AMER, or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER, and (ii) we are not subject to the Exchange Act, but any Series B Preferred Stock is still outstanding.

Upon the occurrence of a Change of Control (as defined below), we may, at our option, redeem the Series B Preferred Stock underlying the Series B Depositary Shares, in whole or in part within 120 days after the first date on which such Change of Control occurred, for cash, at a redemption price of $25,000.00 per share (equivalent to $25.00 per depositary share), plus any accrued and unpaid dividends up to, but not including, the date of redemption, and the depositary will redeem a proportional number of Series B Depositary Shares representing the shares redeemed.

With respect to the Series B Preferred Stock, a “Change of Control” occurs when, after the original issuance of the Series B Preferred Stock, the following have occurred and are continuing:

the acquisition by any person, including any syndicate or group deemed to be a “person” under Section 13(d)(3) of the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition transaction or series of purchases, mergers or other acquisition transactions of shares of our company entitling that person to exercise more than 50% of the total voting power of all shares of our company entitled to vote generally in elections of directors (except that such person will be deemed to have beneficial ownership of all securities that such person has the right to acquire, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and

following the closing of any transaction referred to in the bullet point above, neither we nor any acquiring or surviving entity (or if, in connection with such transaction shares of our Common Stock are converted into or exchanged for (in whole or in part) common equity securities of another entity), has a class of common securities (or ADRs representing such securities) listed on Nasdaq, the NYSE or the NYSE AMER, or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER.

We refer to redemption following a Delisting Event or Change of Control as a “special optional redemption.” If, prior to the Delisting Event Conversion Date or the Change of Control Conversion Date (each as defined below), as applicable, we have provided or provide notice of exercise of any of our redemption rights relating to the Series B Preferred Stock (whether our optional redemption right or our special optional redemption right), the holders of Series B Depositary Shares representing interests in the Series B Preferred Stock will not have the conversion right described below.


Conversion. Upon the occurrence of a Delisting Event or a Change of Control, as applicable, each holder of Series B Depositary Shares representing interests in the Series B Preferred Stock will have the right (unless, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide notice of our election to redeem the Series B Preferred Stock) to direct the depositary, on such holder’s behalf, to convert some or all of the Series B Preferred Stock underlying the Series B Depositary Shares held by such holder on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable into a number of shares of our Common Stock (or equivalent value of alternative consideration) per depositary share equal to the lesser of:

the quotient obtained by dividing (1) the sum of the $25.00 per depositary share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable (unless the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and unpaid dividend will be included in this sum) by (2) the Common Stock Price (as defined herein); and

1.25313 (i.e., the Share Cap), subject to certain adjustments; and subject, in each case, to certain conditions, including, under specified circumstances, an aggregate cap on the total number of shares of our Common Stock issuable upon conversion and to provisions for the receipt of alternative consideration.

If, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide a redemption notice, whether pursuant to our special optional redemption right or our optional redemption right, holders of Series B Depositary Shares representing interests in the Series B Preferred Stock will not have any right to direct the depositary to convert the Series B Preferred Stock, and any Series B Preferred Stock subsequently selected for redemption that has been tendered for conversion will be redeemed on the related date of redemption instead of converted on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable.


Because each depositary share represents a 1/1000th interest in a share of the Series B Preferred Stock, the number of shares of Common Stock ultimately received for each depositary share will be equal to the number of shares of Common Stock received upon conversion of each share of Series B Preferred Stock divided by 1000. In the event that the conversion would result in the issuance of fractional shares of Common Stock, we will pay the holder of Series B Depositary Shares cash in lieu of such fractional shares.


Except as provided above in connection with a Delisting Event or Change of Control, shares of the Series B Preferred Stock are not convertible into or exchangeable for any other securities or property.

For purposes of this description of the Series B Preferred Stock and the underlying Series B Depositary Shares, “Change of Control Conversion Date” means a business day fixed by our board of directors that is not fewer than 20 days nor more than 35 days after the date on which we provide the notice described above to the holders of the Series B Depositary Shares representing interests in the Series B Preferred Stock.

For purposes of this description of the Series B Preferred Stock and the underlying Series B Depositary Shares, “Common Stock Price” for any Change of Control will be: (1) if the consideration to be received in the Change of Control by the holders of our Common Stock is solely cash, the amount of cash consideration per share of Common Stock; and (2) if the consideration to be received in the Change of Control by holders of our Common Stock is other than solely cash (x) the average of the closing prices for our Common Stock on the principal U.S. securities exchange on which our Common Stock is then traded (or, if no closing sale price is reported, the average of the closing bid and ask prices per share or, if more than one in either case, the average of the average closing bid and the average closing ask prices per share) for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred as reported on the principal U.S. securities exchange on which our Common Stock is then traded, or (y) the average of the last quoted bid prices for our Common Stock in the over-the-counter market as reported by OTC Markets Group Inc. or similar organization for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred, if our Common Stock is not then


listed for trading on a U.S. securities exchange. The “Common Stock Price” for any Delisting Event will be the average of the closing price per share of our Common Stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the Delisting Event.

For purposes of this description of the Series B Preferred Stock and the underlying Series B Depositary Shares, “Delisting Event Conversion Date” means a business day fixed by our board of directors that is not fewer than 20 days nor more than 35 days after the date on which we provide the notice described above to the holders of the Series B Depositary Shares representing interests in the Series B Preferred Stock.

Voting Rights. Holders of the Series B Depositary Shares representing interests in the Series B Preferred Stock generally will have no voting rights. However, if we do not pay dividends on any outstanding shares of Series B Preferred Stock for six or more quarterly dividend periods (whether or not declared or consecutive), holders of Series B Preferred Stock (voting separately as a class with all other outstanding series of preferred stock upon which like voting rights have been conferred and are exercisable) will be entitled to elect two additional directors to our Board of Directors to serve until all unpaid dividends have been fully paid or declared and set apart for payment. In addition, certain material and adverse changes to the terms of the Series B Preferred Stock cannot be made without the affirmative vote of holders of at least 66 2/3% of the outstanding shares of Series B Preferred Stock, voting as a separate class. In any matter in which the Series B Preferred Stock may vote, each share of Series B Preferred Stock shall be entitled to one vote. As a result, each depositary share will be entitled to 1/1000th of a vote.

The Series X Preferred Stock. We have designated 5,003 shares of our Preferred Stock as Series X Preferred Stock. The Series X Preferred Stock ranks:

senior to any class or series of our capital stock created specifically ranking by its terms junior to the Series X Preferred Stock;

on parity to our Common Stock;

on parity to any class or series of our capital stock created specifically ranking by its terms on parity with the Series X Preferred Stock; and

junior to any class or series of our capital stock created specifically ranking by its terms senior to the Series X Preferred Stock;

in each case, as to distributions of assets upon our liquidation, dissolution or winding up whether voluntarily or involuntarily.

Dividends. Holders of Series X Preferred Stock are entitled to receive dividends on shares of Series X Preferred Stock equal (on an as-converted basis) to and in the same form as dividends actually paid on our Common Stock or other junior securities.

Liquidation Preference. In the event of our liquidation, dissolution, or winding up, holders of our Series X Preferred Stock will participate pari passu (on an as-converted basis, without regard to any blocker provisions) with any distribution of proceeds to holders of our Common Stock.

Redemption. We are not obligated to redeem or repurchase any shares of Series X Preferred Stock. Shares of Series X Preferred Stock are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.

Conversion. The Series X Preferred Stock is convertible at the option of the holders thereof at any time after issuance into the number of registered shares of Common Stock determined by dividing the aggregate stated value of the Series X Preferred Stock being converted by the conversion price then in effect. The initial conversion price is $4.03 and is subject to adjustment as described below. No holder may request a conversion of its Series X Preferred Stock to the extent such conversion would result in the holder and its affiliates beneficially owning more than a pre-


set conversion blocker threshold, which will initially be set at 19.99% of our Common Stock then outstanding (the “Beneficial Ownership Limitation”). The amount of beneficial ownership of a holder and its affiliates will be determined in accordance with Section 13(d) of the Exchange Act, and the rules and regulations of that section.

Conversion Price Adjustment-Stock Dividends and Stock Splits. If we pay a stock dividend or otherwise make a distribution payable in Common Stock on our Common Stock or any Common Stock equivalents, subdivide or combine our outstanding Common Stock, or reclassify our Common Stock in such a way that we issue additional shares of our capital stock, the conversion price will be adjusted by multiplying the then-existing conversion price by a fraction, the numerator of which is the number of shares of Common Stock outstanding immediately before the distribution, dividend, adjustment or recapitalization and the denominator of which is the number of shares of Common Stock outstanding immediately after such action.

Fundamental Transaction. If we effect a “fundamental transaction” (as defined below), then upon any future conversion of the Series X Preferred Stock, the holders will have the right to receive, for each share of Common Stock they would have received upon such conversion, the same kind and amount of securities, cash or property as such holder would have been entitled to receive in the fundamental transaction had it been the holder of Common Stock immediately prior to the fundamental transaction. The term “fundamental transaction” means any of the following:

a merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the Company is not the surviving entity;

the sale of all or substantially all of our assets in one transaction or a series of related transactions;

any completed tender offer or exchange offer involving holders of Common Stock in which more than 50% of the Common Stock is converted or exchanged into other securities, cash or property, regardless of who makes such offer; or

any reclassification of Common Stock or any compulsory share exchange by which our Common Stock is effectively converted into or exchanged for other securities, cash or property (but not a reverse stock split).

If the holders of Common Stock are given a choice as to the securities, cash or property to be received in a fundamental transaction, the holders of Series X Preferred Stock will be given the same choice on conversion of such holders’ shares.

Voting Rights. The Series X Preferred Stock has no voting rights, except to the extent expressly provided in our Certificate of Incorporation or as otherwise required by law. However, so long as 2,502 shares of Series X Preferred Stock are outstanding, we may not take any of the following actions without the affirmative consent of holders of a majority of the outstanding Series X Preferred Stock:

amend our Certificate of Incorporation, By-laws or other charter documents so as to materially, specifically and adversely affect the preferences, rights, or privileges of the Series X Preferred Stock;

issue additional shares of Series X Preferred Stock or increase or decrease the number of authorized shares of Series X Preferred Stock;

sell, assign, monetize, pledge or otherwise divest or encumber our rights under any material license agreement, joint venture or other partnership agreement to which we are a party as of the date of this offering and involving any drug or drug candidate;

issue or commit to issue any other equity securities, with certain exceptions;

issue any equity-based award or compensation to certain of our officers, unless the award has been unanimously approved by our compensation committee at a time when a designee appointed by the Series X Preferred holders is then serving on that committee; or

enter into any agreement or understanding to take any of the actions listed above.

Anti-takeover Effects of Provisions of our Certificate of Incorporation and By-laws and Delaware Law

Certificate of Incorporation and By-laws Provisions. Our Certificate of Incorporation authorizes our board of directors to issue up to 1,000,000 shares of Preferred Stock without stockholder approval and to set the rights, preferences and other designations, including voting rights, of those shares as the board of directors may determine. In addition, our By-laws require certain procedures to be followed and time periods to be met for any stockholder to propose matters to be considered at annual meetings of stockholders, including nominating directors for election at those meetings. Our By-laws also provide that our board of directors is able to elect a director to fill a vacancy created by the expansion of the board of directors or due to the resignation or departure of an existing board member. Provisions of Delaware law and our Certificate of Incorporation and By-laws could make the acquisition of our company through a tender offer, a proxy contest or other means more difficult and could make the removal of incumbent officers and directors more difficult. We expect these provisions to discourage coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of our company to first negotiate with our board of directors. We believe that the benefits provided by our ability to negotiate with the proponent of an unfriendly or unsolicited proposal outweigh the disadvantages of discouraging these proposals. We believe the negotiation of an unfriendly or unsolicited proposal could result in an improvement of its terms.

Delaware Law. We are subject to Section 203 of the DGCL, an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years following the date the person became an interested stockholder, unless:

prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66% of the outstanding voting stock which is not owned by the interested stockholder.

Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An “interested stockholder” is a person who, together with affiliates and associates, beneficially owns, or is an affiliate of the corporation and within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s outstanding voting securities. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance.


EX-10.26 3 tmb-20211231xex10d26.htm EX-10.26

Exhibit 10.26

AMENDED AND RESTATED EMPLOYMENT AGREEMENT  

This Amended and Restated Employment Agreement (“Agreement”) between James R. Neal (“Employee”) and XOMA Corporation (“XOMA” or the “Company”) (collectively, the “Parties”) is effective as of December 15, 2021 (the “Agreement Effective Date”).

Preamble:

XOMA wishes to enter into this Agreement to assure the continued services of Employee for a period until a new CEO is hired or until December 31, 2022, whichever occurs first; and
Employee is willing to enter into this Agreement and to serve in the employ of XOMA upon the terms and conditions hereinafter provided;
NOW, THEREFORE, in consideration of the mutual covenants herein contained, the Parties agree as follows: 
1.Employment.  Employee is currently employed with XOMA in the position of Chief Executive Officer (“CEO”).  Employee will continue to serve in this role until the Company hires a new CEO.  Upon the hiring of a new CEO, the Board of Directors (the “Board”) will determine Employee’s employment termination date (the “Separation Date”), at which time Employee’s employment with the Company will cease.  If the Company has not hired a new CEO as of January 1, 2023, then such date will become Employee’s Separation Date, unless the Parties mutually agree in writing to a different Separation Date.  Employee’s terms of employment between the Agreement Effective Date and the Separation Date (the “Transition Period”) will be governed by the terms of this Agreement, which shall supersede and replace, in entirety, the Officer Employment Agreement between Employee and the Company dated August 7, 2017.
2.Position and Responsibilities.   Employee shall devote reasonable best efforts and substantially all of Employee’s time and attention to employment with XOMA.  Employee shall perform those duties and responsibilities as may be directed by the Board, to whom Employee will report.  Such duties shall include (without limitation) delivering 2022 operating results, serving as the external face of XOMA, retaining and recruiting talent, and leading the search for a new CEO (to be approved and appointed by the Board).  Effective as of the Agreement Effective Date, Employee will also be appointed to serve as the Chair of the Board, with such appointment to terminate in the discretion of the Board.  While employed by XOMA, Employee may not accept consulting or other business or non-profit opportunities without first obtaining written approval from the Board.  The Company acknowledges that the Board has previously approved the following appointments by Employee:  Chairman of the Board of Palisade Bio, Inc. and Chairman of the Board of Monterey Bio.  In addition, while employed by XOMA, except on behalf of XOMA, Employee will not directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative or consultant of any other person, corporation, firm, partnership or other entity whatsoever known by Employee to compete with XOMA (or that is planning or preparing to compete with XOMA), anywhere in the world, in any line of business engaged in (or planned to be engaged in) by XOMA; provided, however, that Employee may purchase or otherwise acquire up to (but not more than) five percent (5%) of any class of securities
Background image

260523219 v5


of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange.    
3.Term of Employment.    The term of Employee’s employment with XOMA shall be the Transition Period.  Consistent with XOMA policy, Employee’s employment relationship with XOMA is at-will.  Accordingly, Employee may resign Employee’s employment with XOMA at any time and for any reason whatsoever simply by notifying XOMA; and XOMA may terminate Employee’s employment at any time, with or without Cause (as defined in Section 7(d)) or advance notice, subject to the provisions of Sections 7 and 8.  
4.Compensation and Reimbursement of Expenses.  
(a)Compensation. Employee will receive for services to be rendered hereunder a Base Salary paid at the rate of $725,000 per year, less applicable payroll deductions and withholdings (the “Base Salary”), paid on XOMA’s ordinary payroll cycle.  In addition, starting on January 1, 2022, Employee will receive a bonus equal to 60% of Base Salary, which will be paid in equal installments on the Company’s ordinary payroll cycle.      
(b)Equity Awards.  Employee has already been granted Stock Awards, which will continue to be governed by the terms of the applicable stock option and equity incentive award plans or agreements and grant notices.  For purposes of this Agreement, “Stock Awards” shall mean all stock options, restricted stock and restricted stock units and such other awards granted pursuant to XOMA’s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof.  In addition, following the Agreement Effective Date, in accordance with the Company’s option grant policy, the Company will grant Employee a stock option to purchase 60,000 shares of the Company’s common stock, subject to the terms of the Company’s equity incentive plan and a vesting schedule to be set forth in the applicable option award documentation.
(c)Reimbursement of Expenses. XOMA shall reimburse Employee for all reasonable travel and other expenses incurred in performing Employee’s obligations under this Agreement in a manner consistent with XOMA policies.
5.Participation in Benefit Plans. The payments provided in Section 4 are in addition to benefits Employee is entitled to under any employee benefit plan of XOMA for which Employee is or becomes eligible.  
6.Compliance with Proprietary Information Agreement and XOMA Policies.  Employee is required to remain in compliance with the terms of the Employee Confidential Information and Inventions Assignment Agreement that Employee has previously executed (the “Confidentiality Agreement”).  In addition, Employee is required to abide by XOMA’s policies and procedures (including but not limited to XOMA’s Employee Handbook), as adopted or modified from time to time within XOMA’s discretion; provided, however, that in the event the terms of this Agreement differ from or are in conflict with XOMA’s general employment policies or practices, this Agreement shall control.
7.Termination of Employment.

-2-

Background image

260523219 v5


(a)Termination by Employee.  As provided in Section 3, Employee may resign Employee’s employment with XOMA at any time, including for “Good Reason.” For purposes of this Agreement, Employee shall have “Good Reason” for resignation from employment with XOMA in the event of a material breach of this Agreement by the Company.  In order to resign for Good Reason, Employee must provide the Company with notice of the material breach giving rise to Good Reason within thirty (30) days after its occurrence; the Company will then have thirty (30) days to cure; and then Employee must resign within thirty (30) days after the end of the cure period if the material breach has not been cured.  Employee will not be entitled to the Continuity Incentive set forth in Section 8 if Employee resigns without Good Reason prior to the Company hiring a new CEO, or December 31, 2022, whichever comes first.  If Employee resigns with Good Reason prior to the Company hiring a new CEO, or December 31, 2022, whichever comes first, then Employee will be entitled to the Continuity Incentive set forth in Section 8 below, subject to the terms and conditions therein.  
(b)Termination by XOMA Without Cause.  Employee may be terminated by XOMA without Cause, but in such case, Employee shall be entitled to the Continuity Incentive set forth in Section 8 below, subject to the terms and conditions therein.  The termination of Employee’s employment upon the hiring of a new CEO will be deemed a termination without Cause.
(c)Termination Upon Death or Permanent Disability.  Except as required by law and as provided in Section 8, all benefits and other rights of Employee under this Agreement shall be terminated by Employee’s death or Permanent Disability.  For purposes of this Agreement, “Permanent Disability” is defined as Employee being incapable of performing duties to XOMA by reason of any medically determined physical or mental impairment that can be expected to last for a period of more than six (6) consecutive months from the first date of Employee’s absence due to the disability.  XOMA will give Employee at least four (4) weeks written notice of termination due to such disability.  The Company may terminate Employee’s employment due to death or Permanent Disability, in which case Employee shall be entitled to the Continuity Incentive benefits set forth in Section 8, subject to the terms and conditions therein.
(d)Termination by XOMA for Cause.  XOMA may terminate Employee’s employment for Cause, in which case, Employee will not be entitled to the Continuity Incentive benefits under Section 8.  For purposes of this Agreement, XOMA will have Cause to terminate Employee’s employment as the result of:  
(i)willful material fraud or material dishonesty in connection with Employee’s performance under this Agreement;
(ii)failure by Employee to materially perform the duties of CEO;  
(iii)material breach of this Agreement or of XOMA’s Code of Ethics;  
(iv)misappropriation of a material business opportunity of XOMA;

-3-

Background image

260523219 v5


(v)misappropriation of any XOMA funds or property; or
(vi)conviction of, or the entering of a plea of guilty or no contest with respect to, a felony.
(e)Notice and Opportunity to Cure.  It shall be a condition precedent to XOMA’s right to terminate Employee’s employment for the reasons set forth in Sections 7(d)(ii) or (iii) of this Agreement that (i) XOMA shall first have given Employee written notice stating with specificity the reason for the termination (“Breach”) and (ii) if such Breach is capable of cure or remedy, Employee will have a period of thirty (30) days after the notice is given to remedy the Breach.
(f)Return of XOMA Property.  Upon termination of employment for any reason, and as a precondition to Employee’s receipt of the Continuity Incentive benefits set forth in Section 8, Employee shall immediately return to XOMA all documents, telephones, computers, keys, credit cards, other property and records of XOMA, and all copies, within Employee’s possession, custody or control. 
(g)Release of Claims.  As a condition of receiving the Continuity Incentive benefits set forth in Section 8, Employee shall execute and deliver to XOMA a release of claims in favor of XOMA substantially in the form attached hereto as Exhibit A (the “Release Agreement”) within the timeframe set forth in the Release Agreement, but not later than forty-five (45) days following Employee’s Separation Date, and allow the Release Agreement to become effective according to its terms (by not invoking any legal right to revoke it) within any applicable time period set forth in the Release Agreement.
8.Continuity Incentive.  Subject to Sections 7(f) and 7(g) and Employee’s continued compliance with all legal and contractual obligations to the Company, upon the termination of Employee’s employment with XOMA due to a resignation for Good Reason, or as provided in Section 7(b) (Termination without Cause) or Section 7(c) (Termination due to death or Permanent Disability), Employee shall be entitled to a Continuity Incentive in the amount of $1,160,000.  In addition, if Employee’s resignation for Good Reason or Termination without Cause is effective before September 30, 2022, then the Continuity Incentive shall be increased to include the amount of salary and bonus that Employee would have received had he remained employed through September 30, 2022.  This Continuity Incentive will be paid in equal monthly installments over a twelve (12) month period, starting in January 2023, less deductions and withholdings; provided that, if the Release Agreement does not become fully effective prior to January 31, 2023, then the first Continuity Incentive payment will occur on the date the Release Agreement becomes fully effective, and the remaining Continuity Incentive payments will be made on last day of each calendar month in 2023.  
9.Change in Control Benefits.  This Transition Agreement shall not affect the terms and conditions of the Parties’ Amended and Restated Change of Control Severance Agreement, effective as of August 7, 2017 (the “CoC Agreement”), which agreement shall remain in full force and effect.  In the event such severance provisions are triggered, then the provisions of the CoC Agreement providing for severance benefits to Employee as a result of such termination shall apply in lieu of the provisions of this Agreement, provided that if the economic benefits to the Employee

-4-

Background image

260523219 v5


under the CoC are less than those provided in this Agreement, then the economic terms herein shall apply.  
10.Binding Agreement. This Agreement shall be binding upon, and inure to the benefit of, the Parties and their respective permitted successors and assigns.  
11.Compliance with Section 409A of the Code.
(a)It is intended that this Agreement will comply with Section 409A of the Code and its regulations and guidelines (collectively, “Section 409A”), to the extent the Agreement is subject to Section 409A, and the Agreement shall be interpreted on a basis consistent with such intent.  If an amendment of the Agreement is necessary in order for it to comply with Section 409A, the Parties will negotiate in good faith to amend the Agreement in a manner that preserves the original intent of the Parties to the extent reasonably possible.  No action or failure to act under this Section 11 shall subject XOMA to any claim, liability, or expense, and XOMA shall not have any obligation to indemnify or otherwise protect Employee from the obligation to pay any taxes, interest or penalties under Section 409A.
(b)If Employee is deemed on the date of “separation from service” (under Treas. Reg. Section 1.409A-1(h)) to be a “specified employee” (under Treas. Reg. Section 1.409A-1(i)), then with regard to any payment or benefit that is considered deferred compensation under Section 409A of the Code payable on account of a “separation from service” that is required to be delayed under Section 409A(a)(2)(B) of the Code (after taking into account any applicable exceptions to such requirement), such payment or benefit shall be made or provided on the earlier of (i) the expiration of the six (6)-month period measured from the date of Employee’s “separation from service,” or (ii) the date of Employee’s death (“Delay Period”).  Upon expiration of the Delay Period, all payments and benefits delayed under this Section 11(b) shall be paid or reimbursed to Employee in a lump sum and any remaining payments and benefits due under this Agreement shall be paid or provided on the payment dates specified.  For purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment, references to Employee’s “termination of employment” (and corollary terms) shall be construed to refer to Employee’s “separation from service” (under Treas. Reg. Section 1.409A-1(h)).
(c)With respect to any reimbursement or in-kind benefit arrangements of XOMA and its subsidiaries that constitute deferred compensation for purposes of Section 409A, except as otherwise permitted by Section 409A, the following conditions shall be applicable: (A) the amount eligible for reimbursement, or in-kind benefits provided, under any such arrangement in one calendar year may not affect the amount eligible for reimbursement, or in-kind benefits to be provided, under such arrangement in any other calendar year (except that the benefit plans may impose a limit on the amount that may be reimbursed or paid), (B) any reimbursement must be made on or before the last day of the calendar year following the calendar year in which the expense was incurred, and (C) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for

-5-

Background image

260523219 v5


another benefit.  Whenever payments under this Agreement are to be made in installments, each such installment shall be deemed to be a separate payment for purposes of Section 409A.
12.Notices.  Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given upon actual confirmed receipt by mail, courier or email.  In the case of Employee, mailed notices shall be addressed to Employee at the home or personal email address that Employee most recently communicated to XOMA in writing.  In the case of XOMA, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.
13.Successors.  

(a)XOMA’s Successors.  Any successor to XOMA (direct or indirect, by purchase, lease, merger, amalgamation, consolidation, liquidation or otherwise) to all or substantially all of XOMA’s business or assets shall assume XOMA’s obligations under this Agreement and agree expressly to perform XOMA’s obligations under this Agreement in the same manner and to the same extent as XOMA would be required to perform such obligations in the absence of a succession.  For all purposes under this Agreement, the term “XOMA” shall include any successor to XOMA’s business or assets which executes and delivers the assumption agreement described in this Section 13(a) or which becomes bound by the terms of this Agreement by operation of law.

(b)Employee’s Successors.  Without the written consent of XOMA, Employee shall not assign or transfer this Agreement or any right or obligation under this Agreement to any other person or entity.  However, except as otherwise set forth herein, the terms of this Agreement and all rights of Employee shall inure to the benefit of, and be enforceable by, Employee’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.  

14.Amendment of Agreement. Changes in Employee’s employment terms, other than those changes expressly reserved to XOMA’s or the Board’s discretion in this Agreement, require a written modification approved by XOMA and signed by Employee and a duly authorized officer of XOMA other than Employee.  
15.Waiver. Any party’s failure to enforce any provision or provisions of the Agreement will not in any way be construed as a waiver of any such provision or provisions, nor prevent any party from thereafter enforcing each and every other provision of the Agreement.  The rights granted to the Parties herein are cumulative and will not constitute a waiver of any party’s right to assert all other legal remedies available to it under the circumstances.   
16.Severability. In the event any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any remaining part of such provision or any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the Parties insofar as possible under applicable law.  

-6-

Background image

260523219 v5


17.Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles.  Employee expressly consents to personal jurisdiction and venue in the state and federal courts for Alameda County, California for any lawsuit filed there against Employee by XOMA arising from or related to this Agreement.
18.Fees and Costs.  The Parties shall each bear their own costs, expert fees, attorneys’ fees and other fees incurred in connection with this Agreement.
19.Counterparts.  This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic signatures shall be equivalent to original signatures.
20.Complete Agreement. This Agreement, together with Employee’s Confidentiality Agreement and the CoC Agreement, forms the complete and exclusive embodiment of the entire agreement between the Parties with regard to this subject matter, and supersedes and replaces any other agreements or promises made to Employee by anyone, whether oral or written.   

COMPANY:XOMA CORPORATION

By: /s/ W. Denman Van Ness​ ​​ ​
W. Denman Van Ness

Chairman of the Board

EMPLOYEE:/s/ James R. Neal​ ​
James R. Neal

-7-

Background image

260523219 v5


EXHIBIT A

FORM RELEASE OF CLAIMS AGREEMENT

This Release of Claims Agreement (“Release Agreement”) is entered into between XOMA Corporation (“XOMA”) and James R. Neal (“Employee”).  XOMA and Employee (collectively, the “Parties”) are parties to an Amended and Restated Employment Agreement (“Transition Agreement”) and agree as follows:

1.Termination.  Employee’s employment with XOMA terminated on _________, 20__.
2.Release of Claims.  In exchange for the compensation, benefits and other consideration to be provided to Employee under the Transition Agreement that Employee is not otherwise entitled to receive, Employee hereby generally and completely releases XOMA and XOMA (US) LLC, and their past and present officers, agents, directors, employees, investors, shareholders, administrators, partners, attorneys,  agents, insurers, affiliates, divisions, subsidiaries, parents, predecessor and successor corporations, and assigns (collectively, the “Released Parties”), from, and agrees not to sue or otherwise institute any legal or administrative proceedings concerning, any and all claims, duties, liabilities, obligations and causes of action, both known and unknown, that arise out of or are in any way related to events, acts, conduct or omissions occurring prior to or on the date Employee signs this Release Agreement (collectively, the “Released Claims”).

The Released Claims include but are not limited to:

(a)all claims arising out of or in any way related to Employee’s employment with XOMA or the termination of that employment;
(b)all claims related to compensation or benefits from XOMA, including salary, bonuses, commissions, vacation, paid time off, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity or profits interests in XOMA (including but not limited to any right to purchase, or actual purchase, of shares of stock of XOMA);
(c)all claims for breach of contract, wrongful termination and breach of the implied covenant of good faith and fair dealing;
(d)all tort claims, including claims for fraud, defamation, emotional distress and discharge in violation of public policy;
(e)all federal, state and local statutory claims, including  claims for discrimination, harassment, retaliation, attorneys’ fees or other claims arising under the Federal Civil Rights Act of 1964, the federal Civil Rights Act of 1991, the federal Age Discrimination in Employment Act of 1967 (the “ADEA”), the federal Americans with Disabilities Act of 1990, the federal Fair Labor Standards Act, the federal the Employee Retirement Income Security Act of 1974, the federal Worker Adjustment and Retraining Notification Act, the California Fair Employment and Housing Act and the California Labor Code, and all amendments to and regulations issued under each such statute;
Background image

260523219 v5


(f)all claims for violation of the federal or any state constitution;
(g)all claims arising out of any other laws and regulations relating to employment or employment discrimination; and
(h)all claims for attorneys’ fees and costs.
3.Acknowledgment of Waiver of Claims under ADEA.  Employee acknowledges that Employee is knowingly and voluntarily waiving and releasing any rights Employee may have under the ADEA, and that the consideration given for the waiver and release in this Section 3 is in addition to anything of value to which Employee is already entitled.  Employee further acknowledges that Employee has been advised, as required by the ADEA, that:  (a) Employee’s waiver and release do not apply to any rights or claims that may arise after the date Employee signs this Release Agreement; (b) Employee should consult with an attorney prior to signing this Release Agreement (although Employee may choose voluntarily not to do so); (c) Employee has twenty-one (21) days to consider this Release Agreement (although Employee may choose voluntarily to sign it earlier); (d) Employee has seven (7) days following the date Employee signs this Release Agreement to revoke the Release Agreement (by providing written notice of Employee’s revocation to the Legal Department at XOMA); and (e) this Release Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth (8th) day after the date that this Release Agreement is signed by Employee provided that Employee does not revoke it (the “Effective Date”).  
4.Waiver of Unknown Claims.  In giving the releases set forth in this Release Agreement, which include claims which may be unknown to Employee at present, Employee acknowledges that Employee has read and understands Section 1542 of the California Civil Code which reads as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.

Employee hereby expressly waives and relinquishes all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to Employee’s release of claims herein, including but not limited to the release of unknown and unsuspected claims.

5.Excluded Claims.  Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”):  (a) any rights or claims for indemnification Employee may have pursuant to any written indemnification agreement with XOMA to which Employee is a party or under applicable law; (b) any rights which cannot be waived as a matter of law; (c) any rights Employee has to file or pursue a claim for workers’ compensation or unemployment insurance; and (d) any claims for breach of the Transition Agreement or this Release Agreement.  In addition, nothing in this Release Agreement prevents Employee from filing, cooperating
Background image

260523219 v5


with or participating in any proceedings before the Equal Employment Opportunity Commission, the Department of Labor, the California Department of Fair Employment and Housing or any analogous federal or state government agency, except that Employee acknowledges and agrees that Employee hereby waives Employee’s right to any monetary benefits in connection with any such claim, charge or proceeding.  Employee represents and warrants that, other than the Excluded Claims, Employee is not aware of any claims Employee has or might have against any of the Released Parties that are not included in the Released Claims.
6.Representations.  Employee represents that Employee has been paid all compensation owed and for all time worked; Employee has received all the leave and leave benefits and protections for which Employee is eligible pursuant to the federal Family and Medical Leave Act, the California Family Rights Act, any applicable law or XOMA policy; and Employee has not suffered any on the job injury for which Employee has not already filed a workers’ compensation claim.
7.Nondisparagement.  Employee agrees not to disparage XOMA, and XOMA’s officers, directors, employees, shareholder, members and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation.  Similarly, Employee understands that XOMA agrees to direct its directors and officers not to disparage Employee in any manner likely to be harmful to Employee’s business reputation or personal reputation.  Nothing in this provision, however, shall prevent either Employee or XOMA from responding accurately and fully to any request for information if required by legal process or in connection with a government investigation.  In addition, nothing in this provision or this Release Agreement is intended to prohibit or restrain Employee in any manner from making disclosures that are protected under the whistleblower provisions of federal law or regulation or under other applicable law or regulation.
8.No Voluntary Adverse Action.  Employee agrees that Employee will not voluntarily provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any person or entity in connection with any proposed or pending litigation, arbitration, administrative claim, cause of action, or other formal proceeding of any kind brought against XOMA, its parent or subsidiary entities, affiliates, officers, directors, employees or agents, nor shall Employee induce or encourage any person or entity to bring any such claims; provided, however, that Employee must respond accurately and truthfully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation.
9.Return of XOMA Property; Compliance with Proprietary Information Agreement.  Employee represents that Employee has complied fully with Section 7(g) of the Transition Agreement and the provisions of Employee’s Employee Confidential Information and Invention Assignment Agreement with XOMA (the “Confidentiality Agreement”), and further agrees to continue to abide by Employee’s continuing obligations under the Confidentiality Agreement.  
10.Fees and Costs.  The Parties shall each bear their own costs, expert fees, attorneys’ fees and other fees incurred in connection with this Release Agreement.
11.No Representations.  Employee represents that Employee has had the opportunity to consult with an attorney, and has carefully read and understands the scope and effect of the
Background image

260523219 v5


provisions of this Release Agreement.  Neither Party has relied upon any representations or statements made by the other Party which are not specifically set forth in this Release Agreement.
12.Severability.  In the event any provision of this Release Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any remaining part of such provision or any other provision of this Release Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the Parties insofar as possible under applicable law.
13.Entire Agreement.  This Release Agreement, together with the Transition Agreement, forms the complete and exclusive embodiment of the entire agreement between the Parties with regard to this subject matter.  This Release Agreement may only be modified or amended in a writing signed by Employee and a duly authorized officer of XOMA other than Employee.
14.Governing Law.  This Release Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles.  Employee expressly consents to personal jurisdiction and venue in the state and federal courts for Alameda County, California for any lawsuit filed there against Employee by XOMA arising from or related to this Release Agreement.  
15.Counterparts.  This Release Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic signatures shall be equivalent to original signatures.  

COMPANY:XOMA CORPORATION

By:

/s/ XOMA CORPORATION​ ​


EMPLOYEE:/s/ James R. Neal​ ​
James R. Neal

Background image

260523219 v5


EX-10.48 4 tmb-20211231xex10d48.htm EX-10.48

EXECUTION COPY

Exhibit 10.48

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.








COMMERCIAL PAYMENT PURCHASE AGREEMENT

dated as of October 6, 2021

between

Affitech Research AS, as Seller,

and

XOMA (US) LLC, as Purchaser


COMMERCIAL PAYMENT PURCHASE AGREEMENT

This COMMERCIAL PAYMENT PURCHASE AGREEMENT (this “Agreement”), dated as of October 6, 2021 (the “Effective Date”), is between AFFITECH RESEARCH AS (formerly known as Affitech AS), a Norwegian company with the organization number 976 567 900, with their office and place of business at Lillogata SM, 0484 Oslo, Norway (“Seller” or “Assignor”), and XOMA (US) LLC, a Delaware limited liability company with its principal place of business at 2200 Powell Street, Suite 310, Emeryville, California 94608 (“Purchaser” or “Assignee”).

W I T N E S E T H:

WHEREAS, Seller and its Affiliates (collectively, “Affitech”) on the one hand, and F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“Roche Little Falls”; Roche Basel and Roche Little Falls together referred to as “Roche”) on the other hand, were parties to that certain Research and License Agreement effective as of May 4, 2007 (the “Roche License Agreement”), pursuant to which Affitech performed certain research and granted Roche certain rights and licenses;

WHEREAS, pursuant to that certain Asset Purchase Agreement, effective as of December 14, 2020, by and between Affitech and Roche (the “Roche APA”), the parties thereto terminated and superseded the Roche License Agreement, and, among other matters, Affitech sold to Roche certain assets and granted to Roche certain rights and licenses in exchange for certain payments to be made by Roche to Affitech or its assignee;

WHEREAS, Seller has [*] (as defined in the Roche APA) under the Roche APA and provided written notice and instructions to Roche as required thereunder and, as a result, is entitled to receive such payments in the amount of 0.5% of Net Sales of Products, pursuant to and subject to the terms and conditions of the Roche APA;

WHEREAS, Seller now desires to sell, assign, transfer, convey and grant to Purchaser, free and clear of all Liens (as defined below), and Purchaser desires to purchase, acquire and accept from Seller, the Purchased Commercial Payments (as defined below), upon the terms and subject to the conditions set forth in this Agreement.

NOW, THEREFORE, in consideration of the premises and the mutual agreements, representations and warranties set forth herein, and of other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto (each a “Party,” and collectively, the “Parties”) covenant and agree as follows:

Article I
DEFINED TERMS AND RULES OF CONSTRUCTION
Section 1.1Defined Terms. The following terms, as used herein, shall have the following respective meanings.  Capitalized terms used but not defined in this Agreement shall have the meaning given to them or referenced in the Assignment Agreement.

1

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


Affiliate” means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with such Person.

Affitech” has the meaning set forth in the recitals.

Agreement” has the meaning set forth in the preamble.

Applicable Law” means, with respect to any Person, all laws, rules, regulations and orders of Governmental Authorities applicable to such Person or any of its properties or assets.

Assigned Commercial Payments” has the meaning set forth in the Assignment Agreement.

Assignment Agreement” means the Assignment Agreement executed by Roche, Seller and Purchaser, substantially in the form attached hereto as Exhibit 1.

Bankruptcy Event” means the occurrence of any of the following in respect of a Person: (a) an admission in writing by such Person of its inability to pay its debts generally or a general assignment by such Person for the benefit of creditors; (b) the filing of any petition or answer by such Person seeking to adjudicate itself as bankrupt or insolvent, or seeking for itself any liquidation, winding-up, reorganization, arrangement, adjustment, protection, relief or composition of such Person or its debts under any Applicable Law relating to bankruptcy, insolvency, receivership, winding-up, liquidation, reorganization, examination, relief of debtors or other similar Applicable Law now or hereafter in effect, or seeking, consenting to or acquiescing in the entry of an order for relief in any case under any such Applicable Law, or the appointment of or taking possession by a receiver, trustee, custodian, liquidator, examiner, assignee, sequestrator or other similar official for such Person or for any substantial part of its property; (c) corporate or other entity action taken by such Person to authorize any of the actions set forth in clause (a) or clause (b) above; or (d) without the consent or acquiescence of such Person, the entering of an order for relief or approving a petition for relief or reorganization or any other petition seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or other similar relief under any present or future bankruptcy, insolvency or similar Applicable Law, or the filing of any such petition against such Person, or, without the consent or acquiescence of such Person, the entering of an order appointing a trustee, custodian, receiver or liquidator of such Person or of all or any substantial part of the property of such Person, in each case where such petition or order shall remain unstayed or shall not have been stayed or dismissed within ninety (90) days from entry thereof; provided that in the case of an involuntary petition, such Person has not challenged such petition within ninety (90) days thereof.

Bill of Sale” means that certain bill of sale dated as of the Closing Date executed by Seller and Purchaser substantially in the form attached hereto as Exhibit 2.

Business Day” means any day that is not a Saturday, Sunday or other day on which commercial banks in California are authorized or required by Applicable Law to remain closed.

CDA” has the meaning set forth in Section 7.9.

Closing” has the meaning set forth in Section 2.5.

2

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


Closing Date” has the meaning set forth in Section 2.5.

Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto.

Dollar” or the sign “$” means United States dollars.

EMA” shall mean the European Medicines Agency and any successor agency thereto.

Excluded Liabilities and Obligations” has the meaning set forth in Section 2.3.

FDA” means the U.S. Food and Drug Administration and any successor agency thereto.

GAAP” means generally accepted accounting principles in effect in the United States from time to time.

Governmental Authority” means the government of the United States, any other nation or any political subdivision thereof, whether state or local, and any agency, authority (including supranational authority), commission, instrumentality, regulatory body, self-regulatory body, court, central bank or other Person exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government, including the FDA, the EMA and any other government authority in any jurisdiction.

Lien” means any security interest, mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or otherwise), charge against or interest in property or other priority or preferential arrangement of any kind or nature whatsoever, in each case to secure payment of a debt or other liability or performance of an obligation, including any conditional sale or any sale with recourse.

Net Sales” has the meaning given to it in the Assignment Agreement.

Party” and “Parties” has the meaning set forth in the preamble.

Payment Period” has the meaning given to it in the Assignment Agreement.

Permitted Liens” means any Liens created, permitted or required by the Transaction Documents in favor of Purchaser or its Affiliates.

Person” means any natural person, firm, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, Governmental Authority or any other legal entity, including public bodies, whether acting in an individual, fiduciary or other capacity.

Product” has the meaning given to it in the Assignment Agreement.

Product Approval” means, with respect to the Product for a particular indication, a successful biologics license application (BLA) or new drug application (NDA) approval by the FDA or

3

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


marketing authorization application (MAA) grant by the EMA, as applicable, of the Product for such indication, the official approval of which is required before any lawful commercial sale or marketing of the Product for such indication.

Purchase Price” has the meaning set forth in Section 2.2.

Purchased Commercial Payments” or “Purchased Assets” means all of Seller’s rights under the Roche APA to receive or obtain:

(a) 0.50% of Nets Sales of all Products during the applicable Payment Period in all countries payable by Roche pursuant to Section [*] of the Roche APA (a monetary claim (Nw. enkelt pengekrav) under Norwegian law) and Section [*] of the Assignment Agreement at the times set forth in the Assignment Agreement and all of Sellers’ entire right to receive payment of all such amounts (including the right to receive [*] under the Roche APA and the rights assigned to Purchaser pursuant to the Assignment Agreement), in each case, (i) regardless of how Roche and/or Affitech characterize such payments or consideration and (ii) without reduction, deduction or other Set-off, including any such reduction, deduction or other Set-off [*] (such as those relating to [*]), subject to the terms of the Assignment Agreement.
(b) all accounts evidencing the rights to the payments and amounts described in clause (a) above;
(c) all proceeds of any of the foregoing; and
(d) all of Seller’s rights under [*] and [*] of the Roche APA, in each case to the extent pertaining to the Assigned Commercial Payments including the right to enforce such rights directly against Roche.

Purchaser” has the meaning set forth in the preamble.

Purchaser Account” means Purchaser’s deposit account with Silicon Valley Bank which account Purchaser may change from time to time by furnishing written notice to Roche.

Roche” has the meaning set forth in the recitals.

Roche Basel” has the meaning set forth in the recitals.

Roche Little Falls” has the meaning set forth in the recitals.

Roche APA” has the meaning set forth in the recitals.

Roche License Agreement” has the meaning set forth in the recitals.

SEC” means the U.S. Securities and Exchange Commission.

Seller” has the meaning set forth in the preamble.

Seller Account” means the Seller’s account with DB Norway which account Seller may change from time to time by furnishing written notice to Purchaser.

4

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


Set-off” means any set-off, off-set, rescission, counterclaim, credit, reduction, or deduction, including any of the foregoing resulting from Seller’s breach of the Roche License Agreement, Roche APA, or the Assignment Agreement.

Tax” or “Taxes” means any federal, state, local or non-U.S. income, gross receipts, license, payroll, employment, excise, severance, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, abandoned property, value added, alternative or add-on minimum, estimated or other tax of any kind whatsoever, including any interest, penalty or addition thereto, whether disputed or not.

Third Party” shall mean any Person other than Seller or Purchaser or their respective Affiliates.

Transaction Documents” means this Agreement, the Settlement Agreement (as defined in the Assignment Agreement), the Assignment Agreement, the Bill of Sale, and the CDA.

U.S.” or “United States” means the United States of America, its fifty (50) states, each territory thereof and the District of Columbia.

Section 1.2Rules of Construction. Unless the context otherwise requires, in this Agreement:
(a)A term has the meaning assigned to it, and an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP.
(b)Words of the masculine, feminine or neuter gender shall mean and include the correlative words of other genders.
(c)The definitions of terms shall apply equally to the singular and plural forms of the terms defined.
(d)The terms “include,” “including” and similar terms shall be construed as if followed by the phrase “without limitation.”
(e)Unless otherwise specified, references to an agreement or other document include references to such agreement or document as from time to time amended, restated, reformed, supplemented or otherwise modified in accordance with the terms thereof (subject to any restrictions on such amendments, restatements, reformations, supplements or modifications set forth herein or in any of the other Transaction Documents) and include any annexes, exhibits and schedules attached thereto.
(f)References to any Applicable Law shall include such Applicable Law as from time to time in effect, including any amendment, modification, codification, replacement or reenactment thereof or any substitution therefor.
(g)References to any Person shall be construed to include such Person’s successors and permitted assigns (subject to any restrictions on assignment, transfer or delegation

5

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


set forth herein or in any of the other Transaction Documents), and any reference to a Person in a particular capacity excludes such Person in other capacities.
(h)The word “will” shall be construed to have the same meaning and effect as the word “shall.”
(i)The words “hereof,” “herein,” “hereunder” and similar terms when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision hereof, and Article, Section and Exhibit references herein are references to Articles and Sections of, and Exhibits to, this Agreement unless otherwise specified.
(j)In the computation of a period of time from a specified date to a later specified date, the word “from” means “from and including” and each of the words “to” and “until” means “to but excluding.”
(k)Where any payment is to be made, any funds are to be applied or any calculation is to be made under this Agreement on a day that is not a Business Day; unless this Agreement otherwise provides, such payment shall be made, such funds shall be applied and such calculation shall be made on the succeeding Business Day, and payments shall be adjusted accordingly.
(l)Any reference herein to a term that is defined by reference to its meaning in the Roche APA shall refer to such term’s meaning in the Roche APA as in existence on the date hereof.
Article II
PURCHASE AND SALE OF THE PURCHASED COMMERCIAL PAYMENTS
Section 2.1Purchase and Sale.
(a)Subject to the terms and conditions of this Agreement, on the Closing Date, Seller hereby sells, assigns, transfers and conveys to Purchaser, and Purchaser hereby purchases, acquires and accepts from Seller, all of Seller’s rights, title and interest in and to the Purchased Commercial Payments, free and clear of any and all Liens, other than Permitted Liens. Seller and Purchaser intend and agree that the sale, assignment, transfer and conveyance of the Purchased Commercial Payments under this Agreement shall be, and are, a true, complete, absolute and irrevocable assignment and sale by Seller to Purchaser of the Purchased Commercial Payments and that such assignment and sale shall provide Purchaser with the full benefits of ownership and as purchaser of the Purchased Commercial Payments. Neither Seller nor Purchaser intends the transactions contemplated under the Transaction Documents to be, or for any purpose to be characterized as, a loan from Purchaser to Seller or a pledge. Seller waives any right to contest or otherwise assert that this Agreement does not constitute a true, complete, absolute and irrevocable sale and assignment by Seller to Purchaser of the Purchased Commercial Payments under Applicable Law, which waiver shall be enforceable against Seller in any Bankruptcy Event in respect of Seller.
(b)The Parties further acknowledge and agree that the Purchased Commercial Payments and the sale, assignment, transfer and conveyance thereof under this Agreement fully

6

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


comply with and do not violate any Applicable Law and that they will not contest the validity or enforceability of the Purchased Commercial Payments thereunder.  Without limiting the foregoing, each Party represents and warrants to the other Party that, to the best of its knowledge, all such payment obligations and the sale and assignment thereof, as contemplated herein and as described in the Assignment Agreement, are fully enforceable against the Parties and the parties thereto under all such Applicable Law.  To the fullest extent possible under Applicable Law, Seller waives any right to contest or otherwise assert that any such payment obligations or the sale, assignment, transfer and conveyance of the Purchased Commercial Payments under this Agreement fail to comply with, violate, or are otherwise unenforceable under Applicable Law, which waiver shall be enforceable against Seller in any Bankruptcy Event in respect of Seller.
Section 2.2Purchase Price. In full consideration for the sale, assignment, transfer and conveyance of the Purchased Commercial Payments, and subject to the terms and conditions set forth herein, Purchaser shall pay (or cause to be paid) to Seller, or Seller’s designee the following amount(s) (the “Purchase Price”):
(a)on the Closing Date, the sum of Six Million Dollars ($6,000,000), in immediately available funds by wire transfer to Seller Account (“Initial Payment”);
(b)the following one-time milestone payments within [*] Business Days from the first achievement of the corresponding milestone event specified below (collectively, the “Affitech Milestone Payments”):
(i)Product Approvals:

Milestone Event achieved by Roche

Affitech Milestone Payment

Product Approval in the U.S. of the Product for a first (1st) indication by FDA

Two million, five hundred thousand Dollars ($2,500,000 USD)

[*]

[*]

Product Approval in the U.S. of the Product for a second (2nd) indication by FDA

Two million, five hundred thousand Dollars ($2,500,000 USD)

[*]

[*]

Total Affitech Milestone Payments possible under this Section 2.2(b)(i):

[*]

(ii)Sales-Based Milestones: Purchaser shall pay to Seller out of its receipts of the Assigned Commercial Payments from Roche a one-time, sales-based milestone payment, within [*] Business Days from the end of the applicable Calendar Year, following the first achievement by Roche of annual Net Sales of the Product in a given Calendar Year (“Annual Net Sales”) that exceed each of the following thresholds in such Calendar Year (each, the “Annual Net Sales Threshold”):

7

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


Annual Net Sales Threshold

Affitech Milestone Payment

First Calendar Year ending on or before [*] in which Roche’s Annual Net Sales of the Product exceed [*] in such Calendar Year*

[*]

First Calendar Year in which Roche’s Annual Net Sales of the Product exceed [*] in such Calendar Year

[*]

First Calendar Year in which Roche’s Annual Net Sales of the Product exceed [*] in such Calendar Year

[*]

First Calendar Year in which Roche’s Annual Net Sales of the Product exceed [*] in such Calendar Year

[*]

Total Affitech Milestone Payments possible under this Section 2.2(b)(ii):

[*]

*If the first Annual Net Sales Threshold set forth in the table above is not achieved in a given Calendar Year prior to [*], the corresponding first Affitech Milestone Payment of [*] shall terminate and shall not be payable (regardless of whether the corresponding Annual Net Sales threshold is later achieved), although other Affitech Milestone Payments set forth above remain eligible to become payable upon achievement of the Annual Net Sales thresholds corresponding to such other Affitech Milestone Payments as otherwise required in this Section 2.2(b).

For clarity, each of the foregoing Affitech Milestone Payments shall only be paid once, regardless of whether such Annual Net Sales Threshold is subsequently achieved in a future Calendar Year.  In the event that more than one of the foregoing Annual Net Sales Thresholds is first achieved in a single Calendar Year, then the corresponding sales-based Affitech Milestone Payment for each such milestone event shall be payable to Seller hereunder.

Section 2.3No Assumed Obligations. Notwithstanding any provision in this Agreement or any other writing to the contrary, Purchaser is purchasing, acquiring and accepting only the Purchased Commercial Payments and is not assuming any liability or obligation of Seller or any of Seller’s Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter, whether known or unknown (including any liability or obligation of Seller under the Roche License Agreement, the Roche APA, or the Assignment Agreement and any payments required to be made to Third Parties). All such liabilities and obligations shall be retained by and remain liabilities and obligations of Seller or its Affiliates, as the case may be (the “Excluded Liabilities and Obligations”).
Section 2.4Excluded Assets. Purchaser does not, by purchase, acquisition or acceptance of the rights, title or interest granted hereunder or otherwise pursuant to any of the Transaction Documents, purchase, acquire or accept any assets or rights, contract or otherwise, of Seller other than the Purchased Commercial Payments.
Section 2.5Closing. The closing of the transactions contemplated under this Agreement (the “Closing”) shall take place remotely simultaneously with the execution and delivery of this

8

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


Agreement via electronic delivery of the executed Transaction Documents and other deliverables. The date on which the Closing occurs is referred to herein as the “Closing Date”.

Section 2.6Closing Deliverables of Seller. At the Closing, Seller shall deliver or cause to be delivered to Purchaser the following:
(a)this Agreement executed by Seller;
(b)the Bill of Sale executed by Seller;
(c)the Assignment Agreement duly executed by Roche and Seller;
Section 2.7Closing Deliverables of Purchaser. At the Closing, Purchaser shall execute and deliver or cause to be delivered to Seller the following:
(a)this Agreement executed by Purchaser;
(b)the Bill of Sale executed by Purchaser;
(c)the Assignment Agreement duly executed by Purchaser; and
(d)the Initial Payment in accordance with Section 2.2(a).
Article III
REPRESENTATIONS AND WARRANTIES OF SELLER

Seller hereby represents and warrants to Purchaser as follows:

Section 3.1Organization. Seller is a corporation duly organized, validly existing and in good standing under the laws of Norway and has all necessary power and authority, and all licenses, permits, franchises, authorizations, consents and approvals, required to own its property and conduct its business as now conducted and to exercise its rights and to perform its obligations under the Roche APA and the Transaction Documents. Seller is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification or good standing is required by Applicable Law.
Section 3.2Solvency. Seller has determined that, and by virtue of its entering into the transactions contemplated by the Transaction Documents and its authorization, execution and delivery of the Transaction Documents, Seller’s incurrence of any liability hereunder or thereunder or contemplated hereby or thereby is in its own best interests. Upon consummation of the transactions contemplated by the Transaction Documents and the application of the proceeds therefrom, (a) the present fair saleable value of Seller’s property and assets will be greater than the sum of its debts, liabilities and other obligations, including contingent liabilities; (b) the present fair saleable value of Seller’s property and assets will be greater than the amount that would be required to pay its probable liabilities on its existing debts, liabilities and other obligations, including contingent liabilities, as they become absolute and matured; (c) Seller will be able to realize upon its assets and pay its debts, liabilities and other obligations, including contingent liabilities, as they mature; (d) Seller will not be rendered insolvent, will not have unreasonably

9

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


small capital with which to engage in its business and will not be unable to pay its debts as they mature; (e) Seller has not incurred, will not incur and does not have any present plans or intentions to incur debts, liabilities or other obligations beyond its ability to pay such debts, liabilities or other obligations as they become absolute and matured; (f) Seller will not have become subject to any Bankruptcy Event; (g) after the Closing, Seller will have enough capital to operate its business for at least one (1) year following the Closing; and (h) Seller will not have been rendered insolvent within the meaning of Section 101(32) of Title 11 of the United States Code. No step has been taken or is intended by Seller or, to the knowledge of Seller, any other Person to make Seller subject to a Bankruptcy Event,

Section 3.3Taxes; No Liens or Conflicts. Seller has paid all Taxes required to be paid by it, except for any such Taxes that are not yet due or delinquent, and there are no unpaid Taxes or other amounts due by Seller to any taxing authority. There are no Liens for Taxes upon the Purchased Commercial Payments or any of Seller’s assets. Without limiting the foregoing, the Purchased Commercial Payments are free and clear of all Liens (other than Permitted Liens), and upon the sale, assignment, transfer and conveyance by Seller of the Purchased Commercial Payments to Purchaser, Purchaser shall acquire good, valid and marketable title to and rights as owner of the Purchased Commercial Payments free and clear of all Liens (other than Permitted Liens). None of the execution and delivery by Seller of any of the Transaction Documents, the performance by Seller of the obligations contemplated hereby or thereby or the consummation of the transactions contemplated by this Agreement or any of the other Transaction Documents will contravene, conflict with, result in a breach, violation, cancellation or termination of, constitute a default, give any Person the right to exercise any remedy or obtain any additional rights under any term or provision of (a) any contract, agreement, commitment, or obligation to which Seller or any of its Affiliates is a party or by which Seller or any of its Affiliates or any of their respective assets or properties is bound or committed or (b) any of the organizational documents of Seller.
Section 3.4Roche APA.  Neither Seller, and to the knowledge of Seller, nor Roche are in breach or violation of or in default under or have previously been in breach or violation of or in default under, the Roche APA. Nothing in the redacted portions of the Roche APA will adversely affect the Purchaser’s right to receive the Assigned Commercial Payments.  Seller has not received or sent any notice (i) regarding the termination, breach, default or violation of, or the intention to terminate, breach, default, or violate, the Roche APA, in whole or in part, (ii) that any event has occurred that, with notice or the passage of time or both, would constitute a default under the Roche APA, (iii) challenging the legality, validity or enforceability of the Roche APA or Roche’s obligation [*] thereunder, or (iv) asserting that Seller or Roche is in default of their obligations thereunder. To the knowledge of Seller, no event has occurred that, with notice or the passage of time or both, would (1) give Roche the right to refuse to [*] thereunder, (2) give Roche or Seller the right to terminate the Roche APA, or (3) constitute or give rise to any breach or default in the performance of the Roche APA by Seller or Roche. Without limiting the foregoing, Seller has completed [*] under the Roche APA and the Roche License Agreement and has fully complied with all such obligations under the Roche APA and the Roche License Agreement, including (A) completing [*] (as defined in the Roche APA) under Section [*] of the Roche APA, (B) providing [*] in connection with the [*], providing [*] relating to [*] and [*] as required under Section [*] of the Roche APA, (C) completing [*] (as defined in the Roche APA) and [*] as required under Section [*] of the Roche APA.  Seller has [*] and provided proper and timely notice and instructions to Roche [*] and [*], in each instance, consistent with the terms and conditions of the

10

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


Roche APA, including Section [*] thereof. For the avoidance of doubt, Purchaser acknowledges that the Assigned Commercial Payments, and Roche’s obligations to make such payments, are subject to the terms and conditions of the Roche APA and the Assignment Agreement. For example, Roche may (i) cease the development and/or commercial activities with regard to the Product, and/or (ii) not make a filing of a BLA for the Product or (iii) not launch the Product, in which case the Assigned Commercial Payments would not accrue.

Article IV
REPRESENTATIONS AND WARRANTIES OF PURCHASER

Purchaser hereby represents and warrants to Seller as of the date hereof as follows:

Section 4.1Organization. Purchaser is a limited liability company, duly organized, validly existing and in good standing under the laws of the State of Delaware, and has all necessary powers and authority, and all licenses, permits, franchises, authorizations, consents and approvals of all Governmental Authorities, required to own its property and conduct its business as now conducted and to exercise its rights and to perform its obligations under the Transaction Documents. Purchaser is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification or good standing is required by Applicable Law.
Section 4.2Solvency. Purchaser has determined that, and by virtue of its entering into the transactions contemplated by the Transaction Documents and its authorization, execution and delivery of the Transaction Documents, Purchaser’s incurrence of any liability hereunder or thereunder or contemplated hereby or thereby is in its own best interests. Prior to and upon consummation of the transactions contemplated by the Transaction Documents and the application of the proceeds therefrom, (a) the present fair saleable value of Purchaser’s property and assets will be greater than the sum of its debts, liabilities and other obligations; (b) the present fair saleable value of Purchaser’s property and assets will be greater than the amount that would be required to pay its probable liabilities on its existing debts, liabilities and other obligations, as they become absolute and matured; (c) Purchaser will be able to realize upon its assets and pay its debts, liabilities and other obligations, as they mature; (d) Purchaser will not be rendered insolvent and will not be unable to pay its debts as they mature; (e) Purchaser has not incurred, will not incur and does not have any present plans or intentions to incur debts, liabilities or other obligations beyond its ability to pay such debts, liabilities or other obligations as they become absolute and matured; (f) Purchaser will not have become subject to any Bankruptcy Event; (g) after the Closing, Purchaser will have enough capital to operate its business for at least one (1) year following the Closing; and (h) Seller will not have been rendered insolvent within the meaning of Section 101(32) of Title 11 of the United States Code. No step has been taken or is intended by Purchaser or, to the knowledge of Purchaser, any other Person to make Purchaser subject to a Bankruptcy Event.
Section 4.3No Conflicts. None of the execution and delivery by Purchaser of any of the Transaction Documents, the performance by Purchaser of the obligations contemplated hereby or thereby or the consummation of the transactions contemplated by this Agreement or any of the other Transaction Documents will contravene, conflict with, result in a breach, violation,

11

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


cancellation or termination of, constitute a default, give any Person the right to exercise any remedy or obtain any additional rights under any term or provision of (a) any contract, agreement, commitment, or obligation to which Purchaser or any of its Affiliates is a party or by which Purchaser or any of its Affiliates or any of their respective assets or properties is bound or committed or (b) any of the organizational documents of Purchaser.

Section 4.4No Broker.  There is no broker, finder, investment banker, financial advisor or other Person acting or who has acted on behalf of Purchaser or its Affiliates, who is entitled to receive any brokerage, finder’s or financial advisory fee from Seller or any of its Affiliates in connection with the transactions contemplated by this Agreement.
Article V
COVENANTS

The Parties covenant and agree as follows:

Section 5.1Commercially Reasonable Efforts; Further Assurances.
(a)Subject to the terms and conditions of this Agreement, each Party will use commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary to consummate the transactions contemplated by the Transaction Documents to which Seller or Purchaser, as applicable, is party, including to (i) effect the sale, assignment, transfer and conveyance of the Purchased Commercial Payments to Purchaser pursuant to this Agreement, (ii) execute and deliver such other documents, certificates, instruments, agreements and other writings and to take such other actions as may be necessary or desirable, or reasonably requested by the other Party, in order to consummate or implement expeditiously the transactions contemplated by any Transaction Document to which Seller or Purchaser, as applicable, is party, and (iii) enable the other Party to exercise or enforce any of its rights under the Transaction Documents.
(b)Each Party shall comply with all Applicable Laws with respect to the Transaction Documents, their respective performance thereunder and the transactions pursuant thereto.
(c)Neither Party shall enter into any contract, agreement or other legally binding arrangement (whether written or oral), or grant any right to any other Person, in each case that would (i) conflict with the Transaction Documents or the assignments made, rights granted or obligations to be performed by it thereunder, (ii) impair the other Party’s ability to perform its obligations under the Transaction Documents, or (iii) serve or operate to limit, circumscribe or impair any of the other Party’s rights under the Transaction Documents (or the other Party’s ability to exercise any such rights).
Section 5.2Non-Impairment of Purchaser’s Rights. Seller shall not, without the prior written consent of Purchaser, (i) forgive, release or reduce any amount, or delay or postpone any amount, owed to Seller or Purchaser relating to the Purchased Commercial Payments or take  any action inconsistent with or that otherwise impairs any right of Purchaser to receive the full benefit and payment in full of the Purchased Commercial Payments as contemplated herein or as otherwise contemplated in the Assignment Agreement (including to perform and comply in all respects with

12

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


its duties and obligations under the Roche APA), (ii) waive, amend, cancel, terminate or fail to terminate any material rights constituting or relating to the Purchased Commercial Payments, nor (iii) withhold any consent, grant any consent, exercise or waive (or fail to exercise or waive) any right or option, send (or refrain from sending) any notice, or take or fail to take any action in respect of, affecting or relating to the Purchased Commercial Payments.
Section 5.3Existence. Seller shall (a) preserve and maintain its existence, (b) preserve and maintain its rights, franchises and privileges, and (c) qualify and remain qualified in good standing in each jurisdiction in which it is organized or qualified to do business for at least [*] following the Closing.
Article VI
Payments; Damages
Section 6.1Payments.
(a)General.
(i)In accordance with this Agreement and the Assignment Agreement, Purchaser has the right to directly receive all Purchased Commercial Payments to the Purchaser Account.  Without limiting the foregoing, the Parties intend that Seller and Roche shall follow the payment instructions set forth in the Assignment Agreement.  
(ii)Upon execution of the Assignment Agreement, Purchaser will be solely responsible to collect payment of the Purchased Commercial Payments from the payor pursuant to the Assignment Agreement.  Without limiting the foregoing, other than Seller’s performance of its obligations under this Agreement and the Assignment Agreement, Seller has no obligation with respect to the payment or non-payment of the Purchased Commercial Payments to Purchaser by Roche, and Purchaser understands that the accrual of the Purchased Commercial Payments are subject to the conditions set forth in the Roche APA and the Assignment Agreement, as applicable.
(iii)Purchaser shall make all payments required to be made by it to Seller pursuant to this Agreement by wire transfer of immediately available funds.
(iv)Purchaser shall be entitled to deduct and withhold from any consideration payable pursuant to this Agreement such amounts as it is required to deduct and withhold with respect to the making of such payment under any Applicable Law relating to Tax. To the extent that any amounts are so deducted and withheld and paid over to or deposited with the relevant Governmental Authority, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to Seller in respect to which such deduction and withholding were made; provided that Purchaser must (1) promptly furnish to Seller evidence of any and all such amounts withheld and/or deducted and payments thereof and (2) provide full cooperation with Seller to reduce or avoid any withholding.

13

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


(b)Erroneous Payments.  
(i)If Roche or any other Person (notwithstanding the terms of the Assignment Agreement (as applicable) or any other payment instructions specified by Purchaser from time to time) makes any payment in respect of the Purchased Commercial Payments that is owed to Purchaser as a Purchased Commercial Payment hereunder, to Seller (or to any of its Affiliates) instead of to Purchaser, then (1) Seller shall hold (or cause such Affiliate to hold) such payment in trust for the sole benefit of Purchaser; (2) Seller (or such Affiliate) shall have no right, title or interest whatsoever in such payment and shall not create or suffer to exist any Lien thereon; and (3) Seller (or such Affiliate) promptly, and in any event no later than [*] Business Days following the receipt by Seller (or such Affiliate) of such payment, shall remit, or cause to be remitted, an amount equal to such payment to the Purchaser Account, without Set-off, by wire transfer of immediately available funds, in the exact form received with all necessary endorsements.
(ii)If Roche takes (1) any Set-off in full or partial satisfaction of a judgment against Seller or a settlement with Seller, (2) any Set-off resulting from Seller’s breach of the Roche APA or this Agreement for which Roche may otherwise be entitled to take or claim based on Seller’s breach of the Roche APA, or the Assignment Agreement, as applicable, or (3) any other Set-off based on other amounts Seller allegedly owes Roche, in any case where such Set-off has the effect of reducing the amount of any Commercial Payment otherwise required to be paid by Roche to Purchaser pursuant to the Assignment Agreement, then, without limiting any other rights or remedies of Purchaser, Purchaser shall have the right to credit and set-off against any Affitech Milestone Payments otherwise payable under Section 2.2 the amount of any such Set-off taken by Roche.
(iii)If Seller fails to timely comply with its obligations under the foregoing clause (i), then all amounts not timely paid by the due date provided therein shall accrue interest from and including the date such amount was due through but excluding the date such payment in full (together with all interest thereon) is made to Purchaser, at a rate, calculated on a 365-day or 366-day basis, as applicable, equal to the then-current prime rate of interest quoted in the Money Rates section of the on-line edition of the Wall Street Journal (at http://www.markets.wsj.com) plus [*], compounded annually, not to exceed the maximum interest that may be charged under Applicable Law.
(c)Seller shall not attempt to revoke, amend, modify, supplement, restate, waive, cancel or terminate the executed Assignment Agreement or the Roche APA without the prior written consent of Purchaser.
Article VII
MISCELLANEOUS
Section 7.1Termination. This Agreement shall terminate six (6) months following the full payment and satisfaction of any amounts due to the Purchaser under the Roche APA, the Assignment Agreement and this Agreement and receipt by Purchaser of all payments of the Purchased Commercial Payments to which it is entitled pursuant to the terms of this Agreement. In the event of the termination of this Agreement pursuant to this Section 7.1, this Agreement shall

14

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


become void and of no further force and effect, except for those rights and obligations that have accrued prior to the date of such termination or relate to any period prior thereto, including the payment in accordance with the terms hereof of the Purchased Commercial Payments or other monetary payment on account of the Purchased Commercial Payments, or remain outstanding pursuant to the terms of this Agreement. Notwithstanding the foregoing, (a) Article I, Section 5.3, Article VI, and Article VII shall survive such termination; and (b) other than with respect to the surviving provisions enumerated in clause (a), there shall be no liability on the part of any Party, any of its Affiliates or Controlling Persons or any of their respective officers, directors, equity-holders, debtholders, members, partners, Controlling Persons, managers, agents or employees, other than as provided for in this Section 7.1. Nothing contained in this Section 7.1 shall relieve any Party from liability for any breach of this Agreement that occurs prior to such termination, which liability shall survive such termination.
Section 7.2Survival. All representations, warranties and covenants made herein and in any other Transaction Document or any certificate or other written documentation delivered pursuant thereto shall survive the Closing and shall continue in full force and effect, and any Party shall be entitled to recover any losses related thereto until the termination of this Agreement pursuant to Section 7.1 hereof.
Section 7.3Specific Performance; Equitable Relief. Each of the Parties acknowledges that the other Party will have no adequate remedy at law if it fails to perform any of its obligations under any of the Transaction Documents. In such event, each of the Parties agrees that the other Party shall have the right, in addition to any other rights it may have (whether at law or in equity), to specific performance of this Agreement and to pursue any other equitable remedies including injunction. Each of the Parties may pursue such specific performance or other equitable remedies without going through any of the procedures set forth in Article VI.
Section 7.4Notices. All notices, consents, waivers and other communications hereunder shall be in writing and shall be effective (a) upon receipt when sent through registered, certified or first-class mail, return receipt requested, postage prepaid, with such receipt to be effective the date of delivery indicated on the return receipt, (b) upon receipt when sent by an overnight courier, (c) on the date personally delivered to an authorized officer of the Party to which sent, or (d) on the date transmitted by facsimile or other electronic transmission with a confirmation of receipt, in each case confirmed in writing as above with a copy emailed and addressed to the recipient as follows:

if to Seller, to:

Affitech Research AS

Lillogata 5M

0484 Oslo

Norway

Attn: Managing Director

Email: [*]

with a copy to (which shall not constitute notice):

15

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


Actigen Ltd

St. John’s Innovation Centre

Cowley Road, Cambridge

CB4 0WS

United Kingdom

Attn: Managing Director

if to Purchaser, to:

XOMA (US) LLC
2200 Powell Street, Suite 310
Emeryville, CA 94608
Attention: Legal Department
Telephone: [*]
Facsimile: [*]
Email: [*]

with a copy to (which shall not constitute notice):

Paul Hastings LLP
4747 Executive Drive
Twelfth Floor
San Diego, CA 92121
Attention: Deyan Spiridonov
Telephone: (858) 458-3000
Email: spiri@paulhastings.com

Each Party may, by notice given in accordance herewith to the other Party, designate any further or different address to which subsequent notices, consents, waivers and other communications shall be sent.

Section 7.5Successors and Assigns. The provisions of this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. Except as set forth in the penultimate sentence of this Section 7.5, Seller shall not be entitled to transfer or assign (including by merger, consolidation, operation of law or otherwise) any of Seller’s obligations and rights under this Agreement, without the written consent of the Purchaser. Purchaser may assign any of its rights to receive the Purchased Commercial Payments hereunder, in whole or in part, to any Third Party, subject to the terms of the Assignment Agreement. Purchaser shall give notice of any such assignment to Seller promptly after the occurrence thereof. Notwithstanding the foregoing, either Party may, except that in the case of Seller not before the first anniversary of the Effective Date, without the written consent of the other, assign this Agreement and its rights and delegate its obligations hereunder to (1) an Affiliate or (2) an entity that acquires all or substantially all of the business or assets of the assigning party to which this Agreement pertains in connection with (i) the transfer or sale of all or substantially all of its business, or (ii) in the event of its merger, consolidation, change in control or similar transaction, in the case of each of (i) and (ii), if and only if any such permitted assignee assumes

16

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


unconditionally in a written document all obligations of its assignor under this Agreement and delivers to the non-assigning Party such written document at least [*] Business Days prior to the consummation of the applicable transaction.  Any purported assignment in violation of this Section 7.5 shall be null and void ab initio.

Section 7.6Nature of Relationship. The relationship between Seller and Purchaser is solely that of seller and purchaser, and neither Seller nor Purchaser has any fiduciary or other special relationship with the other Party or any of its Affiliates. Nothing contained herein or in any other Transaction Document shall be deemed to constitute Seller and Purchaser as a partnership, an association, a joint venture or any other kind of entity or legal form for any purposes, including any Tax purposes. The Parties agree that they shall not take any inconsistent position with respect to such treatment in any filing with any Governmental Authority.
Section 7.7Entire Agreement. This Agreement, together with the Exhibits hereto (which are incorporated herein by reference), the CDA, and the other Transaction Documents constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior agreements (except for the CDA), understandings and negotiations, both written and oral, between the Parties with respect to the subject matter of this Agreement. No representation, inducement, promise, understanding, condition or warranty not set forth herein (or in the Exhibits hereto or the other Transaction Documents) has been made or relied upon by either Party. Neither this Agreement nor any provision hereof is intended to confer upon any Person other than the Parties and the other Persons referenced in Article VI any rights or remedies hereunder.
Section 7.8Governing Law.
(a)THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL SUBSTANTIVE LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO THE RULES THEREOF RELATING TO CONFLICTS OF LAW, AND THE OBLIGATIONS, RIGHTS AND REMEDIES OF THE PARTIES HEREUNDER SHALL BE DETERMINED IN ACCORDANCE WITH SUCH LAWS.
(b)Each of the Parties hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of a court with applicable jurisdiction located in the Southern District of New York located in the Borough of Manhattan, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the Parties hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such court located in the Southern District of New York in the Borough of Manhattan. Each of the Parties agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Applicable Law.
(c)Each of the Parties hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any court referred to in this Section 7.8. Each of the Parties hereby irrevocably waives, to the

17

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


fullest extent permitted by Applicable Law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.
(d)Each of the Parties irrevocably consents to service of process in the manner provided for notices in Section 7.4. Nothing in this Agreement will affect the right of any Party to serve process in any other manner permitted by Applicable Law.
Section 7.9Confidentiality. All Confidential Information (as defined in that certain Mutual Confidentiality Agreement, effective as of [*], by and between the Parties (the “CDA”)) exchanged by the Parties for purposes of fulfilling this Agreement, shall remain in the ownership of the originating Party, shall be considered and be maintained as Confidential Information as specified in the CDA, the terms and conditions of which are hereby incorporated herein by reference in their entirety and made part of this Agreement. The Parties agree that the Parties are and shall be subject to the terms and conditions of the CDA as applied to all such Confidential Information exchanged by the Parties for purposes of fulfilling this Agreement, which terms and conditions shall continue to apply hereunder and run concurrently with the term of this Agreement and for a period of [*] years thereafter.  Notwithstanding the foregoing, the terms and conditions of the CDA as incorporated herein are expressly amended to further include the obligation to use Confidential Information only for the purpose of fulfilling obligations hereunder, and shall not otherwise be used for the benefit of the Party receiving Confidential Information or for the benefit of a Third Party without prior written approval from the Party disclosing the Confidential Information.
Section 7.10Severability. If one or more provisions of this Agreement are held to be invalid, illegal or unenforceable by a court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement, which shall remain in full force and effect, and the Parties shall replace such invalid, illegal or unenforceable provision with a new provision permitted by Applicable Law and having an economic effect as close as possible to the invalid, illegal or unenforceable provision. Any provision of this Agreement held invalid, illegal or unenforceable only in part or degree by a court of competent jurisdiction shall remain in full force and effect to the extent not held invalid, illegal or unenforceable.
Section 7.11Counterparts. This Agreement may be signed in any number of counterparts, each of which shall be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each Party shall have received a counterpart hereof signed by the other Party. Any counterpart may be executed by facsimile or other electronic transmission, and such facsimile or other electronic transmission shall be deemed an original.
Section 7.12Amendments; No Waivers. Neither this Agreement nor any term or provision hereof may be amended, supplemented, restated, waived, changed or modified except with the written consent of the Parties. No failure or delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. No notice to or demand on either Party in any case shall entitle it to any notice or demand in similar or other circumstances. No waiver or approval hereunder shall, except as may otherwise be stated in such waiver or approval, be applicable to subsequent transactions. No

18

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


waiver or approval hereunder shall require any similar or dissimilar waiver or approval thereafter to be granted hereunder.

Section 7.13Cumulative Remedies. The remedies herein provided are cumulative and not exclusive of any remedies provided by Applicable Law.
Section 7.14Table of Contents and Headings. The Table of Contents and headings of the Articles and Sections of this Agreement have been inserted for convenience of reference only, are not to be considered a part hereof and shall in no way modify or restrict any of the terms or provisions hereof.
Section 7.15No Presumption Against Drafting Party. Each of the Parties acknowledges that each Party to this Agreement has been represented by counsel in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly, any rule of law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement or any other Transaction Document against the drafting party has no application and is expressly waived.

[SIGNATURE PAGE FOLLOWS]

19

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

Affitech Research AS

By: ​ ​/s/ Michael Braunagel​ ​​ ​
Name: Michael Braunagel
Title: Managing Director

XOMA (US) LLC

By:​ ​/s/ Jim Neal​ ​​ ​​ ​
Name: Jim Neal
Title: Chief Executive Officer


Exhibit List

Exhibit A: Form of Assignment Agreement

Exhibit B: Bill of Sale

Exhibit C: Roche APA

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


EX-21.1 5 tmb-20211231xex21d1.htm EX-21.1

Exhibit 21.1

Subsidiaries of the Company

Jurisdiction of Organization

XOMA Technology Ltd.

Bermuda

XOMA (US) LLC

Delaware

XOMA UK Limited

United Kingdom


EX-23.1 6 tmb-20211231xex23d1.htm EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements (Nos. 333-151416, 333-171429, 333-174730, 333-181849, 333-198719, 333-204367, 333-212238, 333-218378 and 333-232398) on Form S-8 pertaining to the Amended and Restated 2010 Long Term Incentive and Stock Award Plan and the Amended 2015 Employee Stock Purchase Plan of XOMA Corporation and in the Registration Statement (No. 333- 223493) on Form S-3 of our report dated March 8, 2022, relating to the consolidated financial statements of XOMA Corporation, appearing in this Annual Report on Form 10-K for the year ended December 31, 2021.

/s/ Deloitte & Touche LLP

San Francisco, California

March 8, 2022


EX-31.1 7 tmb-20211231xex31d1.htm EX-31.1

Exhibit 31.1

Certification

I, James R. Neal, certify that:

1. I have reviewed this annual report on Form 10-K of XOMA Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f))) for the registrant and we have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 8, 2022

/s/ JAMES R. NEAL

James R. Neal

Chief Executive Officer and Chairman of the Board of Directors


EX-31.2 8 tmb-20211231xex31d2.htm EX-31.2

Exhibit 31.2

Certification

I, Thomas Burns, certify that:

1. I have reviewed this annual report on Form 10-K of XOMA Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f))) for the registrant and we have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 8, 2022

/s/ THOMAS BURNS

Thomas Burns

Senior Vice President, Finance and Chief Financial Officer


EX-32.1 9 tmb-20211231xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), James R. Neal, Chief Executive Officer and Chairman of the Board of Directors of XOMA Corporation (the “Company”), and Thomas Burns, Senior Vice President, Finance and Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

1.The Company’s Annual Report on Form 10-K for the year ended December 31, 2021, to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
2.The information contained in Exhibit 32.1 fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 8th day of March, 2022

/s/ JAMES R. NEAL

James R. Neal

Chief Executive Officer and Chairman of the Board of Directors

/s/ THOMAS BURNS

Thomas Burns

Senior Vice President, Finance and Chief Financial Officer

3.This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of XOMA Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

GRAPHIC 10 tmb-20211231xex10d26002.jpg GRAPHIC begin 644 tmb-20211231xex10d26002.jpg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end EX-101.SCH 11 tmb-20211231.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited) (calc 2) link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Consolidated Financial Statement Detail - Accrued and Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Lease Agreement - Maturity of lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Leases - Maturity of lease liabilities (Details) (calc 2) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Lease Agreement - Rent Expense and Lease costs (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Income Taxes - Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Net Income Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Lease Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - Description of Business - Repayment of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Use of Estimates (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Basis of Presentation and Significant Accounting Policies - Purchase of Rights to Future Milestones and Royalties and Income Taxes and Net Income (Loss) per Share (Details) link:presentationLink link:calculationLink link:definitionLink 40205 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Consolidated Financial Statement Detail - Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Licensing and Other Arrangements - Takeda (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - Licensing and Other Arrangements - Rezolute (Details) link:presentationLink link:calculationLink link:definitionLink 40405 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details) link:presentationLink link:calculationLink link:definitionLink 40406 - Disclosure - Licensing and Other Arrangements - Affimed (Details) link:presentationLink link:calculationLink link:definitionLink 40407 - Disclosure - Licensing and Other Arrangements - NIAID (Details) link:presentationLink link:calculationLink link:definitionLink 40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details) link:presentationLink link:calculationLink link:definitionLink 40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details) link:presentationLink link:calculationLink link:definitionLink 40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details) link:presentationLink link:calculationLink link:definitionLink 40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details) link:presentationLink link:calculationLink link:definitionLink 40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Acquisition of Royalty Rights (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Fair Value Measurements - Summary of Changes In Estimated Fair Value of Level 3 Financial Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Lease Agreement - Leased facilities (Details) link:presentationLink link:calculationLink link:definitionLink 40704 - Disclosure - Lease Agreement - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Long-Term Debt and Other Financings - SVB Loan (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Long-Term Debt and Other Financings - Novartis Note (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Long-Term Debt and Other Financings - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Income Taxes - CARES Act (Details) link:presentationLink link:calculationLink link:definitionLink 40905 - Disclosure - Income Taxes - NOL (Details) link:presentationLink link:calculationLink link:definitionLink 40906 - Disclosure - Income Taxes - Tax credit carryforward (Details) link:presentationLink link:calculationLink link:definitionLink 40907 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Stock Based Compensation - ESPP (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Stock Based Compensation - Deferred Savings Plan (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Stock Based Compensation - Stock Option Plans (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - Stock Based Compensation - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 41005 - Disclosure - Stock Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41006 - Disclosure - Stock Based Compensation - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 41007 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Net Income Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Capital Stock - Series X and Series Y Convertible Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Capital Stock - Series A Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - Capital Stock - Series B Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 41204 - Disclosure - Capital Stock - Dividends (Details) link:presentationLink link:calculationLink link:definitionLink 41205 - Disclosure - Capital Stock - BVF Ownership (Details) link:presentationLink link:calculationLink link:definitionLink 41206 - Disclosure - Capital Stock - ATM Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 41207 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 41208 - Disclosure - Capital Stock - Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 41403 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Consolidated Financial Statement Detail link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Licensing and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Lease Agreement link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Long-Term Debt and Other Financings link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Net Income Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Concentration of Risk, Segment and Geographic Information link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Consolidated Financial Statement Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Long-Term Debt and Other Financings (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Net Income Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Capital Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Description of Business - Cash and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 tmb-20211231_cal.xml EX-101.CAL EX-101.DEF 13 tmb-20211231_def.xml EX-101.DEF EX-101.LAB 14 tmb-20211231_lab.xml EX-101.LAB EX-101.PRE 15 tmb-20211231_pre.xml EX-101.PRE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 03, 2022
Jun. 30, 2021
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Document Transition Report false    
Entity File Number 001-39801    
Entity Registrant Name XOMA CORPORATION    
Entity Incorporation State Country Code DE    
Entity Tax Identification Number 52-2154066    
Entity Address Address Line1 2200 Powell Street    
Entity Address Address Line2 Suite 310    
Entity Address City Or Town Emeryville    
Entity Address State Or Province CA    
Entity Address Postal Zip Code 94608    
City Area Code 510    
Local Phone Number 204-7200    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 240,018,070
Entity Common Stock, Shares Outstanding   11,319,124  
Auditor Firm ID 34    
Auditor Name DELOITTE & TOUCHE LLP    
Auditor Location San Francisco, California    
Entity Central Index Key 0000791908    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Amendment Flag false    
Common Stock      
Security12b Title Common Stock, $0.0075 par value    
Trading Symbol XOMA    
Security Exchange Name NASDAQ    
8.625% Series A Cumulative, Perpetual Preferred Stock      
Security12b Title 8.625% Series A Cumulative, Perpetual Preferred Stock, par value $0.05    
Trading Symbol XOMAP    
Security Exchange Name NASDAQ    
Series B Depositary Shares      
Security12b Title Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)    
Trading Symbol XOMAO    
Security Exchange Name NASDAQ    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash $ 93,328 $ 84,222
Restricted cash 2,049 1,611
Short-term equity securities 774  
Trade and other receivables, net 209 263
Income tax receivable   1,526
Prepaid expenses and other current assets 613 443
Total current assets 96,973 88,065
Long-term restricted cash   531
Property and equipment, net 13 21
Operating lease right-of-use assets 200 359
Long-term royalty and commercial payment receivables 69,075 34,575
Long-term equity securities   1,693
Other assets - long term 301 41
Total assets 166,562 125,285
Current liabilities:    
Accounts payable 1,072 456
Accrued and other liabilities 525 642
Income taxes payable 91  
Contingent consideration under RPAs and CPPAs 8,075 75
Operating lease liabilities 195 179
Unearned revenue recognized under units-of-revenue method 1,641 1,452
Contingent liabilities 0 1,410
Current portion of long-term debt   8,088
Preferred stock dividend accrual 1,368  
Total current liabilities 12,967 12,302
Unearned revenue recognized under units-of-revenue method - long-term 11,685 13,516
Long-term debt   12,764
Long-term operating lease liabilities 34 229
Other liabilities - long term   50
Total liabilities 24,686 38,861
Commitments and Contingencies (Note 13)
Stockholders' equity:    
Preferred Stock
Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,315,263 and 11,228,792 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively 85 84
Additional paid-in capital 1,307,030 1,267,377
Accumulated deficit (1,165,288) (1,181,086)
Total stockholders' equity 141,876 86,424
Total liabilities and stockholders' equity 166,562 125,285
8.625% Series A Cumulative, Perpetual Preferred Stock    
Stockholders' equity:    
Preferred Stock 49 49
8.375% Series B Cumulative, Perpetual Preferred Stock    
Stockholders' equity:    
Preferred Stock
Convertible preferred stock    
Stockholders' equity:    
Preferred Stock
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Preferred stock, par value (in dollars per share) $ 0.05 $ 0.05
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Common stock, par value (in dollars per share) $ 0.0075 $ 0.0075
Common stock, shares authorized (in shares) 277,333,332 277,333,332
Common stock, shares issued (in shares) 11,315,263 11,228,792
Common stock, shares outstanding (in shares) 11,315,263 11,228,792
8.625% Series A Cumulative, Perpetual Preferred Stock    
Preferred stock, par value (in dollars per share) $ 0.05 $ 0.05
Preferred stock, shares authorized (in shares) 984,000 984,000
Preferred stock, dividend rate (as a percent) 8.625% 8.625%
Preferred stock, shares issued (in shares) 984,000 984,000
Preferred stock, shares outstanding (in shares) 984,000 984,000
8.375% Series B Cumulative, Perpetual Preferred Stock    
Preferred stock, par value (in dollars per share) $ 0.05 $ 0.05
Preferred stock, shares authorized (in shares) 3,600  
Preferred stock, dividend rate (as a percent) 8.375% 8.375%
Preferred stock, shares issued (in shares) 1,600 0
Preferred stock, shares outstanding (in shares) 1,600 0
Convertible preferred stock    
Preferred stock, shares issued (in shares) 5,003 5,003
Preferred stock, shares outstanding (in shares) 5,003 5,003
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenues:    
Revenue from contracts with customers $ 36,518 $ 27,941
Revenue recognized under units-of-revenue method 1,642 1,444
Total revenues 38,160 29,385
Operating expenses:    
Research and development 171 170
General and administrative 20,460 16,799
Total operating expenses 20,631 16,969
Income from operations 17,529 12,416
Other (expense) income, net:    
Interest expense (461) (1,844)
Loss on extinguishment of debt (300)  
Other (expense) income, net (879) 1,225
Income before income tax 15,889 11,797
Income tax (expense) benefit (91) 1,501
Net income 15,798 13,298
Net comprehensive income 15,798 13,298
Net income and comprehensive income available to common stockholders (Note 11), basic 7,787 8,793
Net income and comprehensive income available to common stockholders (Note 11), diluted $ 7,968 $ 9,010
Basic net income per share available to common stockholders (in dollars per share) $ 0.69 $ 0.82
Diluted net income per share available to common stockholders (in dollars per share) $ 0.65 $ 0.78
Weighted average shares used in computing basic net income per share available to common stockholders 11,288 10,674
Weighted average shares used in computing diluted net income per share available to common stockholders 12,192 11,503
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Preferred Stock
8.625% Series A Cumulative, Perpetual Preferred Stock
Preferred Stock
8.375% Series B Cumulative, Perpetual Preferred Stock
Preferred Stock
Convertible preferred stock
Common Stock
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Total
Balance at beginning of period at Dec. 31, 2019       $ 73 $ 1,238,299 $ (1,194,384) $ 43,988
Balance at beginning of period (in shares) at Dec. 31, 2019     6,000 9,759,000      
Increase (Decrease) in Stockholders' Equity              
Issuance of stock $ 49       22,572   22,621
Issuance of stock, net (in shares) 984,000            
Issuance of common stock related to Series Y preferred stock conversion       $ 10 (10)    
Issuance of common stock related to Series Y preferred stock conversion (in shares)     (1,000) 1,253,000      
Stock-based compensation expense         3,961   3,961
Exercise of stock options       $ 1 2,406   2,407
Exercise of stock options (in shares)       211,000      
Issuance of common stock related to 401(k) contribution and ESPP         136   136
Issuance of common stock related to 401(k) contribution and ESPP (in shares)       6,000      
Disgorgement of stockholder's short-swing profits         13   13
Net income and comprehensive income           13,298 13,298
Balance at end of period at Dec. 31, 2020 $ 49     $ 84 1,267,377 (1,181,086) 86,424
Balance at end of period (in shares) at Dec. 31, 2020 984,000   5,000 11,229,000      
Increase (Decrease) in Stockholders' Equity              
Issuance of stock         37,140   37,140
Issuance of stock, net (in shares)   2,000          
Preferred stock dividends         (4,867)   (4,867)
Stock-based compensation expense         6,195   6,195
Exercise of stock options       $ 1 1,052   $ 1,053
Exercise of stock options (in shares)       77,000     77,305
Exercise of common stock warrants (in shares)       5,000      
Issuance of common stock related to 401(k) contribution and ESPP         133   $ 133
Issuance of common stock related to 401(k) contribution and ESPP (in shares)       4,000      
Net income and comprehensive income           15,798 15,798
Balance at end of period at Dec. 31, 2021 $ 49     $ 85 $ 1,307,030 $ (1,165,288) $ 141,876
Balance at end of period (in shares) at Dec. 31, 2021 984,000 2,000 5,000 11,315,000      
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS
$ in Thousands
12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Cash flows from operating activities:    
Net income $ 15,798 $ 13,298
Adjustments to reconcile net income to net cash provided by operating activities:    
Stock-based compensation expense 6,195 3,961
Common stock contribution to 401(k) 90 88
Depreciation 7 22
Amortization of debt issuance costs, debt discount and final payment on debt 200 698
Non-cash portion of Novartis Milestone Payment   (7,300)
Reduction of contingent NIH refund liability (105)  
Non-cash lease expense 160 150
Loss on extinguishment of debt 300  
Change in fair value of equity securities 919 (1,012)
Changes in assets and liabilities:    
Trade and other receivables, net 54 2,670
Income tax receivable 1,526 (1,526)
Prepaid expenses and other assets (169) 83
Accounts payable and accrued liabilities 765 (542)
Income tax payable 91  
Operating lease liabilities (179) (163)
Unearned revenue recognized under units-of-revenue method (1,642) (1,444)
Contingent NIH refund liability (1,305) 612
Other liabilities (27) 497
Net cash provided by operating activities 22,678 10,092
Cash flows from investing activities:    
Payments related to purchase of royalty rights and other commercial payment rights (26,500) (1,200)
Receipts related to purchased royalty rights   1,000
Purchase of property and equipment   (9)
Net cash used in investing activities (26,500) (209)
Cash flows from financing activities:    
Proceeds from issuance of preferred stock 40,000 24,600
Payment of preferred and common stock issuance costs (3,385) (1,945)
Proceeds from exercise of options and other share-based compensation 1,584 4,850
Principal payments - debt (4,250) (5,313)
Payment for extinguishment of debt (17,103)  
Payment for preferred stock dividends (3,499)  
Taxes paid related to net share settlement of equity awards (488) (2,395)
Other (24) (4)
Net cash provided by financing activities 12,835 19,793
Net increase in cash and restricted cash 9,013 29,676
Cash and restricted cash at the beginning of the period 86,364 56,688
Cash and restricted cash at the end of the period 95,377 86,364
Supplemental Cash Flow Information:    
Cash paid for interest 311 692
Non-cash investing and financing activities:    
Estimated fair value of contingent consideration under the Affitech CPPA 8,000  
Preferred stock dividend accrual $ 1,368  
Interest added to principal balance on long-term debt   490
Accrued cost related to issuance of capital stock   $ 264
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business
12 Months Ended
Dec. 31, 2021
Description of Business  
Description of Business

1. Description of Business

XOMA (referred to as “XOMA” or the “Company”), a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. The Company’s portfolio was built through licensing its proprietary products and platforms from its legacy discovery and development business, combined with the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs.

Liquidity and Financial Condition

The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December 31, 2021, the Company had unrestricted and restricted cash of $93.3 million and $2.0 million, respectively. The restricted cash balance may only be used to pay dividends on the outstanding Series A Preferred Stock and the outstanding Series B Preferred Stock (Note 12).

In June 2021, the Company repaid its outstanding debt obligations to SVB and Novartis, for a total of $17.1 million (Note 8). Based on the Company’s current cash balance and its ability to control discretionary spending, such as royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these consolidated financial statements are issued.

XML 23 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Basis of Presentation and Significant Accounting Policies
12 Months Ended
Dec. 31, 2021
Basis of Presentation and Significant Accounting Policies  
Basis of Presentation and Significant Accounting Policies

2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X. 

Use of Estimates

The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts and amortization of the payments received from HCRP. Under the Company’s contracts with the NIAID, a part of the NIH, the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. As of December 31, 2020, the audit procedures were completed, and the Company adjusted its estimated liability owed to NIH to $1.4 million. In December 2021, the NIH

completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and the Company adjusted its liability owed to NIH to $1.3 million. In December 2021, the Company paid the final approved refund liability of $1.3 million. As such, no contingent liability remained on the Company’s consolidated balance sheets as of December 31, 2021.

In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.

The COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.

Cash and Restricted Cash

Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2021 and 2020, the Company did not have any cash equivalent balances, defined as highly liquid financial instruments purchased with original maturities of three months or less.

Restricted cash consists of bank deposits held to pay dividends on the Company’s Series A Preferred Stock and Series B Preferred Stock.

The Company maintains cash and restricted cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash and restricted cash.

The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):

Year Ended December 31, 

2021

2020

Cash

$

93,328

$

84,222

Restricted cash

2,049

2,142

Total cash and restricted cash

$

95,377

$

86,364

Revenue Recognition

The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.

To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once

the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.

The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.

License of intellectual property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).

Milestone payments

At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments.

If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract

inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.

Sale of Future Revenue Streams

The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment.

Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.

Stock-Based Compensation

The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.

Equity Securities

The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive income in the period of sale.

In October 2020, Rezolute completed a 1:50 reverse stock split of its common shares (the “Rezolute Reverse Stock Split”) and started trading on the Nasdaq Stock Market. As a result, the Company’s number of shares of Rezolute common stock was reduced from 8,093,010 shares (pre reverse-split shares) to 161,861 shares (post reverse-split shares). All subsequent disclosures of Rezolute share numbers will be presented post reverse-split.

Purchase of Rights to Future Milestones, Royalties and Commercial Payments

The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product

development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive income.

The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.

The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2021 and December 31, 2020.

Leases

The Company leases its headquarters office space in Emeryville, California.

The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.

Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive income.

The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.

Income Taxes

The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.

The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Prior Period Reclassifications

Within the consolidated statement of cash flows, the Company presented principal payments on its finance lease and proceeds from disgorgement of stockholder's short-swing profits together in order for the prior period to conform with current period presentation.

Net Income per Share Attributable to Common Stockholders

The Company calculates basic and diluted income per share attributable to common stockholders using the two-class method. The Company’s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.

Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period and any deemed dividends related to beneficial conversion features on convertible preferred stock, if applicable, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income per share attributable to common stockholders is then calculated by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.

Diluted net income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock. The calculation of diluted net income per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options or warrants, the presumed exercise of such securities are dilutive to net income per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and therefore, are not included in the diluted shares until the contingency is resolved.

Comprehensive Income

Comprehensive income is comprised of two components: net income and other comprehensive income. Other comprehensive income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net income. The Company did not record any transactions within other comprehensive income in the periods presented and, therefore, the net income and comprehensive income were the same for all periods presented.

Accounting Pronouncements Recently Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company on January 1, 2021. The Company adopted ASU 2019-12, on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the Company’s consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. These amendments provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The ASU provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. It is intended to help stakeholders during the global market-wide reference rate transition period. The guidance is effective for all entities as of March 12, 2020 through December 31, 2022 and can be adopted as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company adopted ASU 2020-04 as of January 1, 2021. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusion. In addition, this ASU improves and amends the related EPS guidance. These amendments are effective for the Company for fiscal years beginning after December 15, 2023, including interim period within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The Company adopted ASU 2020-06 on January 1, 2021. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for all entities except public companies that are not smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted. The Company plans to adopt ASU 2016-13 and related updates as of January 1, 2023. The Company is currently evaluating the impact of adopting this new accounting guidance on its consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations – Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. Early adoption is permitted. The Company is currently evaluating the impacts of the provisions of ASU 2021-08 and the Company does not expect this ASU to have a material impact on its consolidated financial statements.

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Financial Statement Detail
12 Months Ended
Dec. 31, 2021
Consolidated Financial Statement Detail  
Consolidated Financial Statement Detail

3. Consolidated Financial Statement Detail

Equity Securities

As of December 31, 2021 and December 31, 2020, equity securities consisted of an investment in Rezolute’s common stock of $0.8 million and $1.7 million, respectively (Note 4). For the years ended December 31, 2021 and December 31, 2020, the Company recognized a loss of $0.9 million and a gain of $1.0 million, respectively, due to the change in fair value of its investment in Rezolute’s common stock in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income.

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

December 31, 

December 31, 

    

2021

    

2020

Accrued legal and accounting fees

295

351

Accrued payroll and benefits

 

135

 

136

Accrued incentive compensation

55

71

Other accrued liabilities

40

84

Total

$

525

$

642

XML 25 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Licensing and Other Arrangements
12 Months Ended
Dec. 31, 2021
Licensing and Other Arrangements  
Licensing and Other Arrangements

4. Licensing and Other Arrangements

Novartis – Anti-TGFβ Antibody (NIS793)

On September 30, 2015, the Company and Novartis entered into the Anti-TGFβ Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company’s anti-transforming growth factor beta (“TGFβ”) antibody program (now “NIS793”). Under the terms of the Anti-TGFβ Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGFβ Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’s royalty obligations end. The Anti-TGFβ Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGFβ Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days’ notice.

The Company concluded that there were multiple promised goods and services under the Anti-TGFβ Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December 31, 2015.

The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGFβ Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGFβ Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment which was recognized as license fees in the consolidated statement of operations and comprehensive income.

The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when

the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid single-digit percentage rate to up to a low double-digit percentage rate. Novartis’s obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.

On October 21, 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis’ first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGFβ Antibody License Agreement, the Company received $17.7 million in cash and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis.

On October 20, 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis’ first NIS793 Phase 3 clinical trial. The Company is eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGFβ Antibody License Agreement.

As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company recognized $35.0 million and $25.0 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the years ended December 31, 2021 and 2020, respectively.

Novartis – Anti-IL-1β Antibody (VPM087) and IL-1 Beta

On August 24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (“VPM087”), a novel anti-Interleukin-1 (“IL-1”) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087.

On August 24, 2017, pursuant to a separate agreement (the “IL-1 Target License Agreement”), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the “Exclusivity Option”) to such intellectual property for the treatment and prevention of cardiovascular disease.

Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company’s outstanding debt with Les Laboratories Servier (“Servier”) (the “Servier Loan”). In addition, Novartis extended the maturity date on the Company’s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company’s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August 24, 2017, resulting in a $0.2 million premium paid to the Company.

Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications

covered by the Company’s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid single-digits.

Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months’ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice.

The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.

At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the year ended December 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.

The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2021 and 2020.

Takeda

On November 1, 2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.

Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and TAK-169, and low single-digit royalties on future sales of all products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all

research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 13.5 years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).

In February 2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.

As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. During the years ended December 31, 2021 and 2020, the Company recognized annual license fee revenue of $0.1 million from Takeda. On November 16, 2020, the first patient was dosed in Takeda’s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda. The Company is eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement. During the years ended December 31, 2021 and 2020, the Company recognized $0.1 million and $2.1 million, respectively, as revenue from contracts with customers in the consolidated statement of operations and comprehensive income.  

Rezolute

On December 6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now “RZ358”) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.

Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute’s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute’s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.

Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute’s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical testing. Rezolute’s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee’s obligation to make payments to Rezolute based on sales of such product in such country

The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days’ notice at any time. To the extent

permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.

No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute’s financing activities.

The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute’s achievement of financing activities and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute’s common stock.

As of December 31, 2021 and December 31, 2020, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2021 and 2020.

The Company reassessed the development and regulatory milestones and concluded that such variable consideration is fully constrained and excluded from the transaction price as of December 31, 2021 and 2020.   

Janssen Biotech

The Company and Janssen were parties to a license agreement which was terminated in 2017. In August 2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen’s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen’s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties.

The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019 as it had completed its performance obligation.

The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen’s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

In May 2021, the Company earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets. In December 2021, the Company earned a $0.2 million milestone pursuant to its agreement with Janssen.

As of December 31, 2021 and December 31, 2020, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. Milestone revenue of $0.7 million and $0.4 million was recognized for the years ended December 31, 2021 and 2020, respectively.

Affimed

In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE molecules and preloaded natural killer cells containing the ICE molecules. Additionally, the Company is eligible to receive a milestone upon the first product candidate in each program achieving marketing approval.

The Company concluded that the commercial milestone payments are solely dependent on Affimed’s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

As of December 31, 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the year ended December 31, 2021.

NIAID

Prior to the sale of the Company’s biodefense business in 2016, the Company performed services under contracts funded with federal funds from NIAID including under a $64.8 million multiple-year contract (Contract No. HHSN272200800028C), for development of anti-botulinum antibody product candidates and a $28.0 million multiple-year contract (Contract No. HHSN272201100031C) for development of broad-spectrum antitoxins for the treatment of human botulism poisoning. The contract work was being performed on a cost plus fixed fee basis over a three-year period. The Company recognized revenue under the arrangement as the services were performed on a proportional performance basis. Consistent with the Company’s other contracts with the U.S. government, invoices were provisional until finalized. The Company operated under provisional rates from 2010 through 2015, subject to adjustment based on actual rates upon agreement with the government. In 2014, upon completion of NIAID’s review of hours and external expenses, XOMA agreed to exclude certain hours and external expenses resulting in a $0.4 million receivable and $0.8 million deferred revenue balances. As of December 31, 2017, the Company wrote off the $0.4 million receivable from NIAID as the likelihood of collection was remote. In October of 2019, NIH, which includes NIAID, notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. The KPMG testing procedures were completed in December 2020. As a result, the Company recognized $1.4 million as estimated refund liabilities owed to NIH on the consolidated balance sheet as of December 31, 2020. The additional $0.6 million liability was recognized as a reduction of revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the year ended December 31, 2020. In December 2021, NIH completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and approved a finalized refund liability of $1.3 million. The $0.1 million reduction in the liability, from its previously recorded $1.4 million estimate, was recognized as revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the year ended December 31, 2021. In December 2021, the Company paid the finalized refund liability owed to NIH of $1.3 million and no balance of the contingent liability remained on the consolidated balance sheets as of December 31, 2021.

Sale of Future Revenue Streams

On December 21, 2016, the Company entered into two royalty interest sale agreements (together, the “Royalty Sale Agreements”) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale

Agreement entered into in December 2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.

The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under units-of-revenue method over the life of the license agreements because of the Company’s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company’s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period’s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.

The Company recognized $1.6 million and $1.4 million as revenue under units-of-revenue method under these arrangements during the years ended December 31, 2021 and December 31, 2020, respectively. As of December 31, 2020, the current and non-current portion of the remaining unearned revenue recognized under units-of-revenue method was $1.5 million and $13.5 million, respectively. As of December 31, 2021, the Company classified $1.6 million and $11.7 million as current and non-current unearned revenue recognized under units-of-revenue method, respectively.

XML 26 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Royalty and Commercial Payment Purchase Agreements
12 Months Ended
Dec. 31, 2021
Royalty and Commercial Payment Purchase Agreements  
Royalty and Commercial Payment Purchase Agreements

5. Royalty and Commercial Payment Purchase Agreements

Royalty Purchase Agreement with Agenus

On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (“Incyte”) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentage of applicable net sales.

In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company’s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.

Under the terms of the Agenus RPA, the Company paid Agenus $15.0 million.

At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets.

In November 2020, MK-4830 advanced into Phase 2 development and Agenus earned a $10.0 million clinical development milestone under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.

The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

Royalty Purchase Agreement with Bioasis

On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product.

Under the terms of the Bioasis RPA, the Company paid $0.3 million and will make contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the “Bioasis Contingent Consideration”).

At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $0.1 million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income. As of December 31, 2021, there was no change in the fair value of the contingent consideration from its initial value and no amounts were paid during the year ended December 31, 2021. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights.

At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under the Second Bioasis RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

Royalty Purchase Agreement with Aronora

On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the “Non-Royalties”) related to five anti-thrombotic hematology drug candidates. Three candidates were subject to Aronora’s collaboration with Bayer (the “Bayer Products”), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the “non-Bayer Products”) for which the Company will receive low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will

be reduced from 10% to 5% upon the Company’s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.

Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB (Note 8). The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the “Aronora Contingent Consideration”). Pursuant to the Aronora RPA, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the “Royalty Milestones”). The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product. Royalties per product in excess of $250.0 million are retained by the Company.

At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term.

Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. 

Royalty Purchase Agreement with Palobiofarma

On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin’s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the “Palo Licensed Products”) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis.

Under the terms of the Palo RPA, the Company paid Palo a $10.0 million payment at the close of the transaction which occurred simultaneously upon parties’ entry into the Palo RPA on September 26, 2019.

At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

Royalty Purchase Agreement with Viracta

On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0

million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved.

At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

Royalty Purchase Agreement with Kuros

On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals’ vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestones.

At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

Commercial Payment Purchase Agreement with Affitech

On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche’s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones (Note 15). At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which includes the $6.0 million upfront payment and $8.0 million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million meet the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.

Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the investment has been fully collected.  The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.

The following table summarizes the long-term royalty receivable activities including acquisitions of royalty rights, commercial payment rights and cash receipts for achievement of contractual milestones during the years ended December 31, 2021 and 2020 (in thousands):

Balance at January 1, 2020

    

$

34,375

Acquisition of royalty rights:

Bioasis

1,200

Cash receipts for achievement of contractual milestones:

Agenus

(1,000)

Balance at December 31, 2020

    

34,575

Acquisition of royalty and commercial payment rights:

Viracta

 

13,500

Kuros

 

7,000

Affitech

14,000

Balance at December 31, 2021

$

69,075

XML 27 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements
12 Months Ended
Dec. 31, 2021
Fair Value Measurements  
Fair Value Measurements

6. Fair Value Measurements

The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company’s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

Fair Value Measurements at December 31, 2021 Using

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

Total

Assets:

Equity securities

$

774

$

$

$

774

Liabilities:

Contingent consideration under RPAs and CPPAs

$

$

$

8,075

$

8,075

Fair Value Measurements at December 31, 2020 Using

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

Total

Assets:

  

  

  

  

Equity securities

$

$

$

1,693

$

1,693

Liabilities:

Contingent consideration

$

$

$

75

$

75

Transfers to and from Levels 1, 2, and 3 are recognized at the end of the reporting period. On June 30, 2021, the Company’s equity investment in Rezolute’s common stock transferred from Level 3 to Level 1. In reporting periods prior to June 30, 2021, the Company applied an illiquidity discount to the fair value of Rezolute’s common stock due to the lack of trading volume, resulting in classification as Level 3. Since June 30, 2021, there has been sufficient and consistent trading volume on the Nasdaq Stock Market to provide an estimate of fair value utilizing quoted prices in an active market for the identical securities as of the reporting date, resulting in classification as Level 1. There were no transfers between levels during 2020.

Equity Securities

The following table reconciles the beginning and ending balance for the Level 3 financial assets recurring fair value measurement for the year ended December 31, 2021 (in thousands):

Year Ended

December 31, 2021

Balance at December 31, 2019

$

681

Change in fair value

1,012

Balance at December 31, 2020

$

1,693

Change in fair value

 

617

Transfer out of Level 3 as of June 30, 2021

(2,310)

Balance at December 31, 2021

$

The equity securities consisted of an investment in Rezolute’s common stock and are classified on the consolidated balance sheets as current assets as of December 31, 2021, and long-term assets as of December 31, 2020. The reclassification from noncurrent to current assets was due to the equity securities achieving sufficient and consistent trading volume on the Nasdaq Stock Market during the second quarter of 2021. The equity securities are revalued each reporting period with changes in fair value recorded in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income.

As of December 31, 2020, the Company and its valuation specialist, valued the equity securities using the closing price for Rezolute’s common stock traded on the Nasdaq Stock Market and adjusted for an illiquidity discount. The inputs that were used to calculate the illiquidity discount were based on observable and unobservable estimates and judgments and therefore were classified as a Level 3 fair value measurement. As the Company has the right and option to sell up to 100,000 shares of Rezolute’s common stock back to Rezolute after December 31, 2019 (Note 4), the fair value of the equity securities was determined by dividing the total shares of Rezolute’s common stock held by the Company into two tranches based on the estimated time to a potential liquidity event.

As of December 31, 2021, the Company valued the equity securities using the closing price for Rezolute’s common stock traded on the Nasdaq Stock Market. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement.

The closing price of Rezolute’s common stock as per the Nasdaq Stock Market was $4.78 and $11.99 as of December 31, 2021 and December 31, 2020, respectively. The estimated fair value of the equity securities as of December 31, 2020 was calculated based on the following assumptions:

December 31, 

December 31, 

2021

2020

 

Closing common stock price

$

4.78

$

11.99

Tranche 1:

Discount for lack of marketability

 

N/A(1)

%  

12

%

Estimated time to liquidity of shares

 

0.25 year

Tranche 2:

Discount for lack of marketability

N/A(1)

%

14

%

Estimated time to liquidity of shares

0.67 years

(1)Due to sufficient and consistent trading volume, the equity investment will be measured at the closing price per the Nasdaq Stock Market. The assumptions related to the unobservable inputs identified above, and any changes in those assumptions thereto, will no longer be considered in determining the fair value of the equity securities.

Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the equity securities.

Contingent Consideration

The estimated fair value of the contingent consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate.

The estimated fair value of the contingent consideration liability at the inception of the Affitech CPPA represents the future consideration that is contingent upon the achievement of specified regulatory milestones. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving regulatory milestones.

Changes in the fair value of the liability for contingent consideration will be recorded in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income until settlement. As of December 31, 2021, there were no changes in the estimated fair value of the contingent consideration recorded pursuant to the Bioasis RPA and Affitech CPPA from the initial values of $0.1 million and $8.0 million, respectively.

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Lease Agreement
12 Months Ended
Dec. 31, 2021
Lease Agreement  
Lease Agreement

7. Lease Agreement

The Company leases one facility in Emeryville, California under an operating lease that expires in February 2023. The Emeryville lease contains an option to extend the lease for an additional term, however, the Company is not reasonably certain to exercise this option.

The following table summarizes maturity of the Company’s operating lease liabilities as of December 31, 2021 (in thousands):

Operating

Undiscounted lease payments

    

Leases

2022

 

202

2023

 

34

2024

 

Total undiscounted lease payments

 

236

Present value adjustment

 

(7)

Total net lease liabilities

 

$

229

The following table summarizes the cost components of the Company’s operating lease for the years ended December 31, 2021 and 2020, respectively (in thousands):

    

Year Ended December 31, 

    

2021

    

2020

Lease costs:

Operating lease cost

$

177

 

$

177

Variable lease cost (1)

8

 

7

Total lease costs

$

185

$

184

(1)Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.

The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):

    

Year Ended December 31, 

    

2021

2020

Cash paid for amounts included in the measurement of lease liabilities

 

 

Operating cash flows under operating leases

$

196

$

189

The present value assumptions used in calculating the present value of the lease payments for the Company’s operating lease as of December 31, 2021 and December 31, 2020 were as follows:

    

December 31, 

December 31, 

    

2021

2020

Weighted-average remaining lease term

1.17 years

2.17 years

Weighted-average discount rate

5.51

%

5.51

%

XML 29 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Long-Term Debt and Other Financings
12 Months Ended
Dec. 31, 2021
Long-Term Debt and Other Financings  
Long-Term Debt and Other Financings

8. Long-Term Debt and Other Financings

SVB Loan

On May 7, 2018 (the “Effective Date”), the Company executed the SVB Loan Agreement with SVB. Under the Loan Agreement, upon the Company’s request, SVB made advances (each, a “Term Loan Advance”) available to the Company up to $20.0 million (the “Term Loan”). The Company was allowed to borrow advances under the Term Loan from the Effective Date until the earlier of March 31, 2019 or an event of default (the “Draw Period”). The interest rate was calculated at a rate equal to the greater of (i) 4.75%, or (ii) 0.25% plus the prime rate as reported from time to time in The Wall Street Journal.

Payments under the Loan Agreement were interest only until the first anniversary of the funding date of each Term Loan Advance. The interest-only period was followed by equal monthly payments of principal and interest over 24 months. Each Term Loan Advance was scheduled to mature at the earlier of (i) the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii) March 1, 2023, or (iii) 30 days prior to the earliest maturity of any portion of the Company’s loan with Novartis (the “Loan Maturity Date”). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed. The entire principal balance, including a final payment fee equal to 8.5% of the original principal, was due and payable on the Loan Maturity Date.

In June 2021, the Company repaid its principal balance of $6.5 million and paid the 8.5% final payment fee of $1.4 million to SVB. The Company also paid SVB a prepayment fee of 1% of the outstanding principal balance.

In connection with the Loan Agreement, the Company issued a warrant to SVB which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share (the “Warrant”). The Warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the Warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. In addition, the Company incurred debt issuance costs of $0.2 million in connection with the Loan Agreement.

On March 4, 2019, the Loan Agreement was amended to extend the Draw Period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million.

Both warrants may be exercised on a cashless basis and are exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. As of December 31, 2021, both warrants are outstanding.

In September 2018, the Company borrowed advances of $7.5 million under the Loan Agreement in connection with the Agenus RPA (Note 5). The Company recorded a discount of $0.3 million against the debt, which was being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.

During the year ended December 31, 2019, the Company borrowed advances totaling $9.5 million under the Loan Agreement in connection with the Aronora RPA, Palo RPA and payment of the Aronora Contingent Consideration (Note 5). The Company recorded a discount of $45,000 against the debt, which was being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.

The Company recorded $0.2 million of non-cash interest expense resulting from the amortization of the discount and accretion of the final payment before the loan was extinguished in June 2021 and $0.6 million for the year ended December 31, 2020.  

As of December 31, 2020, the carrying value of the debt under the Loan Agreement was $11.8 million. Of this amount, $8.1 million was classified as current portion of long-term debt and $3.7 million was classified as long-term debt on the consolidated balance sheet. In June 2021, the Company paid off its entire outstanding principal balance to SVB. Upon repayment of the principal balance, the Company recognized a loss on extinguishment of $0.3 million in other (expense) income, net of the consolidated statement of operations for the year ended December 31, 2021. As of December 31, 2021, there was no carrying value of the debt under the Loan Agreement.

Novartis Note

In May 2005, the Company executed the Novartis Note Agreement with Novartis, which was due and payable in full in June 2015. Under the Novartis Note Agreement, the Company borrowed semi-annually to fund up to 75% of the Company’s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50.0 million in aggregate principal amount. Interest on the principal amount of the loan accrued at six-month LIBOR plus 2% and the interest rate reset in June and December annually. Accrued interest was payable semi-annually in

June and December of each year or, at the Company’s election, the semi-annual interest payments could be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount did not exceed $50.0 million. The Company made this election for all interest payments. Loans under the Novartis Note Agreement were secured by the Company’s interest in its collaboration with Novartis, including any payments owed to it thereunder. In June 2021, the Company repaid its outstanding principal balance to Novartis of $9.1 million and extinguished its debt obligation.

On September 30, 2015, concurrent with the execution of a license agreement with Novartis as discussed in Note 4, XOMA and Novartis, who assumed the rights to the note from Novartis Vaccines Diagnostics, Inc. executed an amendment to the Novartis Note Agreement (the “Secured Novartis Note Amendment”) under which the parties extended the maturity date of the note from September 30, 2015 to September 30, 2020, and eliminated the mandatory prepayment previously required to be made with certain proceeds of pre-tax profits and royalties. In addition, upon achievement of a specified development and regulatory milestone, the then-outstanding principal amount of the note was to be reduced by $7.3 million rather than the Company receiving such amount as a cash payment.

On September 22, 2017, in connection with the Gevokizumab License Agreement with Novartis, the Company and Novartis executed an amendment to the Novartis Secured Note Amendment under which the parties further extended the maturity date of the Novartis Secured Note Amendment from September 30, 2020 to September 30, 2022.

On October 21, 2020, the first patient was dosed in Novartis’s first NIS793 Phase 2 clinical trial and the Company earned a $25.0 million milestone pursuant to the Anti-TGFβ Antibody License Agreement, of which $17.7 million was received in cash and $7.3 million was recognized as a reduction to the debt obligation to Novartis.

As of December 31, 2020, the outstanding principal balance under the Novartis Secured Note Amendment was $9.1 million and was included in long-term debt in the accompanying consolidated balance sheet. In June 2021, the Company repaid its entire outstanding debt balance to Novartis. The repayment of principal did not result in any gain or loss on extinguishment. As of December 31, 2021, there was no carrying value of the debt under the Novartis Note Agreement.

Interest Expense

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive income for the years ended December 31, 2021 and 2020, relates to the following debt instruments (in thousands):

Year Ended December 31, 

    

2021

    

2020

SVB Loan

$

373

$

1,365

Novartis Note

 

88

 

477

Other

 

 

2

Total interest expense

$

461

$

1,844

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
12 Months Ended
Dec. 31, 2021
Income Taxes  
Income Taxes

9. Income Taxes

The Company has pre-tax book income of $15.9 million and $11.8 million for the year ended December 31, 2021 and 2020, respectively.  The Company has $0.1 million income tax expense and $1.5 million income tax benefit for the years ended December 31, 2021 and 2020, respectively.  

The provision (benefit) for income taxes, all classified as current, consists of the following (in thousands):

Year Ended December 31, 

    

2021

    

2020

Federal

$

91

$

(1,501)

State

 

 

Total

$

91

$

(1,501)

Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company’s actual effective income tax rate is as follows:

Year Ended December 31, 

 

    

2021

    

2020

 

Federal tax at statutory rate

 

21

%  

21

%

Stock compensation and other permanent differences

 

9

%  

(6)

%

Federal orphan drug credit

 

(2)

%  

%

Tax benefit related to CARES Act

 

%  

(13)

%

Tax benefit related to net operating loss carryforward utilization

 

(11)

%  

%

Valuation allowance

 

(16)

%  

(15)

%

Total

 

1

%  

(13)

%

On March 27, 2020, the CARES Act was enacted, which includes a five-year NOL carryback provision which enabled the Company to benefit from certain losses at the former federal tax rate of 34%. In 2020, the Company recorded tax benefits of $1.5 million related to the NOL carryback provision. During the year ended December 31, 2021, the Company received $1.5 million in cash for its income tax receivable.

The significant components of net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):

December 31, 

    

2021

    

2020

Capitalized research and development expenses

$

7,822

$

11,500

Net operating loss carryforwards

 

17,657

 

17,638

Research and development and other tax credit carryforwards

 

13,125

 

13,454

Stock compensation

 

4,778

 

5,158

Unearned revenue

 

2,817

 

3,462

Other

 

807

 

401

Total deferred tax assets

 

47,006

 

51,613

Valuation allowance

 

(47,006)

 

(51,613)

Net deferred tax assets

$

$

The net decrease in the valuation allowance was $4.6 million and $3.9 million, for the years ended December 31, 2021 and 2020, respectively.

Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company’s four sources of taxable income including historical operating performance and the repeal of NOL carryback, the Company has determined that total deferred tax assets should be fully offset by a valuation allowance.

Based on an analysis under Section 382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to annual limitations), the Company experienced an ownership change in February 2017 which substantially limits the future use of its pre-change NOLs and certain other pre-change tax attributes per year. The Company has excluded the related tax attributes that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2021 and December 31, 2020. To the extent that the Company

does not utilize its carryforwards within the applicable statutory carryforward periods, either because of Section 382 limitations or the lack of sufficient taxable income, the carryforwards will expire unused.

As of December 31, 2021, the Company had federal NOL carry-forwards of approximately $78.8 million and state NOL carry-forwards of approximately $38.1 million to offset future taxable income. $13.6 million of federal NOL carryforwards will begin to expire in 2036 and the remainder may be carried forward indefinitely. The state NOL carryforwards will begin to expire in 2033. The Company had federal orphan credit of $2.0 million which if not utilized will expire in 2037. The Company also had $19.8 million of California research and development tax credits which have no expiration date.

Under the 2017 federal income tax law, as modified by the federal tax law changes enacted in March 2020, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but, for taxable years beginning after December 31, 2020, the deductibility of such federal NOLs may only be utilized to offset 80% of taxable income annually.  

The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company’s federal income tax returns for tax years 2018 and beyond remain subject to examination by the Internal Revenue Service. The Company’s state income tax returns for tax years 2017 and beyond remain subject to examination by state tax authorities. In addition, all of the NOLs and research and development credit carryforwards that may be used in future years are still subject to adjustment.

The following table summarizes the Company’s activity related to its unrecognized tax benefits (in thousands):

Year Ended December 31, 

    

2021

    

2020

Balance at January 1

$

5,938

$

5,517

Increase related to current year tax position

 

 

Increase related to prior year tax position

 

 

421

Balance at December 31

$

5,938

$

5,938

As of December 31, 2021, the Company had a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as the Company currently has a full valuation allowance against its deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.

The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through December 31, 2021, the Company has not accrued interest or penalties related to uncertain tax positions.

XML 31 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Based Compensation
12 Months Ended
Dec. 31, 2021
Stock Based Compensation  
Stock Based Compensation

10. Stock Based Compensation

The Company may grant qualified and non-qualified stock options, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company’s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period.

Employee Stock Purchase Plan

In May 2015, the Company’s stockholders approved the 2015 Employee Stock Purchase Plan (the “2015 ESPP”), which replaced the Company’s legacy 1998 ESPP. Under the 2015 ESPP, the Company reserved 15,000 shares of common stock for issuance as of its effective date of July 1, 2015, subject to adjustment in the event of a stock split, stock dividend,

combination or reclassification or similar event. The 2015 ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2015 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period.

In February 2017, the Compensation Committee and the Board of Directors adopted, and in May 2017, the Company’s stockholders approved, an amendment to the Company’s 2015 ESPP. The amendment (a) increased by 250,000 the shares of common stock (from 15,000 shares to a total of 265,000 shares) available for issuance under the 2015 ESPP; and (b) increased the maximum number of shares of common stock an employee may purchase in any offering period to 2,500. As of December 31, 2021, the Company had 237,072 remaining authorized shares available for purchase under the ESPP.

During the years ended December 31, 2021 and 2020, employees purchased 2,225 and 2,746 shares of common stock, respectively, under the 2015 ESPP.

Deferred Savings Plan

Under section 401(k) of the Internal Revenue Code of 1986, the Board of Directors adopted, effective June 1, 1987, a tax-qualified deferred compensation plan for employees of the Company. Participants may make contributions which defer up to 50%of their eligible compensation per payroll period, up to a maximum for 2021 and 2020 of $19,500 (or $26,000 for employees over 50 years of age). The Company may, at its sole discretion, make contributions each plan year, in cash or in shares of the Company’s common stock, in amounts which match up to 50% of the salary deferred by the participants. The expense related to these contributions was $0.1 million for the years ended December 31, 2021 and December 31, 2020, and 100% was paid in common stock for each year. The Company applies shares from plan forfeitures of terminated employees toward the Company’s matching contribution.  

Stock Option Plans

In May 2010, the Compensation Committee and Board of Directors adopted, and in July 2010 the Company’s stockholders approved the 2010 Plan. The 2010 Plan was amended in 2016, 2017 and 2019 to (a) increase the number of shares of common stock issuable under the 2010 Plan; (b) increase the number of shares of common stock issuable under the 2010 Plan as incentive stock options; and (c) extend the term of the 2010 Plan to April 1, 2029. As of December 31, 2021, the number of shares of common stock reserved for issuance under the 2010 Plan is 3,029,062 shares.

From the 2010 Plan, the Company grants stock options to eligible employees, consultants and directors. Stock-based awards granted under the 2010 Plan may be exercised when vested and generally expire ten years from the date of the grant or three to six months from the date of termination of employment (longer in case of death or certain retirements).

As of December 31, 2021, the Company had 161,140 shares available for grant under the 2010 Plan. As of December 31, 2021, options to purchase 1,911,177 shares of common stock were outstanding under the 2010 Plan.

Stock Options

Stock options generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement.

Stock Option Plans Summary

The following table summarizes the Company’s stock option activity for the year ended December 31, 2021.

As of December 31, 2021

Weighted

    

Weighted

Average

Average

Aggregate

Exercise

Contractual 

Intrinsic

Number of

Price

Term

Value

shares

Per Share

(in years)

(in thousands)

Outstanding at January 1, 2021

1,827,906

$

20.66

 

6.31

 

$

51,401

Granted

 

325,211

 

32.02

 

  

 

  

Exercised

 

(77,305)

 

13.61

 

  

 

  

Forfeited, expired or cancelled

(164,635)

 

46.59

 

  

 

  

Outstanding at December 31, 2021

1,911,177

$

20.64

 

6.33

$

15,103

Exercisable at December 31, 2021

1,553,696

$

18.75

 

5.69

$

14,894

The aggregate intrinsic value of stock options exercised in 2021 and 2020 was $1.6 million and $5.4 million, respectively.

The weighted-average grant-date fair value per share of the options granted in 2021 and 2020 was $22.23 and $18.41, respectively.

As of December 31, 2021, $4.1 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.21 years.

Stock-based Compensation Expense

The fair value of stock options granted during the years ended December 31, 2021 and 2020, was estimated based on the following weighted average assumptions for:

Year Ended December 31, 

 

    

2021

    

2020

 

Dividend yield

 

0

%  

0

%

Expected volatility

 

83

%  

100

%

Risk-free interest rate

 

0.95

%  

0.72

%

Expected term

 

5.66 years

5.64 years

The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive income (in thousands):

Year Ended December 31, 

    

2021

    

2020

Research and development

$

$

General and administrative

 

6,195

 

3,961

Total stock-based compensation expense

$

6,195

$

3,961

XML 32 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Income Per Share Attributable to Common Stockholders
12 Months Ended
Dec. 31, 2021
Net Income Per Share Attributable to Common Stockholders  
Net Income Per Share Attributable to Common Stockholders

11. Net Income Per Share Attributable to Common Stockholders

Potentially dilutive securities are excluded from the calculation of diluted net income per share attributable to common stockholders if their inclusion is anti-dilutive.

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income per share attributable to common stockholders (in thousands):

Year Ended December 31, 

    

2021

    

2020

Convertible preferred stock

Common stock options

 

479

616

Warrants for common stock

 

6

Total

 

479

 

622

The following is a reconciliation of the numerator (net income) and denominator (number of shares) used in the calculation of basic and diluted net income per share attributable to common stockholders (in thousands):

Year Ended December 31, 

    

2021

    

2020

Numerator

 

  

 

  

Net income

$

15,798

$

13,298

Less: Series A accumulated dividends

 

(2,122)

 

(88)

Less: Series B accumulated dividends

(2,438)

Less: Allocation of undistributed earnings to participating securities

 

(3,451)

 

(4,417)

Net income available to common stockholders, basic

$

7,787

$

8,793

Add: Adjustments to undistributed earnings allocated to participating securities

 

181

217

Net income available to common stockholders, diluted

$

7,968

$

9,010

 

Denominator

 

 

Weighted average shares used in computing basic net income per share available to common stockholders

 

11,288

 

10,674

Effect of dilutive stock options

 

900

824

Effect of dilutive warrants

 

4

5

Weighted average shares used in computing diluted net income per share available to common stockholders

 

12,192

 

11,503

Basic net income per share available to common stockholders

$

0.69

$

0.82

Diluted net income per share of common stock

$

0.65

$

0.78

XML 33 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Capital Stock
12 Months Ended
Dec. 31, 2021
Capital Stock  
Capital Stock

12. Capital Stock

Series X and Series Y Convertible Preferred Stock

The Company sold directly to BVF 5,003 shares of Series X convertible preferred stock in 2017 and 1,252.772 shares of Series Y convertible preferred stock in 2018. There were no shares of Series Y convertible preferred stock outstanding as of December 31, 2021, after BVF converted all Series Y preferred stock into common stock on April 15, 2020.

As of December 31, 2021 and 2020, there were 5,003 shares authorized and issued of Series X convertible preferred stock.

The Series X and Series Y convertible preferred stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.

Dividends— Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock.

Liquidation Rights— In the event of the Company’s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.

Conversion— Each share of Series X and Series Y is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share and $13.00 per share of common stock respectively.

Voting Rights— Convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.

Classification— The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the convertible preferred stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.

Beneficial Conversion Feature— The fair value of the common stock into which the Series X convertible preferred stock is convertible exceeded the allocated purchase price of the Series X convertible preferred stock by $5.6 million on the date of issuance, as such the Company recorded a deemed dividend. The Company recognized the resulting beneficial conversion feature as a deemed dividend equal to the number of shares of Series X convertible preferred stock sold on February 16, 2017 multiplied by the difference between the fair value of the common stock and the Series X convertible preferred stock effective conversion price per share on that date. The dividend was reflected as a one-time, non-cash, deemed dividend to the holders of Series X convertible preferred stock on the date of issuance, which is the date the stock first became convertible. There was no beneficial conversion feature associated with the issuance of Series Y convertible preferred stock.

Series A Preferred Stock

On December 15, 2020, the Company sold 984,000 shares of its 8.625% Series A cumulative, perpetual preferred stock at the price of $25.00 per share, through a public offering for aggregate gross proceeds of $24.6 million. Total offering costs of $2.0 million were offset against the proceeds from the sale of Series A Preferred Stock, for total net proceeds of $22.6 million.

Mr. Matthew Perry, a member of the Company’s Board of Directors and President of BVF, purchased 200,000 shares of Series A Preferred Stock in the public offering at the public offering price of $25.00 per share for an aggregate amount of $5.0 million. The spouse of James Neal, the Company’s Chief Executive Officer and Chairman of the Board of Directors, purchased 8,000 shares of the Series A Preferred Stock in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million.

As of December 31, 2021 and 2020, there were 984,000 shares authorized and issued of Series A Preferred Stock.

The Series A preferred stock have the following characteristics, which are set forth in the Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.

Dividends— Holders of the Series A Preferred Stock shall be entitled to receive, when, and if authorized by the Board of Directors and declared by the Corporation, cumulative cash dividends at the rate of 8.625% per annum of the $25.00 liquidation preference per share of the Series A Preferred Stock. Such dividends will accumulate and be cumulative from, and including, the date of original issue of the Series A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October of each year beginning on or about April 15, 2021. The amount of

any dividend payable on the Series A Preferred Stock for any period greater or less than a full Dividend Period shall be prorated and computed on the basis of a 360-day year consisting of twelve 30-day months. 

Liquidation Rights— In the event of the Company’s liquidation, dissolution or winding up, holders of Series A Preferred Stock will rank senior to all classes or series of common stock as to dividend rights and rights upon liquidation, dissolution or winding-up and on parity with respect to the distribution of assets with the Company’s Series X Preferred Stock. The Series A Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25.00 per share plus any accrued and unpaid dividends.

Redemption and Special Optional Redemption— The Company, at its option, may redeem the Series A Preferred Stock, in whole or in part, at any time for a cash redemption price, plus any accrued and unpaid dividends, as follows: (i) $26.00 per share between December 15, 2021 and December 15, 2022, (ii) $25.75 per share between December 15, 2022 and December 15, 2023, (iii) $25.50 per share between December 15, 2023 and December 15, 2024 (iv) $25.25 per share between December 15, 2024 and December 15, 2025 and $25.00 per share on or after December 15, 2025. The Company also has a special optional redemption option whereby, upon the occurrence of a delisting event or change of control event, the Company may redeem outstanding Series A Preferred Stock at an amount of $25.00 per share.

Conversion— The shares of Series A Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company except upon the occurrence of a delisting event or change in control event and the Company has not, on or before the date of such an event, provided the required notice of its election to redeem the Series A Preferred Stock pursuant to its redemption right or special optional redemption right. In this case, the holder of shares of Series A Preferred Stock can convert some or all of their Series A Preferred Stock into a number of shares of common stock per share equal to the lesser of (A) (i) the sum of the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus (y) the amount of any accrued and unpaid dividends to, but not including, the event date, as applicable by (ii) the common stock price and (B) 1.46071 (the “Share Cap”). The common stock price to be used in the latter noted calculation for a delisting event will be the average of the closing price per share of the Company’s common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the delisting event. The common stock price used in the event of a change in control event will, alternatively, be based on market price according to the definition in the Certificate of Designation.

Voting Rights— Holders of the Series A Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.

Classification—The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.

Depositary Shares Representing Interest in Series B Preferred Stock

On April 9, 2021, the Company sold 1,600,000 Series B Depositary Shares, at the price of $25.00 per Series B Depositary Share, through a public offering for aggregate gross proceeds of $40.0 million. Total offering costs of $2.9 million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $37.1 million.

The spouse of James Neal, the Chief Executive Officer and Chairman of the Board of Directors, purchased 8,000 shares of the Series B Depositary Shares in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million.

As of December 31, 2021, there were 3,600 shares authorized and 1,600 issued of Series B Preferred Stock.

The Series B Preferred Stock has the following characteristics, which are set forth in the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock, as corrected, filed with the Delaware Secretary of State.

Dividends— Holders of Series B Preferred Stock shall be entitled to receive cash dividends, when and if declared by the Board of Directors at the rate of 8.375% per annum of the $25,000.00 liquidation preference per share, which equals

$2,093.75 per share each year. Such dividends shall be payable quarterly in arrears on or about the 15th calendar day of each January, April, July and October commencing on or about July 15, 2021. The dividends will accumulate and be cumulative from, and including, the date of original issue of the Series B Preferred Stock, on the basis of a 360-day year consisting of twelve 30-day months. Dividends will be payable to holders of record as they appear in the stockholder records of the Company (or the depositary in the case of Series B Depositary Shares representing underlying Series B Preferred Stock) at the close of business on the applicable dividend record date.

Liquidation Preference - Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Company ranking junior to the Series B Preferred Stock, the holders of shares of Series B Preferred Stock shall be paid out of the assets of the Company, after payment of or provision for the debts and other liabilities and any class or series of capital stock, as to rights upon any voluntary or involuntary liquidation, dissolution or winding up, senior to the Series B Preferred Stock. The Series B Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25,000.00 per share plus any accrued and unpaid dividends.

Redemption and Special Redemption - On and after April 15, 2022, the Company, at its option, may redeem the Series B Preferred Stock, for cash, in whole or in part, at any time or from time to time, as follows: (i) between April 15, 2022 to April 15, 2023, at a redemption price of $26,000.00 per share ($26.00 per depositary share), (ii) between April 15, 2023 to April 15, 2024, at a redemption price of $25,750.00 per share ($25.75 per depositary share), (iii) between April 15, 2024 to April 15, 2025, at a redemption price of $25,500.00 per share ($25.50 per depositary share), (iv) between April 15, 2025 to April 15, 2026, at a redemption price of $25,250.00 per share ($25.25 per depositary share), and (v) after April 15, 2026, at a redemption price of $25,000.00 per share ($25.00 per depositary share), and in each case, plus any accrued and unpaid dividends thereon up to but not including the date fixed for redemption, without interest. If fewer than all of the outstanding shares of Series B Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata or by lot. Upon the occurrence of a delisting event or change of control the Company will have the option to redeem the Series B Preferred Stock, in whole or in part, for cash at $25,000.00 per share plus accrued and unpaid dividends.

Conversion - The shares of Series B Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company, except upon the occurrence of a delisting event or a change of control, each holder Series B Preferred Stock will have the right (unless the Company has elected to redeem the Series B Preferred Stock) to convert some or all of the shares of Series B Preferred Stock held by such holder on the delisting event conversion date or change of control conversion date into a number of shares of the common stock (or equivalent value of alternative consideration) per share of Series B Preferred Stock, equal to the lesser of (A) the quotient obtained by dividing (1) the sum of the $25,000.00 per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the delisting event conversion date or change of control conversion date, as applicable (unless the delisting event conversion date or change of control conversion date, is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and then remaining unpaid dividend will be included in this sum) by (2) the common stock price (such quotient, the “Conversion Rate”); and (B) 1,253.13 (1.25313 per depositary share) (i.e., the “Share Cap”), subject to certain adjustments described in the Series B Preferred Stock Certificate of Designation.

Voting Rights— Holders of the Series B Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.

Classification—The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.

Dividends

During the year ended December 31, 2021, the Company’s Board of Directors declared and paid cash dividends on the Company’s Series A Preferred Stock and Series B Depositary shares as follows.

Series A Preferred Stock

Series B Depositary Share

Cash Dividend Declared

Cash Dividend Declared

Dividend Declaration Date

    

($ per share)

    

($ per share)

    

Dividend Payment Date

March 17, 2021

$

0.71875

    

$

N/A (1)

April 15, 2021

May 21, 2021

$

0.53906

$

0.55833

July 15, 2021

July 28, 2021

$

0.53906

$

0.52344

October 15, 2021

October 20, 2021

$

0.53906

$

0.52344

January 18, 2022

(1)The Company sold 1,600,000 Series B Depositary Shares on April 9, 2021. As such, the first dividend was declared on May 21, 2021.

As of December 31, 2021, the Company held restricted cash of $2.0 million in a segregated account that may only be used to pay dividends on the Series A and Series B Preferred Stock.

BVF Ownership

In February 2020, BVF elected to increase the beneficial ownership limitation of the Series Y preferred stock to 50%, which became effective on April 11, 2020. On April 15, 2020, BVF converted all of its shares of Series Y preferred stock into common stock. As of December 31, 2021, BVF owned approximately 31.2% of the Company’s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own 52.3% of the Company’s total outstanding shares of common stock. The Company’s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of December 31, 2021, the contingency was not met, therefore the Series A Preferred Stock is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.

2018 Common Stock ATM Agreement

On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.

2021 Series B Preferred Stock ATM Agreement

On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed.

Common Stock Warrants

As of December 31, 2021 and 2020, the following common stock warrants were outstanding:

    

    

    

Exercise Price

    

December 31, 

    

December 31,

Issuance Date

Expiration Date

Balance Sheet Classification

per Share

2021

2020

February 2016

 

February 2021

 

Stockholders’ equity

$

15.40

 

 

8,249

May 2018

 

May 2028

 

Stockholders’ equity

$

23.69

 

6,332

 

6,332

March 2019

March 2029

Stockholders’ equity

$

14.71

4,845

4,845

 

  

 

  

 

  

 

11,177

 

19,426

In February 2016, in conjunction with services provided by a third-party consultant, the Company issued a warrant to purchase up to an aggregate of 8,249 unregistered shares of the Company’s common stock at an exercise price equal to $15.40 per share. The warrant was exercisable immediately and had a five-year term expiring in February 2021. As of December 31, 2020, the estimated fair value of the warrant of $0.1 million was calculated using the Black-Scholes Model and was classified in stockholders’ equity on the consolidated balance sheet. In February 2021, the Company issued 4,917 shares of common stock upon a cashless exercise of the common stock warrants held by Torreya Partners LLC. There is no balance of these warrants on the consolidated balance sheet as of December 31, 2021.

In May 2018, the Company issued SVB a warrant in connection with the SVB Loan Agreement (Note 8) which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share. The warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. The warrant is classified in stockholders’ equity on the consolidated balance sheets.

In March 2019, the Loan Agreement was amended to extend the Draw Period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The second warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. As of December 31, 2021, both warrants are outstanding and no shares have been issued upon exercise of the warrants.

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2021
Commitments and Contingencies  
Commitments and Contingencies

13. Commitments and Contingencies

Collaborative Agreements, Royalties and Milestone Payments

The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company’s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.

Contingent Consideration

Pursuant to the Company’s royalty and commercial payment purchase agreements with Bioasis, Aronora, Kuros and Affitech, the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones and the Affitech regulatory and sales milestones. The Company recorded $0.1 million and $8.0 million for the Bioasis Contingent Consideration and the Affitech Regulatory Milestones, respectively, which, represents the estimated fair value of these potential future payments at the inception of the respective agreements. The contingent

consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other (expense) income, net. As of December 31, 2021, there were no changes in the estimated fair value of the Bioasis Contingent Consideration and the Affitech Sales Milestones from the initial value. The liability for future Aronora Royalty Milestones, Kuros Sales Milestones and Affitech Sales Milestones will be recorded when the amounts, by product, are estimable and probable. As of December 31, 2021, none of these Aronora Royalty Milestones, Kuros Sales Milestones or Affitech Sales Milestones were assessed to be probable and as such, no liability was recorded on the consolidated balance sheet.

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Concentration of Risk, Segment and Geographic Information
12 Months Ended
Dec. 31, 2021
Concentration of Risk, Segment and Geographic Information  
Concentration of Risk, Segment and Geographic Information

14. Concentration of Risk, Segment and Geographic Information

Concentration of Risk

Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.  

The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the year ended December 31, 2021, one partner represented 92% of total revenues. For the year ended December 31, 2020, one partner represented 85% of total revenues. As of December 31, 2021 and 2020, one partner represented 100% of the trade receivables balance.

Segment Information

The Company has determined that it operates in one business segment as it only reports operating results on an aggregate basis to the chief operating decision maker of the Company.

Geographic Information

Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:

Year Ended December 31, 

    

2021

    

2020

Europe

$

35,000

$

25,010

United States

 

2,610

 

1,275

Asia Pacific

 

550

 

3,100

Total

$

38,160

$

29,385

The Company’s property and equipment is held in the United States.

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2021
Subsequent Events  
Subsequent Events

15. Subsequent Events

On January 28, 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize faricimab (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. Upon approval, the Company became eligible to receive a 0.5% commercial payment stream on net sales associated with faricimab for a ten-year period following its first commercial sale in the United States.  The Company acquired this interest under the Affitech CPPA, pursuant to which, the Company paid Affitech a $5.0 million milestone tied to these U.S. marketing approvals. The Company may pay up to an additional $15.0 million to Affitech based on the achievement of certain regulatory approval and sales milestones.

In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to XOMA pursuant to the Company’s Rezolute License Agreement.

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Basis of Presentation and Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2021
Basis of Presentation and Significant Accounting Policies  
Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X. 

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts and amortization of the payments received from HCRP. Under the Company’s contracts with the NIAID, a part of the NIH, the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. As of December 31, 2020, the audit procedures were completed, and the Company adjusted its estimated liability owed to NIH to $1.4 million. In December 2021, the NIH

completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and the Company adjusted its liability owed to NIH to $1.3 million. In December 2021, the Company paid the final approved refund liability of $1.3 million. As such, no contingent liability remained on the Company’s consolidated balance sheets as of December 31, 2021.

In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.

The COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.

Cash and Restricted Cash

Cash and Restricted Cash

Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2021 and 2020, the Company did not have any cash equivalent balances, defined as highly liquid financial instruments purchased with original maturities of three months or less.

Restricted cash consists of bank deposits held to pay dividends on the Company’s Series A Preferred Stock and Series B Preferred Stock.

The Company maintains cash and restricted cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash and restricted cash.

The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):

Year Ended December 31, 

2021

2020

Cash

$

93,328

$

84,222

Restricted cash

2,049

2,142

Total cash and restricted cash

$

95,377

$

86,364

Revenue Recognition

Revenue Recognition

The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.

To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once

the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.

The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.

License of intellectual property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).

Milestone payments

At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments.

If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract

inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.

Sale of Future Revenue Streams

Sale of Future Revenue Streams

The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment.

Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.

Stock-Based Compensation

Stock-Based Compensation

The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.

Equity Securities

Equity Securities

The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive income in the period of sale.

In October 2020, Rezolute completed a 1:50 reverse stock split of its common shares (the “Rezolute Reverse Stock Split”) and started trading on the Nasdaq Stock Market. As a result, the Company’s number of shares of Rezolute common stock was reduced from 8,093,010 shares (pre reverse-split shares) to 161,861 shares (post reverse-split shares). All subsequent disclosures of Rezolute share numbers will be presented post reverse-split.

Purchase of Rights to Future Milestones, Royalties and Commercial Payments

Purchase of Rights to Future Milestones, Royalties and Commercial Payments

The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product

development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive income.

The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.

The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2021 and December 31, 2020.

Leases

Leases

The Company leases its headquarters office space in Emeryville, California.

The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.

Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive income.

The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.

Income Taxes

Income Taxes

The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.

The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Prior Period Reclassifications

Prior Period Reclassifications

Within the consolidated statement of cash flows, the Company presented principal payments on its finance lease and proceeds from disgorgement of stockholder's short-swing profits together in order for the prior period to conform with current period presentation.

Net Income per Share Attributable to Common Stockholders

Net Income per Share Attributable to Common Stockholders

The Company calculates basic and diluted income per share attributable to common stockholders using the two-class method. The Company’s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.

Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period and any deemed dividends related to beneficial conversion features on convertible preferred stock, if applicable, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income per share attributable to common stockholders is then calculated by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.

Diluted net income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock. The calculation of diluted net income per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options or warrants, the presumed exercise of such securities are dilutive to net income per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and therefore, are not included in the diluted shares until the contingency is resolved.

Comprehensive Income

Comprehensive Income

Comprehensive income is comprised of two components: net income and other comprehensive income. Other comprehensive income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net income. The Company did not record any transactions within other comprehensive income in the periods presented and, therefore, the net income and comprehensive income were the same for all periods presented.

Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements

Accounting Pronouncements Recently Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company on January 1, 2021. The Company adopted ASU 2019-12, on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the Company’s consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. These amendments provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The ASU provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. It is intended to help stakeholders during the global market-wide reference rate transition period. The guidance is effective for all entities as of March 12, 2020 through December 31, 2022 and can be adopted as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company adopted ASU 2020-04 as of January 1, 2021. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusion. In addition, this ASU improves and amends the related EPS guidance. These amendments are effective for the Company for fiscal years beginning after December 15, 2023, including interim period within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The Company adopted ASU 2020-06 on January 1, 2021. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for all entities except public companies that are not smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted. The Company plans to adopt ASU 2016-13 and related updates as of January 1, 2023. The Company is currently evaluating the impact of adopting this new accounting guidance on its consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations – Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. Early adoption is permitted. The Company is currently evaluating the impacts of the provisions of ASU 2021-08 and the Company does not expect this ASU to have a material impact on its consolidated financial statements.

XML 38 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Basis of Presentation and Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2021
Basis of Presentation and Significant Accounting Policies  
Schedule of cash and restricted cash

The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):

Year Ended December 31, 

2021

2020

Cash

$

93,328

$

84,222

Restricted cash

2,049

2,142

Total cash and restricted cash

$

95,377

$

86,364

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Financial Statement Detail (Tables)
12 Months Ended
Dec. 31, 2021
Consolidated Financial Statements  
Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

December 31, 

December 31, 

    

2021

    

2020

Accrued legal and accounting fees

295

351

Accrued payroll and benefits

 

135

 

136

Accrued incentive compensation

55

71

Other accrued liabilities

40

84

Total

$

525

$

642

Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders

The following is a reconciliation of the numerator (net income) and denominator (number of shares) used in the calculation of basic and diluted net income per share attributable to common stockholders (in thousands):

Year Ended December 31, 

    

2021

    

2020

Numerator

 

  

 

  

Net income

$

15,798

$

13,298

Less: Series A accumulated dividends

 

(2,122)

 

(88)

Less: Series B accumulated dividends

(2,438)

Less: Allocation of undistributed earnings to participating securities

 

(3,451)

 

(4,417)

Net income available to common stockholders, basic

$

7,787

$

8,793

Add: Adjustments to undistributed earnings allocated to participating securities

 

181

217

Net income available to common stockholders, diluted

$

7,968

$

9,010

 

Denominator

 

 

Weighted average shares used in computing basic net income per share available to common stockholders

 

11,288

 

10,674

Effect of dilutive stock options

 

900

824

Effect of dilutive warrants

 

4

5

Weighted average shares used in computing diluted net income per share available to common stockholders

 

12,192

 

11,503

Basic net income per share available to common stockholders

$

0.69

$

0.82

Diluted net income per share of common stock

$

0.65

$

0.78

Outstanding Securities Considered Anti-Dilutive

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income per share attributable to common stockholders (in thousands):

Year Ended December 31, 

    

2021

    

2020

Convertible preferred stock

Common stock options

 

479

616

Warrants for common stock

 

6

Total

 

479

 

622

XML 40 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Royalty and Commercial Payment Purchase Agreements (Tables)
12 Months Ended
Dec. 31, 2021
Royalty and Commercial Payment Purchase Agreements  
Summary of Acquisition of Royalty Rights

The following table summarizes the long-term royalty receivable activities including acquisitions of royalty rights, commercial payment rights and cash receipts for achievement of contractual milestones during the years ended December 31, 2021 and 2020 (in thousands):

Balance at January 1, 2020

    

$

34,375

Acquisition of royalty rights:

Bioasis

1,200

Cash receipts for achievement of contractual milestones:

Agenus

(1,000)

Balance at December 31, 2020

    

34,575

Acquisition of royalty and commercial payment rights:

Viracta

 

13,500

Kuros

 

7,000

Affitech

14,000

Balance at December 31, 2021

$

69,075

XML 41 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2021
Fair Value Measurements  
Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

Fair Value Measurements at December 31, 2021 Using

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

Total

Assets:

Equity securities

$

774

$

$

$

774

Liabilities:

Contingent consideration under RPAs and CPPAs

$

$

$

8,075

$

8,075

Fair Value Measurements at December 31, 2020 Using

Quoted Prices in

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Assets

Inputs

Inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

Total

Assets:

  

  

  

  

Equity securities

$

$

$

1,693

$

1,693

Liabilities:

Contingent consideration

$

$

$

75

$

75

Summary of Changes in Estimated Fair Value of Level 3 Financial Assets

The following table reconciles the beginning and ending balance for the Level 3 financial assets recurring fair value measurement for the year ended December 31, 2021 (in thousands):

Year Ended

December 31, 2021

Balance at December 31, 2019

$

681

Change in fair value

1,012

Balance at December 31, 2020

$

1,693

Change in fair value

 

617

Transfer out of Level 3 as of June 30, 2021

(2,310)

Balance at December 31, 2021

$

Schedule of Estimated Fair Value of Equity Securities Assumptions

December 31, 

December 31, 

2021

2020

 

Closing common stock price

$

4.78

$

11.99

Tranche 1:

Discount for lack of marketability

 

N/A(1)

%  

12

%

Estimated time to liquidity of shares

 

0.25 year

Tranche 2:

Discount for lack of marketability

N/A(1)

%

14

%

Estimated time to liquidity of shares

0.67 years

(1)Due to sufficient and consistent trading volume, the equity investment will be measured at the closing price per the Nasdaq Stock Market. The assumptions related to the unobservable inputs identified above, and any changes in those assumptions thereto, will no longer be considered in determining the fair value of the equity securities.

XML 42 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Lease Agreement (Tables)
12 Months Ended
Dec. 31, 2021
Lease Agreement  
Schedule of maturity of operating lease liabilities

The following table summarizes maturity of the Company’s operating lease liabilities as of December 31, 2021 (in thousands):

Operating

Undiscounted lease payments

    

Leases

2022

 

202

2023

 

34

2024

 

Total undiscounted lease payments

 

236

Present value adjustment

 

(7)

Total net lease liabilities

 

$

229

Schedule of cost components of operating leases

Operating

Undiscounted lease payments

    

Leases

2022

 

202

2023

 

34

2024

 

Total undiscounted lease payments

 

236

Present value adjustment

 

(7)

Total net lease liabilities

 

$

229

Summary of supplemental cash flow information related to operating leases

The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):

    

Year Ended December 31, 

    

2021

2020

Cash paid for amounts included in the measurement of lease liabilities

 

 

Operating cash flows under operating leases

$

196

$

189

Schedule of present value assumptions used in calculating the present value of lease payments

    

December 31, 

December 31, 

    

2021

2020

Weighted-average remaining lease term

1.17 years

2.17 years

Weighted-average discount rate

5.51

%

5.51

%

XML 43 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Long-Term Debt and Other Financings (Tables)
12 Months Ended
Dec. 31, 2021
Long-Term Debt and Other Financings  
Interest Expense and Amortization of Debt Issuance Costs and Discounts

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive income for the years ended December 31, 2021 and 2020, relates to the following debt instruments (in thousands):

Year Ended December 31, 

    

2021

    

2020

SVB Loan

$

373

$

1,365

Novartis Note

 

88

 

477

Other

 

 

2

Total interest expense

$

461

$

1,844

XML 44 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Income Taxes  
Schedule of Provision for Income Taxes (All Current)

The provision (benefit) for income taxes, all classified as current, consists of the following (in thousands):

Year Ended December 31, 

    

2021

    

2020

Federal

$

91

$

(1,501)

State

 

 

Total

$

91

$

(1,501)

Reconciliation Between the Tax Provision Computed at the Federal Statutory Income Tax Rate and Actual Effective Income Tax Rate

Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company’s actual effective income tax rate is as follows:

Year Ended December 31, 

 

    

2021

    

2020

 

Federal tax at statutory rate

 

21

%  

21

%

Stock compensation and other permanent differences

 

9

%  

(6)

%

Federal orphan drug credit

 

(2)

%  

%

Tax benefit related to CARES Act

 

%  

(13)

%

Tax benefit related to net operating loss carryforward utilization

 

(11)

%  

%

Valuation allowance

 

(16)

%  

(15)

%

Total

 

1

%  

(13)

%

Components of Net Deferred Tax Assets

The significant components of net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):

December 31, 

    

2021

    

2020

Capitalized research and development expenses

$

7,822

$

11,500

Net operating loss carryforwards

 

17,657

 

17,638

Research and development and other tax credit carryforwards

 

13,125

 

13,454

Stock compensation

 

4,778

 

5,158

Unearned revenue

 

2,817

 

3,462

Other

 

807

 

401

Total deferred tax assets

 

47,006

 

51,613

Valuation allowance

 

(47,006)

 

(51,613)

Net deferred tax assets

$

$

Schedule of Unrecognized Tax Benefits

The following table summarizes the Company’s activity related to its unrecognized tax benefits (in thousands):

Year Ended December 31, 

    

2021

    

2020

Balance at January 1

$

5,938

$

5,517

Increase related to current year tax position

 

 

Increase related to prior year tax position

 

 

421

Balance at December 31

$

5,938

$

5,938

XML 45 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Based Compensation (Tables)
12 Months Ended
Dec. 31, 2021
Stock Based Compensation  
Weighted Average Assumptions

The fair value of stock options granted during the years ended December 31, 2021 and 2020, was estimated based on the following weighted average assumptions for:

Year Ended December 31, 

 

    

2021

    

2020

 

Dividend yield

 

0

%  

0

%

Expected volatility

 

83

%  

100

%

Risk-free interest rate

 

0.95

%  

0.72

%

Expected term

 

5.66 years

5.64 years

Stock Option Activity

The following table summarizes the Company’s stock option activity for the year ended December 31, 2021.

As of December 31, 2021

Weighted

    

Weighted

Average

Average

Aggregate

Exercise

Contractual 

Intrinsic

Number of

Price

Term

Value

shares

Per Share

(in years)

(in thousands)

Outstanding at January 1, 2021

1,827,906

$

20.66

 

6.31

 

$

51,401

Granted

 

325,211

 

32.02

 

  

 

  

Exercised

 

(77,305)

 

13.61

 

  

 

  

Forfeited, expired or cancelled

(164,635)

 

46.59

 

  

 

  

Outstanding at December 31, 2021

1,911,177

$

20.64

 

6.33

$

15,103

Exercisable at December 31, 2021

1,553,696

$

18.75

 

5.69

$

14,894

Stock-based Compensation Expense

The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive income (in thousands):

Year Ended December 31, 

    

2021

    

2020

Research and development

$

$

General and administrative

 

6,195

 

3,961

Total stock-based compensation expense

$

6,195

$

3,961

XML 46 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Income Per Share Attributable to Common Stockholders (Tables)
12 Months Ended
Dec. 31, 2021
Net Income Per Share Attributable to Common Stockholders  
Outstanding Securities Considered Anti-Dilutive

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income per share attributable to common stockholders (in thousands):

Year Ended December 31, 

    

2021

    

2020

Convertible preferred stock

Common stock options

 

479

616

Warrants for common stock

 

6

Total

 

479

 

622

Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders

The following is a reconciliation of the numerator (net income) and denominator (number of shares) used in the calculation of basic and diluted net income per share attributable to common stockholders (in thousands):

Year Ended December 31, 

    

2021

    

2020

Numerator

 

  

 

  

Net income

$

15,798

$

13,298

Less: Series A accumulated dividends

 

(2,122)

 

(88)

Less: Series B accumulated dividends

(2,438)

Less: Allocation of undistributed earnings to participating securities

 

(3,451)

 

(4,417)

Net income available to common stockholders, basic

$

7,787

$

8,793

Add: Adjustments to undistributed earnings allocated to participating securities

 

181

217

Net income available to common stockholders, diluted

$

7,968

$

9,010

 

Denominator

 

 

Weighted average shares used in computing basic net income per share available to common stockholders

 

11,288

 

10,674

Effect of dilutive stock options

 

900

824

Effect of dilutive warrants

 

4

5

Weighted average shares used in computing diluted net income per share available to common stockholders

 

12,192

 

11,503

Basic net income per share available to common stockholders

$

0.69

$

0.82

Diluted net income per share of common stock

$

0.65

$

0.78

XML 47 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Capital Stock (Tables)
12 Months Ended
Dec. 31, 2021
Capital Stock  
Schedule of declared and paid cash dividends

Series A Preferred Stock

Series B Depositary Share

Cash Dividend Declared

Cash Dividend Declared

Dividend Declaration Date

    

($ per share)

    

($ per share)

    

Dividend Payment Date

March 17, 2021

$

0.71875

    

$

N/A (1)

April 15, 2021

May 21, 2021

$

0.53906

$

0.55833

July 15, 2021

July 28, 2021

$

0.53906

$

0.52344

October 15, 2021

October 20, 2021

$

0.53906

$

0.52344

January 18, 2022

(1)The Company sold 1,600,000 Series B Depositary Shares on April 9, 2021. As such, the first dividend was declared on May 21, 2021.
Summary of Common Stock Warrants Outstanding

    

    

    

Exercise Price

    

December 31, 

    

December 31,

Issuance Date

Expiration Date

Balance Sheet Classification

per Share

2021

2020

February 2016

 

February 2021

 

Stockholders’ equity

$

15.40

 

 

8,249

May 2018

 

May 2028

 

Stockholders’ equity

$

23.69

 

6,332

 

6,332

March 2019

March 2029

Stockholders’ equity

$

14.71

4,845

4,845

 

  

 

  

 

  

 

11,177

 

19,426

XML 48 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Concentration of Risk, Segment and Geographic Information (Tables)
12 Months Ended
Dec. 31, 2021
Concentration of Risk, Segment and Geographic Information  
Revenue by Geographical Region

Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:

Year Ended December 31, 

    

2021

    

2020

Europe

$

35,000

$

25,010

United States

 

2,610

 

1,275

Asia Pacific

 

550

 

3,100

Total

$

38,160

$

29,385

XML 49 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business - Cash and Restricted Cash (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Description of Business      
Unrestricted and restricted cash $ 95,377 $ 86,364 $ 56,688
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business - Repayment of Debt (Details)
$ in Millions
1 Months Ended
Jun. 30, 2021
USD ($)
Silicon Valley Bank And Novartis Pharma AG  
Long-term debt  
Repayments of debt $ 17.1
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Basis of Presentation and Significant Accounting Policies - Use of Estimates (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 15, 2021
Basis of Presentation and Significant Accounting Policies        
Contingent liabilities $ 0 $ 0 $ 1,410 $ 1,300
Payment of contract with customer refund liability $ 1,300 $ 1,305 $ (612)  
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Basis of Presentation and Significant Accounting Policies      
Cash $ 93,328 $ 84,222  
Restricted cash 2,049 2,142  
Total cash and restricted cash $ 95,377 $ 86,364 $ 56,688
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Basis of Presentation and Significant Accounting Policies - Equity Securities (Details)
1 Months Ended
Oct. 31, 2020
shares
Sep. 30, 2020
shares
Rezolute    
Equity investments    
Number of shares owned 161,861 8,093,010
Rezolute    
Equity investments    
Reverse stock split 0.02  
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Basis of Presentation and Significant Accounting Policies - Purchase of Rights to Future Milestones and Royalties and Income Taxes and Net Income (Loss) per Share (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Purchase of Rights to Future Milestones and Royalties    
Impairment of long-term royalty receivable $ 0.0 $ 0.0
Income tax penalties or interest charged 0.0  
Dividends declared $ 0.0  
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)
Jan. 01, 2021
ASU 2019-12  
Adopted Accounting Pronouncements  
Change in Accounting Principle, Accounting Standards Update, Adopted true
ASU 2020-06  
Adopted Accounting Pronouncements  
Change in Accounting Principle, Accounting Standards Update, Adopted true
ASU 2020-04  
Adopted Accounting Pronouncements  
Change in Accounting Principle, Accounting Standards Update, Adopted true
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Financial Statement Detail - Equity Securities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Equity Securities    
Long-term equity securities   $ 1,693
Gain (loss) recognized due to change in fair value of investment $ (919) 1,012
Rezolute    
Equity Securities    
Long-term equity securities 800 1,700
Gain (loss) recognized due to change in fair value of investment $ (900) $ 1,000
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Financial Statement Detail - Accrued and Other Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Accrued and other liabilities    
Accrued legal and accounting fees $ 295 $ 351
Accrued payroll and benefits 135 136
Accrued incentive compensation 55 71
Other accrued liabilities 40 84
Total $ 525 $ 642
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Licensing and Other Arrangements - Novartis - NIS793 (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Oct. 20, 2021
USD ($)
Oct. 21, 2020
USD ($)
Sep. 30, 2015
USD ($)
item
Sep. 30, 2015
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Licensing and other arrangements                
Revenue from contracts with customers         $ 36,518 $ 27,941    
Novartis Note                
Licensing and other arrangements                
Reduction in debt obligation   $ 7,300            
Novartis International | License Agreement                
Licensing and other arrangements                
Agreement termination prior written notice period     180 days          
Number of performance obligations | item     1          
Cash payment received   17,700           $ 37,000
Revenue from contracts with customers $ 35,000 $ 25,000     35,000 25,000 $ 10,000 $ 37,000
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 410,000   $ 480,000 $ 480,000        
Royalty payment period       10 years        
Contract assets         0 0    
Contract liabilities         0 0    
Capitalized contract costs         $ 0 $ 0    
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)
$ / shares in Units, $ in Thousands, € in Millions
12 Months Ended
Aug. 24, 2017
USD ($)
item
agreement
$ / shares
shares
Aug. 24, 2017
EUR (€)
item
agreement
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2017
USD ($)
Licensing and other arrangements          
Revenue from contracts with customers     $ 36,518 $ 27,941  
Novartis Pharma AG [Member] | Gevokizumab License Agreement and IL-1 Target License Agreement          
Licensing and other arrangements          
Transaction price $ 40,200        
Cash payment received 25,700        
License agreement consideration received, repayment of debt 14,300        
Common stock premium $ 200        
Number of license agreements | agreement 2 2      
Number of arrangements | item 1 1      
Number of performance obligations | item 2 2      
Remaining performance obligations     0    
Revenue from contracts with customers     0 0 $ 40,200
Contract assets     0 0  
Contract liabilities     0 0  
Capitalized contract costs     $ 0 $ 0  
Novartis Pharma AG [Member] | Gevokizumab License Agreement          
Licensing and other arrangements          
License agreement consideration received $ 30,000        
Cash payment received 15,700        
License agreement consideration received, repayment of debt 14,300 € 12.0      
Proceeds from issuance of common stock 5,000        
Common stock premium 200        
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 438,000        
Agreement termination prior written notice period 6 months 6 months      
Novartis Pharma AG [Member] | Gevokizumab License Agreement | Common Stock          
Licensing and other arrangements          
Shares issued (in shares) | shares 539,131 539,131      
Purchase price (in dollars per share) | $ / shares $ 9.2742        
Issuance of common stock, fair value $ 4,800        
Closing stock price (in dollars per share) | $ / shares $ 8.93        
Novartis Pharma AG [Member] | IL-1 Target License Agreement [Member]          
Licensing and other arrangements          
Cash payment received $ 10,000        
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Licensing and Other Arrangements - Takeda (Details) - USD ($)
1 Months Ended 12 Months Ended
Nov. 16, 2020
Feb. 28, 2009
Nov. 30, 2006
Dec. 31, 2021
Dec. 31, 2020
Licensing and other arrangements          
Revenue from contracts with customers       $ 36,518,000 $ 27,941,000
Takeda | Collaboration agreement          
Licensing and other arrangements          
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones       16,000,000.0  
Revenue from contracts with customers $ 2,000,000.0     100,000 2,100,000
Contract assets       0 0
Contract liabilities       0 0
Capitalized contract costs       0 0
Takeda | Collaboration agreement | TAK-079          
Licensing and other arrangements          
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones     $ 19,000,000.0    
Royalty payment period     13 years 6 months    
Takeda | Collaboration agreement | Other antibodies          
Licensing and other arrangements          
Maximum eligible milestone payments receivable per discovery product candidate   $ 3,300,000      
Royalty payment period   10 years      
Takeda | License Agreement          
Licensing and other arrangements          
Revenue from contracts with customers       $ 100,000 $ 100,000
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Licensing and Other Arrangements - Rezolute (Details)
$ in Thousands
1 Months Ended 12 Months Ended 35 Months Ended
Dec. 06, 2017
USD ($)
Oct. 31, 2020
shares
Apr. 30, 2018
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Oct. 31, 2020
USD ($)
shares
Sep. 30, 2020
shares
Licensing and other arrangements              
Revenue recognized       $ 36,518 $ 27,941    
Rezolute              
Licensing and other arrangements              
Number of shares owned | shares   161,861       161,861 8,093,010
Rezolute | License Agreement and Common Stock Purchase Agreement [Member]              
Licensing and other arrangements              
Payments received upon achievement of financing activities           $ 6,000  
Installment payments received           $ 8,500  
Number of shares received | shares     161,861        
Contract assets       0 0    
Contract liabilities       0 0    
Capitalized contract costs       0 0    
Rezolute | License Agreement              
Licensing and other arrangements              
Percentage of decrease in future royalty obligations 20.00%            
Agreement termination prior written notice period 90 days            
Revenue recognized       $ 0 $ 0    
Rezolute | License Agreement, RZ358              
Licensing and other arrangements              
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 232,000            
Royalty payment period 12 years            
Rezolute | License Agreement, Non-RZ358 products              
Licensing and other arrangements              
Royalty payment period 12 years            
Rezolute              
Licensing and other arrangements              
Reverse stock split   0.02          
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Dec. 31, 2021
May 31, 2021
Aug. 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Licensing and other arrangements            
Revenue from contracts with customers       $ 36,518 $ 27,941  
Janssen Biotech Inc. | License Agreement            
Licensing and other arrangements            
Cash payment received     $ 2,500      
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events     $ 3,000      
Percentage of royalty on worldwide net sales of each product upon commercialization     0.75%      
Revenue from contracts with customers $ 200 $ 500   700 400 $ 2,500
Contract assets 0     0 0  
Contract liabilities 0     0 0  
Capitalized contract costs $ 0     $ 0 $ 0  
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Licensing and Other Arrangements - Affimed (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Licensing and other arrangements    
Revenue from contracts with customers $ 36,518,000 $ 27,941,000
License Agreement | Affimed    
Licensing and other arrangements    
Contract assets 0  
Contract liabilities 0  
Capitalized contract costs 0  
Revenue from contracts with customers $ 0  
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Licensing and Other Arrangements - NIAID (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2008
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2017
Dec. 15, 2021
Dec. 31, 2014
Oct. 31, 2011
Licensing and other arrangements                
Reduction of contingent refund liability     $ 105          
Payment of contract with customer refund liability $ 1,300   1,305 $ (612)        
Revenue recognized     36,518 27,941        
Contingent liabilities 0   0 1,410   $ 1,300    
Arrangement with Governmental Agency | National Institute of Allergy and Infectious Diseases "NIAID" [Member]                
Licensing and other arrangements                
Contractual term   3 years            
Accounts receivable             $ 400  
Deferred revenue/Contract liabilities             $ 800  
Accounts receivable written off         $ 400      
Estimated refund liability 1,300   1,300 1,400        
Reduction of contingent refund liability 100              
Payment of contract with customer refund liability 1,300              
Revenue recognized       $ (600)        
Contingent liabilities $ 0   $ 0          
Arrangement with Governmental Agency, Development One | National Institute of Allergy and Infectious Diseases "NIAID" [Member]                
Licensing and other arrangements                
Total contract amount awarded   $ 64,800            
Arrangement with Governmental Agency, Development Two | National Institute of Allergy and Infectious Diseases "NIAID" [Member]                
Licensing and other arrangements                
Total contract amount awarded               $ 28,000
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)
$ in Thousands
12 Months Ended
Dec. 21, 2016
USD ($)
agreement
period
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Licensing and other arrangements      
Unearned revenue recognized under units-of-revenue method   $ (1,642) $ (1,444)
Revenue recognized under units-of-revenue method   1,642 1,444
Unearned revenue recognized under units-of-revenue method, current   1,641 1,452
Unearned revenue recognized under units-of-revenue method, noncurrent   11,685 13,516
HealthCare Royalty Partners II, L.P | Royalty Sale Agreements      
Licensing and other arrangements      
Number of agreements | agreement 2    
Unearned revenue recognized under units-of-revenue method $ 18,000    
Revenue recognized under units-of-revenue method   1,600 1,400
Unearned revenue recognized under units-of-revenue method, current   1,600 1,500
Unearned revenue recognized under units-of-revenue method, noncurrent   $ 11,700 $ 13,500
HealthCare Royalty Partners II, L.P | First Royalty Sale Agreement      
Licensing and other arrangements      
Cash payment received 6,500    
Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years $ 4,000    
Number of milestone periods | period 3    
HealthCare Royalty Partners II, L.P | Second Royalty Sale Agreement      
Licensing and other arrangements      
Cash payment received $ 11,500    
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Royalty and Commercial Payment Purchase Agreements - Agenus (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Sep. 20, 2018
USD ($)
product
Nov. 30, 2020
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Agreements          
Payments related to purchase of royalty rights and other commercial payment rights     $ 26,500 $ 1,200  
Long-term royalty and commercial payment receivables     69,075 34,575 $ 34,375
Revenue from contracts with customers     36,518 27,941  
Impairment of long-term royalty receivable     0 0  
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus [Member]          
Agreements          
Amount of milestone achieved   $ 10,000      
Agenus [Member]          
Agreements          
Cash receipts for achievement of contractual milestones       $ 1,000  
Agenus [Member] | Royalty Purchase Agreement          
Agreements          
Payments related to purchase of royalty rights and other commercial payment rights $ 15,000        
Long-term royalty and commercial payment receivables $ 15,000        
Impairment of long-term royalty receivable     $ 0    
Agenus [Member] | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets          
Agreements          
Royalties entity has right to receive (as a percent) 33.00%        
Number of licensed products related to milestone and royalties | product 6        
Purchased percentage of milestones 10.00%        
Agenus [Member] | Royalty Purchase Agreement | Merck Immuno-Oncology Product          
Agreements          
Royalties entity has right to receive (as a percent) 33.00%        
Purchased percentage of milestones 10.00%        
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones $ 59,500        
Amount of milestone achieved   1,000      
Cash receipts for achievement of contractual milestones   $ 1,000      
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)
$ in Thousands
12 Months Ended
Nov. 02, 2020
USD ($)
Feb. 25, 2019
USD ($)
agreement
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Agreements          
Payments related to purchase of royalty rights and other commercial payment rights     $ 26,500 $ 1,200  
Long-term royalty and commercial payment receivables     69,075 34,575 $ 34,375
Contingent consideration under RPAs and CPPAs     8,075 75  
Impairment of long-term royalty receivable     0 $ 0  
Bioasis | Royalty Purchase Agreement          
Agreements          
Percentage of option to purchase royalty right on future license agreements   1.00%      
Number of future license agreements under optional purchase right | agreement   2      
Obligation upon exercise of options per licensed product, second agreement   $ 300      
Obligation upon exercise of options per licensed product, third agreement   400      
Payments related to purchase of royalty rights and other commercial payment rights   300      
Long-term royalty and commercial payment receivables   400      
Contingent consideration under RPAs and CPPAs   100 100    
Changes in estimated fair value of contingent consideration     0    
Payments of contingent consideration     0    
Impairment of long-term royalty receivable     0    
Bioasis | Royalty Purchase Agreement | Maximum          
Agreements          
Potential future cash payments   $ 200      
Bioasis | Second Royalty Purchase Agreement          
Agreements          
Payments related to purchase of royalty rights and other commercial payment rights $ 1,200        
Long-term royalty and commercial payment receivables $ 1,200        
Impairment of long-term royalty receivable     $ 0    
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Royalty and Commercial Payment Purchase Agreements - Aronora (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Apr. 07, 2019
USD ($)
item
Sep. 30, 2019
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Agreements          
Long-term royalty and commercial payment receivables     $ 69,075 $ 34,575 $ 34,375
Contingent consideration under RPAs and CPPAs     8,075 75  
Impairment of long-term royalty receivable     0 $ 0  
Aronora | Royalty Purchase Agreement          
Agreements          
Number of drug candidates | item 5        
Non-royalties to be received (as a percent) 10.00%        
Future non-royalty payments to be received (as a percent) 5.00%        
Multiplier for cumulative amount of consideration paid | item 2        
Upfront payment $ 6,000        
Threshold amount of cumulative royalties on net sales per product 250,000        
Aggregate milestones payments per product 85,000        
Long-term royalty and commercial payment receivables 9,000        
Contingent consideration under RPAs and CPPAs 3,000        
Payments of contingent consideration   $ 3,000      
Impairment of long-term royalty receivable     $ 0    
Aronora | Royalty Purchase Agreement | SVB Loan          
Agreements          
Upfront payment $ 3,000        
Aronora | Royalty Purchase Agreement | Bayer Products          
Agreements          
Number of drug candidates | item 3        
Number of drug candidates subject to exclusive license option | item 1        
Royalties entity has right to receive (as a percent) 100.00%        
Non-royalties to be received (as a percent) 10.00%        
Contingent future cash payment for each product $ 1,000        
Potential future cash payments $ 3,000        
Aronora | Royalty Purchase Agreement | Non-Bayer Products          
Agreements          
Number of drug candidates | item 2        
Non-royalties to be received (as a percent) 10.00%        
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Royalty and Commercial Payment Purchase Agreements - Palo (Details)
12 Months Ended
Sep. 26, 2019
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Agreements        
Payments related to purchase of royalty rights and other commercial payment rights   $ 26,500,000 $ 1,200,000  
Long-term royalty and commercial payment receivables   69,075,000 34,575,000 $ 34,375,000
Impairment of long-term royalty receivable   0 $ 0  
Palo | Royalty Purchase Agreement        
Agreements        
Number of drug candidates 6      
Payments related to purchase of royalty rights and other commercial payment rights $ 10,000,000.0      
Long-term royalty and commercial payment receivables $ 10,000,000.0      
Impairment of long-term royalty receivable   $ 0    
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Royalty and Commercial Payment Purchase Agreements - Viracta (Details)
$ in Thousands
12 Months Ended
Mar. 22, 2021
USD ($)
item
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Agreements        
Payments related to purchase of royalty rights and other commercial payment rights   $ 26,500 $ 1,200  
Long-term royalty and commercial payment receivables   69,075 34,575 $ 34,375
Impairment of long-term royalty receivable   0 $ 0  
Viracta | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item 2      
Payments related to purchase of royalty rights and other commercial payment rights $ 13,500      
Maximum amount of potential milestones and other payments receivable 54,000      
Amount of maximum consideration retained 20,000      
Maximum amount of potential regulatory and commercial milestones receivable 57,000      
Long-term royalty and commercial payment receivables $ 13,500      
Impairment of long-term royalty receivable   $ 0    
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Royalty and Commercial Payment Purchase Agreements - Kuros (Details) - USD ($)
$ in Thousands
12 Months Ended
Jul. 14, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Agreements        
Long-term royalty and commercial payment receivables   $ 69,075 $ 34,575 $ 34,375
Impairment of long-term royalty receivable   0 $ 0  
Kuros | Royalty Purchase Agreement        
Agreements        
Royalties entity has right to receive (as a percent) 100.00%      
Pre-commercial milestone payments $ 25,500      
Upfront payment 7,000      
Potential future sales milestone payments 142,500      
Long-term royalty and commercial payment receivables $ 7,000      
Impairment of long-term royalty receivable   $ 0    
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)
$ in Thousands
12 Months Ended
Oct. 06, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Agreements        
Long-term royalty and commercial payment receivables   $ 69,075 $ 34,575 $ 34,375
Contingent consideration under RPAs and CPPAs   8,075 75  
Impairment of long-term royalty receivable   0 $ 0  
Affitech | Commercial payment purchase agreement        
Agreements        
Upfront payment $ 6,000      
Payments eligible to receive (as a percent) 0.50%      
Commercial payment receivable term 10 years      
Maximum additional payments upon achievement of regulatory and sales milestones $ 20,000      
Maximum payable on regulatory milestone 8,000      
Maximum payable on sales milestone 12,000      
Long-term royalty and commercial payment receivables 14,000      
Contingent consideration under RPAs and CPPAs $ 8,000      
Impairment of long-term royalty receivable   $ 0    
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Royalty and Commercial Payment Purchase Agreements - Summary of Acquisition of Royalty Rights (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Agreements    
Balance at beginning of period $ 34,575 $ 34,375
Balance at end of period 69,075 34,575
Agenus [Member]    
Agreements    
Cash receipts for achievement of contractual milestones   (1,000)
Bioasis    
Agreements    
Acquisition of royalty rights   $ 1,200
Viracta    
Agreements    
Acquisition of royalty and commercial payment rights 13,500  
Kuros    
Agreements    
Acquisition of royalty and commercial payment rights 7,000  
Affitech    
Agreements    
Acquisition of royalty and commercial payment rights $ 14,000  
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Transfers between Levels    
Transfer into Level 3   $ 0
Transfer out of Level 3 $ 2,310,000 0
Level 1 to Level 2 transfers, Assets   0
Level 2 to Level 1 transfers, Assets   0
Level 1 to Level 2 transfers, Liabilities   0
Level 2 to Level 1 transfers, Liabilities   0
Recurring    
Assets:    
Equity securities 774,000 1,693,000
Liabilities:    
Contingent consideration 8,075,000 75,000
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Equity securities 774,000  
Recurring | Significant Unobservable Inputs (Level 3)    
Assets:    
Equity securities   1,693,000
Liabilities:    
Contingent consideration $ 8,075,000 $ 75,000
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Summary of Changes In Estimated Fair Value of Level 3 Financial Assets (Details)
12 Months Ended
Jan. 01, 2020
USD ($)
item
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Changes in the estimated fair value of Level 3 financial assets      
Balance at beginning of period $ 681,000 $ 1,693,000 $ 681,000
Change in fair value   617,000 1,012,000
Transfer out of Level 3   $ (2,310,000) 0
Balance at end or period     $ 1,693,000
License Agreement and Common Stock Purchase Agreement [Member] | Rezolute      
Changes in the estimated fair value of Level 3 financial assets      
Number of Rezolute's post-split shares Company has right and option to sell | shares 100,000    
Number of tranches | item 2    
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)
Dec. 31, 2021
$ / shares
Dec. 31, 2020
$ / shares
Y
Rezolute    
Fair Value Measurements    
Closing stock price (in dollars per share) | $ / shares $ 4.78 $ 11.99
Closing Common Stock Price [Member]    
Fair Value Measurements    
Valuation assumptions, measurement input | $ / shares 4.78 11.99
Discount for Lack of Marketability [Member] | Tranche 1 [Member]    
Fair Value Measurements    
Valuation assumptions, measurement input   0.12
Discount for Lack of Marketability [Member] | Tranche 2 [Member]    
Fair Value Measurements    
Valuation assumptions, measurement input   0.14
Estimated time to liquidity of shares | Tranche 1 [Member]    
Fair Value Measurements    
Valuation assumptions, measurement input | Y   0.25
Estimated time to liquidity of shares | Tranche 2 [Member]    
Fair Value Measurements    
Valuation assumptions, measurement input | Y   0.67
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Contingent Consideration (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Oct. 06, 2021
Dec. 31, 2020
Feb. 25, 2019
Fair Value Measurements        
Contingent consideration under RPAs and CPPAs $ 8,075   $ 75  
Bioasis | Royalty Purchase Agreement        
Fair Value Measurements        
Changes in estimated fair value of contingent consideration 0      
Contingent consideration under RPAs and CPPAs 100     $ 100
Affitech | Royalty Purchase Agreement        
Fair Value Measurements        
Changes in estimated fair value of contingent consideration 0      
Contingent consideration under RPAs and CPPAs $ 8,000 $ 8,000    
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Lease Agreement - Leased facilities (Details)
12 Months Ended
Dec. 31, 2021
facility
Leased facilities, Emeryville, California  
Leases  
Operating leases, number of leased facilities 1
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Lease Agreement - Maturity of lease liabilities (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Lease Agreement  
2022 $ 202
2023 34
Total undiscounted lease payments 236
Present value adjustment (7)
Total net lease liabilities $ 229
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
Lease Agreement - Rent Expense and Lease costs (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Lease costs    
Operating lease cost $ 177 $ 177
Variable lease cost 8 7
Total lease costs $ 185 $ 184
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
Lease Agreement - Additional information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Lease Agreement    
Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases $ 196 $ 189
Weighted-average remaining lease term, Operating leases 1 year 2 months 1 day 2 years 2 months 1 day
Weighted-average discount rate, Operating leases 5.51% 5.51%
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
Long-Term Debt and Other Financings - SVB Loan (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Mar. 07, 2018
Jun. 30, 2021
Mar. 31, 2019
Sep. 30, 2018
May 31, 2018
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Long-term debt                
Current portion of long-term debt             $ 8,088  
Long-term debt             $ 12,764  
Loss on extinguishment of debt           $ (300)    
Ten Year Warrants Issued in May 2018                
Long-term debt                
Exercise price of warrants (in dollars per share)           $ 23.69 $ 23.69  
Common stock warrant, Exercise price $14.71 per share, Issued March 2019                
Long-term debt                
Exercise price of warrants (in dollars per share)           $ 14.71 $ 14.71  
SVB Loan                
Long-term debt                
Maximum borrowing capacity under loan agreement $ 20              
Period of monthly payments of principal and interest 24 months              
Maximum period following loan amortization date for which loan will mature 23 months              
Maximum period prior to loan maturity date of Novartis loan for which loan will mature 30 days              
Repayments of debt   $ 6,500            
Final payment fee (as a percent) 8.50% 8.50%            
Final payment fee   $ 1,400            
Prepayment fee (as a percent)   1.00%            
Exercisable period of warrants           10 years    
Debt issuance costs $ 200              
Non-cash interest expense resulting from amortization of discount and accretion           $ 200 $ 600  
Debt amount           0 11,800  
Current portion of long-term debt             8,100  
Long-term debt             $ 3,700  
Loss on extinguishment of debt           $ (300)    
SVB Loan | Minimum                
Long-term debt                
Interest rate (as a percent) 4.75%              
SVB Loan | Ten Year Warrants Issued in May 2018                
Long-term debt                
Aggregate number of shares of common stock called by warrants         6,332      
Exercise price of warrants (in dollars per share)         $ 23.69      
Exercisable period of warrants         10 years      
Fair value of warrant         $ 100      
SVB Loan | Common stock warrant, Exercise price $14.71 per share, Issued March 2019                
Long-term debt                
Aggregate number of shares of common stock called by warrants     4,845          
Exercise price of warrants (in dollars per share)     $ 14.71          
Exercisable period of warrants     10 years          
Fair value of warrant     $ 100          
SVB Loan | Common stock warrant, Exercise price $23.69 per share, Issued May 2018                
Long-term debt                
Aggregate number of shares of common stock called by warrants 6,332              
Exercise price of warrants (in dollars per share) $ 23.69              
Exercisable period of warrants 10 years              
Fair value of warrant $ 100              
SVB Loan | Prime Rate                
Long-term debt                
Basis spread on variable rate 0.25%              
SVB First Term Loan                
Long-term debt                
Proceeds from issuance of long-term debt       $ 7,500        
Unamortized discount       $ 300        
SVB Loan, Second Term Loan                
Long-term debt                
Proceeds from issuance of long-term debt               $ 9,500
Unamortized discount               $ 45,000
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
Long-Term Debt and Other Financings - Novartis Note (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Oct. 20, 2021
Oct. 21, 2020
Jun. 30, 2021
Mar. 31, 2005
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2017
Dec. 31, 2015
Sep. 30, 2015
Long-term debt                  
Revenue from contracts with customers         $ 36,518 $ 27,941      
Loss on extinguishment of debt         (300)        
Novartis Note                  
Long-term debt                  
Research and development expenses funded through loan facility, maximum (as a percent)       75.00%          
Maximum borrowing capacity under loan agreement       $ 50,000          
Repayments of debt     $ 9,100            
Amount by which note will be reduced upon achievement of specified milestones   $ 25,000             $ 7,300
Reduction in debt obligation   7,300              
Debt amount         0 9,100      
Novartis Note | Six-month LIBOR                  
Long-term debt                  
Basis spread on variable rate       2.00%          
Novartis International | License Agreement                  
Long-term debt                  
Revenue from contracts with customers $ 35,000 25,000     $ 35,000 $ 25,000 $ 10,000 $ 37,000  
Cash payment received   $ 17,700           $ 37,000  
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.22.0.1
Long-Term Debt and Other Financings - Interest Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Interest expense    
Interest expense $ 461 $ 1,844
SVB Loan    
Interest expense    
Interest expense 373 1,365
Novartis Note    
Interest expense    
Interest expense $ 88 477
Other    
Interest expense    
Interest expense   $ 2
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Provision for Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Taxes    
Income before income tax $ 15,889 $ 11,797
Federal 91 (1,501)
Total income tax provision (benefit) $ 91 $ (1,501)
XML 86 R71.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Reconciliation between statutory rate and effective rate (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2017
Unrecognized tax benefits activity      
Federal tax at statutory rate 21.00% 21.00% 34.00%
Stock compensation and other permanent differences 9.00% (6.00%)  
Federal orphan drug credit (2.00%)    
Tax benefit related to CARES Act   (13.00%)  
Tax benefit related to net operating loss carryforward utilization (11.00%)    
Valuation allowance (16.00%) (15.00%)  
Total 1.00% (13.00%)  
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - CARES Act (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2017
Income Taxes      
Federal statutory income tax rate 21.00% 21.00% 34.00%
Tax benefit related to NOL carryback provision   $ 1.5  
Cash received for Cares Act income tax receivable $ 1.5    
XML 88 R73.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Taxes    
Capitalized research and development expenses $ 7,822 $ 11,500
Net operating loss carryforwards 17,657 17,638
Research and development and other tax credit carryforwards 13,125 13,454
Stock compensation 4,778 5,158
Unearned revenue 2,817 3,462
Other 807 401
Total deferred tax assets 47,006 51,613
Valuation allowance (47,006) (51,613)
(Decrease) increase in the valuation allowance $ (4,600) $ (3,900)
XML 89 R74.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - NOL (Details)
$ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
Federal  
Operating Loss Carryforwards  
Net operating loss carry-forwards $ 78.8
Net operating loss carryforwards expiration year 2036
Net operating loss carry forward subject to expiration $ 13.6
State [Member]  
Operating Loss Carryforwards  
Net operating loss carry-forwards $ 38.1
Net operating loss carryforwards expiration year 2033
XML 90 R75.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Tax credit carryforward (Details)
$ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
Operating Loss Carryforwards  
Operating loss carryforward offset (as a percent) 80.00%
Federal Orphan Credit [Member]  
Operating Loss Carryforwards  
Tax credit carry forward amount $ 2.0
Tax credit carry forward expiration year 2037
California [Member] | Research [Member]  
Operating Loss Carryforwards  
Tax credit carry forward amount $ 19.8
XML 91 R76.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Unrecognized tax benefits activity    
Beginning Balance $ 5,938 $ 5,517
Increase related to current year tax position 0 0
Increase (decrease) related to prior year tax position   421
Ending Balance 5,938 $ 5,938
Unrecognized tax benefits that would impact effective tax rate 0  
Unrecognized tax benefits expected to change significantly over the next twelve months 0  
Accrued interest or penalties related to uncertain tax positions $ 0  
XML 92 R77.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Based Compensation - ESPP (Details) - 2015 ESPP [Member] - shares
1 Months Ended 12 Months Ended
May 31, 2017
Dec. 31, 2021
Dec. 31, 2020
Apr. 30, 2017
May 31, 2015
Share-based compensation          
Common stock reserved for future issuance (in shares)         15,000
Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions   10.00%      
Offering period   6 months      
Percentage related to employees to purchase shares at the lower fair market value at offering period   85.00%      
Shares available for purchase   237,072      
Common Stock          
Share-based compensation          
Increase in aggregate number of shares authorized for issuance 250,000        
Shares authorized for issuance 265,000     15,000  
Maximum shares per employee 2,500        
Shares purchased (in shares)   2,225 2,746    
XML 93 R78.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Based Compensation - Deferred Savings Plan (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Deferred Savings Plan    
Maximum annual contribution per employee (as a percent) 50.00% 50.00%
Age requirement for participant to be eligible for a catch-up contribution, minimum 50 years 50 years
Contribution expense $ 100 $ 100
Deferred savings plan expense paid in common shares (as a percent) 100.00% 100.00%
Maximum    
Deferred Savings Plan    
Employer matching contribution (as a percent) 50.00% 50.00%
Employee, Under Age Fifty    
Deferred Savings Plan    
Maximum annual contribution per employee $ 19,500 $ 19,500
Employee, Age Fifty or Over    
Deferred Savings Plan    
Maximum annual contribution per employee $ 26,000 $ 26,000
XML 94 R79.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Based Compensation - Stock Option Plans (Details) - shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based compensation    
Number of options outstanding 1,911,177 1,827,906
2010 Plan [Member]    
Share-based compensation    
Shares authorized for issuance 3,029,062  
Expiration period 10 years  
2010 Plan [Member] | Minimum | Terminated employee    
Share-based compensation    
Expiration period 3 months  
2010 Plan [Member] | Maximum | Terminated employee    
Share-based compensation    
Expiration period 6 months  
2010 Plan [Member] | Stock Options [Member]    
Share-based compensation    
Shares available for grant 161,140  
XML 95 R80.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Based Compensation - Stock Options (Details) - Stock Options [Member]
12 Months Ended
Dec. 31, 2021
Share-based compensation  
Minimum age required for employees to qualify for immediate vesting of award 55 years
Threshold years required for retirement age 70 years
Employees  
Share-based compensation  
Vesting period 3 years
Directors  
Share-based compensation  
Vesting period 1 year
XML 96 R81.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based compensation    
Number of shares, Outstanding at beginning of period 1,827,906  
Number of shares, Granted 325,211  
Number of shares, Exercised (77,305)  
Number of shares, Forfeited, expired or cancelled (164,635)  
Number of shares, Outstanding at end of period 1,911,177 1,827,906
Number of shares, Exercisable at end of period 1,553,696  
Weighted Average Exercise Price Per Share, Outstanding at beginning of period $ 20.66  
Weighted Average Exercise Price Per Share, Granted 32.02  
Weighted Average Exercise Price Per Share, Exercised 13.61  
Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled 46.59  
Weighted Average Exercise Price Per Share, Outstanding at end of period 20.64 $ 20.66
Weighted Average Exercise Price Per Share, Exercisable at end of period $ 18.75  
Weighted Average Contractual Term, Outstanding 6 years 3 months 29 days 6 years 3 months 21 days
Weighted Average Contractual Term, Exercisable 5 years 8 months 8 days  
Aggregate Intrinsic Value, Outstanding $ 15,103 $ 51,401
Aggregate Intrinsic Value, Exercisable 14,894  
Options exercised, aggregate intrinsic value $ 1,600 $ 5,400
Weighted-average grant-date fair value (in dollars per share) $ 22.23 $ 18.41
Unrecognized compensation expense related to stock options (in dollars) $ 4,100  
Stock Options [Member]    
Share-based compensation    
Weighted average period of unrecognized compensation expense expected to be recognized 2 years 2 months 15 days  
XML 97 R82.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Based Compensation - Weighted Average Assumptions (Details) - Stock Options [Member]
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Weighted average assumptions    
Dividend yield 0.00% 0.00%
Expected volatility 83.00% 100.00%
Risk-free interest rate 0.95% 0.72%
Expected term 5 years 7 months 28 days 5 years 7 months 20 days
XML 98 R83.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based compensation expense    
Stock-based compensation expense $ 6,195 $ 3,961
General and Administrative [Member]    
Share-based compensation expense    
Stock-based compensation expense $ 6,195 $ 3,961
XML 99 R84.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Income Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details) - shares
shares in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share    
Antidilutive securities excluded from computation of net loss per share (in shares) 479 622
Common stock options    
Antidilutive Securities Excluded From Computation Of Earnings Per Share    
Antidilutive securities excluded from computation of net loss per share (in shares) 479 616
Warrants for Common Stock [Member]    
Antidilutive Securities Excluded From Computation Of Earnings Per Share    
Antidilutive securities excluded from computation of net loss per share (in shares)   6
XML 100 R85.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Income Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Numerator    
Net income $ 15,798 $ 13,298
Less: Allocation of undistributed earnings to participating securities (3,451) (4,417)
Net (loss) income available to common stockholders, basic 7,787 8,793
Add: Adjustments to undistributed earnings allocated to participating securities 181 217
Net (loss) income available to common stockholders, diluted $ 7,968 $ 9,010
Denominator    
Weighted average shares used in computing basic net income per share available to common stockholders 11,288 10,674
Effect of dilutive stock options 900 824
Effect of dilutive warrants 4 5
Weighted average shares used in computing diluted net income per share available to common stockholders 12,192 11,503
Basic net income per share available to common stockholders (in dollars per share) $ 0.69 $ 0.82
Diluted net income per share of common stock (in dollars per share) $ 0.65 $ 0.78
8.625% Series A Cumulative, Perpetual Preferred Stock    
Numerator    
Less: Accumulated preferred dividends $ (2,122) $ (88)
8.375% Series B Cumulative, Perpetual Preferred Stock    
Numerator    
Less: Accumulated preferred dividends $ (2,438)  
XML 101 R86.htm IDEA: XBRL DOCUMENT v3.22.0.1
Capital Stock - Series X and Series Y Convertible Preferred Stock (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Feb. 28, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2021
Dec. 31, 2020
Sale of stock          
Preferred stock, shares authorized (in shares)       1,000,000 1,000,000
Series X And Series Y Convertible Preferred Stock          
Sale of stock          
Number of shares issued for each share of convertible preferred stock that is converted   1,000 1,000    
Series X Convertible Preferred Stock          
Sale of stock          
Shares issued (in shares)     5,003    
Preferred stock, shares authorized (in shares)       5,003 5,003
Preferred stock, shares issued (in shares)       5,003 5,003
Preferred stock conversion price per share     $ 4.03    
Fair value of common stock amount exceeded purchase price of convertible preferred stock $ 5.6        
Series Y Convertible Preferred Stock          
Sale of stock          
Shares issued (in shares)   1,252.772      
Preferred stock, shares outstanding (in shares)       0  
Preferred stock conversion price per share   $ 13.00      
XML 102 R87.htm IDEA: XBRL DOCUMENT v3.22.0.1
Capital Stock - Series A Preferred Stock (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 15, 2020
USD ($)
D
M
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 15, 2025
$ / shares
Dec. 15, 2024
$ / shares
Dec. 15, 2023
$ / shares
Dec. 15, 2022
$ / shares
Dec. 15, 2021
$ / shares
Sale of stock                
Preferred stock, shares authorized (in shares) | shares   1,000,000 1,000,000          
Gross proceeds from issuance of preferred stock | $   $ 40,000 $ 24,600          
Stock issuance costs | $   $ 3,385 $ 1,945          
Preferred stock, par value (in dollars per share)   $ 0.05 $ 0.05          
8.625% Series A Cumulative, Perpetual Preferred Stock                
Sale of stock                
Preferred stock, shares authorized (in shares) | shares   984,000 984,000          
Preferred stock, shares issued (in shares) | shares   984,000 984,000          
Preferred stock, dividend rate (as a percent) 8.625% 8.625% 8.625%          
Purchase price (in dollars per share) $ 25.00              
Gross proceeds from issuance of preferred stock | $ $ 24,600              
Stock issuance costs | $ 2,000              
Net proceeds from issuance of stock | $ $ 22,600              
Liquidation preference (in dollars per share) $ 25.00              
Number of days in year over which dividend will be prorated and computed | D 360              
Number of months in year over which dividend will be prorated and compute | M 12              
Number of days in month over which dividend will be prorated and computed | D 30              
Preferred stock, par value (in dollars per share)   $ 0.05 $ 0.05          
Redemption price (in dollars per share)               $ 26.00
Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share) $ 25.00              
Share cap (in shares) | shares 1.46071              
Trading days | D 10              
8.625% Series A Cumulative, Perpetual Preferred Stock | Directors                
Sale of stock                
Purchase price (in dollars per share) $ 25.00              
Gross proceeds from issuance of preferred stock | $ $ 5,000              
8.625% Series A Cumulative, Perpetual Preferred Stock | Chief Executive Officer                
Sale of stock                
Purchase price (in dollars per share) $ 25.00              
Gross proceeds from issuance of preferred stock | $ $ 200              
Forecast | 8.625% Series A Cumulative, Perpetual Preferred Stock                
Sale of stock                
Redemption price (in dollars per share)       $ 25.00 $ 25.25 $ 25.50 $ 25.75  
Preferred Stock | 8.625% Series A Cumulative, Perpetual Preferred Stock                
Sale of stock                
Shares issued (in shares) | shares 984,000   984,000          
Preferred Stock | 8.625% Series A Cumulative, Perpetual Preferred Stock | Directors                
Sale of stock                
Shares issued (in shares) | shares 200,000              
Preferred Stock | 8.625% Series A Cumulative, Perpetual Preferred Stock | Chief Executive Officer                
Sale of stock                
Shares issued (in shares) | shares 8,000              
XML 103 R88.htm IDEA: XBRL DOCUMENT v3.22.0.1
Capital Stock - Series B Preferred Stock (Details)
$ / shares in Units, $ in Thousands
5 Months Ended 12 Months Ended
Apr. 09, 2021
USD ($)
D
M
$ / shares
shares
Dec. 31, 2021
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Apr. 15, 2026
$ / shares
Apr. 15, 2025
$ / shares
Apr. 15, 2024
$ / shares
Apr. 15, 2023
$ / shares
Apr. 15, 2022
$ / shares
Sale of stock                  
Proceeds from issuance of preferred stock | $     $ 40,000 $ 24,600          
Preferred stock, shares authorized (in shares) | shares   1,000,000 1,000,000 1,000,000          
Stock issuance costs | $     $ 3,385 $ 1,945          
Preferred stock, par value (in dollars per share)   $ 0.05 $ 0.05 $ 0.05          
8.375% Series B Cumulative, Perpetual Preferred Stock                  
Sale of stock                  
Preferred stock, shares authorized (in shares) | shares   3,600 3,600            
Preferred stock, shares issued (in shares) | shares   1,600 1,600 0          
Preferred stock, dividend rate (as a percent) 8.375%   8.375% 8.375%          
Liquidation preference (in dollars per share) $ 25,000.00                
Preferred stock, dividend amount (in dollars per share) $ 2,093.75                
Number of days in year over which dividend will be prorated and computed | D 360                
Number of months in year over which dividend will be prorated and compute | M 12                
Number of days in month over which dividend will be prorated and computed | D 30                
Preferred stock, par value (in dollars per share)   $ 0.05 $ 0.05 $ 0.05          
Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share) $ 25,000.00                
Share cap (in shares) | shares 1,253.13                
8.375% Series B Cumulative, Perpetual Preferred Stock | Forecast                  
Sale of stock                  
Redemption price (in dollars per share)         $ 25,000.00 $ 25,250.00 $ 25,500.00 $ 25,750.00 $ 26,000.00
Series B Depositary Shares                  
Sale of stock                  
Shares issued (in shares) | shares 1,600,000                
Purchase price (in dollars per share) $ 25.00                
Proceeds from issuance of preferred stock | $ $ 40,000                
Stock issuance costs | $ 2,900                
Net proceeds from issuance of preferred stock | $ $ 37,100                
Share cap (in shares) | shares 1.25313                
Series B Depositary Shares | Forecast                  
Sale of stock                  
Redemption price (in dollars per share)         $ 25.00 $ 25.25 $ 25.50 $ 25.75 $ 26.00
Series B Depositary Shares | Spouse of James Neal, Chief Executive Officer and a director                  
Sale of stock                  
Shares issued (in shares) | shares 8,000                
Purchase price (in dollars per share) $ 25.00                
Proceeds from issuance of preferred stock | $ $ 200                
Series B Depositary Shares | 2021 ATM Agreement                  
Sale of stock                  
Shares issued (in shares) | shares   0              
XML 104 R89.htm IDEA: XBRL DOCUMENT v3.22.0.1
Capital Stock - Dividends (Details) - USD ($)
$ / shares in Units, $ in Thousands
Jan. 18, 2022
Oct. 20, 2021
Oct. 15, 2021
Jul. 28, 2021
Jul. 15, 2021
May 21, 2021
Apr. 15, 2021
Apr. 09, 2021
Mar. 17, 2021
Dec. 31, 2021
Dec. 31, 2020
Dividends                      
Restricted cash                   $ 2,049 $ 2,142
8.625% Series A Cumulative, Perpetual Preferred Stock                      
Dividends                      
Cash dividend declared (in dollars per share)   $ 0.53906   $ 0.53906   $ 0.53906     $ 0.71875    
Cash dividend paid (in dollars per share)     $ 0.53906   $ 0.53906   $ 0.71875        
Series B Depositary Shares                      
Dividends                      
Cash dividend declared (in dollars per share)   $ 0.52344   $ 0.52344   $ 0.55833          
Cash dividend paid (in dollars per share)     $ 0.52344   $ 0.55833            
Issuance of stock, net (in shares)               1,600,000      
Subsequent Event | 8.625% Series A Cumulative, Perpetual Preferred Stock                      
Dividends                      
Cash dividend paid (in dollars per share) $ 0.53906                    
Subsequent Event | Series B Depositary Shares                      
Dividends                      
Cash dividend paid (in dollars per share) $ 0.52344                    
XML 105 R90.htm IDEA: XBRL DOCUMENT v3.22.0.1
Capital Stock - BVF Ownership (Details) - BVF
Dec. 31, 2021
Feb. 29, 2020
Series Y Convertible Preferred Stock    
Sale of stock    
Beneficial ownership limitation (as a percent)   50.00%
Xoma Corporation | Common Stock    
Sale of stock    
Ownership interest (as a percent) 31.20%  
Ownership interest, if shares are converted (as a percent) 52.30%  
XML 106 R91.htm IDEA: XBRL DOCUMENT v3.22.0.1
Capital Stock - ATM Agreements (Details) - USD ($)
$ in Millions
5 Months Ended 36 Months Ended
Aug. 05, 2021
Apr. 09, 2021
Dec. 18, 2018
Dec. 31, 2021
Dec. 31, 2021
Mar. 10, 2021
Series B Depositary Shares            
Sale of stock            
Shares issued (in shares)   1,600,000        
2018 Common Stock ATM Agreement            
Sale of stock            
Maximum amount of common shares to be issued     $ 30.0     $ 50.0
2018 Common Stock ATM Agreement | Maximum            
Sale of stock            
Sales commission paid per transaction (as a percent)     3.00%      
2021 ATM Agreement            
Sale of stock            
Maximum amount of shares to be issued $ 50.0          
2021 ATM Agreement | Series B Depositary Shares            
Sale of stock            
Shares issued (in shares)       0    
2021 ATM Agreement | Maximum            
Sale of stock            
Sales commission paid per transaction, preferred stock (as a percent) 3.00%          
Common Stock | 2018 Common Stock ATM Agreement            
Sale of stock            
Shares issued (in shares)         0  
XML 107 R92.htm IDEA: XBRL DOCUMENT v3.22.0.1
Capital Stock - Summary of Common Stock Warrants Outstanding (Details) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Warrants    
Warrant outstanding (in shares) 11,177 19,426
Five Year Warrants Issued in February 2016    
Warrants    
Exercise price of warrants (in dollars per share)   $ 15.40
Warrant outstanding (in shares) 0 8,249
Ten Year Warrants Issued in May 2018    
Warrants    
Exercise price of warrants (in dollars per share) $ 23.69 $ 23.69
Warrant outstanding (in shares) 6,332 6,332
Common stock warrant, Exercise price $14.71 per share, Issued March 2019    
Warrants    
Exercise price of warrants (in dollars per share) $ 14.71 $ 14.71
Warrant outstanding (in shares) 4,845 4,845
XML 108 R93.htm IDEA: XBRL DOCUMENT v3.22.0.1
Capital Stock - Common Stock Warrants (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Feb. 28, 2021
Mar. 31, 2019
May 31, 2018
Feb. 29, 2016
Dec. 31, 2021
Dec. 31, 2020
SVB Loan            
Warrants            
Exercisable period of warrants         10 years  
Five Year Warrants Issued in February 2016            
Warrants            
Exercise price of warrants (in dollars per share)           $ 15.40
Five Year Warrants Issued in February 2016 | Third-Party Consultant            
Warrants            
Aggregate number of unregistered shares of common stock called by warrants (in shares)       8,249    
Exercise price of warrants (in dollars per share)       $ 15.40    
Exercisable period of warrants       5 years    
Estimated fair value of warrants       $ 0.1    
Exercise of warrant 4,917          
Ten Year Warrants Issued in May 2018            
Warrants            
Exercise price of warrants (in dollars per share)         $ 23.69 23.69
Ten Year Warrants Issued in May 2018 | SVB Loan            
Warrants            
Aggregate number of unregistered shares of common stock called by warrants (in shares)     6,332      
Exercise price of warrants (in dollars per share)     $ 23.69      
Exercisable period of warrants     10 years      
Estimated fair value of warrants     $ 0.1      
Common stock warrant, Exercise price $14.71 per share, Issued March 2019            
Warrants            
Exercise price of warrants (in dollars per share)         $ 14.71 $ 14.71
Common stock warrant, Exercise price $14.71 per share, Issued March 2019 | SVB Loan            
Warrants            
Aggregate number of unregistered shares of common stock called by warrants (in shares)   4,845        
Exercise price of warrants (in dollars per share)   $ 14.71        
Exercisable period of warrants   10 years        
Estimated fair value of warrants   $ 0.1        
Exercise of warrant         0  
XML 109 R94.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)
$ in Millions
Dec. 31, 2021
USD ($)
product
Commitments and Contingencies  
Estimate of milestone payments | $ $ 6.3
Assumed number of products per contract | product 1
XML 110 R95.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Contingent Consideration (Details) - USD ($)
1 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2021
Oct. 06, 2021
Dec. 31, 2020
Apr. 07, 2019
Feb. 25, 2019
Commitments And Contingencies            
Contingent consideration under RPAs and CPPAs   $ 8,075,000   $ 75,000    
Royalty Purchase Agreement | Bioasis            
Commitments And Contingencies            
Contingent consideration under RPAs and CPPAs   100,000       $ 100,000
Payments of contingent consideration   0        
Changes in estimated fair value of contingent consideration   0        
Royalty Purchase Agreement | Aronora            
Commitments And Contingencies            
Contingent consideration under RPAs and CPPAs         $ 3,000,000.0  
Payments of contingent consideration $ 3,000,000.0          
Royalty Purchase Agreement | Affitech            
Commitments And Contingencies            
Contingent consideration under RPAs and CPPAs   8,000,000.0 $ 8,000,000.0      
Changes in estimated fair value of contingent consideration   0        
Royalty Purchase Agreement | Bioasis & Affitech            
Commitments And Contingencies            
Changes in estimated fair value of contingent consideration   0        
Royalty Purchase Agreement | Aronora Kuros And Affitech            
Commitments And Contingencies            
Contingent consideration under RPAs and CPPAs   $ 0        
XML 111 R96.htm IDEA: XBRL DOCUMENT v3.22.0.1
Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details) - customer
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Customer Concentration Risk [Member] | Revenues.    
Concentration of Risk    
Number of major partners 1 1
Customer Concentration Risk [Member] | Revenues. | Partner 1    
Concentration of Risk    
Concentration risk (as a percent) 92.00% 85.00%
Credit Concentration Risk | Accounts Receivable    
Concentration of Risk    
Number of major partners   1
Credit Concentration Risk | Accounts Receivable | Partner 1    
Concentration of Risk    
Concentration risk (as a percent)   100.00%
XML 112 R97.htm IDEA: XBRL DOCUMENT v3.22.0.1
Concentration of Risk, Segment and Geographic Information - Segment Information (Details)
12 Months Ended
Dec. 31, 2021
segment
Concentration of Risk, Segment and Geographic Information  
Number of operating segments 1
XML 113 R98.htm IDEA: XBRL DOCUMENT v3.22.0.1
Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenues from External Customers    
Revenues $ 38,160 $ 29,385
Europe    
Revenues from External Customers    
Revenues 35,000 25,010
Asia Pacific    
Revenues from External Customers    
Revenues 550 3,100
United States    
Revenues from External Customers    
Revenues $ 2,610 $ 1,275
XML 114 R99.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsequent Events (Details) - USD ($)
$ in Millions
1 Months Ended
Jan. 28, 2022
Oct. 06, 2021
Jan. 31, 2022
Affitech | Commercial payment purchase agreement      
Subsequent Event      
Payments eligible to receive (as a percent)   0.50%  
Commercial payment receivable term   10 years  
Maximum additional payments upon achievement of regulatory and sales milestones   $ 20.0  
Subsequent Event | Affitech | Commercial payment purchase agreement      
Subsequent Event      
Payments eligible to receive (as a percent) 0.50%    
Commercial payment receivable term 10 years    
Milestone payment $ 5.0    
Maximum additional payments upon achievement of regulatory and sales milestones $ 15.0    
Subsequent Event | Rezolute | License Agreement      
Subsequent Event      
Milestone payment     $ 2.0
XML 115 tmb-20211231x10k_htm.xml IDEA: XBRL DOCUMENT 0000791908 xoma:AronoraIncMember xoma:SiliconValleyBankMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 2019-04-07 0000791908 xoma:FederalOrphanCreditMember 2021-01-01 2021-12-31 0000791908 xoma:ThirdPartyConsultantMember xoma:FiveYearWarrantsIssuedSecondRangeMember 2021-02-01 2021-02-28 0000791908 xoma:CommonStockWarrantExercisePrice14.71Member xoma:SiliconValleyBankMember 2021-01-01 2021-12-31 0000791908 xoma:BioasisTechnologiesIncMember 2020-01-01 2020-12-31 0000791908 xoma:ViractaTherapeuticsInc.Member 2021-01-01 2021-12-31 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember 2021-01-01 2021-12-31 0000791908 xoma:AffitechResearchAsMember 2021-01-01 2021-12-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementRz358Member 2017-12-06 2017-12-06 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementNonRz358ProductsMember 2017-12-06 2017-12-06 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2015-09-01 2015-09-30 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:MezagitamabMember xoma:CollaborationAgreementMember 2006-11-01 2006-11-30 0000791908 xoma:AgenusIncMember xoma:MerckImmunoOncologyProductMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 0000791908 xoma:AgenusIncMember xoma:IncyteImmunoOncologyAssetsMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 0000791908 xoma:AgenusIncMember xoma:MerckImmunoOncologyProductMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 2018-09-20 0000791908 xoma:NovartisPharmaAGMember xoma:IL1TargetLicenseAgreementMember 2017-08-24 2017-08-24 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:SecondRoyaltyInterestAcquisitionAgreementMember 2016-12-21 2016-12-21 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:FirstRoyaltyInterestAcquisitionAgreementMember 2016-12-21 2016-12-21 0000791908 xoma:SeriesYConvertiblePreferredStockMember 2018-12-31 0000791908 xoma:SeriesXConvertiblePreferredStockMember 2017-12-31 0000791908 srt:MaximumMember xoma:AtMarketIssuanceSalesAgreement2021Member 2021-08-05 2021-08-05 0000791908 srt:MaximumMember xoma:TwoThousandEighteenAtMarketAgreementMember 2018-12-18 2018-12-18 0000791908 xoma:ViractaTherapeuticsInc.Member xoma:RoyaltyPurchaseAgreementMember 2021-03-22 2021-03-22 0000791908 xoma:BioasisTechnologiesIncMember xoma:RoyaltyPurchaseAgreementTwoMember 2020-11-02 2020-11-02 0000791908 xoma:PalobiofarmaSLMember xoma:RoyaltyPurchaseAgreementMember 2019-09-26 2019-09-26 0000791908 xoma:AgenusIncMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 2018-09-20 0000791908 xoma:AronoraIncMember xoma:RoyaltyPurchaseAgreementMember 2019-09-01 2019-09-30 0000791908 xoma:LeasedFacilitiesEmeryvilleCaliforniaMember 2021-01-01 2021-12-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember 2020-01-01 2020-01-01 0000791908 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000791908 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000791908 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-12-31 0000791908 xoma:AgenusIncMember xoma:IncyteImmunoOncologyAssetsMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 2018-09-20 0000791908 xoma:BioasisTechnologiesIncMember xoma:RoyaltyPurchaseAgreementMember 2019-02-25 2019-02-25 0000791908 us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0000791908 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0000791908 xoma:RezoluteIncMember us-gaap:SubsequentEventMember xoma:LicenseAgreementMember 2022-01-01 2022-01-31 0000791908 xoma:MerckImmunoOncologyProductMember xoma:RoyaltyPurchaseAgreementMember xoma:AgenusIncMember 2020-11-01 2020-11-30 0000791908 xoma:AtMarketIssuanceSalesAgreement2021Member 2021-08-05 2021-08-05 0000791908 xoma:TwoThousandEighteenAtMarketAgreementMember 2021-03-10 0000791908 xoma:TwoThousandEighteenAtMarketAgreementMember 2018-12-18 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:ArrangementWithGovernmentalAgency2DevelopmentTwoMember 2011-10-31 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:ArrangementWithGovernmentalAgency2DevelopmentOneMember 2008-09-30 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2019-08-01 2019-08-31 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember xoma:RoyaltyPurchaseAgreementMember 2021-07-14 0000791908 xoma:BioasisTechnologiesIncMember xoma:RoyaltyPurchaseAgreementTwoMember 2020-11-02 0000791908 xoma:AgenusIncMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember 2018-04-01 2018-04-30 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember 2017-12-06 2020-10-31 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member 2021-12-01 2021-12-31 0000791908 2021-12-01 2021-12-31 0000791908 xoma:ViractaTherapeuticsInc.Member xoma:RoyaltyPurchaseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:PalobiofarmaSLMember xoma:RoyaltyPurchaseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember xoma:RoyaltyPurchaseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:BioasisTechnologiesIncMember xoma:RoyaltyPurchaseAgreementTwoMember 2021-01-01 2021-12-31 0000791908 xoma:AronoraIncMember xoma:RoyaltyPurchaseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:AgenusIncMember xoma:RoyaltyPurchaseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:AffitechResearchAsMember xoma:CommercialPaymentPurchaseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:SeriesXConvertiblePreferredStockMember 2017-02-01 2017-02-28 0000791908 xoma:CommonStockWarrantExercisePrice14.71Member xoma:SiliconValleyBankMember 2019-03-01 2019-03-31 0000791908 xoma:TenYearWarrantsIssuedThirdRangeMember xoma:SiliconValleyBankMember 2018-05-01 2018-05-31 0000791908 xoma:CommonStockWarrantExercisePrice23.69PerShareIssuedMay2018Member xoma:SiliconValleyBankMember 2018-03-07 2018-03-07 0000791908 xoma:ThirdPartyConsultantMember xoma:FiveYearWarrantsIssuedSecondRangeMember 2016-02-01 2016-02-29 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember 2020-01-01 0000791908 xoma:RezoluteIncMember 2020-10-31 0000791908 xoma:RezoluteIncMember 2020-09-30 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:FirstRoyaltyInterestAcquisitionAgreementMember 2016-12-21 0000791908 xoma:AffitechResearchAsMember us-gaap:SubsequentEventMember xoma:CommercialPaymentPurchaseAgreementMember 2022-01-28 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember xoma:RoyaltyPurchaseAgreementMember 2021-07-14 2021-07-14 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2021-10-20 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementRz358Member 2017-12-06 0000791908 xoma:NovartisPharmaAGMember xoma:XOMA052LicenseAgreementMember 2017-08-24 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2015-09-30 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:MezagitamabMember xoma:CollaborationAgreementMember 2006-11-30 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:OtherAntibodiesMember xoma:CollaborationAgreementMember 2009-02-01 2009-02-28 0000791908 xoma:SiliconValleyBankMember 2018-03-07 2018-03-07 0000791908 xoma:SiliconValleyBankMember 2021-06-30 0000791908 xoma:NovartisNoteMember 2020-10-21 0000791908 xoma:NovartisNoteMember 2015-09-30 0000791908 xoma:AronoraIncMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 2019-04-07 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member 2008-09-01 2008-09-30 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member 2017-01-01 2017-12-31 0000791908 xoma:AronoraIncMember xoma:BayerProductsMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 2019-04-07 0000791908 xoma:BioasisTechnologiesIncMember srt:MaximumMember xoma:RoyaltyPurchaseAgreementMember 2019-02-25 0000791908 xoma:BioasisTechnologiesIncMember xoma:RoyaltyPurchaseAgreementMember 2021-12-31 0000791908 xoma:AronoraKurosAndAffitechMember xoma:RoyaltyPurchaseAgreementMember 2021-12-31 0000791908 xoma:AffitechResearchAsMember xoma:RoyaltyPurchaseAgreementMember 2021-12-31 0000791908 xoma:AffitechResearchAsMember xoma:RoyaltyPurchaseAgreementMember 2021-10-06 0000791908 xoma:AffitechResearchAsMember xoma:CommercialPaymentPurchaseAgreementMember 2021-10-06 0000791908 xoma:BioasisTechnologiesIncMember xoma:RoyaltyPurchaseAgreementMember 2019-02-25 0000791908 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000791908 xoma:AffitechResearchAsMember us-gaap:SubsequentEventMember xoma:CommercialPaymentPurchaseAgreementMember 2022-01-28 2022-01-28 0000791908 xoma:AffitechResearchAsMember xoma:CommercialPaymentPurchaseAgreementMember 2021-10-06 2021-10-06 0000791908 xoma:NovartisNoteMember 2005-03-01 2005-03-31 0000791908 xoma:BioasisTechnologiesIncMember xoma:RoyaltyPurchaseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:BioasisAffitechMember xoma:RoyaltyPurchaseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:AffitechResearchAsMember xoma:RoyaltyPurchaseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:AgenusIncMember xoma:MerckImmunoOncologyProductMember xoma:RoyaltyPurchaseAgreementMember 2020-11-01 2020-11-30 0000791908 xoma:AgenusIncMember 2020-01-01 2020-12-31 0000791908 xoma:SeriesYConvertiblePreferredStockMember xoma:BiotechnologyValueFundLPMember 2020-02-29 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2017-08-24 2017-08-24 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementMember 2017-12-06 2017-12-06 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2015-09-30 2015-09-30 0000791908 xoma:ViractaTherapeuticsInc.Member xoma:RoyaltyPurchaseAgreementMember 2021-03-22 0000791908 xoma:PalobiofarmaSLMember xoma:RoyaltyPurchaseAgreementMember 2019-09-26 0000791908 xoma:AronoraIncMember xoma:NonBayerProductsMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908 xoma:AronoraIncMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908 xoma:AronoraIncMember xoma:BayerProductsMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908 stpr:CA us-gaap:ResearchMember 2021-12-31 0000791908 xoma:FederalOrphanCreditMember 2021-12-31 0000791908 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000791908 dei:AdrMember xoma:AtMarketIssuanceSalesAgreement2021Member 2021-08-01 2021-12-31 0000791908 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000791908 srt:DirectorMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-15 2020-12-15 0000791908 srt:ChiefExecutiveOfficerMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-15 2020-12-15 0000791908 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-15 2020-12-15 0000791908 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000791908 us-gaap:CommonStockMember xoma:TwoThousandEighteenAtMarketAgreementMember 2018-12-18 2021-12-31 0000791908 xoma:SeriesYConvertiblePreferredStockMember 2018-01-01 2018-12-31 0000791908 xoma:NovartisPharmaAGMember us-gaap:CommonStockMember xoma:XOMA052LicenseAgreementMember 2017-08-24 2017-08-24 0000791908 xoma:SeriesXConvertiblePreferredStockMember 2017-01-01 2017-12-31 0000791908 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000791908 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000791908 xoma:RezoluteIncMember 2020-10-01 2020-10-31 0000791908 us-gaap:RetainedEarningsMember 2021-12-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000791908 us-gaap:RetainedEarningsMember 2020-12-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000791908 us-gaap:RetainedEarningsMember 2019-12-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000791908 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000791908 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000791908 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000791908 us-gaap:CommonStockMember 2021-12-31 0000791908 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000791908 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000791908 us-gaap:CommonStockMember 2020-12-31 0000791908 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000791908 us-gaap:CommonStockMember 2019-12-31 0000791908 us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember dei:AdrMember 2021-04-09 0000791908 dei:AdrMember 2021-04-09 0000791908 srt:DirectorMember us-gaap:SeriesAPreferredStockMember 2020-12-15 0000791908 srt:ChiefExecutiveOfficerMember us-gaap:SeriesAPreferredStockMember 2020-12-15 0000791908 xoma:RezoluteIncMember 2021-12-31 0000791908 xoma:RezoluteIncMember 2020-12-31 0000791908 xoma:NovartisPharmaAGMember us-gaap:CommonStockMember xoma:XOMA052LicenseAgreementMember 2017-08-24 0000791908 xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000791908 xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000791908 xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0000791908 us-gaap:EmployeeStockOptionMember xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2021-12-31 0000791908 xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember 2021-12-31 0000791908 xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2021-12-31 0000791908 xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2017-05-31 0000791908 xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2017-04-30 0000791908 xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2017-05-01 2017-05-31 0000791908 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000791908 srt:MinimumMember xoma:EmployeeTerminatedMember xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2021-01-01 2021-12-31 0000791908 srt:MaximumMember xoma:EmployeeTerminatedMember xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2021-01-01 2021-12-31 0000791908 xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2021-01-01 2021-12-31 0000791908 xoma:EmployeeMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000791908 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000791908 srt:EuropeMember 2021-01-01 2021-12-31 0000791908 srt:AsiaPacificMember 2021-01-01 2021-12-31 0000791908 country:US 2021-01-01 2021-12-31 0000791908 srt:EuropeMember 2020-01-01 2020-12-31 0000791908 srt:AsiaPacificMember 2020-01-01 2020-12-31 0000791908 country:US 2020-01-01 2020-12-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:RoyaltyInterestAcquisitionAgreementsMember 2021-01-01 2021-12-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:RoyaltyInterestAcquisitionAgreementsMember 2020-01-01 2020-12-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2021-12-01 2021-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2021-10-20 2021-10-20 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2021-05-01 2021-05-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:LicenseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:CollaborationAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:AffimedMember xoma:LicenseAgreementMember 2021-01-01 2021-12-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:CollaborationAgreementMember 2020-11-16 2020-11-16 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2020-10-21 2020-10-21 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:LicenseAgreementMember 2020-01-01 2020-12-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:CollaborationAgreementMember 2020-01-01 2020-12-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementMember 2020-01-01 2020-12-31 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2020-01-01 2020-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2020-01-01 2020-12-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2020-01-01 2020-12-31 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member 2020-01-01 2020-12-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2019-01-01 2019-12-31 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2017-01-01 2017-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2017-01-01 2017-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2015-01-01 2015-12-31 0000791908 xoma:SiliconValleyBankMember 2021-06-01 2021-06-30 0000791908 xoma:SiliconValleyBankAndNovartisPharmaAgMember 2021-06-01 2021-06-30 0000791908 xoma:NovartisNoteMember 2021-06-01 2021-06-30 0000791908 us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember dei:AdrMember 2021-04-09 2021-04-09 0000791908 srt:DirectorMember us-gaap:SeriesAPreferredStockMember 2020-12-15 2020-12-15 0000791908 srt:ChiefExecutiveOfficerMember us-gaap:SeriesAPreferredStockMember 2020-12-15 2020-12-15 0000791908 xoma:SecondTermLoanMember 2019-01-01 2019-12-31 0000791908 xoma:FirstTermLoanMember 2018-09-01 2018-09-30 0000791908 xoma:NovartisPharmaAGMember xoma:XOMA052LicenseAgreementMember 2017-08-24 2017-08-24 0000791908 xoma:SeriesYConvertiblePreferredStockMember 2021-12-31 0000791908 us-gaap:ConvertiblePreferredStockMember 2021-12-31 0000791908 us-gaap:ConvertiblePreferredStockMember 2020-12-31 0000791908 xoma:SeriesXConvertiblePreferredStockMember 2021-12-31 0000791908 xoma:SeriesXConvertiblePreferredStockMember 2020-12-31 0000791908 srt:ScenarioForecastMember us-gaap:SeriesBPreferredStockMember 2026-04-15 0000791908 srt:ScenarioForecastMember dei:AdrMember 2026-04-15 0000791908 srt:ScenarioForecastMember us-gaap:SeriesAPreferredStockMember 2025-12-15 0000791908 srt:ScenarioForecastMember us-gaap:SeriesBPreferredStockMember 2025-04-15 0000791908 srt:ScenarioForecastMember dei:AdrMember 2025-04-15 0000791908 srt:ScenarioForecastMember us-gaap:SeriesAPreferredStockMember 2024-12-15 0000791908 srt:ScenarioForecastMember us-gaap:SeriesBPreferredStockMember 2024-04-15 0000791908 srt:ScenarioForecastMember dei:AdrMember 2024-04-15 0000791908 srt:ScenarioForecastMember us-gaap:SeriesAPreferredStockMember 2023-12-15 0000791908 srt:ScenarioForecastMember us-gaap:SeriesBPreferredStockMember 2023-04-15 0000791908 srt:ScenarioForecastMember dei:AdrMember 2023-04-15 0000791908 srt:ScenarioForecastMember us-gaap:SeriesAPreferredStockMember 2022-12-15 0000791908 srt:ScenarioForecastMember us-gaap:SeriesBPreferredStockMember 2022-04-15 0000791908 srt:ScenarioForecastMember dei:AdrMember 2022-04-15 0000791908 us-gaap:SeriesAPreferredStockMember 2021-12-15 0000791908 us-gaap:SeriesBPreferredStockMember 2021-12-31 0000791908 us-gaap:SeriesAPreferredStockMember 2021-12-31 0000791908 us-gaap:SeriesBPreferredStockMember 2020-12-31 0000791908 us-gaap:SeriesAPreferredStockMember 2020-12-31 0000791908 us-gaap:SeriesBPreferredStockMember 2021-04-09 0000791908 us-gaap:SeriesAPreferredStockMember 2020-12-15 0000791908 us-gaap:SeriesAPreferredStockMember 2021-10-20 2021-10-20 0000791908 dei:AdrMember 2021-10-20 2021-10-20 0000791908 us-gaap:SeriesAPreferredStockMember 2021-07-28 2021-07-28 0000791908 dei:AdrMember 2021-07-28 2021-07-28 0000791908 us-gaap:SeriesAPreferredStockMember 2021-05-21 2021-05-21 0000791908 dei:AdrMember 2021-05-21 2021-05-21 0000791908 us-gaap:SeriesAPreferredStockMember 2021-03-17 2021-03-17 0000791908 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2022-01-18 2022-01-18 0000791908 dei:AdrMember us-gaap:SubsequentEventMember 2022-01-18 2022-01-18 0000791908 us-gaap:SeriesAPreferredStockMember 2021-10-15 2021-10-15 0000791908 dei:AdrMember 2021-10-15 2021-10-15 0000791908 us-gaap:SeriesAPreferredStockMember 2021-07-15 2021-07-15 0000791908 dei:AdrMember 2021-07-15 2021-07-15 0000791908 us-gaap:SeriesAPreferredStockMember 2021-04-15 2021-04-15 0000791908 us-gaap:SeriesBPreferredStockMember 2021-04-09 2021-04-09 0000791908 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0000791908 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-12-31 0000791908 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-31 0000791908 dei:AdrMember 2021-04-09 2021-04-09 0000791908 us-gaap:SeriesAPreferredStockMember 2020-12-15 2020-12-15 0000791908 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000791908 us-gaap:DomesticCountryMember 2021-12-31 0000791908 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000791908 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000791908 xoma:XomaCorporationMember us-gaap:CommonStockMember xoma:BiotechnologyValueFundLPMember 2021-12-31 0000791908 xoma:SiliconValleyBankMember 2021-12-31 0000791908 xoma:NovartisNoteMember 2021-12-31 0000791908 xoma:SiliconValleyBankMember 2020-12-31 0000791908 xoma:NovartisNoteMember 2020-12-31 0000791908 xoma:NovartisNoteMember 2005-03-31 0000791908 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000791908 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000791908 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000791908 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000791908 xoma:NovartisNoteMember 2021-01-01 2021-12-31 0000791908 xoma:OtherFinancingsMember 2020-01-01 2020-12-31 0000791908 xoma:NovartisNoteMember 2020-01-01 2020-12-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:RoyaltyInterestAcquisitionAgreementsMember 2016-12-21 2016-12-21 0000791908 xoma:RezoluteIncMember 2021-01-01 2021-12-31 0000791908 xoma:RezoluteIncMember 2020-01-01 2020-12-31 0000791908 xoma:RezoluteIncMember 2021-12-31 0000791908 xoma:RezoluteIncMember 2020-12-31 0000791908 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0000791908 xoma:EquitySecuritiesTrancheTwoMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0000791908 xoma:EquitySecuritiesTrancheTwoMember us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember 2020-12-31 0000791908 xoma:EquitySecuritiesTrancheOneMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0000791908 xoma:EquitySecuritiesTrancheOneMember us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember 2020-12-31 0000791908 us-gaap:MeasurementInputSharePriceMember 2020-12-31 0000791908 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000791908 2017-01-01 2017-12-31 0000791908 xoma:EmployeeUnderAgeFiftyMember 2021-01-01 2021-12-31 0000791908 xoma:EmployeeAgeFiftyOrOverMember 2021-01-01 2021-12-31 0000791908 xoma:EmployeeUnderAgeFiftyMember 2020-01-01 2020-12-31 0000791908 xoma:EmployeeAgeFiftyOrOverMember 2020-01-01 2020-12-31 0000791908 srt:MaximumMember 2021-01-01 2021-12-31 0000791908 srt:MaximumMember 2020-01-01 2020-12-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:RoyaltyInterestAcquisitionAgreementsMember 2021-12-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:RoyaltyInterestAcquisitionAgreementsMember 2020-12-31 0000791908 xoma:SiliconValleyBankMember 2018-03-07 0000791908 xoma:SecondTermLoanMember 2019-12-31 0000791908 xoma:FirstTermLoanMember 2018-09-30 0000791908 srt:MinimumMember xoma:SiliconValleyBankMember 2018-03-07 0000791908 xoma:NovartisNoteMember 2020-10-21 2020-10-21 0000791908 xoma:SiliconValleyBankMember us-gaap:PrimeRateMember 2018-03-07 2018-03-07 0000791908 xoma:NovartisNoteMember us-gaap:LondonInterbankOfferedRateLIBORMember 2005-03-01 2005-03-31 0000791908 xoma:SeriesXAndSeriesYConvertiblePreferredStockMember 2018-12-31 0000791908 xoma:SeriesXAndSeriesYConvertiblePreferredStockMember 2017-12-31 0000791908 2021-12-15 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member 2021-12-31 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member 2020-12-31 0000791908 xoma:Partner1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000791908 xoma:Partner1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000791908 xoma:Partner1Member us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-12-31 0000791908 xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember 2015-05-31 0000791908 xoma:FiveYearWarrantsIssuedSecondRangeMember 2021-12-31 0000791908 xoma:TenYearWarrantsIssuedThirdRangeMember 2021-12-31 0000791908 xoma:CommonStockWarrantExercisePrice14.71Member 2021-12-31 0000791908 xoma:TenYearWarrantsIssuedThirdRangeMember 2020-12-31 0000791908 xoma:FiveYearWarrantsIssuedSecondRangeMember 2020-12-31 0000791908 xoma:CommonStockWarrantExercisePrice14.71Member 2020-12-31 0000791908 xoma:CommonStockWarrantExercisePrice14.71Member xoma:SiliconValleyBankMember 2019-03-31 0000791908 xoma:TenYearWarrantsIssuedThirdRangeMember xoma:SiliconValleyBankMember 2018-05-31 0000791908 xoma:CommonStockWarrantExercisePrice23.69PerShareIssuedMay2018Member xoma:SiliconValleyBankMember 2018-03-07 0000791908 xoma:ThirdPartyConsultantMember xoma:FiveYearWarrantsIssuedSecondRangeMember 2016-02-29 0000791908 us-gaap:AccountingStandardsUpdate202006Member 2021-01-01 0000791908 us-gaap:AccountingStandardsUpdate202004Member 2021-01-01 0000791908 us-gaap:AccountingStandardsUpdate201912Member 2021-01-01 0000791908 2019-12-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:CollaborationAgreementMember 2021-12-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember 2021-12-31 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2021-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2021-12-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2021-12-31 0000791908 xoma:AffimedMember xoma:LicenseAgreementMember 2021-12-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:CollaborationAgreementMember 2020-12-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember 2020-12-31 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2020-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2020-12-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2020-12-31 0000791908 us-gaap:StockCompensationPlanMember 2021-01-01 2021-12-31 0000791908 us-gaap:WarrantMember 2020-01-01 2020-12-31 0000791908 us-gaap:StockCompensationPlanMember 2020-01-01 2020-12-31 0000791908 xoma:SiliconValleyBankMember 2021-01-01 2021-12-31 0000791908 xoma:SiliconValleyBankMember 2020-01-01 2020-12-31 0000791908 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0000791908 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000791908 2020-01-01 2020-12-31 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member 2014-12-31 0000791908 2021-12-31 0000791908 2020-12-31 0000791908 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0000791908 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000791908 dei:AdrMember 2021-01-01 2021-12-31 0000791908 2021-06-30 0000791908 2022-03-03 0000791908 2021-01-01 2021-12-31 xoma:period xoma:agreement xoma:customer xoma:facility xoma:D xoma:M shares iso4217:USD iso4217:USD shares pure xoma:Y xoma:segment xoma:item xoma:product iso4217:EUR 0000791908 2021 FY false 0 0 0 0 984000 984000 0 0 0 0 0 0 5003 5003 No No Yes Yes 984000 984000 984000 1600 0 5003 5003 5003 11228792 11315263 15798000 13298000 0.02 37000000 0 0 0 0 0 0 0 P3M 0.71875 0.53906 0.55833 0.53906 0.52344 0.53906 0.52344 10-K true 2021-12-31 --12-31 false 001-39801 XOMA CORPORATION DE 52-2154066 2200 Powell Street Suite 310 Emeryville CA 94608 510 204-7200 Common Stock, $0.0075 par value XOMA NASDAQ 8.625% Series A Cumulative, Perpetual Preferred Stock, par value $0.05 XOMAP NASDAQ Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05) XOMAO NASDAQ Non-accelerated Filer true false false false 240018070 11319124 34 DELOITTE & TOUCHE LLP San Francisco, California 93328000 84222000 2049000 1611000 774000 209000 263000 1526000 613000 443000 96973000 88065000 531000 13000 21000 200000 359000 69075000 34575000 1693000 301000 41000 166562000 125285000 1072000 456000 525000 642000 91000 8075000 75000 195000 179000 1641000 1452000 1410000 8088000 1368000 12967000 12302000 11685000 13516000 12764000 34000 229000 50000 24686000 38861000 0.05 0.05 1000000 1000000 0.08625 0.08625 984000 49000 49000 0.08375 0.08375 1600 0 5003 0.0075 0.0075 277333332 277333332 11315263 11228792 85000 84000 1307030000 1267377000 -1165288000 -1181086000 141876000 86424000 166562000 125285000 36518000 27941000 1642000 1444000 38160000 29385000 171000 170000 20460000 16799000 20631000 16969000 17529000 12416000 461000 1844000 -300000 -879000 1225000 15889000 11797000 91000 -1501000 15798000 13298000 7787000 8793000 7968000 9010000 0.69 0.82 0.65 0.78 11288000 10674000 12192000 11503000 984000 49000 5000 11229000 84000 1267377000 -1181086000 86424000 2000 37140000 37140000 4867000 4867000 6195000 6195000 77000 1000 1052000 1053000 5000 4000 133000 133000 15798000 15798000 984000 49000 2000 5000 11315000 85000 1307030000 -1165288000 141876000 6000 9759000 73000 1238299000 -1194384000 43988000 984000 49000 22572000 22621000 1000 -1253000 10000 -10000 3961000 3961000 211000 1000 2406000 2407000 6000 136000 136000 13000 13000 13298000 13298000 984000 49000 5000 11229000 84000 1267377000 -1181086000 86424000 15798000 13298000 6195000 3961000 90000 88000 7000 22000 200000 698000 7300000 105000 -160000 -150000 -300000 -919000 1012000 -54000 -2670000 -1526000 1526000 169000 -83000 765000 -542000 91000 -179000 -163000 -1642000 -1444000 -1305000 612000 -27000 497000 22678000 10092000 26500000 1200000 1000000 9000 -26500000 -209000 40000000 24600000 3385000 1945000 1584000 4850000 4250000 5313000 17103000 3499000 488000 2395000 -24000 -4000 12835000 19793000 9013000 29676000 86364000 56688000 95377000 86364000 311000 692000 8000000 1368000 490000 264000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">XOMA (referred to as “XOMA” or the “Company”), a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. The Company’s portfolio was built through licensing its proprietary products and platforms from its legacy discovery and development business, combined with the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December 31, 2021, the Company had unrestricted and restricted cash of $93.3 million and $2.0 million, respectively. The restricted cash balance may only be used to pay dividends on the outstanding Series A Preferred Stock and the outstanding Series B Preferred Stock (Note 12).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2021, the Company repaid its outstanding debt obligations to SVB and Novartis, for a total of $17.1 million (Note 8). Based on the Company’s current cash balance and its ability to control discretionary spending, such as royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these consolidated financial statements are issued.</p> 93300000 2000000.0 17100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation and Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts and amortization of the payments received from HCRP. Under the Company’s contracts with the NIAID, a part of the NIH, the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. As of December 31, 2020, the audit procedures were completed, and the Company adjusted its estimated liability owed to NIH to $1.4 million. In December 2021, the NIH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and the Company adjusted its liability owed to NIH to $1.3 million. In December 2021, the Company paid the final approved refund liability of $1.3 million. As such, no contingent liability remained on the Company’s consolidated balance sheets as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Cash and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2021 and 2020, the Company did not have any cash equivalent balances, defined as highly liquid financial instruments purchased with original maturities of three months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of bank deposits held to pay dividends on the Company’s Series A Preferred Stock and Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;">The Company maintains cash and restricted cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash and restricted cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,222</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,142</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86,364</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive income in the period of sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, Rezolute completed a <span style="-sec-ix-hidden:Hidden_RffCcxHKX0CVQUTUA0NDpw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1:50</span></span> reverse stock split of its common shares (the “Rezolute Reverse Stock Split”) and started trading on the Nasdaq Stock Market. As a result, the Company’s number of shares of Rezolute common stock was reduced from 8,093,010 shares (pre reverse-split shares) to 161,861 shares (post reverse-split shares). All subsequent disclosures of Rezolute share numbers will be presented post reverse-split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2021 and December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters office space in Emeryville, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Prior Period Reclassifications</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Within the consolidated statement of cash flows, the Company presented principal payments on its finance lease and proceeds from disgorgement of stockholder's short-swing profits together in order for the prior period to conform with current period presentation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Net Income per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted income per share attributable to common stockholders using the two-class method. The Company’s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period and any deemed dividends related to beneficial conversion features on convertible preferred stock, if applicable, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income per share attributable to common stockholders is then calculated by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock. The calculation of diluted net income per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options or warrants, the presumed exercise of such securities are dilutive to net income per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and therefore, are not included in the diluted shares until the contingency is resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Comprehensive Income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income is comprised of two components: net income and other comprehensive income. Other comprehensive income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net income. The Company did not record any transactions within other comprehensive income in the periods presented and, therefore, the net income and comprehensive income were the same for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. </i>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company on January 1, 2021. The Company adopted ASU 2019-12<span style="color:#212529;">, on January 1, 2021. </span>The adoption of ASU 2019-12 did not have a material impact on the Company’s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): <i style="font-style:italic;">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>. These amendments provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The ASU provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. It is intended to help stakeholders during the global market-wide reference rate transition period. The guidance is effective for all entities as of March 12, 2020 through December 31, 2022 and can be adopted as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company adopted ASU 2020-04 as of January 1, 2021. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2020, the FASB issued ASU 2020-06, <i style="font-style:italic;">Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity</i> (Subtopic 815-40). This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusion. In addition, this ASU improves and amends the related EPS guidance. These amendments are effective for the Company for fiscal years beginning after December 15, 2023, including interim period within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The Company adopted ASU 2020-06 on January 1, 2021. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for all entities except public companies that are not smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted. The Company plans to adopt ASU 2016-13 and related updates as of January 1, 2023. The Company is currently evaluating the impact <span style="color:#212529;">of adopting this new accounting guidance </span>on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, <i style="font-style:italic;">Business Combinations – Accounting for Contract Assets and Contact Liabilities from Contracts with Customers</i>. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. Early adoption is permitted. The Company is currently evaluating the impacts of the provisions of ASU 2021-08 and the Company does not expect this ASU to have a material impact on its consolidated financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts and amortization of the payments received from HCRP. Under the Company’s contracts with the NIAID, a part of the NIH, the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. As of December 31, 2020, the audit procedures were completed, and the Company adjusted its estimated liability owed to NIH to $1.4 million. In December 2021, the NIH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and the Company adjusted its liability owed to NIH to $1.3 million. In December 2021, the Company paid the final approved refund liability of $1.3 million. As such, no contingent liability remained on the Company’s consolidated balance sheets as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</p> 1400000 1300000 -1300000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Cash and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2021 and 2020, the Company did not have any cash equivalent balances, defined as highly liquid financial instruments purchased with original maturities of three months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of bank deposits held to pay dividends on the Company’s Series A Preferred Stock and Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;">The Company maintains cash and restricted cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash and restricted cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,222</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,142</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86,364</p></td></tr></table> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,222</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,142</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86,364</p></td></tr></table> 93328000 84222000 2049000 2142000 95377000 86364000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive income in the period of sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, Rezolute completed a <span style="-sec-ix-hidden:Hidden_RffCcxHKX0CVQUTUA0NDpw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1:50</span></span> reverse stock split of its common shares (the “Rezolute Reverse Stock Split”) and started trading on the Nasdaq Stock Market. As a result, the Company’s number of shares of Rezolute common stock was reduced from 8,093,010 shares (pre reverse-split shares) to 161,861 shares (post reverse-split shares). All subsequent disclosures of Rezolute share numbers will be presented post reverse-split.</p> 8093010 161861 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2021 and December 31, 2020.</p> 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters office space in Emeryville, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p> 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Prior Period Reclassifications</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Within the consolidated statement of cash flows, the Company presented principal payments on its finance lease and proceeds from disgorgement of stockholder's short-swing profits together in order for the prior period to conform with current period presentation. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Net Income per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted income per share attributable to common stockholders using the two-class method. The Company’s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period and any deemed dividends related to beneficial conversion features on convertible preferred stock, if applicable, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net income per share attributable to common stockholders is then calculated by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock. The calculation of diluted net income per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options or warrants, the presumed exercise of such securities are dilutive to net income per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and therefore, are not included in the diluted shares until the contingency is resolved.</p> 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Comprehensive Income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income is comprised of two components: net income and other comprehensive income. Other comprehensive income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net income. The Company did not record any transactions within other comprehensive income in the periods presented and, therefore, the net income and comprehensive income were the same for all periods presented.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. </i>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company on January 1, 2021. The Company adopted ASU 2019-12<span style="color:#212529;">, on January 1, 2021. </span>The adoption of ASU 2019-12 did not have a material impact on the Company’s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): <i style="font-style:italic;">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>. These amendments provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The ASU provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. It is intended to help stakeholders during the global market-wide reference rate transition period. The guidance is effective for all entities as of March 12, 2020 through December 31, 2022 and can be adopted as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company adopted ASU 2020-04 as of January 1, 2021. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2020, the FASB issued ASU 2020-06, <i style="font-style:italic;">Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity</i> (Subtopic 815-40). This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusion. In addition, this ASU improves and amends the related EPS guidance. These amendments are effective for the Company for fiscal years beginning after December 15, 2023, including interim period within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The Company adopted ASU 2020-06 on January 1, 2021. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for all entities except public companies that are not smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted. The Company plans to adopt ASU 2016-13 and related updates as of January 1, 2023. The Company is currently evaluating the impact <span style="color:#212529;">of adopting this new accounting guidance </span>on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, <i style="font-style:italic;">Business Combinations – Accounting for Contract Assets and Contact Liabilities from Contracts with Customers</i>. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. Early adoption is permitted. The Company is currently evaluating the impacts of the provisions of ASU 2021-08 and the Company does not expect this ASU to have a material impact on its consolidated financial statements.</p> true true true <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Consolidated Financial Statement Detail</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and December 31, 2020, equity securities consisted of an investment in Rezolute’s common stock of $0.8 million and $1.7 million, respectively (Note 4). For the years ended December 31, 2021 and December 31, 2020, the Company recognized a loss of $0.9 million and a gain of $1.0 million, respectively, due to the change in fair value of its investment in Rezolute’s common stock in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accrued and Other Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Accrued payroll and benefits </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 136</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 642</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 800000 1700000 -900000 1000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Accrued payroll and benefits </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 136</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 642</p></td></tr></table> 295000 351000 135000 136000 55000 71000 40000 84000 525000 642000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Licensing and Other Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis – Anti-TGFβ Antibody (NIS793)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 30, 2015, the Company and Novartis entered into the Anti-TGFβ Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company’s anti-transforming growth factor beta (“TGFβ”) antibody program (now “NIS793”). Under the terms of the Anti-TGFβ Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGFβ Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’s royalty obligations end. The Anti-TGFβ Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGFβ Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days’ notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that there were multiple promised goods and services under the Anti-TGFβ Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of <span style="-sec-ix-hidden:Hidden_OiG0jO37t0mvc9zkhvSa9w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December 31, 2015</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGFβ Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGFβ Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment which was recognized as license fees in the consolidated statement of operations and comprehensive income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid single-digit percentage rate to up to a low double-digit percentage rate. Novartis’s obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 21, 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis’ first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGFβ Antibody License Agreement, the Company received $17.7 million in cash and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 20, 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis’ first NIS793 Phase 3 clinical trial. The Company is eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGFβ Antibody License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company recognized $35.0 million and $25.0 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the years ended December 31, 2021 and 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis – Anti-IL-1β Antibody (VPM087) and IL-1 Beta</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">On August 24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (“VPM087”), a novel anti-Interleukin-1 (“IL-1”) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 24, 2017, pursuant to a separate agreement (the “IL-1 Target License Agreement”), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the “Exclusivity Option”) to such intellectual property for the treatment and prevention of cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company’s outstanding debt with Les Laboratories Servier (“Servier”) (the “Servier Loan”). In addition, Novartis extended the maturity date on the Company’s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company’s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August 24, 2017, resulting in a $0.2 million premium paid to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">covered by the Company’s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid single-digits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months’ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the year ended December 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Takeda</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and TAK-169, and low single-digit royalties on future sales of all products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 13.5 years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and December 31, 2020, there are no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. During the years ended December 31, 2021 and 2020, the Company recognized annual license fee revenue of $0.1 million from Takeda. On November 16, 2020, the first patient was dosed in Takeda’s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda. The Company is eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement. During the years ended December 31, 2021 and 2020, the Company recognized $0.1 million and $2.1 million, respectively, as revenue from contracts with customers in the consolidated statement of operations and comprehensive income.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Rezolute</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now “RZ358”) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute’s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute’s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute’s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical testing. Rezolute’s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee’s obligation to make payments to Rezolute based on sales of such product in such country</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days’ notice at any time. To the extent </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute’s financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute’s achievement of financing activities and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute’s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and December 31, 2020, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reassessed the development and regulatory milestones and concluded that such variable consideration is fully constrained and excluded from the transaction price as of December 31, 2021 and 2020.   </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Janssen Biotech</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company and Janssen were parties to a license agreement which was terminated in 2017.</span> In August 2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen’s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen’s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019 as it had completed its performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen’s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2021, the Company earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets. In December 2021, the Company earned a $0.2 million milestone pursuant to its agreement with Janssen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and December 31, 2020, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. Milestone revenue of $0.7 million and $0.4 million was recognized for the years ended December 31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Affimed</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE<span style="font-size:12pt;"> </span>molecules and preloaded natural killer cells containing the ICE molecules. Additionally, the Company is eligible to receive a milestone upon the first product candidate in each program achieving marketing approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the commercial milestone payments are solely dependent on Affimed’s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, there were no contract assets or <span style="-sec-ix-hidden:Hidden_spMnRxU-EUK3IKdtTTmaWg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contract liabilities</span></span> related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">NIAID</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the sale of the Company’s biodefense business in 2016, the Company performed services under contracts funded with federal funds from NIAID including under a $64.8 million multiple-year contract (Contract No. HHSN272200800028C), for development of anti-botulinum antibody product candidates and a $28.0 million multiple-year contract (Contract No. HHSN272201100031C) for development of broad-spectrum antitoxins for the treatment of human botulism poisoning. The contract work was being performed on a cost plus fixed fee basis over a three-year period. The Company recognized revenue under the arrangement as the services were performed on a proportional performance basis. Consistent with the Company’s other contracts with the U.S. government, invoices were provisional until finalized. The Company operated under provisional rates from 2010 through 2015, subject to adjustment based on actual rates upon agreement with the government. In 2014, upon completion of NIAID’s review of hours and external expenses, XOMA agreed to exclude certain hours and external expenses resulting in a $0.4 million receivable and $0.8 million deferred revenue balances. As of December 31, 2017, the Company wrote off the $0.4 million receivable from NIAID as the likelihood of collection was remote. In October of 2019, NIH, which includes NIAID, notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. The KPMG testing procedures were completed in December 2020. As a result, the Company recognized $1.4 million as estimated refund liabilities owed to NIH on the consolidated balance sheet as of December 31, 2020. The additional $0.6 million liability was recognized as a reduction of revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the year ended December 31, 2020. In December 2021, NIH completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and approved a finalized refund liability of $1.3 million. The $0.1 million reduction in the liability, from its previously recorded $1.4 million estimate, was recognized as revenue from contracts with customers in the consolidated statement of operations and comprehensive income for the year ended December 31, 2021. In December 2021, the Company paid the finalized refund liability owed to NIH of $1.3 million and no balance of the contingent liability remained on the consolidated balance sheets as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December 21, 2016, the Company entered into two royalty interest sale agreements (together, the “Royalty Sale Agreements”) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agreement entered into in December 2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under units-of-revenue method over the life of the license agreements because of the Company’s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company’s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period’s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $1.6 million and $1.4 million as revenue under units-of-revenue method under these arrangements during the years ended December 31, 2021 and December 31, 2020, respectively. As of December 31, 2020, the current and non-current portion of the remaining unearned revenue recognized under units-of-revenue method was $1.5 million and $13.5 million, respectively. As of December 31, 2021, the Company classified $1.6 million and $11.7 million as current and non-current unearned revenue recognized under units-of-revenue method, respectively.</p> P180D 1 37000000.0 480000000.0 10000000.0 P10Y 25000000.0 17700000 -7300000 35000000.0 410000000.0 0 0 0 0 35000000.0 25000000.0 30000000.0 15700000 14300000 12000000.0 5000000.0 539131 9.2742 4800000 8.93 200000 438000000.0 10000000.0 2 P6M 1 0 40200000 25700000 14300000 200000 2 2 40200000 0 0 0 0 0 0 19000000.0 P13Y6M 3300000 P10Y 0 0 0 0 100000 100000 2000000.0 16000000.0 100000 2100000 232000000.0 P12Y 0.20 P12Y P90D 6000000.0 8500000 161861 0 0 0 0 0 0 2500000 3000000.0 0.0075 2500000 500000 200000 0 0 0 0 700000 400000 0 0 0 64800000 28000000.0 P3Y 400000 800000 400000 1400000 -600000 1300000 100000 1400000 -1300000 0 2 6500000 4000000.0 3 11500000 18000000.0 2 1600000 1400000 1500000 13500000 1600000 11700000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Royalty and Commercial Payment Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalty Purchase Agreement with Agenus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (“Incyte”) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentage of applicable net sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company’s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Agenus RPA, the Company paid Agenus $15.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, MK-4830 advanced into Phase 2 development and Agenus earned a $10.0 million clinical development milestone under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalty Purchase Agreement with Bioasis </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Bioasis RPA, the Company paid $0.3 million and will make contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the “Bioasis Contingent Consideration”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $0.1 million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other (expense) income, net line item of the consolidated statement of operations and comprehensive income. As of December 31, 2021, there was no change in the fair value of the contingent consideration from its initial value and no amounts were paid during the year ended December 31, 2021. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under the Second Bioasis RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalty Purchase Agreement with Aronora</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the “Non-Royalties”) related to five anti-thrombotic hematology drug candidates. Three candidates were subject to Aronora’s collaboration with Bayer (the “Bayer Products”), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the “non-Bayer Products”) for which the Company will receive low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">be reduced from 10% to 5% upon the Company’s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB (Note 8). The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the “Aronora Contingent Consideration”). Pursuant to the Aronora RPA, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the “Royalty Milestones”). The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product. Royalties per product in excess of $250.0 million are retained by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalty Purchase Agreement with Palobiofarma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin’s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the “Palo Licensed Products”) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Palo RPA, the Company paid Palo a $10.0 million payment at the close of the transaction which occurred simultaneously upon parties’ entry into the Palo RPA on September 26, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalty Purchase Agreement with Viracta </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalty Purchase Agreement with Kuros </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals’ vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Commercial Payment Purchase Agreement with Affitech </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche’s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones (Note 15). At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which includes the $6.0 million upfront payment and $8.0 million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million meet the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the investment has been fully collected.  The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the long-term royalty receivable activities including acquisitions of royalty rights, commercial payment rights and cash receipts for achievement of contractual milestones during the years ended December 31, 2021 and 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,375</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty rights:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bioasis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash receipts for achievement of contractual milestones:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Agenus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,000)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,575</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment rights:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Viracta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,500</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,000</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,000</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,075</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 0.33 6 0.10 0.33 0.10 59500000 15000000.0 15000000.0 10000000.0 1000000.0 1000000.0 0 0.01 2 300000 400000 300000 200000 400000 100000 0 0 0 1200000 1200000 0 5 3 1 1 0.10 2 0.10 0.10 0.05 2 6000000.0 3000000.0 1000000.0 3 3000000.0 250000000.0 85000000.0 250000000.0 250000000.0 9000000.0 3000000.0 3000000.0 0 6 10000000.0 10000000.0 0 2 13500000 54000000.0 20000000.0 57000000.0 13500000 0 1 25500000 7000000.0 142500000 7000000.0 0 6000000.0 0.0050 P10Y 20000000.0 14000000.0 6000000.0 8000000.0 8000000.0 12000000.0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the long-term royalty receivable activities including acquisitions of royalty rights, commercial payment rights and cash receipts for achievement of contractual milestones during the years ended December 31, 2021 and 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,375</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty rights:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bioasis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash receipts for achievement of contractual milestones:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Agenus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,000)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,575</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment rights:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Viracta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,500</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,000</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,000</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,075</p></td></tr></table> 34375000 1200000 1000000 34575000 13500000 7000000 14000000 69075000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company’s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2 – Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements at December 31, 2021 Using </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 774</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration under RPAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,075</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurements at December 31, 2020 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active Markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,693</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transfers to and from Levels 1, 2, and 3 are recognized at the end of the reporting period. On June 30, 2021, the Company’s equity investment in Rezolute’s common stock transferred from Level 3 to Level 1. In reporting periods prior to June 30, 2021, the Company applied an illiquidity discount to the fair value of Rezolute’s common stock due to the lack of trading volume, resulting in classification as <span style="-sec-ix-hidden:Hidden_UPPJdDLmwkabPPYadYc3TQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level</span></span> <span style="-sec-ix-hidden:Hidden_hrsurQ3D10m3-z2DkFqdQw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span>. Since <span style="-sec-ix-hidden:Hidden_4DYBNy0gHUGbI7KOiVTUmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">June 30, 2021</span></span>, there has been sufficient and consistent trading volume on the Nasdaq Stock Market to provide an estimate of fair value utilizing quoted prices in an active market for the identical securities as of the reporting date, resulting in classification as Level <span style="-sec-ix-hidden:Hidden_ZVZxXMPsDEKlvC14J-A4Gg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>. There were no transfers between levels during <span style="-sec-ix-hidden:Hidden_c6I2_eJOJkWIrq2F96kkMg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2020</span></span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table reconciles the beginning and ending balance for the Level 3 financial assets recurring fair value measurement for the year ended December 31, 2021 (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 681</p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,012</p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,693</p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 617</p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transfer out of Level 3 as of June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,310)</p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The equity securities consisted of an investment in Rezolute’s common stock and are classified on the consolidated balance sheets as current assets as of December 31, 2021, and long-term assets as of December 31, 2020. The reclassification from noncurrent to current assets was due to the equity securities achieving sufficient and consistent trading volume on the Nasdaq Stock Market during the second quarter of 2021. The equity securities are revalued each reporting period with changes in fair value recorded in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, the Company and its valuation specialist, valued the equity securities using the closing price for Rezolute’s common stock traded on the Nasdaq Stock Market and adjusted for an illiquidity discount. The inputs that were used to calculate the illiquidity discount were based on observable and unobservable estimates and judgments and therefore were classified as a Level 3 fair value measurement. As the Company has the right and option to sell up to 100,000 shares of Rezolute’s common stock back to Rezolute after December 31, 2019 (Note 4), the fair value of the equity securities was determined by dividing the total shares of Rezolute’s common stock held by the Company into two tranches based on the estimated time to a potential liquidity event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company valued the equity securities using the closing price for Rezolute’s common stock traded on the Nasdaq Stock Market. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The closing price of Rezolute’s common stock as per the Nasdaq Stock Market was $4.78 and $11.99 as of December 31, 2021 and December 31, 2020, respectively. The estimated fair value of the equity securities as of December 31, 2020 was calculated based on the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing common stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Tranche 1:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount for lack of marketability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">N/A<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Estimated time to liquidity of shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.25 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Tranche 2:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount for lack of marketability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">N/A<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Estimated time to liquidity of shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.67 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Due to sufficient and consistent trading volume, the equity investment will be measured at the closing price per the Nasdaq Stock Market. The assumptions related to the unobservable inputs identified above, and any changes in those assumptions thereto, will no longer be considered in determining the fair value of the equity securities. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Consideration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the contingent consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the contingent consideration liability at the inception of the Affitech CPPA represents the future consideration that is contingent upon the achievement of specified regulatory milestones. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving regulatory milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the fair value of the liability for contingent consideration will be recorded in the other (expense) income, net line item of the consolidated statements of operations and comprehensive income until settlement. As of <span style="-sec-ix-hidden:Hidden_eb3ePzEfWkC3q5ZsRAMURw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December 31, 2021</span></span>, there were no changes in the estimated fair value of the contingent consideration recorded pursuant to the Bioasis RPA and Affitech CPPA from the initial values of $0.1 million and $8.0 million, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements at December 31, 2021 Using </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 774</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration under RPAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,075</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurements at December 31, 2020 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted Prices in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active Markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,693</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td></tr></table> 774000 774000 8075000 8075000 1693000 1693000 75000 75000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table reconciles the beginning and ending balance for the Level 3 financial assets recurring fair value measurement for the year ended December 31, 2021 (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 681</p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,012</p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,693</p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 617</p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transfer out of Level 3 as of June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,310)</p></td></tr><tr><td style="vertical-align:bottom;width:81.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table> 681000 1012000 1693000 617000 2310000 100000 2 4.78 11.99 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing common stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Tranche 1:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount for lack of marketability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">N/A<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Estimated time to liquidity of shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.25 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Tranche 2:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount for lack of marketability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">N/A<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Estimated time to liquidity of shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.67 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Due to sufficient and consistent trading volume, the equity investment will be measured at the closing price per the Nasdaq Stock Market. The assumptions related to the unobservable inputs identified above, and any changes in those assumptions thereto, will no longer be considered in determining the fair value of the equity securities. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p> 4.78 11.99 0.12 0.25 0.14 0.67 0 100000 8000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Lease Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases one facility in Emeryville, California under an operating lease that expires in February 2023. The Emeryville lease contains an option to extend the lease for an additional term, however, the Company is not reasonably certain to exercise this option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes maturity of the Company’s operating lease liabilities as of December 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Undiscounted lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total net lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table summarizes the cost components of the Company’s operating lease for the years ended December 31, 2021 and 2020, respectively (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">     </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 189</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The present value assumptions used in calculating the present value of the lease payments for the Company’s operating lease as of December 31, 2021 and December 31, 2020 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">     </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes maturity of the Company’s operating lease liabilities as of December 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Undiscounted lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total net lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229</p></td></tr></table> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Undiscounted lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total net lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229</p></td></tr></table> 202000 34000 236000 7000 229000 177000 177000 8000 7000 185000 184000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">     </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 189</p></td></tr></table> 196000 189000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">     </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> P1Y2M1D P2Y2M1D 0.0551 0.0551 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Long-Term Debt and Other Financings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">SVB Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 7, 2018 (the “Effective Date”), the Company executed the SVB Loan Agreement with SVB. Under the Loan Agreement, upon the Company’s request, SVB made advances (each, a “Term Loan Advance”) available to the Company up to $20.0 million (the “Term Loan”). The Company was allowed to borrow advances under the Term Loan from the Effective Date until the earlier of March 31, 2019 or an event of default (the “Draw Period”). The interest rate was calculated at a rate equal to the greater of (i) 4.75%, or (ii) 0.25% plus the prime rate as reported from time to time in The Wall Street Journal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments under the Loan Agreement were interest only until the first anniversary of the funding date of each Term Loan Advance. The interest-only period was followed by equal monthly payments of principal and interest over 24 months. Each Term Loan Advance was scheduled to mature at the earlier of (i) the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii) March 1, 2023, or (iii) 30 days prior to the earliest maturity of any portion of the Company’s loan with Novartis (the “Loan Maturity Date”). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed. The entire principal balance, including a final payment fee equal to 8.5% of the original principal, was due and payable on the Loan Maturity Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2021, the Company repaid its principal balance of $6.5 million and paid the 8.5% final payment fee of $1.4 million to SVB. The Company also paid SVB a prepayment fee of 1% of the outstanding principal balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Loan Agreement, the Company issued a warrant to SVB which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share (the “Warrant”). The Warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the Warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. In addition, the Company incurred debt issuance costs of $0.2 million in connection with the Loan Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 4, 2019, the Loan Agreement was amended to extend the Draw Period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Both warrants may be exercised on a cashless basis and are exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. As of December 31, 2021, both warrants are outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2018, the Company borrowed advances of $7.5 million under the Loan Agreement in connection with the Agenus RPA (Note 5). The Company recorded a discount of $0.3 million against the debt, which was being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company borrowed advances totaling $9.5 million under the Loan Agreement in connection with the Aronora RPA, Palo RPA and payment of the Aronora Contingent Consideration (Note 5). The Company recorded a discount of $45,000 against the debt, which was being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $0.2 million of non-cash interest expense resulting from the amortization of the discount and accretion of the final payment before the loan was extinguished in June 2021 and $0.6 million for the year ended December 31, 2020.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, the carrying value of the debt under the Loan Agreement was $11.8 million. Of this amount, $8.1 million was classified as current portion of long-term debt and $3.7 million was classified as long-term debt on the consolidated balance sheet. In June 2021, the Company paid off its entire outstanding principal balance to SVB. Upon repayment of the principal balance, the Company recognized a loss on extinguishment of $0.3 million in other (expense) income, net of the consolidated statement of operations for the year ended December 31, 2021. As of December 31, 2021, there was no carrying value of the debt under the Loan Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis Note</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May 2005, the Company executed the Novartis Note Agreement with Novartis, which was due and payable in full in June 2015. Under the Novartis Note Agreement, the Company borrowed semi-annually to fund up to 75% of the Company’s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50.0 million in aggregate principal amount. Interest on the principal amount of the loan accrued at six-month LIBOR plus 2% and the interest rate reset in June and December annually. Accrued interest was payable semi-annually in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">June and December of each year or, at the Company’s election, the semi-annual interest payments could be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount did not exceed $50.0 million. The Company made this election for all interest payments. Loans under the Novartis Note Agreement were secured by the Company’s interest in its collaboration with Novartis, including any payments owed to it thereunder. In June 2021, the Company repaid its outstanding principal balance to Novartis of $9.1 million and extinguished its debt obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 30, 2015, concurrent with the execution of a license agreement with Novartis as discussed in Note 4, XOMA and Novartis, who assumed the rights to the note from Novartis Vaccines Diagnostics, Inc. executed an amendment to the Novartis Note Agreement (the “Secured Novartis Note Amendment”) under which the parties extended the maturity date of the note from September 30, 2015 to September 30, 2020, and eliminated the mandatory prepayment previously required to be made with certain proceeds of pre-tax profits and royalties. In addition, upon achievement of a specified development and regulatory milestone, the then-outstanding principal amount of the note was to be reduced by $7.3 million rather than the Company receiving such amount as a cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 22, 2017, in connection with the Gevokizumab License Agreement with Novartis, the Company and Novartis executed an amendment to the Novartis Secured Note Amendment under which the parties further extended the maturity date of the Novartis Secured Note Amendment from September 30, 2020 to September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 21, 2020, the first patient was dosed in Novartis’s first NIS793 Phase 2 clinical trial and the Company earned a $25.0 million milestone pursuant to the Anti-TGFβ Antibody License Agreement, of which $17.7 million was received in cash and $7.3 million was recognized as a reduction to the debt obligation to Novartis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, the outstanding principal balance under the Novartis Secured Note Amendment was $9.1 million and was included in long-term debt in the accompanying consolidated balance sheet. In June 2021, the Company repaid its entire outstanding debt balance to Novartis. The repayment of principal did not result in any gain or loss on extinguishment. As of December 31, 2021, there was no carrying value of the debt under the Novartis Note Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive income for the years ended December 31, 2021 and 2020, relates to the following debt instruments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVB Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,365</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis Note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 477</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,844</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 20000.0 0.0475 0.0025 P24M P23M P30D 0.085 6500000 0.085 1400000 0.01 6332 23.69 P10Y 100000 200000 4845 14.71 100000 P10Y 7500000 300000 9500000 45000000 200000 600000 11800000 8100000 3700000 -300000 0 0.75 50000000.0 0.02 50000000.0 9100000 7300000 25000000.0 17700000 -7300000 9100000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive income for the years ended December 31, 2021 and 2020, relates to the following debt instruments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVB Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,365</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis Note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 477</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,844</p></td></tr></table> 373000 1365000 88000 477000 2000 461000 1844000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">9. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has pre-tax book income of $15.9 million and $11.8 million for the year ended December 31, 2021 and 2020, respectively.  The Company has $0.1 million income tax expense and $1.5 million income tax benefit for the years ended December 31, 2021 and 2020, respectively.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The provision (benefit) for income taxes, all classified as current, consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,501)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,501)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company’s actual effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock compensation and other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal orphan drug credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax benefit related to CARES Act </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax benefit related to net operating loss carryforward utilization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 27, 2020, the CARES Act was enacted, which includes a five-year NOL carryback provision which enabled the Company to benefit from certain losses at the former federal tax rate of 34%. In 2020, the Company recorded tax benefits of $1.5 million related to the NOL carryback provision. During the year ended December 31, 2021, the Company received $1.5 million in cash for its income tax receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The significant components of net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,500</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,638</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development and other tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,454</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,158</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,462</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 401</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,613</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47,006)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,613)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The net decrease in the valuation allowance was $4.6 million and $3.9 million, for the years ended December 31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company’s four sources of taxable income including historical operating performance and the repeal of NOL carryback, the Company has determined that total deferred tax assets should be fully offset by a valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Based on an analysis under Section 382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to annual limitations), the Company experienced an ownership change in February 2017 which substantially limits the future use of its pre-change NOLs and certain other pre-change tax attributes per year. The Company has excluded the related tax attributes that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2021 and December 31, 2020. To the extent that the Company </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">does not utilize its carryforwards within the applicable statutory carryforward periods, either because of Section 382 limitations or the lack of sufficient taxable income, the carryforwards will expire unused.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had federal NOL carry-forwards of approximately $78.8 million and state NOL carry-forwards of approximately $38.1 million to offset future taxable income. $13.6 million of federal NOL carryforwards will begin to expire in 2036 and the remainder may be carried forward indefinitely. The state NOL carryforwards will begin to expire in 2033. The Company had federal orphan credit of $2.0 million which if not utilized will expire in 2037. The Company also had $19.8 million of California research and development tax credits which have no expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the 2017 federal income tax law, as modified by the federal tax law changes enacted in March 2020, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but, for taxable years beginning after December 31, 2020, the deductibility of such federal NOLs may only be utilized to offset 80% of taxable income annually.   </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company’s federal income tax returns for tax years 2018 and beyond remain subject to examination by the Internal Revenue Service. The Company’s state income tax returns for tax years 2017 and beyond remain subject to examination by state tax authorities. In addition, all of the NOLs and research and development credit carryforwards that may be used in future years are still subject to adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company’s activity related to its unrecognized tax benefits (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,517</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to prior year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 421</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as the Company currently has a full valuation allowance against its deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through December 31, 2021, the Company has not accrued interest or penalties related to uncertain tax positions.</p> 15900000 11800000 100000 -1500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The provision (benefit) for income taxes, all classified as current, consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,501)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,501)</p></td></tr></table> 91000 -1501000 91000 -1501000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company’s actual effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock compensation and other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal orphan drug credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax benefit related to CARES Act </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax benefit related to net operating loss carryforward utilization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 0.21 0.21 0.09 -0.06 0.02 -0.13 -0.11 -0.16 -0.15 0.01 -0.13 0.34 1500000 1500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The significant components of net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,500</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,638</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development and other tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,454</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,158</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,462</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 401</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,613</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47,006)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,613)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table> 7822000 11500000 17657000 17638000 13125000 13454000 4778000 5158000 2817000 3462000 807000 401000 47006000 51613000 47006000 51613000 -4600000 -3900000 78800000 38100000 13600000 2036 2033 2000000.0 2037 19800000 0.80 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company’s activity related to its unrecognized tax benefits (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,517</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to prior year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 421</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td></tr></table> 5938000 5517000 0 0 421000 5938000 5938000 5900000 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Stock Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may grant qualified and non-qualified stock options, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company’s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May 2015, the Company’s stockholders approved the 2015 Employee Stock Purchase Plan (the “2015 ESPP”), which replaced the Company’s legacy 1998 ESPP. Under the 2015 ESPP, the Company reserved 15,000 shares of common stock for issuance as of its effective date of July 1, 2015, subject to adjustment in the event of a stock split, stock dividend, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">combination or reclassification or similar event. The 2015 ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2015 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2017, the Compensation Committee and the Board of Directors adopted, and in May 2017, the Company’s stockholders approved, an amendment to the Company’s 2015 ESPP. The amendment (a) increased by 250,000 the shares of common stock (from 15,000 shares to a total of 265,000 shares) available for issuance under the 2015 ESPP; and (b) increased the maximum number of shares of common stock an employee may purchase in any offering period to 2,500. As of December 31, 2021, the Company had 237,072 remaining authorized shares available for purchase under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2021 and 2020, employees purchased 2,225 and 2,746 shares of common stock, respectively, under the 2015 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Savings Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under section 401(k) of the Internal Revenue Code of 1986, the Board of Directors adopted, effective June 1, 1987, a tax-qualified deferred compensation plan for employees of the Company. Participants may make contributions which defer up to 50%of their eligible compensation per payroll period, up to a maximum for 2021 and 2020 of $19,500 (or $26,000 for employees over 50 years of age). The Company may, at its sole discretion, make contributions each plan year, in cash or in shares of the Company’s common stock, in amounts which match up to 50% of the salary deferred by the participants. The expense related to these contributions was $0.1 million for the years ended December 31, 2021 and December 31, 2020, and 100% was paid in common stock for each year. The Company applies shares from plan forfeitures of terminated employees toward the Company’s matching contribution.   </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2010, the Compensation Committee and Board of Directors adopted, and in July 2010 the Company’s stockholders approved the 2010 Plan. The 2010 Plan was amended in 2016, 2017 and 2019 to (a) increase the number of shares of common stock issuable under the 2010 Plan; (b) increase the number of shares of common stock issuable under the 2010 Plan as incentive stock options; and (c) extend the term of the 2010 Plan to April 1, 2029. As of December 31, 2021, the number of shares of common stock reserved for issuance under the 2010 Plan is 3,029,062 shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From the 2010 Plan, the Company grants stock options to eligible employees, consultants and directors. Stock-based awards granted under the 2010 Plan may be exercised when vested and generally expire ten years from the date of the grant or <span style="-sec-ix-hidden:Hidden_wfC0Cq-TbUWpgNQdlNyZtw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to six months from the date of termination of employment (longer in case of death or certain retirements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had 161,140 shares available for grant under the 2010 Plan. As of December 31, 2021, options to purchase 1,911,177 shares of common stock were outstanding under the 2010 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Plans Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company’s stock option activity for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:middle;white-space:nowrap;width:59.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,827,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,401</p></td></tr><tr><td style="vertical-align:middle;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 325,211</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32.02</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:middle;width:38.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77,305)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.61</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:middle;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (164,635)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46.59</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:middle;width:38.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,911,177</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.64</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.33</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,103</p></td></tr><tr><td style="vertical-align:middle;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December 31, 2021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,553,696</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.75</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.69</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,894</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options exercised in 2021 and 2020 was $1.6 million and $5.4 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of the options granted in 2021 and 2020 was $22.23 and $18.41, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, $4.1 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.21 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of stock options granted during the years ended December 31, 2021 and 2020, was estimated based on the following weighted average assumptions for:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.66 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.64 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive income (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,961</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,961</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 0.85 15000 0.10 P6M 0.85 250000 15000 265000 2500 237072 2225 2746 0.50 0.50 19500000 19500000 26000000 26000000 P50Y P50Y 0.50 0.50 100000 100000 1 1 3029062 P10Y P6M 161140 1911177 P3Y P1Y P55Y P70Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company’s stock option activity for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:middle;white-space:nowrap;width:59.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,827,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,401</p></td></tr><tr><td style="vertical-align:middle;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 325,211</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32.02</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:middle;width:38.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77,305)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.61</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:middle;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (164,635)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46.59</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:middle;width:38.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,911,177</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.64</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.33</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,103</p></td></tr><tr><td style="vertical-align:middle;width:38.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December 31, 2021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,553,696</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.75</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.69</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,894</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 1827906 20.66 P6Y3M21D 51401000 325211 32.02 77305 13.61 164635 46.59 1911177 20.64 P6Y3M29D 15103000 1553696 18.75 P5Y8M8D 14894000 1600000 5400000 22.23 18.41 4100000 P2Y2M15D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of stock options granted during the years ended December 31, 2021 and 2020, was estimated based on the following weighted average assumptions for:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.66 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.64 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 0 0 0.83 1 0.0095 0.0072 P5Y7M28D P5Y7M20D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive income (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,961</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,961</p></td></tr></table> 6195000 3961000 6195000 3961000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Net Income Per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potentially dilutive securities are excluded from the calculation of diluted net income per share attributable to common stockholders if their inclusion is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 616</p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 622</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net income) and denominator (number of shares) used in the calculation of basic and diluted net income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,298</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,438)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Allocation of undistributed earnings to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,451)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,417)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income available to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,793</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Add: Adjustments to undistributed earnings allocated to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income available to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,010</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic net income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,674</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 824</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing diluted net income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,503</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.82</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net income per share of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.78</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 616</p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 622</p></td></tr></table> 479000 616000 6000 479000 622000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net income) and denominator (number of shares) used in the calculation of basic and diluted net income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,298</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,438)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Allocation of undistributed earnings to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,451)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,417)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income available to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,793</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Add: Adjustments to undistributed earnings allocated to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income available to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,010</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic net income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,674</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 824</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing diluted net income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,503</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.82</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net income per share of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.78</p></td></tr></table> 15798000 13298000 2122000 88000 2438000 3451000 4417000 7787000 8793000 -181000 -217000 7968000 9010000 11288000 10674000 900000 824000 4000 5000 12192000 11503000 0.69 0.82 0.65 0.78 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Capital Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Series X and Series Y Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sold directly to BVF 5,003 shares of Series X convertible preferred stock in 2017 and 1,252.772 shares of Series Y convertible preferred stock in 2018. There were no shares of Series Y convertible preferred stock outstanding as of December 31, 2021, after BVF converted all Series Y preferred stock into common stock on April 15, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, there were 5,003 shares authorized and issued of Series X convertible preferred stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series X and Series Y convertible preferred stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends— </i>Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights— </i>In the event of the Company’s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion— </i>Each share of Series X and Series Y is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share and $13.00 per share of common stock respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights— </i>Convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification— </i>The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the convertible preferred stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Beneficial Conversion Feature— </i>The fair value of the common stock into which the Series X convertible preferred stock is convertible exceeded the allocated purchase price of the Series X convertible preferred stock by $5.6 million on the date of issuance, as such the Company recorded a deemed dividend. The Company recognized the resulting beneficial conversion feature as a deemed dividend equal to the number of shares of Series X convertible preferred stock sold on February 16, 2017 multiplied by the difference between the fair value of the common stock and the Series X convertible preferred stock effective conversion price per share on that date. The dividend was reflected as a one-time, non-cash, deemed dividend to the holders of Series X convertible preferred stock on the date of issuance, which is the date the stock first became convertible. There was no beneficial conversion feature associated with the issuance of Series Y convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Series A Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2020, the Company sold 984,000 shares of its 8.625% Series A cumulative, perpetual preferred stock at the price of $25.00 per share, through a public offering for aggregate gross proceeds of $24.6 million. Total offering costs of $2.0 million were offset against the proceeds from the sale of Series A Preferred Stock, for total net proceeds of $22.6 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mr. Matthew Perry, a member of the Company’s Board of Directors and President of BVF, purchased 200,000 shares of Series A Preferred Stock in the public offering at the public offering price of $25.00 per share for an aggregate amount of $5.0 million. <span style="background:#ffffff;">The spouse of James Neal, the Company’s Chief Executive Officer and </span>Chairman of the Board of Directors<span style="background:#ffffff;">, purchased </span><span style="background:#ffffff;">8,000</span><span style="background:#ffffff;"> shares of the Series A Preferred Stock in the public offering at the public offering price of </span><span style="background:#ffffff;">$25.00</span><span style="background:#ffffff;"> per share for an aggregate amount of </span><span style="background:#ffffff;">$0.2</span><span style="background:#ffffff;"> million. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, there were 984,000 shares authorized and issued of Series A Preferred Stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series A preferred stock have the following characteristics, which are set forth in the Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Dividends— </i>Holders of <span style="background:#ffffff;">the Series A Preferred Stock shall be entitled to receive, when, and if authorized by the Board of Directors and declared by the Corporation, cumulative cash dividends at the rate of </span><span style="background:#ffffff;">8.625%</span><span style="background:#ffffff;"> per annum of the </span><span style="background:#ffffff;">$25.00</span><span style="background:#ffffff;"> liquidation preference per share of the Series A Preferred Stock. Such dividends will accumulate and be cumulative from, and including, the date of original issue of the </span>Series<span style="background:#ffffff;"> A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October of each year beginning on or about April 15, 2021. The amount of </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">any dividend payable on the Series A Preferred Stock for any period greater or less than a full Dividend Period shall be prorated and computed on the basis of a </span><span style="background:#ffffff;">360</span><span style="background:#ffffff;">-day year consisting of </span><span style="background:#ffffff;">twelve</span><span style="background:#ffffff;"> </span><span style="background:#ffffff;">30</span><span style="background:#ffffff;">-day months.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights— </i>In the event of the Company’s liquidation, dissolution or winding up, holders of Series A Preferred Stock will <span style="background:#ffffff;">rank senior to all classes or series of common stock as to dividend rights and rights upon liquidation, dissolution or winding-up and on parity with respect to the </span>distribution<span style="background:#ffffff;"> of assets with the Company’s Series X Preferred Stock. </span>The Series A Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25.00 per share plus any accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Redemption and Special Optional Redemption— </i>The Company, at its option, may redeem the Series A Preferred Stock, in whole or in part, at any time for a cash redemption price, plus any accrued and unpaid dividends, as follows: (i) $26.00 per share between December 15, 2021 and December 15, 2022, (ii) $25.75 per share between December 15, 2022 and December 15, 2023, (iii) $25.50 per share between December 15, 2023 and December 15, 2024 (iv) $25.25 per share between December 15, 2024 and December 15, 2025 and $25.00 per share on or after December 15, 2025. The Company also has a special optional redemption option whereby, <span style="background:#ffffff;">upon the occurrence of a delisting event or change of control event, the Company may redeem outstanding Series A Preferred Stock at an amount of </span><span style="background:#ffffff;">$25.00</span><span style="background:#ffffff;"> per share. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion— </i>The shares of Series A Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company except upon the occurrence of a delisting event or change in control event and the Company has not, on or before the date of such an event, provided the required notice of its election to redeem the Series A Preferred Stock pursuant to its redemption right or special optional redemption right. In this case, the holder of shares of Series A Preferred Stock can convert some or all of their Series A Preferred Stock into a number of shares of common stock per share equal to the lesser of (A) (i) the sum of the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus (y) the amount of any accrued and unpaid dividends to, but not including, the event date, as applicable by (ii) the common stock price and (B) 1.46071 (the “Share Cap”). The common stock price to be used in the latter noted calculation for a delisting event will be the average of the closing price per share of the Company’s common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the delisting event. The common stock price used in the event of a change in control event will, alternatively, be based on market price according to the definition in the Certificate of Designation.<span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights— </i>Holders of the Series A Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification—</i>The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Depositary Shares Representing Interest in Series B Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 9, 2021, the Company sold 1,600,000 Series B Depositary Shares, at the price of $25.00 per Series B Depositary Share, through a public offering for aggregate gross proceeds of $40.0 million. Total offering costs of $2.9 million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $37.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The spouse of James Neal, the Chief Executive Officer and Chairman of the Board of Directors, purchased 8,000 shares of the Series B Depositary Shares in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, there were 3,600 shares authorized and 1,600 issued of Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series B Preferred Stock has the following characteristics, which are set forth in the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock, as corrected, filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Dividends</i>— Holders of Series B Preferred Stock shall be entitled to receive cash dividends, when and if declared by the Board of Directors at the rate of 8.375% per annum of the $25,000.00 liquidation preference per share, which equals </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$2,093.75 per share each year. Such dividends shall be payable quarterly in arrears on or about the 15th calendar day of each January, April, July and October commencing on or about July 15, 2021. The dividends will accumulate and be cumulative from, and including, the date of original issue of the Series B Preferred Stock, on the basis of a 360-day year consisting of twelve 30-day months. Dividends will be payable to holders of record as they appear in the stockholder records of the Company (or the depositary in the case of Series B Depositary Shares representing underlying Series B Preferred Stock) at the close of business on the applicable dividend record date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Preference</i> - Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Company ranking junior to the Series B Preferred Stock, the holders of shares of Series B Preferred Stock shall be paid out of the assets of the Company, after payment of or provision for the debts and other liabilities and any class or series of capital stock, as to rights upon any voluntary or involuntary liquidation, dissolution or winding up, senior to the Series B Preferred Stock. The Series B Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25,000.00 per share plus any accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Redemption and Special Redemption</i> - On and after April 15, 2022, the Company, at its option, may redeem the Series B Preferred Stock, for cash, in whole or in part, at any time or from time to time, as follows: (i) between April 15, 2022 to April 15, 2023, at a redemption price of $26,000.00 per share ($26.00 per depositary share), (ii) between April 15, 2023 to April 15, 2024, at a redemption price of $25,750.00 per share ($25.75 per depositary share), (iii) between April 15, 2024 to April 15, 2025, at a redemption price of $25,500.00 per share ($25.50 per depositary share), (iv) between April 15, 2025 to April 15, 2026, at a redemption price of $25,250.00 per share ($25.25 per depositary share), and (v) after April 15, 2026, at a redemption price of $25,000.00 per share ($25.00 per depositary share), and in each case, plus any accrued and unpaid dividends thereon up to but not including the date fixed for redemption, without interest. If fewer than all of the outstanding shares of Series B Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata or by lot. Upon the occurrence of a delisting event or change of control the Company will have the option to redeem the Series B Preferred Stock, in whole or in part, for cash at $25,000.00 per share plus accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion </i>- The shares of Series B Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company, except upon the occurrence of a delisting event or a change of control, each holder Series B Preferred Stock will have the right (unless the Company has elected to redeem the Series B Preferred Stock) to convert some or all of the shares of Series B Preferred Stock held by such holder on the delisting event conversion date or change of control conversion date into a number of shares of the common stock (or equivalent value of alternative consideration) per share of Series B Preferred Stock, equal to the lesser of (A) the quotient obtained by dividing (1) the sum of the $25,000.00 per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the delisting event conversion date or change of control conversion date, as applicable (unless the delisting event conversion date or change of control conversion date, is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and then remaining unpaid dividend will be included in this sum) by (2) the common stock price (such quotient, the “Conversion Rate”); and (B) 1,253.13 (1.25313 per depositary share) (i.e., the “Share Cap”), subject to certain adjustments described in the Series B Preferred Stock Certificate of Designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights</i>— Holders of the Series B Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification</i>—The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, the Company’s Board of Directors declared and paid cash dividends on the Company’s Series A Preferred Stock and Series B Depositary shares as follows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:21.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:20.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">March 17, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_y8W_nJG8-EyxTQQSanvpMw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.71875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;">N/A <sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">April 15, 2021 </p></td></tr><tr><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">May 21, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_iwIHZTWwV0CXRh7AgGTEow;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.23%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_6Cr61u8KK0-GZe2DU8nwmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.55833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 15, 2021</p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 28, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0hcDJJ5bvk68OnQXIl5bcw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_d6IwMghzY0WyqOjkvFl-4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.31%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 15, 2021</p></td></tr><tr><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 20, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_lUDf3hx6w0SJgbKKrFwl5Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.23%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_rX-6KRWQTkeN4_tViCzcKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 18, 2022</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company sold 1,600,000 Series B Depositary Shares on April 9, 2021. As such, the first dividend was declared on May 21, 2021. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of December 31, 2021, the Company held restricted cash of $2.0 million in a segregated account that may only be used to pay dividends on the Series A and Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BVF Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2020, BVF elected to increase the beneficial ownership limitation of the Series Y preferred stock to 50%, which became effective on April 11, 2020. On April 15, 2020, BVF converted all of its shares of Series Y preferred stock into common stock. As of December 31, 2021, BVF owned approximately 31.2% of the Company’s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own 52.3% of the Company’s total outstanding shares of common stock. The Company’s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of December 31, 2021, the contingency was not met, therefore the Series A Preferred Stock is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2018 Common Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Series B Preferred Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2021 and 2020, the following common stock warrants were outstanding:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">February 2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">February 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders’ equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,249</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May 2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders’ equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders’ equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,426</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, in conjunction with services provided by a third-party consultant, the Company issued a warrant to purchase up to an aggregate of 8,249 unregistered shares of the Company’s common stock at an exercise price equal to $15.40 per share. The warrant was exercisable immediately and had a five-year term expiring in February 2021. As of December 31, 2020, the estimated fair value of the warrant of $0.1 million was calculated using the Black-Scholes Model and was classified in stockholders’ equity on the consolidated balance sheet. In February 2021, the Company issued 4,917 shares of common stock upon a cashless exercise of the common stock warrants held by Torreya Partners LLC. There is no balance of these warrants on the consolidated balance sheet as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2018, the Company issued SVB a warrant in connection with the SVB Loan Agreement (Note 8) which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share. The warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. The warrant is classified in stockholders’ equity on the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2019, the Loan Agreement was amended to extend the Draw Period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The second warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million.<span style="letter-spacing:-0.1pt;"> As of December 31, 2021, both warrants are outstanding and </span><span style="letter-spacing:-0.1pt;">no</span><span style="letter-spacing:-0.1pt;"> shares have been </span><span style="letter-spacing:-0.1pt;">issued</span><span style="letter-spacing:-0.1pt;"> upon exercise of the warrants.</span></p> 5003 1252.772 0 5003 5003 1000 1000 4.03 13.00 5600000 984000 0.08625 25.00 24600000 2000000.0 22600000 200000 25.00 5000000.0 8000 25.00 200000 984000 984000 0.08625 25.00 360 12 30 0.05 0.05 25.00 26.00 25.75 25.50 25.25 25.00 25.00 25.00 1.46071 10 1600000 25.00 40000000.0 2900000 37100000 8000 25.00 200000 3600 1600 0.08375 0.08375 25000.00 2093.75 360 12 30 0.05 0.05 25000.00 26000.00 26.00 25750.00 25.75 25500.00 25.50 25250.00 25.25 25000.00 25.00 25000.00 25000.00 1253.13 1.25313 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:21.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:20.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">March 17, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_y8W_nJG8-EyxTQQSanvpMw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.71875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;">N/A <sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">April 15, 2021 </p></td></tr><tr><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">May 21, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_iwIHZTWwV0CXRh7AgGTEow;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.23%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_6Cr61u8KK0-GZe2DU8nwmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.55833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 15, 2021</p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 28, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0hcDJJ5bvk68OnQXIl5bcw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_d6IwMghzY0WyqOjkvFl-4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.31%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 15, 2021</p></td></tr><tr><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 20, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_lUDf3hx6w0SJgbKKrFwl5Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.23%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_rX-6KRWQTkeN4_tViCzcKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.31%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 18, 2022</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company sold 1,600,000 Series B Depositary Shares on April 9, 2021. As such, the first dividend was declared on May 21, 2021. </span></td></tr></table> 0.71875 0.53906 0.55833 0.53906 0.52344 0.53906 0.52344 1600000 0.50 0.312 0.523 30000000.0 0.03 50000000.0 0 50000000.0 0.03 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">February 2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">February 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders’ equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,249</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May 2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders’ equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders’ equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,426</p></td></tr></table> 15.40 8249 23.69 23.69 6332 6332 14.71 14.71 4845 4845 11177 19426 8249 15.40 P5Y 100000 4917 0 6332 23.69 P10Y 100000 4845 14.71 P10Y 100000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaborative Agreements, Royalties and Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company’s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Contingent Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the Company’s royalty and commercial payment purchase agreements with Bioasis, Aronora, Kuros and Affitech, the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones and the Affitech regulatory and sales milestones. The Company recorded $0.1 million and $8.0 million for the Bioasis Contingent Consideration and the Affitech Regulatory Milestones, respectively, which, represents the estimated fair value of these potential future payments at the inception of the respective agreements. The contingent </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other (expense) income, net. As of December 31, 2021, there were no changes in the estimated fair value of the Bioasis Contingent Consideration and the Affitech Sales Milestones from the initial value. The liability for future Aronora Royalty Milestones, Kuros Sales Milestones and Affitech Sales Milestones will be recorded when the amounts, by product, are estimable and probable. As of December 31, 2021, none of these Aronora Royalty Milestones, Kuros Sales Milestones or Affitech Sales Milestones were assessed to be probable and as such, no liability was recorded on the consolidated balance sheet.</p> 6300000 1 100000 8000000.0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Concentration of Risk, Segment and Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the year ended December 31, 2021, one partner represented 92% of total revenues. For the year ended December 31, 2020, one partner represented 85% of total revenues. As of December 31, 2021 and 2020, one partner represented 100% of the trade receivables balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates in one business segment as it only reports operating results on an aggregate basis to the chief operating decision maker of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,010</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,275</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,100</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,385</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s property and equipment is held in the United States.</p> 1 0.92 1 0.85 1 1 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,010</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,275</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,100</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,385</p></td></tr></table> 35000000 25010000 2610000 1275000 550000 3100000 38160000 29385000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 28, 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize faricimab (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. Upon approval, the Company became eligible to receive a 0.5% commercial payment stream on net sales associated with faricimab for a ten-year period following its first commercial sale in the United States.  The Company acquired this interest under the Affitech CPPA, pursuant to which, the Company paid Affitech a $5.0 million milestone tied to these U.S. marketing approvals. The Company may pay up to an additional $15.0 million to Affitech based on the achievement of certain regulatory approval and sales milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to XOMA pursuant to the Company’s Rezolute License Agreement.</p> 0.005 P10Y 5000000.0 15000000.0 2000000.0 EXCEL 116 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 118 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 119 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 345 525 1 false 114 0 false 15 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.xoma.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.xoma.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Sheet http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - Description of Business Sheet http://www.xoma.com/role/DisclosureDescriptionOfBusiness Description of Business Notes 7 false false R8.htm 10201 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Consolidated Financial Statement Detail Sheet http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetail Consolidated Financial Statement Detail Notes 9 false false R10.htm 10401 - Disclosure - Licensing and Other Arrangements Sheet http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements Licensing and Other Arrangements Notes 10 false false R11.htm 10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements Sheet http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements Royalty and Commercial Payment Purchase Agreements Notes 11 false false R12.htm 10601 - Disclosure - Fair Value Measurements Sheet http://www.xoma.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 10701 - Disclosure - Lease Agreement Sheet http://www.xoma.com/role/DisclosureLeaseAgreement Lease Agreement Notes 13 false false R14.htm 10801 - Disclosure - Long-Term Debt and Other Financings Sheet http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings Long-Term Debt and Other Financings Notes 14 false false R15.htm 10901 - Disclosure - Income Taxes Sheet http://www.xoma.com/role/DisclosureIncomeTaxes Income Taxes Notes 15 false false R16.htm 11001 - Disclosure - Stock Based Compensation Sheet http://www.xoma.com/role/DisclosureStockBasedCompensation Stock Based Compensation Notes 16 false false R17.htm 11101 - Disclosure - Net Income Per Share Attributable to Common Stockholders Sheet http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholders Net Income Per Share Attributable to Common Stockholders Notes 17 false false R18.htm 11201 - Disclosure - Capital Stock Sheet http://www.xoma.com/role/DisclosureCapitalStock Capital Stock Notes 18 false false R19.htm 11301 - Disclosure - Commitments and Contingencies Sheet http://www.xoma.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 11401 - Disclosure - Concentration of Risk, Segment and Geographic Information Sheet http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation Concentration of Risk, Segment and Geographic Information Notes 20 false false R21.htm 11501 - Disclosure - Subsequent Events Sheet http://www.xoma.com/role/DisclosureSubsequentEvents Subsequent Events Notes 21 false false R22.htm 20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies 22 false false R23.htm 30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables Basis of Presentation and Significant Accounting Policies (Tables) Tables http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies 23 false false R24.htm 30303 - Disclosure - Consolidated Financial Statement Detail (Tables) Sheet http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailTables Consolidated Financial Statement Detail (Tables) Tables http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetail 24 false false R25.htm 30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables) Sheet http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables Royalty and Commercial Payment Purchase Agreements (Tables) Tables http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements 25 false false R26.htm 30603 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.xoma.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.xoma.com/role/DisclosureFairValueMeasurements 26 false false R27.htm 30703 - Disclosure - Lease Agreement (Tables) Sheet http://www.xoma.com/role/DisclosureLeaseAgreementTables Lease Agreement (Tables) Tables http://www.xoma.com/role/DisclosureLeaseAgreement 27 false false R28.htm 30803 - Disclosure - Long-Term Debt and Other Financings (Tables) Sheet http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsTables Long-Term Debt and Other Financings (Tables) Tables http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings 28 false false R29.htm 30903 - Disclosure - Income Taxes (Tables) Sheet http://www.xoma.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.xoma.com/role/DisclosureIncomeTaxes 29 false false R30.htm 31003 - Disclosure - Stock Based Compensation (Tables) Sheet http://www.xoma.com/role/DisclosureStockBasedCompensationTables Stock Based Compensation (Tables) Tables http://www.xoma.com/role/DisclosureStockBasedCompensation 30 false false R31.htm 31103 - Disclosure - Net Income Per Share Attributable to Common Stockholders (Tables) Sheet http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersTables Net Income Per Share Attributable to Common Stockholders (Tables) Tables http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholders 31 false false R32.htm 31203 - Disclosure - Capital Stock (Tables) Sheet http://www.xoma.com/role/DisclosureCapitalStockTables Capital Stock (Tables) Tables http://www.xoma.com/role/DisclosureCapitalStock 32 false false R33.htm 31403 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables) Sheet http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables Concentration of Risk, Segment and Geographic Information (Tables) Tables http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation 33 false false R34.htm 40101 - Disclosure - Description of Business - Cash and Restricted Cash (Details) Sheet http://www.xoma.com/role/DisclosureDescriptionOfBusinessCashAndRestrictedCashDetails Description of Business - Cash and Restricted Cash (Details) Details 34 false false R35.htm 40102 - Disclosure - Description of Business - Repayment of Debt (Details) Sheet http://www.xoma.com/role/DisclosureDescriptionOfBusinessRepaymentOfDebtDetails Description of Business - Repayment of Debt (Details) Details 35 false false R36.htm 40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Use of Estimates (Details) Sheet http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesDetails Basis of Presentation and Significant Accounting Policies - Use of Estimates (Details) Details 36 false false R37.htm 40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details) Sheet http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details) Details 37 false false R38.htm 40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Equity Securities (Details) Sheet http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails Basis of Presentation and Significant Accounting Policies - Equity Securities (Details) Details 38 false false R39.htm 40204 - Disclosure - Basis of Presentation and Significant Accounting Policies - Purchase of Rights to Future Milestones and Royalties and Income Taxes and Net Income (Loss) per Share (Details) Sheet http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsToFutureMilestonesAndRoyaltiesAndIncomeTaxesAndNetIncomeLossPerShareDetails Basis of Presentation and Significant Accounting Policies - Purchase of Rights to Future Milestones and Royalties and Income Taxes and Net Income (Loss) per Share (Details) Details 39 false false R40.htm 40205 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details) Sheet http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details) Details 40 false false R41.htm 40301 - Disclosure - Consolidated Financial Statement Detail - Equity Securities (Details) Sheet http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailEquitySecuritiesDetails Consolidated Financial Statement Detail - Equity Securities (Details) Details 41 false false R42.htm 40302 - Disclosure - Consolidated Financial Statement Detail - Accrued and Other Liabilities (Details) Sheet http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails Consolidated Financial Statement Detail - Accrued and Other Liabilities (Details) Details 42 false false R43.htm 40401 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details) Sheet http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details Licensing and Other Arrangements - Novartis - NIS793 (Details) Details 43 false false R44.htm 40402 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details) Sheet http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details) Details 44 false false R45.htm 40403 - Disclosure - Licensing and Other Arrangements - Takeda (Details) Sheet http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails Licensing and Other Arrangements - Takeda (Details) Details 45 false false R46.htm 40404 - Disclosure - Licensing and Other Arrangements - Rezolute (Details) Sheet http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails Licensing and Other Arrangements - Rezolute (Details) Details 46 false false R47.htm 40405 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details) Sheet http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails Licensing and Other Arrangements - Janssen Biotech (Details) Details 47 false false R48.htm 40406 - Disclosure - Licensing and Other Arrangements - Affimed (Details) Sheet http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails Licensing and Other Arrangements - Affimed (Details) Details 48 false false R49.htm 40407 - Disclosure - Licensing and Other Arrangements - NIAID (Details) Sheet http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails Licensing and Other Arrangements - NIAID (Details) Details http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements 49 false false R50.htm 40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details) Sheet http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails Licensing and Other Arrangements - Sale of Future Revenue Streams (Details) Details 50 false false R51.htm 40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details) Sheet http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails Royalty and Commercial Payment Purchase Agreements - Agenus (Details) Details http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables 51 false false R52.htm 40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details) Sheet http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails Royalty and Commercial Payment Purchase Agreements - Bioasis (Details) Details http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables 52 false false R53.htm 40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details) Sheet http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails Royalty and Commercial Payment Purchase Agreements - Aronora (Details) Details http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables 53 false false R54.htm 40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details) Sheet http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails Royalty and Commercial Payment Purchase Agreements - Palo (Details) Details http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables 54 false false R55.htm 40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details) Sheet http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails Royalty and Commercial Payment Purchase Agreements - Viracta (Details) Details http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables 55 false false R56.htm 40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details) Sheet http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails Royalty and Commercial Payment Purchase Agreements - Kuros (Details) Details http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables 56 false false R57.htm 40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details) Sheet http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails Royalty and Commercial Payment Purchase Agreements - Affitech (Details) Details http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables 57 false false R58.htm 40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Acquisition of Royalty Rights (Details) Sheet http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails Royalty and Commercial Payment Purchase Agreements - Summary of Acquisition of Royalty Rights (Details) Details 58 false false R59.htm 40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) Sheet http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) Details 59 false false R60.htm 40602 - Disclosure - Fair Value Measurements - Summary of Changes In Estimated Fair Value of Level 3 Financial Assets (Details) Sheet http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails Fair Value Measurements - Summary of Changes In Estimated Fair Value of Level 3 Financial Assets (Details) Details 60 false false R61.htm 40603 - Disclosure - Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details) Sheet http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details) Details 61 false false R62.htm 40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details) Sheet http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails Fair Value Measurements - Contingent Consideration (Details) Details 62 false false R63.htm 40701 - Disclosure - Lease Agreement - Leased facilities (Details) Sheet http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails Lease Agreement - Leased facilities (Details) Details 63 false false R64.htm 40702 - Disclosure - Lease Agreement - Maturity of lease liabilities (Details) Sheet http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails Lease Agreement - Maturity of lease liabilities (Details) Details 64 false false R65.htm 40703 - Disclosure - Lease Agreement - Rent Expense and Lease costs (Details) Sheet http://www.xoma.com/role/DisclosureLeaseAgreementRentExpenseAndLeaseCostsDetails Lease Agreement - Rent Expense and Lease costs (Details) Details 65 false false R66.htm 40704 - Disclosure - Lease Agreement - Additional information (Details) Sheet http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails Lease Agreement - Additional information (Details) Details 66 false false R67.htm 40801 - Disclosure - Long-Term Debt and Other Financings - SVB Loan (Details) Sheet http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails Long-Term Debt and Other Financings - SVB Loan (Details) Details 67 false false R68.htm 40802 - Disclosure - Long-Term Debt and Other Financings - Novartis Note (Details) Sheet http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails Long-Term Debt and Other Financings - Novartis Note (Details) Details 68 false false R69.htm 40803 - Disclosure - Long-Term Debt and Other Financings - Interest Expense (Details) Sheet http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails Long-Term Debt and Other Financings - Interest Expense (Details) Details 69 false false R70.htm 40901 - Disclosure - Income Taxes - Provision for Income Taxes (Details) Sheet http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails Income Taxes - Provision for Income Taxes (Details) Details 70 false false R71.htm 40902 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details) Sheet http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails Income Taxes - Reconciliation between statutory rate and effective rate (Details) Details 71 false false R72.htm 40903 - Disclosure - Income Taxes - CARES Act (Details) Sheet http://www.xoma.com/role/DisclosureIncomeTaxesCaresActDetails Income Taxes - CARES Act (Details) Details 72 false false R73.htm 40904 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details) Sheet http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails Income Taxes - Components of Net Deferred Tax Assets (Details) Details 73 false false R74.htm 40905 - Disclosure - Income Taxes - NOL (Details) Sheet http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails Income Taxes - NOL (Details) Details 74 false false R75.htm 40906 - Disclosure - Income Taxes - Tax credit carryforward (Details) Sheet http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails Income Taxes - Tax credit carryforward (Details) Details 75 false false R76.htm 40907 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) Sheet http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized Tax Benefits (Details) Details 76 false false R77.htm 41001 - Disclosure - Stock Based Compensation - ESPP (Details) Sheet http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails Stock Based Compensation - ESPP (Details) Details 77 false false R78.htm 41002 - Disclosure - Stock Based Compensation - Deferred Savings Plan (Details) Sheet http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails Stock Based Compensation - Deferred Savings Plan (Details) Details 78 false false R79.htm 41003 - Disclosure - Stock Based Compensation - Stock Option Plans (Details) Sheet http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails Stock Based Compensation - Stock Option Plans (Details) Details 79 false false R80.htm 41004 - Disclosure - Stock Based Compensation - Stock Options (Details) Sheet http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails Stock Based Compensation - Stock Options (Details) Details 80 false false R81.htm 41005 - Disclosure - Stock Based Compensation - Stock Option Activity (Details) Sheet http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock Based Compensation - Stock Option Activity (Details) Details 81 false false R82.htm 41006 - Disclosure - Stock Based Compensation - Weighted Average Assumptions (Details) Sheet http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails Stock Based Compensation - Weighted Average Assumptions (Details) Details 82 false false R83.htm 41007 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock Based Compensation - Stock-based Compensation Expense (Details) Details 83 false false R84.htm 41101 - Disclosure - Net Income Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details) Sheet http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails Net Income Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details) Details 84 false false R85.htm 41102 - Disclosure - Net Income Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details) Sheet http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails Net Income Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details) Details 85 false false R86.htm 41201 - Disclosure - Capital Stock - Series X and Series Y Convertible Preferred Stock (Details) Sheet http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails Capital Stock - Series X and Series Y Convertible Preferred Stock (Details) Details 86 false false R87.htm 41202 - Disclosure - Capital Stock - Series A Preferred Stock (Details) Sheet http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails Capital Stock - Series A Preferred Stock (Details) Details 87 false false R88.htm 41203 - Disclosure - Capital Stock - Series B Preferred Stock (Details) Sheet http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails Capital Stock - Series B Preferred Stock (Details) Details 88 false false R89.htm 41204 - Disclosure - Capital Stock - Dividends (Details) Sheet http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails Capital Stock - Dividends (Details) Details 89 false false R90.htm 41205 - Disclosure - Capital Stock - BVF Ownership (Details) Sheet http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails Capital Stock - BVF Ownership (Details) Details 90 false false R91.htm 41206 - Disclosure - Capital Stock - ATM Agreements (Details) Sheet http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails Capital Stock - ATM Agreements (Details) Details 91 false false R92.htm 41207 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details) Sheet http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails Capital Stock - Summary of Common Stock Warrants Outstanding (Details) Details 92 false false R93.htm 41208 - Disclosure - Capital Stock - Common Stock Warrants (Details) Sheet http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails Capital Stock - Common Stock Warrants (Details) Details 93 false false R94.htm 41301 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details) Sheet http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details) Details 94 false false R95.htm 41302 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details) Sheet http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails Commitments and Contingencies - Contingent Consideration (Details) Details 95 false false R96.htm 41401 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details) Sheet http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details) Details 96 false false R97.htm 41402 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details) Sheet http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails Concentration of Risk, Segment and Geographic Information - Segment Information (Details) Details 97 false false R98.htm 41403 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details) Sheet http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details) Details 98 false false R99.htm 41501 - Disclosure - Subsequent Events (Details) Sheet http://www.xoma.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.xoma.com/role/DisclosureSubsequentEvents 99 false false All Reports Book All Reports tmb-20211231x10k.htm tmb-20211231.xsd tmb-20211231_cal.xml tmb-20211231_def.xml tmb-20211231_lab.xml tmb-20211231_pre.xml tmb-20211231xex10d26.htm tmb-20211231xex10d48.htm tmb-20211231xex21d1.htm tmb-20211231xex23d1.htm tmb-20211231xex31d1.htm tmb-20211231xex31d2.htm tmb-20211231xex32d1.htm tmb-20211231xex4d6.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 122 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tmb-20211231x10k.htm": { "axisCustom": 0, "axisStandard": 34, "contextCount": 345, "dts": { "calculationLink": { "local": [ "tmb-20211231_cal.xml" ] }, "definitionLink": { "local": [ "tmb-20211231_def.xml" ] }, "inline": { "local": [ "tmb-20211231x10k.htm" ] }, "labelLink": { "local": [ "tmb-20211231_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20211231_pre.xml" ] }, "schema": { "local": [ "tmb-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 712, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 50, "http://www.xoma.com/20211231": 1, "http://xbrl.sec.gov/dei/2021q4": 8, "total": 59 }, "keyCustom": 144, "keyStandard": 381, "memberCustom": 69, "memberStandard": 41, "nsprefix": "xoma", "nsuri": "http://www.xoma.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:LicensingAndOtherArrangementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Licensing and Other Arrangements", "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements", "shortName": "Licensing and Other Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:LicensingAndOtherArrangementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:RoyaltyPurchaseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements", "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements", "shortName": "Royalty and Commercial Payment Purchase Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:RoyaltyPurchaseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Fair Value Measurements", "role": "http://www.xoma.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:LeaseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Lease Agreement", "role": "http://www.xoma.com/role/DisclosureLeaseAgreement", "shortName": "Lease Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:LeaseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Long-Term Debt and Other Financings", "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings", "shortName": "Long-Term Debt and Other Financings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Income Taxes", "role": "http://www.xoma.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Stock Based Compensation", "role": "http://www.xoma.com/role/DisclosureStockBasedCompensation", "shortName": "Stock Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Net Income Per Share Attributable to Common Stockholders", "role": "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholders", "shortName": "Net Income Per Share Attributable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Capital Stock", "role": "http://www.xoma.com/role/DisclosureCapitalStock", "shortName": "Capital Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Commitments and Contingencies", "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.xoma.com/role/StatementConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Concentration of Risk, Segment and Geographic Information", "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation", "shortName": "Concentration of Risk, Segment and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Subsequent Events", "role": "http://www.xoma.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)", "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables", "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Consolidated Financial Statement Detail (Tables)", "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailTables", "shortName": "Consolidated Financial Statement Detail (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:ScheduleOfRoyaltyRightsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)", "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables", "shortName": "Royalty and Commercial Payment Purchase Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:ScheduleOfRoyaltyRightsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Lease Agreement (Tables)", "role": "http://www.xoma.com/role/DisclosureLeaseAgreementTables", "shortName": "Lease Agreement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Long-Term Debt and Other Financings (Tables)", "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsTables", "shortName": "Long-Term Debt and Other Financings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Income Taxes (Tables)", "role": "http://www.xoma.com/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_MMXwkalQ-EutiQGzp8KDow", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_MMXwkalQ-EutiQGzp8KDow", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Stock Based Compensation (Tables)", "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Net Income Per Share Attributable to Common Stockholders (Tables)", "role": "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersTables", "shortName": "Net Income Per Share Attributable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Capital Stock (Tables)", "role": "http://www.xoma.com/role/DisclosureCapitalStockTables", "shortName": "Capital Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables)", "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables", "shortName": "Concentration of Risk, Segment and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Description of Business - Cash and Restricted Cash (Details)", "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusinessCashAndRestrictedCashDetails", "shortName": "Description of Business - Cash and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_6_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankAndNovartisPharmaAgMember_LMUU-NuH2kyey9S0Tnv6rQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40102 - Disclosure - Description of Business - Repayment of Debt (Details)", "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusinessRepaymentOfDebtDetails", "shortName": "Description of Business - Repayment of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_6_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankAndNovartisPharmaAgMember_LMUU-NuH2kyey9S0Tnv6rQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerRefundLiabilityCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Use of Estimates (Details)", "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesDetails", "shortName": "Basis of Presentation and Significant Accounting Policies - Use of Estimates (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details)", "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails", "shortName": "Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "p", "xoma:EquitySecuritiesPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_JMbb9X99eUqNVg0BX1UVJw", "decimals": "INF", "first": true, "lang": null, "name": "xoma:EquityInvestmentsNumberOfSharesHeld", "reportCount": 1, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Equity Securities (Details)", "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails", "shortName": "Basis of Presentation and Significant Accounting Policies - Equity Securities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-5", "first": true, "lang": null, "name": "xoma:ImpairmentOfLongTermRoyaltyReceivable", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40204 - Disclosure - Basis of Presentation and Significant Accounting Policies - Purchase of Rights to Future Milestones and Royalties and Income Taxes and Net Income (Loss) per Share (Details)", "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsToFutureMilestonesAndRoyaltiesAndIncomeTaxesAndNetIncomeLossPerShareDetails", "shortName": "Basis of Presentation and Significant Accounting Policies - Purchase of Rights to Future Milestones and Royalties and Income Taxes and Net Income (Loss) per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-5", "lang": null, "name": "us-gaap:Dividends", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME", "role": "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_1_1_2021_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201912Member_US266RKQNkuJ3r81Yz_SDg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40205 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)", "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails", "shortName": "Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_1_1_2021_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201912Member_US266RKQNkuJ3r81Yz_SDg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_SFvBQpyGjUajTCt7Jua92g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFVNINoncurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Consolidated Financial Statement Detail - Equity Securities (Details)", "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailEquitySecuritiesDetails", "shortName": "Consolidated Financial Statement Detail - Equity Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_8WI_cLjQ-0mdnC1C8m6HmQ", "decimals": "-5", "lang": null, "name": "us-gaap:EquitySecuritiesFVNINoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Consolidated Financial Statement Detail - Accrued and Other Liabilities (Details)", "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails", "shortName": "Consolidated Financial Statement Detail - Accrued and Other Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)", "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "shortName": "Licensing and Other Arrangements - Novartis - NIS793 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "xoma:LicensingAndOtherArrangementsTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_hZImesQGdky81TstWkSgBg", "decimals": null, "lang": "en-US", "name": "xoma:AgreementTerminationPriorWrittenNoticePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)", "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "shortName": "Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_Lj4CHL0Ecku2_4LozjnTzA", "decimals": "-5", "lang": null, "name": "xoma:LicenseAgreementTransactionPrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Licensing and Other Arrangements - Takeda (Details)", "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "shortName": "Licensing and Other Arrangements - Takeda (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_ijwl2X2fjEWt33kE1ned3Q", "decimals": "-5", "lang": null, "name": "xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40404 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)", "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "shortName": "Licensing and Other Arrangements - Rezolute (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_-ybaDKXME0uc2noqWw6U2w", "decimals": "-5", "lang": null, "name": "xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40405 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)", "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "shortName": "Licensing and Other Arrangements - Janssen Biotech (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_nPYN6CjK9022Hn570QFp-A", "decimals": "-5", "lang": null, "name": "xoma:ProceedsFromUpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40406 - Disclosure - Licensing and Other Arrangements - Affimed (Details)", "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "shortName": "Licensing and Other Arrangements - Affimed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_icd00vXqUkmonE0zW2EU9A", "decimals": "0", "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "xoma:ReductionOfContingentRefundLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40407 - Disclosure - Licensing and Other Arrangements - NIAID (Details)", "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "shortName": "Licensing and Other Arrangements - NIAID (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_9_1_2008_To_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_RoFtMUc_z0ieygB_JtXsbQ", "decimals": null, "lang": "en-US", "name": "xoma:ContractualTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I6Nudtzyt02vW4gKkq5wxw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I6Nudtzyt02vW4gKkq5wxw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInDeferredRevenue", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)", "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "shortName": "Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_eGsLBTnmQ0mMda8KMu8RTw", "decimals": "INF", "lang": null, "name": "xoma:NumberOfRoyaltyInterestAcquisitionAgreements", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_agreement_gA0aMC4WAEuVu6LkKVSDtg", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)", "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "shortName": "Royalty and Commercial Payment Purchase Agreements - Agenus (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "xoma:RoyaltyPurchaseAgreementTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3sTVWIoYOEakBGsgHBQQ_Q", "decimals": "-5", "lang": null, "name": "xoma:MilestoneAchieved", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)", "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "shortName": "Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-qbk83RyvUmyckwKvG0cjg", "decimals": "INF", "lang": null, "name": "xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "xoma:LongTermRightsReceivableNonCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)", "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "shortName": "Royalty and Commercial Payment Purchase Agreements - Aronora (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_DOSIYlviokCpdm7LXcPqAQ", "decimals": "INF", "lang": null, "name": "xoma:AgreementDrugCandidatesNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_8qxAFcGbuUmiRvRmtsjSnw", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)", "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "shortName": "Royalty and Commercial Payment Purchase Agreements - Palo (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_0vBQ-M6eVkqkQsllyOIwOw", "decimals": "INF", "lang": null, "name": "xoma:AgreementDrugCandidatesNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)", "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "shortName": "Royalty and Commercial Payment Purchase Agreements - Viracta (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_noY0LNI60E-GUGEk4QWL2A", "decimals": "INF", "lang": null, "name": "xoma:AgreementDrugCandidatesNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_8qxAFcGbuUmiRvRmtsjSnw", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "xoma:LongTermRightsReceivableNonCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)", "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "shortName": "Royalty and Commercial Payment Purchase Agreements - Kuros (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lPLBQtHMLEyjCcZ6i_W9Kg", "decimals": "INF", "lang": null, "name": "xoma:RoyaltyReceivablePercentageOnNetSales", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "xoma:LongTermRightsReceivableNonCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)", "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "shortName": "Royalty and Commercial Payment Purchase Agreements - Affitech (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_jHJidrOfY0SgJ9DWeY3u4w", "decimals": "-5", "lang": null, "name": "xoma:UpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_SFvBQpyGjUajTCt7Jua92g", "decimals": "-3", "first": true, "lang": null, "name": "xoma:LongTermRightsReceivableNonCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Acquisition of Royalty Rights (Details)", "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails", "shortName": "Royalty and Commercial Payment Purchase Agreements - Summary of Acquisition of Royalty Rights (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "xoma:ScheduleOfRoyaltyRightsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_pixdVdQRtUCOmXF1X33OPw", "decimals": "-3", "lang": null, "name": "xoma:RoyaltyRightsAcquired", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)", "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_SFvBQpyGjUajTCt7Jua92g", "decimals": "0", "lang": null, "name": "us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2019_TLRrxIVr90CsS5oa3ZwiQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Fair Value Measurements - Summary of Changes In Estimated Fair Value of Level 3 Financial Assets (Details)", "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails", "shortName": "Fair Value Measurements - Summary of Changes In Estimated Fair Value of Level 3 Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_Oh37iIM_z0mTYQ4fXhTMag", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_MMXwkalQ-EutiQGzp8KDow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)", "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails", "shortName": "Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_Oh37iIM_z0mTYQ4fXhTMag", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_MMXwkalQ-EutiQGzp8KDow", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "xoma:ContingentConsiderationUnderPurchaseAgreements", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)", "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "shortName": "Fair Value Measurements - Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R63": { "firstAnchor": { "ancestors": [ "p", "xoma:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_llOJNCkcDk6BCs0MSl-3Qw", "decimals": "INF", "first": true, "lang": null, "name": "xoma:OperatingLeasesNumberOfLeasedFacilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_facility_j5v71_GreUu4SuGHED0DWg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Lease Agreement - Leased facilities (Details)", "role": "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails", "shortName": "Lease Agreement - Leased facilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "xoma:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_llOJNCkcDk6BCs0MSl-3Qw", "decimals": "INF", "first": true, "lang": null, "name": "xoma:OperatingLeasesNumberOfLeasedFacilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_facility_j5v71_GreUu4SuGHED0DWg", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Lease Agreement - Maturity of lease liabilities (Details)", "role": "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails", "shortName": "Lease Agreement - Maturity of lease liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - Lease Agreement - Rent Expense and Lease costs (Details)", "role": "http://www.xoma.com/role/DisclosureLeaseAgreementRentExpenseAndLeaseCostsDetails", "shortName": "Lease Agreement - Rent Expense and Lease costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40704 - Disclosure - Lease Agreement - Additional information (Details)", "role": "http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails", "shortName": "Lease Agreement - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_SFvBQpyGjUajTCt7Jua92g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Long-Term Debt and Other Financings - SVB Loan (Details)", "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "shortName": "Long-Term Debt and Other Financings - SVB Loan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_3_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_BZEZiyy-V0-qpMxgsYRSBA", "decimals": "-3", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Long-Term Debt and Other Financings - Novartis Note (Details)", "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "shortName": "Long-Term Debt and Other Financings - Novartis Note (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_3_1_2005_To_3_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_VGApwZLZDEqRVPjAXjMXDw", "decimals": "2", "lang": null, "name": "xoma:CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Long-Term Debt and Other Financings - Interest Expense (Details)", "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails", "shortName": "Long-Term Debt and Other Financings - Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "xoma:InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_n8FVwHJgXkSn22ip7xIM8A", "decimals": "-3", "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Description of Business", "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Income Taxes - Provision for Income Taxes (Details)", "role": "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails", "shortName": "Income Taxes - Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "lang": null, "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)", "role": "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails", "shortName": "Income Taxes - Reconciliation between statutory rate and effective rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "2", "lang": null, "name": "xoma:EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Income Taxes - CARES Act (Details)", "role": "http://www.xoma.com/role/DisclosureIncomeTaxesCaresActDetails", "shortName": "Income Taxes - CARES Act (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_aJfUq_1Q3UKGVJ1wRkxfMQ", "decimals": "-5", "lang": null, "name": "xoma:IncomeTaxBenefitOperatingLossCarryBackCoronavirusAidReliefAndEconomicSecurityAct", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)", "role": "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails", "shortName": "Income Taxes - Components of Net Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_Xf7zaE3mtEeUMbQxZSUHow", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40905 - Disclosure - Income Taxes - NOL (Details)", "role": "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails", "shortName": "Income Taxes - NOL (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_Xf7zaE3mtEeUMbQxZSUHow", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "2", "first": true, "lang": null, "name": "xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40906 - Disclosure - Income Taxes - Tax credit carryforward (Details)", "role": "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails", "shortName": "Income Taxes - Tax credit carryforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "2", "first": true, "lang": null, "name": "xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_SFvBQpyGjUajTCt7Jua92g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40907 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)", "role": "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2019_TLRrxIVr90CsS5oa3ZwiQg", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_avdtZJ_CkUqNWuGBrjjEwA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Stock Based Compensation - ESPP (Details)", "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "shortName": "Stock Based Compensation - ESPP (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_avdtZJ_CkUqNWuGBrjjEwA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Stock Based Compensation - Deferred Savings Plan (Details)", "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails", "shortName": "Stock Based Compensation - Deferred Savings Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Stock Based Compensation - Stock Option Plans (Details)", "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "shortName": "Stock Based Compensation - Stock Option Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3o5uEahMs0u9gU1Bkq-x5Q", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Basis of Presentation and Significant Accounting Policies", "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies", "shortName": "Basis of Presentation and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_j3Ud0RpZ0EudwdAhQDy2JQ", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41004 - Disclosure - Stock Based Compensation - Stock Options (Details)", "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "shortName": "Stock Based Compensation - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_j3Ud0RpZ0EudwdAhQDy2JQ", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2020_SFvBQpyGjUajTCt7Jua92g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41005 - Disclosure - Stock Based Compensation - Stock Option Activity (Details)", "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "shortName": "Stock Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_j3Ud0RpZ0EudwdAhQDy2JQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41006 - Disclosure - Stock Based Compensation - Weighted Average Assumptions (Details)", "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "shortName": "Stock Based Compensation - Weighted Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_j3Ud0RpZ0EudwdAhQDy2JQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41007 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details)", "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "Stock Based Compensation - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Net Income Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)", "role": "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails", "shortName": "Net Income Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Net Income Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)", "role": "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "shortName": "Net Income Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Capital Stock - Series X and Series Y Convertible Preferred Stock (Details)", "role": "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails", "shortName": "Capital Stock - Series X and Series Y Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_Cl91j2_WREaZFj-ZLXTLFw", "decimals": "INF", "lang": null, "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Capital Stock - Series A Preferred Stock (Details)", "role": "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "shortName": "Capital Stock - Series A Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_UjzzmwNY1kOQ0p7ovsIaBg", "decimals": "5", "lang": null, "name": "us-gaap:PreferredStockDividendRatePercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41203 - Disclosure - Capital Stock - Series B Preferred Stock (Details)", "role": "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "shortName": "Capital Stock - Series B Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_pGAYzJ9MK0WWF5h0Cf1hyQ", "decimals": "5", "lang": null, "name": "us-gaap:PreferredStockDividendRatePercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41204 - Disclosure - Capital Stock - Dividends (Details)", "role": "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "shortName": "Capital Stock - Dividends (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_10_20_2021_To_10_20_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wVSfIDMiFkWbjCdPnwO7gQ", "decimals": "5", "lang": null, "name": "us-gaap:PreferredStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_MMXwkalQ-EutiQGzp8KDow", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Consolidated Financial Statement Detail", "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetail", "shortName": "Consolidated Financial Statement Detail", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_2_29_2020_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_j5T37Y9gf0aFpotJETTJ5Q", "decimals": "2", "first": true, "lang": null, "name": "xoma:BeneficialOwnershipLimitation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41205 - Disclosure - Capital Stock - BVF Ownership (Details)", "role": "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "shortName": "Capital Stock - BVF Ownership (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_2_29_2020_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_j5T37Y9gf0aFpotJETTJ5Q", "decimals": "2", "first": true, "lang": null, "name": "xoma:BeneficialOwnershipLimitation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_Z5Ane1hW6EOP-88GWM4sFg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41206 - Disclosure - Capital Stock - ATM Agreements (Details)", "role": "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "shortName": "Capital Stock - ATM Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_eB1FNCaw50CWA4FEQA58dQ", "decimals": "-5", "lang": null, "name": "xoma:MaximumValueOfCommonStockToBeIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41207 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)", "role": "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails", "shortName": "Capital Stock - Summary of Common Stock Warrants Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_n8FVwHJgXkSn22ip7xIM8A", "decimals": null, "first": true, "lang": "en-US", "name": "xoma:ExercisablePeriodOfWarrants", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41208 - Disclosure - Capital Stock - Common Stock Warrants (Details)", "role": "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "shortName": "Capital Stock - Common Stock Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_2_29_2016_srt_CounterpartyNameAxis_xoma_ThirdPartyConsultantMember_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedSecondRangeMember_Ucyok91bKUeJuen5vJmgYA", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_D3OgT6icwke82tG5Nz5h1g", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-5", "first": true, "lang": null, "name": "xoma:ContractualObligationEstimatedMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)", "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails", "shortName": "Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-5", "first": true, "lang": null, "name": "xoma:ContractualObligationEstimatedMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "As_Of_12_31_2021_TMTPctG1FUKHF81BGAYxTQ", "decimals": "-3", "first": true, "lang": null, "name": "xoma:ContingentConsiderationUnderPurchaseAgreements", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)", "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "shortName": "Commitments and Contingencies - Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_BioasisAffitechMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_K96PR034j0qQy40-w_jWLg", "decimals": "0", "lang": null, "name": "xoma:ChangesInEstimatedFairValueOfContingentConsideration", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_UugGbgeTKk-sDgBVadI1Wg", "decimals": "INF", "first": true, "lang": null, "name": "xoma:NumberOfMajorPartners", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_customer_jjhU7KxigkGXlLelzyM8pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)", "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails", "shortName": "Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_UugGbgeTKk-sDgBVadI1Wg", "decimals": "INF", "first": true, "lang": null, "name": "xoma:NumberOfMajorPartners", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_customer_jjhU7KxigkGXlLelzyM8pA", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_P0HHSMBl50SD5S829WR-WA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41402 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details)", "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails", "shortName": "Concentration of Risk, Segment and Geographic Information - Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_P0HHSMBl50SD5S829WR-WA", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_d2y7OJAmU0GYf_7VgOekQg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41403 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)", "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails", "shortName": "Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_EuropeMember_FJENwt8d_EuDjvHv0U_a3g", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GsYuYre_cEyuSXzUtFWIMA", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_jHJidrOfY0SgJ9DWeY3u4w", "decimals": "4", "first": true, "lang": null, "name": "xoma:CommercialSalesReceivablePercentageOnNetSales", "reportCount": 1, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Subsequent Events (Details)", "role": "http://www.xoma.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20211231x10k.htm", "contextRef": "Duration_1_28_2022_To_1_28_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_YJD2Bdn0a0664T7c1v9voA", "decimals": "INF", "lang": null, "name": "xoma:CommercialSalesReceivablePercentageOnNetSales", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_H1gdYssXW0qTAZ9UQyT-mw", "xsiNil": "false" } } }, "segmentCount": 114, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "dei_AdrMember": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "American Depositary Receipt (or American Depositary Share, ADS).", "label": "Series B Depositary Shares" } } }, "localname": "AdrMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.xoma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r51", "r53", "r101", "r102", "r252", "r279" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails", "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "label": "Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r191", "r318", "r323", "r601" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r251", "r278", "r338", "r340", "r519", "r520", "r521", "r522", "r523", "r524", "r543", "r598", "r602", "r632", "r633" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r251", "r278", "r338", "r340", "r519", "r520", "r521", "r522", "r523", "r524", "r543", "r598", "r602", "r632", "r633" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r191", "r318", "r323", "r601" ], "lang": { "en-us": { "role": { "label": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r187", "r318", "r321", "r545", "r597", "r599" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r187", "r318", "r321", "r545", "r597", "r599" ], "lang": { "en-us": { "role": { "label": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r251", "r278", "r327", "r338", "r340", "r519", "r520", "r521", "r522", "r523", "r524", "r543", "r598", "r602", "r632", "r633" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r251", "r278", "r327", "r338", "r340", "r519", "r520", "r521", "r522", "r523", "r524", "r543", "r598", "r602", "r632", "r633" ], "lang": { "en-us": { "role": { "label": "Range" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r52", "r53", "r101", "r102", "r252", "r279" ], "lang": { "en-us": { "role": { "label": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails", "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r118", "r339" ], "lang": { "en-us": { "role": { "label": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r118", "r123", "r339" ], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r188", "r189", "r318", "r322", "r600", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "label": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r188", "r189", "r318", "r322", "r600", "r618", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r118", "r123", "r233", "r339", "r511" ], "lang": { "en-us": { "role": { "label": "Statement Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r192", "r504" ], "lang": { "en-us": { "role": { "label": "Title Of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Relationship to Entity" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "domainItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "California [Member]" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201912Member": { "auth_ref": [ "r413", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.", "label": "ASU 2019-12" } } }, "localname": "AccountingStandardsUpdate201912Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate202004Member": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-04 Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.", "label": "Accounting Standards Update 2020-04 [Member]", "terseLabel": "ASU 2020-04" } } }, "localname": "AccountingStandardsUpdate202004Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "ASU 2020-06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Accounts and Other Receivables, Net, Current", "terseLabel": "Trade and other receivables, net" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36", "r508" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r25", "r580", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable Net", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r11", "r12", "r40" ], "calculation": { "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails": { "order": 3.0, "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued incentive compensation" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r19", "r565", "r583" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities And Other Liabilities [Abstract]", "terseLabel": "Accrued and other liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r11", "r12", "r40" ], "calculation": { "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails": { "order": 1.0, "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Accrued legal and accounting fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "verboseLabel": "Consolidated Financial Statement Detail" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetail" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r26", "r380", "r508" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r105", "r106", "r107", "r377", "r378", "r379", "r445" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r110", "r111", "r112", "r113", "r123", "r194", "r195", "r208", "r209", "r210", "r211", "r212", "r213", "r236", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r413", "r414", "r415", "r416", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r465", "r466", "r468", "r469", "r470", "r471", "r472", "r473", "r501", "r546", "r547", "r548", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r652", "r653", "r654", "r655", "r656" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r342", "r344", "r383", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r344", "r369", "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r71", "r86", "r264", "r482" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization Of Debt Discount Premium", "verboseLabel": "Non-cash interest expense resulting from amortization of discount and accretion" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r86", "r264", "r270", "r271", "r484" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization Of Financing Costs And Discounts", "terseLabel": "Amortization of debt issuance costs, debt discount and final payment on debt" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from computation of net loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements and Non-arrangement Transactions" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r97", "r176", "r179", "r185", "r204", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r427", "r431", "r464", "r506", "r508", "r563", "r581" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r9", "r50", "r97", "r204", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r427", "r431", "r464", "r506", "r508" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r345", "r371" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedContractCostNet": { "auth_ref": [ "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost Net", "terseLabel": "Capitalized contract costs" } } }, "localname": "CapitalizedContractCostNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r33", "r508", "r616", "r617" ], "calculation": { "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r14", "r89" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r82", "r88", "r92" ], "calculation": { "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and restricted cash at the end of the period", "periodStartLabel": "Cash and restricted cash at the beginning of the period", "terseLabel": "Unrestricted and restricted cash", "totalLabel": "Total cash and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails", "http://www.xoma.com/role/DisclosureDescriptionOfBusinessCashAndRestrictedCashDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r82", "r474" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r105", "r106", "r109", "r194", "r195", "r205", "r206", "r207", "r208", "r209", "r236", "r373", "r374", "r375", "r413", "r435", "r437", "r438", "r465", "r467", "r468", "r469", "r472", "r473", "r487", "r501", "r546", "r547", "r603", "r604", "r652" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r94", "r97", "r127", "r132", "r137", "r142", "r146", "r155", "r156", "r157", "r204", "r237", "r241", "r242", "r243", "r246", "r247", "r276", "r277", "r281", "r285", "r464", "r643" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails", "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r303", "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "positiveTerseLabel": "Exercise price of warrants (in dollars per share)", "terseLabel": "Exercise price of warrants (in dollars per share)", "verboseLabel": "Exercise price of warrants (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Warrant Or Right [Line Items]", "terseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Aggregate number of unregistered shares of common stock called by warrants (in shares)", "verboseLabel": "Aggregate number of shares of common stock called by warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Outstanding", "positiveTerseLabel": "Warrant outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r303", "r343" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class Of Warrant Or Right [Table]", "terseLabel": "Class Of Warrant Or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "terseLabel": "Agreements", "verboseLabel": "Licensing and other arrangements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r232", "r570", "r589" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies.", "terseLabel": "Commitments and Contingencies (Note 13)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r229", "r230", "r231", "r234", "r622" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "verboseLabel": "Common stock reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r105", "r106", "r445" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r508" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,315,263 and 11,228,792 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r325", "r326", "r341", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "Stock Based Compensation" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationRelatedCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Based Compensation" } } }, "localname": "CompensationRelatedCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs Policy [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r55", "r57", "r58", "r66", "r573", "r592" ], "calculation": { "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Net comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income Policy Policy [Text Block]", "terseLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r165", "r166", "r191", "r461", "r462", "r621" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r165", "r166", "r191", "r461", "r462", "r615", "r621" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r165", "r166", "r191", "r461", "r462", "r615", "r621" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration of Risk, Segment and Geographic Information" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r165", "r166", "r191", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk (as a percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r163", "r165", "r166", "r167", "r461", "r463", "r621" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r165", "r166", "r191", "r461", "r462", "r621" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r305", "r307", "r319" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract With Customer Asset Net", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r305", "r306", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability", "terseLabel": "Contract liabilities", "verboseLabel": "Deferred revenue/Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiability": { "auth_ref": [ "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.", "label": "Contract with Customer, Refund Liability", "terseLabel": "Estimated refund liability" } } }, "localname": "ContractWithCustomerRefundLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "auth_ref": [ "r320" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.", "label": "Contract with Customer, Refund Liability, Current", "terseLabel": "Contingent liabilities" } } }, "localname": "ContractWithCustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r276", "r277", "r281" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r22", "r23", "r288", "r294", "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock Shares Issued Upon Conversion", "terseLabel": "Number of shares issued for each share of convertible preferred stock that is converted" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r164", "r191" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt and Other Financings" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r19", "r20", "r96", "r103", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r268", "r269", "r270", "r271", "r485", "r564", "r567", "r579" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureDescriptionOfBusinessRepaymentOfDebtDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.", "label": "Debt Instrument, Increase (Decrease), Net", "negatedLabel": "Reduction in debt obligation" } } }, "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r42", "r249" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureDescriptionOfBusinessRepaymentOfDebtDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r43", "r96", "r103", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r268", "r269", "r270", "r271", "r485" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureDescriptionOfBusinessRepaymentOfDebtDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r43", "r96", "r103", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r268", "r269", "r270", "r271", "r294", "r298", "r299", "r300", "r482", "r483", "r485", "r486", "r578" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureDescriptionOfBusinessRepaymentOfDebtDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r255", "r482", "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument Unamortized Discount", "terseLabel": "Unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeCurrent": { "auth_ref": [ "r235" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Income, Current", "terseLabel": "Unearned revenue recognized under units-of-revenue method", "verboseLabel": "Unearned revenue recognized under units-of-revenue method, current" } } }, "localname": "DeferredIncomeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeNoncurrent": { "auth_ref": [ "r235" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Income, Noncurrent", "terseLabel": "Unearned revenue recognized under units-of-revenue method - long-term", "verboseLabel": "Unearned revenue recognized under units-of-revenue method, noncurrent" } } }, "localname": "DeferredIncomeNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r409", "r410" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets Deferred Income", "terseLabel": "Unearned revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r402" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r409", "r410" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets In Process Research And Development", "terseLabel": "Capitalized research and development expenses" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r404" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r409", "r410" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r409", "r410" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r407", "r409", "r410" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards", "terseLabel": "Research and development and other tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r409", "r410" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Stock compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r403" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan Cost Recognized", "terseLabel": "Contribution expense" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]", "terseLabel": "Deferred Savings Plan" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contribution (as a percent)" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Amount", "terseLabel": "Maximum annual contribution per employee" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent", "terseLabel": "Maximum annual contribution per employee (as a percent)" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationNonproduction": { "auth_ref": [ "r86", "r224" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.", "label": "Depreciation" } } }, "localname": "DepreciationNonproduction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r301", "r577" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "terseLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsToFutureMilestonesAndRoyaltiesAndIncomeTaxesAndNetIncomeLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Schedule of declared and paid cash dividends" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r19", "r21", "r566", "r582" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Preferred stock dividend accrual" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Dividends Payable [Line Items]", "terseLabel": "Dividends" } } }, "localname": "DividendsPayableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableTable": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.", "label": "Dividends Payable [Table]" } } }, "localname": "DividendsPayableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPreferredStockStock": { "auth_ref": [ "r301", "r577" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.", "label": "Dividends, Preferred Stock, Stock", "negatedLabel": "Preferred stock dividends" } } }, "localname": "DividendsPreferredStockStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r67", "r115", "r116", "r117", "r118", "r119", "r124", "r127", "r142", "r145", "r146", "r151", "r152", "r446", "r447", "r574", "r593" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "verboseLabel": "Basic net income per share available to common stockholders (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r67", "r115", "r116", "r117", "r118", "r119", "r127", "r142", "r145", "r146", "r151", "r152", "r446", "r447", "r574", "r593" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Diluted net income per share of common stock (in dollars per share)", "verboseLabel": "Diluted net income per share available to common stockholders (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r148", "r149" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Income per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r148", "r149", "r150", "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r391" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Total" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r99", "r391", "r419" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Federal statutory income tax rate", "verboseLabel": "Federal tax at statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesCaresActDetails", "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r391", "r419" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Weighted average period of unrecognized compensation expense expected to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized compensation expense related to stock options (in dollars)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r60", "r61", "r62", "r105", "r106", "r107", "r111", "r120", "r122", "r154", "r211", "r293", "r301", "r377", "r378", "r379", "r415", "r416", "r445", "r475", "r476", "r477", "r478", "r479", "r480", "r605", "r606", "r607", "r656" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r5", "r97", "r204", "r464" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r5", "r97", "r204", "r464" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "auth_ref": [ "r460" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.", "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Long-term equity securities" } } }, "localname": "EquitySecuritiesFVNINoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailEquitySecuritiesDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r460" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI", "terseLabel": "Short-term equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiMeasurementInput": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities Fv Ni Measurement Input", "terseLabel": "Valuation assumptions, measurement input" } } }, "localname": "EquitySecuritiesFvNiMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r201", "r594" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "negatedLabel": "Change in fair value of equity securities", "terseLabel": "Gain (loss) recognized due to change in fair value of investment" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailEquitySecuritiesDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r448", "r449", "r450", "r458" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of Estimated Fair Value of Equity Securities Assumptions" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r450" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount", "terseLabel": "Level 1 to Level 2 transfers, Assets" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r450" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount", "terseLabel": "Level 2 to Level 1 transfers, Assets" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Changes in the estimated fair value of Level 3 financial assets" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r454", "r458" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r454", "r458" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]", "terseLabel": "Summary of Changes in Estimated Fair Value of Level 3 Financial Assets" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r257", "r268", "r269", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r449", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r448", "r449", "r452", "r453", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r257", "r328", "r329", "r334", "r336", "r449", "r516" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r257", "r268", "r269", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r449", "r518" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r450" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount", "terseLabel": "Level 1 to Level 2 transfers, Liabilities" } } }, "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r450" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount", "terseLabel": "Level 2 to Level 1 transfers, Liabilities" } } }, "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value, Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Transfer into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "negatedLabel": "Transfer out of Level 3", "terseLabel": "Transfer out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value", "periodEndLabel": "Balance at end or period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r257", "r268", "r269", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r457", "r459" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Transfers Between Level 1 and Level 2, Description and Policy [Abstract]", "terseLabel": "Transfers between Levels" } } }, "localname": "FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r98", "r390" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "Federal Income Tax Expense Benefit Continuing Operations", "terseLabel": "Federal" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r265", "r291", "r436", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r643", "r644", "r645", "r646", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r86", "r272", "r273" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gains Losses On Extinguishment Of Debt", "negatedLabel": "Loss on extinguishment of debt", "terseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember": { "auth_ref": [ "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Family member whom a principal owner or a member of management might control or influence, or by whom they might be controlled or influenced, because of the family relationship.", "label": "Spouse of James Neal, Chief Executive Officer and a director" } } }, "localname": "ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r64", "r176", "r178", "r181", "r184", "r186", "r561", "r571", "r575", "r595" ], "calculation": { "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Income before income tax", "verboseLabel": "Income before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r227", "r228" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails", "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails", "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r99", "r392", "r400", "r406", "r417", "r420", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r100", "r121", "r122", "r175", "r390", "r418", "r421", "r596" ], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 }, "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax (expense) benefit", "totalLabel": "Total income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r59", "r388", "r389", "r400", "r401", "r405", "r411" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r49", "r569", "r590" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r85" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Trade and other receivables, net" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r85" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r85" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase Decrease In Accrued Income Taxes Payable", "terseLabel": "Income tax payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r85" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Unearned revenue recognized under units-of-revenue method" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r85" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "Increase (Decrease) in Income Taxes Receivable", "negatedLabel": "Income tax receivable" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r85", "r495" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r85" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase Decrease In Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r85" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase Decrease In Stockholders Equity Roll Forward", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r128", "r129", "r130", "r146" ], "calculation": { "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Effect of dilutive warrants" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r128", "r129", "r131", "r146" ], "calculation": { "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of dilutive stock options" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Expense [Abstract]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r71", "r262", "r267", "r270", "r271" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense Debt", "negatedLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r80", "r83", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments Fair Value Disclosure", "terseLabel": "Equity securities" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r498", "r500" ], "calculation": { "http://www.xoma.com/role/DisclosureLeaseAgreementRentExpenseAndLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementRentExpenseAndLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease costs" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementRentExpenseAndLeaseCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of cost components of operating leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Agreement" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of maturity of operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r499" ], "calculation": { "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r499" ], "calculation": { "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r499" ], "calculation": { "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r499" ], "calculation": { "http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Present value adjustment" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r97", "r180", "r204", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r428", "r431", "r432", "r464", "r506", "r507" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r97", "r204", "r464", "r508", "r568", "r587" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41", "r97", "r204", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r428", "r431", "r432", "r464", "r506", "r507", "r508" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity under loan agreement" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "Six-month LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r20", "r256", "r266", "r268", "r269", "r567", "r584" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt", "terseLabel": "Debt amount" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Current", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Noncurrent", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long Term Debt [Text Block]", "verboseLabel": "Long-Term Debt and Other Financings" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.", "label": "Discount for Lack of Marketability [Member]" } } }, "localname": "MeasurementInputDiscountForLackOfMarketabilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Estimated time to liquidity of shares" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Closing Common Stock Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership interest (as a percent)" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r158", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature Of Operations", "terseLabel": "Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r82", "r84", "r87" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r54", "r56", "r62", "r65", "r87", "r97", "r110", "r115", "r116", "r117", "r118", "r121", "r122", "r139", "r176", "r178", "r181", "r184", "r186", "r204", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r447", "r464", "r572", "r591" ], "calculation": { "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net income and comprehensive income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r115", "r116", "r117", "r118", "r124", "r125", "r141", "r146", "r176", "r178", "r181", "r184", "r186" ], "calculation": { "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income Loss Available To Common Stockholders Basic", "totalLabel": "Net (loss) income available to common stockholders, basic", "verboseLabel": "Net income and comprehensive income available to common stockholders (Note 11), basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r126", "r133", "r134", "r135", "r136", "r141", "r146" ], "calculation": { "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income Loss Available To Common Stockholders Diluted", "totalLabel": "Net (loss) income available to common stockholders, diluted", "verboseLabel": "Net income and comprehensive income available to common stockholders (Note 11), diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "verboseLabel": "Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r108", "r110", "r111", "r112", "r113", "r114", "r117", "r123", "r151", "r194", "r195", "r208", "r209", "r210", "r211", "r212", "r213", "r236", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r413", "r414", "r415", "r416", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r465", "r466", "r468", "r469", "r470", "r471", "r472", "r473", "r501", "r546", "r547", "r548", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r652", "r653", "r654", "r655", "r656" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other (expense) income, net:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r176", "r178", "r181", "r184", "r186" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r493", "r500" ], "calculation": { "http://www.xoma.com/role/DisclosureLeaseAgreementRentExpenseAndLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementRentExpenseAndLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r489" ], "calculation": { "http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "verboseLabel": "Total net lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r489" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r489" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r490", "r495" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r488" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r497", "r500" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate, Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r496", "r500" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term, Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r407" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carry-forwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails", "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails", "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r13", "r40" ], "calculation": { "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails": { "order": 4.0, "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets - long term" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other liabilities - long term" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "verboseLabel": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r77" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Payment for preferred stock dividends" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r79" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of preferred and common stock issuance costs", "verboseLabel": "Stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r77" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r73" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r345", "r371" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred stock, dividend rate (as a percent)" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "auth_ref": [ "r125", "r147" ], "calculation": { "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.", "label": "Preferred Stock Dividends and Other Adjustments", "negatedLabel": "Less: Accumulated preferred dividends" } } }, "localname": "PreferredStockDividendsAndOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsPerShareCashPaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Cash dividend paid (in dollars per share)" } } }, "localname": "PreferredStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends Per Share, Declared", "terseLabel": "Cash dividend declared (in dollars per share)" } } }, "localname": "PreferredStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r23", "r94", "r281", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Liquidation preference (in dollars per share)" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r276" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r275", "r294", "r296" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Preferred Stock, Redemption Price Per Share", "terseLabel": "Redemption price (in dollars per share)" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r276" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r508" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r8", "r31", "r32" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r74" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds From Issuance Of Long Term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r74" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock", "terseLabel": "Gross proceeds from issuance of preferred stock", "verboseLabel": "Proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r74", "r372" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercise of options and other share-based compensation" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r76", "r79" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r54", "r56", "r62", "r81", "r97", "r110", "r121", "r122", "r176", "r178", "r181", "r184", "r186", "r204", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r426", "r429", "r430", "r433", "r434", "r447", "r464", "r575" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r226", "r508", "r576", "r588" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r225" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Reclassifications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.", "label": "Reclassifications", "terseLabel": "Prior Period Reclassifications" } } }, "localname": "Reclassifications", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward", "terseLabel": "Unrecognized tax benefits activity" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails", "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r335", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r335", "r502", "r505", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments Of Debt", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureDescriptionOfBusinessRepaymentOfDebtDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r386", "r544", "r634" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r92", "r562", "r585" ], "calculation": { "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails", "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r7", "r14", "r92" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r10", "r17", "r92", "r619" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Long-term restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r301", "r380", "r508", "r586", "r609", "r614" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r105", "r106", "r107", "r111", "r120", "r122", "r211", "r377", "r378", "r379", "r415", "r416", "r445", "r605", "r607" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r173", "r174", "r177", "r182", "r183", "r187", "r188", "r191", "r317", "r318", "r545" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Revenue from contracts with customers", "verboseLabel": "Revenue recognized" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r93", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue From Contract With Customer Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueNotFromContractWithCustomer": { "auth_ref": [ "r63" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606.", "label": "Revenue Not from Contract with Customer", "terseLabel": "Revenue recognized under units-of-revenue method" } } }, "localname": "RevenueNotFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue Remaining Performance Obligation", "terseLabel": "Remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r63", "r97", "r173", "r174", "r177", "r182", "r183", "r187", "r188", "r191", "r204", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r464", "r575" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues From External Customers And Long Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r165", "r191" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenues." } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Accrued and Other Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Outstanding Securities Considered Anti-Dilutive" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailTables", "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and restricted cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]", "terseLabel": "Schedule of Provision for Income Taxes (All Current)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Components of Net Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailTables", "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Reconciliation Between the Tax Provision Computed at the Federal Statutory Income Tax Rate and Actual Effective Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r344", "r368", "r382" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r344", "r368", "r382" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Equity investments" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r5", "r97", "r203", "r204", "r464" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r69", "r188" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule Of Revenue From External Customers Attributed To Foreign Countries By Geographic Area [Text Block]", "terseLabel": "Revenue by Geographical Region" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r63", "r190" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]", "terseLabel": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r345", "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r351", "r357", "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Weighted Average Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r303", "r343" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]", "terseLabel": "Summary of Common Stock Warrants Outstanding" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt and Equity Securities, FV-NI [Line Items]", "terseLabel": "Equity Securities" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r399", "r412" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]", "terseLabel": "Schedule of Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "8.625% Series A Cumulative, Perpetual Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "8.375% Series B Cumulative, Perpetual Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r85" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]", "terseLabel": "Weighted average assumptions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The highest quantity of shares an employee can purchase under the plan per period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee", "terseLabel": "Maximum shares per employee" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized", "terseLabel": "Increase in aggregate number of shares authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Shares authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Shares available for grant", "verboseLabel": "Shares available for purchase" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "periodEndLabel": "Number of shares, Exercisable at end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per Share, Exercisable at end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Options exercised, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period", "negatedLabel": "Number of shares, Forfeited, expired or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "verboseLabel": "Number of shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r353", "r371" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Number of shares, Outstanding at end of period", "periodStartLabel": "Number of shares, Outstanding at beginning of period", "terseLabel": "Number of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per Share, Outstanding at end of period", "periodStartLabel": "Weighted Average Exercise Price Per Share, Outstanding at beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r343", "r371" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award", "terseLabel": "Shares purchased (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r343", "r349" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Closing stock price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r363", "r381" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted Average Contractual Term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted Average Contractual Term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Percentage related to employees to purchase shares at the lower fair market value at offering period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Purchase price (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Unrecognized tax benefits expected to change significantly over the next twelve months" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r22", "r23", "r24", "r94", "r97", "r127", "r132", "r137", "r142", "r146", "r155", "r156", "r157", "r204", "r237", "r241", "r242", "r243", "r246", "r247", "r276", "r277", "r281", "r285", "r293", "r464", "r643" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails", "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r48", "r60", "r61", "r62", "r105", "r106", "r107", "r111", "r120", "r122", "r154", "r211", "r293", "r301", "r377", "r378", "r379", "r415", "r416", "r445", "r475", "r476", "r477", "r478", "r479", "r480", "r605", "r606", "r607", "r656" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r105", "r106", "r107", "r154", "r545" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/DocumentDocumentAndEntityInformation", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Common stock options" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r47", "r259", "r293", "r294", "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "negatedLabel": "Issuance of common stock related to Series Y preferred stock conversion (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r23", "r24", "r293", "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of stock, net (in shares)", "verboseLabel": "Shares issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r293", "r301", "r355" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Number of shares, Exercised", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r48", "r293", "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock related to Series Y preferred stock conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r23", "r24", "r293", "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r48", "r293", "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r28", "r29", "r97", "r193", "r204", "r464", "r508" ], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets", "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r95", "r277", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r292", "r301", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Capital Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r481", "r510" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r481", "r510" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r481", "r510" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r481", "r510" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r509", "r512" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Sale of stock" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r407" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward Amount", "terseLabel": "Tax credit carry forward amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r265", "r291", "r436", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r643", "r644", "r645", "r646", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r110", "r111", "r112", "r113", "r123", "r194", "r195", "r208", "r209", "r210", "r211", "r212", "r213", "r236", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r413", "r414", "r415", "r416", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r465", "r466", "r468", "r469", "r470", "r471", "r472", "r473", "r501", "r546", "r547", "r548", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r652", "r653", "r654", "r655", "r656" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type of Adoption" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "auth_ref": [ "r140", "r143", "r144" ], "calculation": { "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Undistributed Earnings Loss Allocated To Participating Securities Basic", "negatedLabel": "Less: Allocation of undistributed earnings to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": { "auth_ref": [ "r138", "r140", "r143", "r144" ], "calculation": { "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.", "label": "Undistributed Earnings Loss Allocated To Participating Securities Diluted", "negatedLabel": "Add: Adjustments to undistributed earnings allocated to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r387", "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued", "terseLabel": "Income tax penalties or interest charged", "verboseLabel": "Accrued interest or penalties related to uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsToFutureMilestonesAndRoyaltiesAndIncomeTaxesAndNetIncomeLossPerShareDetails", "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r397" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions", "terseLabel": "Increase related to current year tax position" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r159", "r160", "r161", "r162", "r168", "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance Deferred Tax Asset Change In Amount", "terseLabel": "(Decrease) increase in the valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r494", "r500" ], "calculation": { "http://www.xoma.com/role/DisclosureLeaseAgreementRentExpenseAndLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementRentExpenseAndLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants for Common Stock [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "auth_ref": [ "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of warrants not settleable in cash classified as equity.", "label": "Warrants Not Settleable In Cash Fair Value Disclosure", "terseLabel": "Estimated fair value of warrants", "verboseLabel": "Fair value of warrant" } } }, "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r126", "r146" ], "calculation": { "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "totalLabel": "Weighted average shares used in computing diluted net income per share available to common stockholders", "verboseLabel": "Weighted average shares used in computing diluted net income per share available to common stockholders" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r124", "r146" ], "calculation": { "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Weighted average shares used in computing basic net income per share available to common stockholders", "verboseLabel": "Weighted average shares used in computing basic net income per share available to common stockholders" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome" ], "xbrltype": "sharesItemType" }, "xoma_AccruedAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.", "label": "Accrued And Other Liabilities Current", "terseLabel": "Accrued and other liabilities", "totalLabel": "Total" } } }, "localname": "AccruedAndOtherLiabilitiesCurrent", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "xoma_AccruedCostRelatedToIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued cost related to issuance of common stock.", "label": "Accrued Cost Related To Issuance Of Common Stock", "terseLabel": "Accrued cost related to issuance of capital stock" } } }, "localname": "AccruedCostRelatedToIssuanceOfCommonStock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_AccruedPreferredStockDividendCurrent": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Preferred Stock Dividend, Current", "terseLabel": "Preferred stock dividend accrual" } } }, "localname": "AccruedPreferredStockDividendCurrent", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "xoma_AccruedSalariesAndEmployeeBenefitsCurrent": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails": { "order": 2.0, "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries and Employee Benefits, Current", "terseLabel": "Accrued payroll and benefits" } } }, "localname": "AccruedSalariesAndEmployeeBenefitsCurrent", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from disgorgement.", "label": "Adjustments to Additional Paid in Capital, Disgorgement", "terseLabel": "Disgorgement of stockholder's short-swing profits" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalDisgorgement", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "xoma_AffimedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Affimed", "label": "Affimed" } } }, "localname": "AffimedMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" ], "xbrltype": "domainItemType" }, "xoma_AffitechResearchAsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Affitech Research AS, a Norwegian biotech company.", "label": "Affitech", "terseLabel": "Affitech" } } }, "localname": "AffitechResearchAsMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "xoma_AgenusIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agenus Inc.", "label": "Agenus [Member]" } } }, "localname": "AgenusIncMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails" ], "xbrltype": "domainItemType" }, "xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of drug candidates subject to exclusive license option.", "label": "Agreement, Drug Candidates, Exclusive License Option, Number", "terseLabel": "Number of drug candidates subject to exclusive license option" } } }, "localname": "AgreementDrugCandidatesExclusiveLicenseOptionNumber", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "integerItemType" }, "xoma_AgreementDrugCandidatesNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of drug candidates under the terms of the agreement.", "label": "Agreement, Drug Candidates, Number", "terseLabel": "Number of drug candidates" } } }, "localname": "AgreementDrugCandidatesNumber", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "xbrltype": "integerItemType" }, "xoma_AgreementPaymentPercentageFactor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multiplier used in determining change in payment percentage.", "label": "Agreement, Payment Percentage, Factor", "terseLabel": "Multiplier for cumulative amount of consideration paid" } } }, "localname": "AgreementPaymentPercentageFactor", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "integerItemType" }, "xoma_AgreementTerminationPriorWrittenNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days", "label": "Agreement Termination Prior Written Notice Period", "terseLabel": "Agreement termination prior written notice period" } } }, "localname": "AgreementTerminationPriorWrittenNoticePeriod", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "durationItemType" }, "xoma_AronoraIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aronora, Inc.", "label": "Aronora", "terseLabel": "Aronora [Member]" } } }, "localname": "AronoraIncMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails" ], "xbrltype": "domainItemType" }, "xoma_AronoraKurosAndAffitechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aronora, Kuros and Affitech.", "label": "Aronora Kuros And Affitech" } } }, "localname": "AronoraKurosAndAffitechMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "xoma_ArrangementWithGovernmentalAgency2DevelopmentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of deferred revenue arrangement wherein certain rights are granted under a license agreement with a governmental agency for development of anti-botulinum antibody product candidates.", "label": "Arrangement with Governmental Agency, Development One" } } }, "localname": "ArrangementWithGovernmentalAgency2DevelopmentOneMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" ], "xbrltype": "domainItemType" }, "xoma_ArrangementWithGovernmentalAgency2DevelopmentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of deferred revenue arrangement wherein certain rights are granted under a license agreement with a governmental agency for development of broad-spectrum antitoxins for the treatment of human botulism poisoning.", "label": "Arrangement with Governmental Agency, Development Two" } } }, "localname": "ArrangementWithGovernmentalAgency2DevelopmentTwoMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" ], "xbrltype": "domainItemType" }, "xoma_ArrangementsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of arrangements the agreements are accounted for.", "label": "Arrangements, Number", "terseLabel": "Number of arrangements" } } }, "localname": "ArrangementsNumber", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "integerItemType" }, "xoma_AtMarketIssuanceSalesAgreement2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At The Market Issuance Sales Agreement, 2021, in which the company may sell depository shares.", "label": "2021 ATM Agreement" } } }, "localname": "AtMarketIssuanceSalesAgreement2021Member", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails" ], "xbrltype": "domainItemType" }, "xoma_BayerProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bayer products.", "label": "Bayer Products" } } }, "localname": "BayerProductsMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "domainItemType" }, "xoma_BeneficialOwnershipLimitation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the beneficial ownership limitation.", "label": "Beneficial Ownership Limitation", "terseLabel": "Beneficial ownership limitation (as a percent)" } } }, "localname": "BeneficialOwnershipLimitation", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" ], "xbrltype": "percentItemType" }, "xoma_BioasisAffitechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It pertain to both Bioasis and Affitech.", "label": "Bioasis & Affitech" } } }, "localname": "BioasisAffitechMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "xoma_BioasisTechnologiesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bioasis Technologies Inc.", "label": "Bioasis", "terseLabel": "Bioasis" } } }, "localname": "BioasisTechnologiesIncMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails" ], "xbrltype": "domainItemType" }, "xoma_BiotechnologyValueFundLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biotechnology Value Fund, L.P.", "label": "BVF" } } }, "localname": "BiotechnologyValueFundLPMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" ], "xbrltype": "domainItemType" }, "xoma_CashReceivedForAchievementOfContractualMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash receipts for achievement of contractual milestones.", "label": "Cash Received for Achievement of Contractual Milestones", "negatedLabel": "Cash receipts for achievement of contractual milestones", "terseLabel": "Cash receipts for achievement of contractual milestones" } } }, "localname": "CashReceivedForAchievementOfContractualMilestones", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ChangesInEstimatedFairValueOfContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Changes in estimated fair value of contingent consideration.", "label": "Changes In Estimated Fair Value Of Contingent Consideration", "terseLabel": "Changes in estimated fair value of contingent consideration" } } }, "localname": "ChangesInEstimatedFairValueOfContingentConsideration", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" ], "xbrltype": "monetaryItemType" }, "xoma_CollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents about collaboration agreement member.", "label": "Collaboration agreement" } } }, "localname": "CollaborationAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" ], "xbrltype": "domainItemType" }, "xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company.", "label": "Collaborative Arrangement Research And Development Expense Funded Through Debt Instrument Percentage Maximum", "terseLabel": "Research and development expenses funded through loan facility, maximum (as a percent)" } } }, "localname": "CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" ], "xbrltype": "percentItemType" }, "xoma_CommercialPaymentPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial payment purchase agreement.", "label": "Commercial Payment Purchase Agreement [Member]", "terseLabel": "Commercial payment purchase agreement" } } }, "localname": "CommercialPaymentPurchaseAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "xoma_CommercialPaymentReceivableTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of commercial payment receivable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Commercial Payment Receivable Term", "terseLabel": "Commercial payment receivable term" } } }, "localname": "CommercialPaymentReceivableTerm", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "xoma_CommercialSalesReceivablePercentageOnNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payments entity eligible to receive as a percentage of net sales.", "label": "Commercial Sales, Receivable Percentage On Net Sales", "terseLabel": "Payments eligible to receive (as a percent)" } } }, "localname": "CommercialSalesReceivablePercentageOnNetSales", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "xoma_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "xoma_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "xoma_CommonStockPremium": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock premium received on sale of common stock.", "label": "Common Stock Premium", "terseLabel": "Common stock premium" } } }, "localname": "CommonStockPremium", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "monetaryItemType" }, "xoma_CommonStockWarrantExercisePrice14.71Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrant with exercise price of $14.71 per share.", "label": "Common stock warrant, Exercise price $14.71 per share, Issued March 2019" } } }, "localname": "CommonStockWarrantExercisePrice14.71Member", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "domainItemType" }, "xoma_CommonStockWarrantExercisePrice23.69PerShareIssuedMay2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrant with exercise price of $23.69 per share.", "label": "Common stock warrant, Exercise price $23.69 per share, Issued May 2018" } } }, "localname": "CommonStockWarrantExercisePrice23.69PerShareIssuedMay2018Member", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "domainItemType" }, "xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration of risk segment and geographic information.", "label": "Concentration of Risk, Segment and Geographic Information" } } }, "localname": "ConcentrationOfRiskSegmentAndGeographicInformationAbstract", "nsuri": "http://www.xoma.com/20211231", "xbrltype": "stringItemType" }, "xoma_CondensedConsolidatedFinancialStatementsDetailAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Condensed consolidated financial statements detail.", "label": "Consolidated Financial Statements" } } }, "localname": "CondensedConsolidatedFinancialStatementsDetailAbstract", "nsuri": "http://www.xoma.com/20211231", "xbrltype": "stringItemType" }, "xoma_ConsolidatedFinancialStatementDetailAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated financial statement detail.", "label": "Consolidated Financial Statement Detail" } } }, "localname": "ConsolidatedFinancialStatementDetailAbstract", "nsuri": "http://www.xoma.com/20211231", "xbrltype": "stringItemType" }, "xoma_ContingentConsiderationFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent consideration, fair value disclosure.", "label": "Contingent Consideration Fair Value Disclosure", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationFairValueDisclosure", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ContingentConsiderationUnderPurchaseAgreements": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.", "label": "Contingent Consideration Under Purchase Agreements", "terseLabel": "Contingent consideration under RPAs and CPPAs" } } }, "localname": "ContingentConsiderationUnderPurchaseAgreements", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "xoma_ContingentFutureCashPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contingent future cash payments.", "label": "Contingent Future Cash Payments", "terseLabel": "Potential future cash payments" } } }, "localname": "ContingentFutureCashPayments", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ContingentFutureCashPaymentsPerProduct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contingent future cash payment for each product.", "label": "Contingent Future Cash Payments, Per Product", "terseLabel": "Contingent future cash payment for each product" } } }, "localname": "ContingentFutureCashPaymentsPerProduct", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ContractsRevenueWroteOff": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Decrease in accounts receivable due to contracts revenue written off during the period.", "label": "Contracts Revenue Wrote Off", "terseLabel": "Accounts receivable written off" } } }, "localname": "ContractsRevenueWroteOff", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ContractualObligationEstimatedMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees. Represent contingent payments not recorded on balance sheet.", "label": "Contractual Obligation Estimated Milestone Payments", "terseLabel": "Estimate of milestone payments" } } }, "localname": "ContractualObligationEstimatedMilestonePayments", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.", "label": "Contractual Obligation, Estimated Milestone Payments, Number Of Products", "terseLabel": "Assumed number of products per contract" } } }, "localname": "ContractualObligationEstimatedMilestonePaymentsNumberOfProducts", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" ], "xbrltype": "integerItemType" }, "xoma_ContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual term of collaborative, licensing and other arrangements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Contractual Term", "terseLabel": "Contractual term" } } }, "localname": "ContractualTerm", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" ], "xbrltype": "durationItemType" }, "xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Threshold amount of cumulative royalties on net sales per product under the terms of the agreement", "label": "Cumulative Royalties On Net Sales Per Product, Threshold Amount", "terseLabel": "Threshold amount of cumulative royalties on net sales per product" } } }, "localname": "CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "monetaryItemType" }, "xoma_DebtInstrumentDecreaseUponAchievementOfMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the note will be reduced upon achievement of specified milestones rather than receiving cash payment under the terms of the agreement.", "label": "Debt Instrument, Decrease Upon Achievement of Milestones", "terseLabel": "Amount by which note will be reduced upon achievement of specified milestones" } } }, "localname": "DebtInstrumentDecreaseUponAchievementOfMilestones", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" ], "xbrltype": "monetaryItemType" }, "xoma_DebtInstrumentFinalPaymentFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for final payment fee on repayment of debt instrument.", "label": "Debt Instrument, Final Payment Fee", "terseLabel": "Final payment fee" } } }, "localname": "DebtInstrumentFinalPaymentFee", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "monetaryItemType" }, "xoma_DebtInstrumentFinalPaymentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Final payment fee as a percent of principal.", "label": "Debt Instrument, Final Payment Fee, Percentage", "terseLabel": "Final payment fee (as a percent)" } } }, "localname": "DebtInstrumentFinalPaymentFeePercentage", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "percentItemType" }, "xoma_DebtInstrumentPrepaymentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment fee as a percent of outstanding principal balance.", "label": "Debt Instrument, Prepayment Fee, Percentage", "terseLabel": "Prepayment fee (as a percent)" } } }, "localname": "DebtInstrumentPrepaymentFeePercentage", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "percentItemType" }, "xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum period following loan amortization date for which loan will mature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term, Maximum Period Following Loan Amortization Date", "terseLabel": "Maximum period following loan amortization date for which loan will mature" } } }, "localname": "DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "durationItemType" }, "xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum period prior to loan maturity date of specified loan for which loan will mature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term, Maximum Period Prior to Loan Maturity Date of Specified Loan", "terseLabel": "Maximum period prior to loan maturity date of Novartis loan for which loan will mature" } } }, "localname": "DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "durationItemType" }, "xoma_DeferredRevenueArrangementNameOfParty2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Describes the name of the party related to a deferred revenue arrangement. The party named is the other party that participates in a deferred revenue transaction.", "label": "National Institute of Allergy and Infectious Diseases \"NIAID\" [Member]" } } }, "localname": "DeferredRevenueArrangementNameOfParty2Member", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" ], "xbrltype": "domainItemType" }, "xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The age requirement for participants to be eligible for a catch-up contribution amount to a defined contribution plan.", "label": "Defined Contribution Plan Age Required For Catch Up Contribution Minimum", "terseLabel": "Age requirement for participant to be eligible for a catch-up contribution, minimum" } } }, "localname": "DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails" ], "xbrltype": "durationItemType" }, "xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of defined contribution plan expense paid through the issuance of common shares.", "label": "Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage", "terseLabel": "Deferred savings plan expense paid in common shares (as a percent)" } } }, "localname": "DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails" ], "xbrltype": "percentItemType" }, "xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined contribution plan issuance of Common stock for services or claims.", "label": "Defined Contribution Plan Issuance Of Common Stock For Services Or Claims", "terseLabel": "Common stock contribution to 401(k)" } } }, "localname": "DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to federal orphan drug credit.", "label": "Effective Income Tax Rate Reconciliation, Orphan Drug Credit, Percent", "negatedLabel": "Federal orphan drug credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" ], "xbrltype": "percentItemType" }, "xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement and other permanent differences.", "label": "Effective Income Tax Rate Reconciliation Stock Compensation And Other Permanent Differences Percent", "terseLabel": "Stock compensation and other permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" ], "xbrltype": "percentItemType" }, "xoma_EffectiveIncomeTaxRateReconciliationTaxBenefitCoronavirusAidReliefAndEconomicSecurityActPercent": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Benefit Coronavirus Aid, Relief, and Economic Security Act (CARES Act).", "label": "Effective Income Tax Rate Reconciliation, Tax Benefit Coronavirus Aid, Relief, and Economic Security Act, Percent", "terseLabel": "Tax benefit related to CARES Act" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxBenefitCoronavirusAidReliefAndEconomicSecurityActPercent", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" ], "xbrltype": "percentItemType" }, "xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense (benefit) related to net operating loss carryforward utilization.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Net Operating Loss Carryforward Utilization, Percent", "terseLabel": "Tax benefit related to net operating loss carryforward utilization" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" ], "xbrltype": "percentItemType" }, "xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum eligible milestone payments receivable per discovery product candidate.", "label": "Eligible Milestone Payments Receivable Per Discovery Product Candidate", "terseLabel": "Maximum eligible milestone payments receivable per discovery product candidate" } } }, "localname": "EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" ], "xbrltype": "monetaryItemType" }, "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.", "label": "Eligible Milestone Payments Receivable Upon Achievement Of Development Regulatory And Commercial Milestones", "terseLabel": "Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones" } } }, "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" ], "xbrltype": "monetaryItemType" }, "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum eligible milestone payments receivable upon achievement of development, pre-commercial milestones.", "label": "Eligible Milestone Payments Receivable Upon Achievement Of Pre-Commercial Milestones", "terseLabel": "Pre-commercial milestone payments" } } }, "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" ], "xbrltype": "monetaryItemType" }, "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum eligible milestone payments receivable upon achievement of sales and/or regulatory milestones.", "label": "Eligible Milestone Payments Receivable Upon Achievement Of Regulatory and Sales Milestones", "terseLabel": "Maximum additional payments upon achievement of regulatory and sales milestones" } } }, "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum eligible milestone payments receivable upon achievement of sales milestones.", "label": "Eligible Milestone Payments Receivable Upon Achievement Of Sales Milestones", "terseLabel": "Potential future sales milestone payments" } } }, "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" ], "xbrltype": "monetaryItemType" }, "xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Eligible potential additional payments receivable upon achievement of specified future net sales milestones.", "label": "Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones", "terseLabel": "Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years" } } }, "localname": "EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" ], "xbrltype": "monetaryItemType" }, "xoma_EmployeeAgeFiftyOrOverMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee of entity age 50 or over.", "label": "Employee, Age Fifty or Over" } } }, "localname": "EmployeeAgeFiftyOrOverMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails" ], "xbrltype": "domainItemType" }, "xoma_EmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee of entity.", "label": "Employees" } } }, "localname": "EmployeeMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails", "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "domainItemType" }, "xoma_EmployeeTerminatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Terminated employee of entity.", "label": "Terminated employee" } } }, "localname": "EmployeeTerminatedMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "xoma_EmployeeUnderAgeFiftyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee of entity under 50 years old.", "label": "Employee, Under Age Fifty" } } }, "localname": "EmployeeUnderAgeFiftyMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationDeferredSavingsPlanDetails" ], "xbrltype": "domainItemType" }, "xoma_EquityInvestmentsNumberOfSharesHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares owned classified in the consolidated balance sheet as equity securities.", "label": "Equity Investments, Number Of Shares Held", "terseLabel": "Number of shares owned" } } }, "localname": "EquityInvestmentsNumberOfSharesHeld", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "sharesItemType" }, "xoma_EquitySecuritiesNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of equity securities tranches.", "label": "Equity Securities, Number of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "EquitySecuritiesNumberOfTranches", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails" ], "xbrltype": "integerItemType" }, "xoma_EquitySecuritiesPolicy": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity securities.", "label": "Equity Securities Policy", "terseLabel": "Equity Securities" } } }, "localname": "EquitySecuritiesPolicy", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "xoma_EquitySecuritiesTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity securities tranche one.", "label": "Tranche 1 [Member]" } } }, "localname": "EquitySecuritiesTrancheOneMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "xoma_EquitySecuritiesTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity securities tranche two.", "label": "Tranche 2 [Member]" } } }, "localname": "EquitySecuritiesTrancheTwoMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated fair value of contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.", "label": "Estimated Fair Value Of Contingent Consideration Under Purchase Agreements", "terseLabel": "Estimated fair value of contingent consideration under the Affitech CPPA" } } }, "localname": "EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_ExercisablePeriodOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the exercisable period for warrants beginning on the date of issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable Period Of Warrants", "terseLabel": "Exercisable period of warrants" } } }, "localname": "ExercisablePeriodOfWarrants", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "durationItemType" }, "xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of common stock amount exceeded allocated purchase price of convertible preferred stock.", "label": "Fair Value Of Common Stock Amount Exceeded Allocated Purchase Price Of Convertible Preferred Stock", "terseLabel": "Fair value of common stock amount exceeded purchase price of convertible preferred stock" } } }, "localname": "FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "xoma_FederalOrphanCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal orphan tax credit carryforward.", "label": "Federal Orphan Credit [Member]" } } }, "localname": "FederalOrphanCreditMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "domainItemType" }, "xoma_FirstRoyaltyInterestAcquisitionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Royalty Interest Acquisition Agreement.", "label": "First Royalty Sale Agreement" } } }, "localname": "FirstRoyaltyInterestAcquisitionAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" ], "xbrltype": "domainItemType" }, "xoma_FirstTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First term loan from Silicon Valley Bank credit facility.", "label": "First Term Loan [Member]", "terseLabel": "SVB First Term Loan" } } }, "localname": "FirstTermLoanMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "domainItemType" }, "xoma_FiveYearWarrantsIssuedSecondRangeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrant with exercise price of $15.40 per share. Issued in February 2016.", "label": "Five Year Warrants Issued in February 2016" } } }, "localname": "FiveYearWarrantsIssuedSecondRangeMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Policy for future milestones, royalties purchase rights and commercial payments.", "label": "Future Milestones, Royalties Purchase Rights And Commercial Payments Policy [Policy Text Block]", "terseLabel": "Purchase of Rights to Future Milestones, Royalties and Commercial Payments" } } }, "localname": "FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HealthCare Royalty Partners II, L.P (HCRP).", "label": "HealthCare Royalty Partners II, L.P" } } }, "localname": "HealthCareRoyaltyPartnersTwoLimitedPartnersMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" ], "xbrltype": "domainItemType" }, "xoma_IL1TargetLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IL-1 target license agreement with Novartis.", "label": "IL-1 Target License Agreement [Member]" } } }, "localname": "IL1TargetLicenseAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "domainItemType" }, "xoma_ImpairmentOfLongTermRoyaltyReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.", "label": "Impairment Of Long Term Royalty Receivable", "terseLabel": "Impairment of long-term royalty receivable" } } }, "localname": "ImpairmentOfLongTermRoyaltyReceivable", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsToFutureMilestonesAndRoyaltiesAndIncomeTaxesAndNetIncomeLossPerShareDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "xbrltype": "monetaryItemType" }, "xoma_IncomeTaxBenefitOperatingLossCarryBackCoronavirusAidReliefAndEconomicSecurityAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax benefit relating to net operating loss carry back due to Coronavirus Aid, Relief, and Economic Security Act (CARES Act).", "label": "Income Tax Benefit, Operating Loss Carry Back, Coronavirus Aid, Relief, and Economic Security Act", "terseLabel": "Tax benefit related to NOL carryback provision" } } }, "localname": "IncomeTaxBenefitOperatingLossCarryBackCoronavirusAidReliefAndEconomicSecurityAct", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesCaresActDetails" ], "xbrltype": "monetaryItemType" }, "xoma_IncomeTaxesReceivableNetOperatingLossCaresActCashReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash received for income tax receivable from application of the Coronavirus Aid, Relief, and Economic Security (CARES) Act relating to the modifications of limitations on the deductibility of net operating losses.", "label": "Income Taxes Receivable, Net Operating Loss, CARES Act, Cash Received", "terseLabel": "Cash received for Cares Act income tax receivable" } } }, "localname": "IncomeTaxesReceivableNetOperatingLossCaresActCashReceived", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesCaresActDetails" ], "xbrltype": "monetaryItemType" }, "xoma_IncreaseDecreaseInRefundLiability": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in contingent refund liability.", "label": "Increase (Decrease) in Refund Liability", "negatedLabel": "Payment of contract with customer refund liability", "terseLabel": "Contingent NIH refund liability" } } }, "localname": "IncreaseDecreaseInRefundLiability", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_IncyteImmunoOncologyAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incyte immuno-oncology assets.", "label": "Incyte Immuno-Oncology Assets" } } }, "localname": "IncyteImmunoOncologyAssetsMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" ], "xbrltype": "domainItemType" }, "xoma_InterestAddedPrincipalBalancesLongTermDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unpaid interest added to the outstanding principal amount on long-term debt.", "label": "Interest Added Principal Balances Long Term Debt", "terseLabel": "Interest added to principal balance on long-term debt" } } }, "localname": "InterestAddedPrincipalBalancesLongTermDebt", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of aggregate amount of interest expense and the amortization of debt issuance costs and discounts on all borrowings.", "label": "Interest Expense And Amortization Of Debt Issuance Costs And Discounts Table [Text Block]", "terseLabel": "Interest Expense and Amortization of Debt Issuance Costs and Discounts" } } }, "localname": "InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsTables" ], "xbrltype": "textBlockItemType" }, "xoma_JanssenBiotechInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Janssen Biotech, Inc.", "label": "Janssen Biotech Inc." } } }, "localname": "JanssenBiotechInc.Member", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" ], "xbrltype": "domainItemType" }, "xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC.", "label": "Kuros [Member]", "terseLabel": "Kuros" } } }, "localname": "KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails" ], "xbrltype": "domainItemType" }, "xoma_LeaseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of information about leases.", "label": "Lease Disclosure [Text Block]", "terseLabel": "Lease Agreement" } } }, "localname": "LeaseDisclosureTextBlock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreement" ], "xbrltype": "textBlockItemType" }, "xoma_LeasedFacilitiesEmeryvilleCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leased facilities in Emeryville, California.", "label": "Leased facilities, Emeryville, California" } } }, "localname": "LeasedFacilitiesEmeryvilleCaliforniaMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" ], "xbrltype": "domainItemType" }, "xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental cash flows information related to leases.", "label": "Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Summary of supplemental cash flow information related to operating leases" } } }, "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementTables" ], "xbrltype": "textBlockItemType" }, "xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental information related to operating leases. May include, but not limited to, present value assumptions used in calculating the present value of the lease payments.", "label": "Lessee, Operating Lease, Supplemental Information [Table Text Block]", "terseLabel": "Schedule of present value assumptions used in calculating the present value of lease payments" } } }, "localname": "LesseeOperatingLeaseSupplementalInformationTableTextBlock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementTables" ], "xbrltype": "textBlockItemType" }, "xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement and common stock purchase agreement.", "label": "License Agreement and Common Stock Purchase Agreement [Member]" } } }, "localname": "LicenseAgreementAndCommonStockPurchaseAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "domainItemType" }, "xoma_LicenseAgreementConsiderationReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement consideration received.", "label": "License Agreement Consideration Received", "terseLabel": "License agreement consideration received" } } }, "localname": "LicenseAgreementConsiderationReceived", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "monetaryItemType" }, "xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of payments received upon achievement of financing activities during the period.", "label": "License Agreement Consideration Received, Achievement of Financing Activities", "terseLabel": "Payments received upon achievement of financing activities" } } }, "localname": "LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "monetaryItemType" }, "xoma_LicenseAgreementConsiderationReceivedDebtRepayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of license agreement consideration received as repayment of debt.", "label": "License Agreement Consideration Received, Debt Repayment", "terseLabel": "License agreement consideration received, repayment of debt" } } }, "localname": "LicenseAgreementConsiderationReceivedDebtRepayment", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "monetaryItemType" }, "xoma_LicenseAgreementInstallmentPaymentsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of installment payments received during the period.", "label": "License Agreement, Installment Payments Received", "terseLabel": "Installment payments received" } } }, "localname": "LicenseAgreementInstallmentPaymentsReceived", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "monetaryItemType" }, "xoma_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "xoma_LicenseAgreementNonRz358ProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement related to activities associated with non-RZ358 products.", "label": "License Agreement, Non-RZ358 products" } } }, "localname": "LicenseAgreementNonRz358ProductsMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "domainItemType" }, "xoma_LicenseAgreementRz358Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement related to activities associated with RZ358.", "label": "License Agreement, RZ358" } } }, "localname": "LicenseAgreementRz358Member", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "domainItemType" }, "xoma_LicenseAgreementSharesReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of counterparty's common stock entity received under the terms of the agreement.", "label": "License Agreement, Shares Received", "terseLabel": "Number of shares received" } } }, "localname": "LicenseAgreementSharesReceived", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "sharesItemType" }, "xoma_LicenseAgreementTransactionPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement transaction price.", "label": "License Agreement Transaction Price", "terseLabel": "Transaction price" } } }, "localname": "LicenseAgreementTransactionPrice", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "monetaryItemType" }, "xoma_LicensingAndOtherArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing and other arrangements.", "label": "Licensing and Other Arrangements" } } }, "localname": "LicensingAndOtherArrangementsAbstract", "nsuri": "http://www.xoma.com/20211231", "xbrltype": "stringItemType" }, "xoma_LicensingAndOtherArrangementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing and other arrangements.", "label": "Licensing And Other Arrangements [Text Block]", "terseLabel": "Licensing and Other Arrangements" } } }, "localname": "LicensingAndOtherArrangementsTextBlock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" ], "xbrltype": "textBlockItemType" }, "xoma_LongTermRightsReceivableNonCurrent": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-term royalty and commercial rights receivables, non current.", "label": "Long Term Rights Receivable, Non-Current", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Long-term royalty and commercial payment receivables" } } }, "localname": "LongTermRightsReceivableNonCurrent", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.", "label": "Maximum Amount Receivable Milestone Payments Upon Achievement Of Certain Clinical Development And Regulatory Approval Events", "terseLabel": "Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events" } } }, "localname": "MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" ], "xbrltype": "monetaryItemType" }, "xoma_MaximumConsiderationRetained": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.", "label": "Maximum Consideration Retained", "terseLabel": "Amount of maximum consideration retained" } } }, "localname": "MaximumConsiderationRetained", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "xbrltype": "monetaryItemType" }, "xoma_MaximumPayableOnRegulatoryMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount payable on regulatory milestone.", "label": "Maximum Payable on Regulatory Milestone", "terseLabel": "Maximum payable on regulatory milestone" } } }, "localname": "MaximumPayableOnRegulatoryMilestone", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" ], "xbrltype": "monetaryItemType" }, "xoma_MaximumPayableOnSalesMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount payable on sales milestone.", "label": "Maximum Payable on Sales Milestone", "terseLabel": "Maximum payable on sales milestone" } } }, "localname": "MaximumPayableOnSalesMilestone", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" ], "xbrltype": "monetaryItemType" }, "xoma_MaximumRevenueFromContract": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum revenue from contract.", "label": "Maximum Revenue From Contract", "terseLabel": "Total contract amount awarded" } } }, "localname": "MaximumRevenueFromContract", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" ], "xbrltype": "monetaryItemType" }, "xoma_MaximumValueOfCommonStockToBeIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum value of common stock to be issued.", "label": "Maximum Value Of Common Stock To Be Issued", "terseLabel": "Maximum amount of common shares to be issued" } } }, "localname": "MaximumValueOfCommonStockToBeIssued", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "xoma_MaximumValueOfStockToBeIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount of stock to be issued.", "label": "Maximum Value Of Stock To Be Issued", "terseLabel": "Maximum amount of shares to be issued" } } }, "localname": "MaximumValueOfStockToBeIssued", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "xoma_MerckImmunoOncologyProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merck immuno-oncology product.", "label": "Merck Immuno-Oncology Product" } } }, "localname": "MerckImmunoOncologyProductMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" ], "xbrltype": "domainItemType" }, "xoma_MezagitamabMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mezagitamab antibody (TAK-079).", "label": "TAK-079" } } }, "localname": "MezagitamabMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" ], "xbrltype": "domainItemType" }, "xoma_MilestoneAchieved": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of milestone achieved.", "label": "Milestone Achieved", "terseLabel": "Amount of milestone achieved" } } }, "localname": "MilestoneAchieved", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" ], "xbrltype": "monetaryItemType" }, "xoma_MilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of milestone payment during the period.", "label": "Milestone Payment", "terseLabel": "Milestone payment" } } }, "localname": "MilestonePayment", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "xoma_MilestonePaymentNonCashPortion": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-cash portion of milestone payment.", "label": "Milestone Payment, Non-cash Portion", "negatedLabel": "Non-cash portion of Novartis Milestone Payment" } } }, "localname": "MilestonePaymentNonCashPortion", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_MilestonePeriodsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.", "label": "Milestone Periods, Number", "terseLabel": "Number of milestone periods" } } }, "localname": "MilestonePeriodsNumber", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" ], "xbrltype": "integerItemType" }, "xoma_MilestonesPaymentsToAggregateAmountOfPerProduct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement.", "label": "Milestones Payments To Aggregate Amount Of Per Product", "terseLabel": "Aggregate milestones payments per product" } } }, "localname": "MilestonesPaymentsToAggregateAmountOfPerProduct", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "monetaryItemType" }, "xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount of potential milestones and other payments receivable, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones.", "label": "Milestones Receivable, Excluding Consideration Retained, Maximum", "terseLabel": "Maximum amount of potential milestones and other payments receivable" } } }, "localname": "MilestonesReceivableExcludingConsiderationRetainedMaximum", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "xbrltype": "monetaryItemType" }, "xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net income loss available to common stockholders basic and diluted.", "label": "Net Income Loss Available To Common Stockholders Basic And Diluted [Abstract]", "terseLabel": "Numerator" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureNetIncomePerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" ], "xbrltype": "stringItemType" }, "xoma_NetOperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss carryforwards expiration year.", "label": "Net Operating Loss Carryforwards Expiration Year", "terseLabel": "Net operating loss carryforwards expiration year" } } }, "localname": "NetOperatingLossCarryforwardsExpirationYear", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" ], "xbrltype": "gYearItemType" }, "xoma_NonBayerProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-bayer products.", "label": "Non-Bayer Products" } } }, "localname": "NonBayerProductsMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "domainItemType" }, "xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.", "label": "Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted", "terseLabel": "Ownership interest, if shares are converted (as a percent)" } } }, "localname": "NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" ], "xbrltype": "percentItemType" }, "xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of deferred revenue arrangement wherein certain rights are granted under a license agreement with a governmental agency.", "label": "Arrangement with Governmental Agency" } } }, "localname": "NonsoftwareLicenseArrangementWithGovernmentalAgency2Member", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" ], "xbrltype": "domainItemType" }, "xoma_NovartisInternationalPharmaceuticalLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novartis International Pharmaceutical Ltd.", "label": "Novartis International" } } }, "localname": "NovartisInternationalPharmaceuticalLtdMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" ], "xbrltype": "domainItemType" }, "xoma_NovartisNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured note agreement and subsequent amendments with Novartis referred to as the \"Note Agreement\".", "label": "Novartis Note" } } }, "localname": "NovartisNoteMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" ], "xbrltype": "domainItemType" }, "xoma_NovartisPharmaAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novartis Pharma AG.", "label": "Novartis Pharma AG [Member]" } } }, "localname": "NovartisPharmaAGMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "domainItemType" }, "xoma_NumberOfLicenseAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of license agreements.", "label": "Number Of License Agreements", "terseLabel": "Number of license agreements" } } }, "localname": "NumberOfLicenseAgreements", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "integerItemType" }, "xoma_NumberOfLicenseAgreementsFutureLicenseAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of future license agreements under optional purchase right.", "label": "Number Of License Agreements, Future License Agreements", "terseLabel": "Number of future license agreements under optional purchase right" } } }, "localname": "NumberOfLicenseAgreementsFutureLicenseAgreements", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" ], "xbrltype": "integerItemType" }, "xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of licensed products related to milestones and royalties purchased.", "label": "Number Of Licensed Products Related To Milestones And Royalties Purchased", "terseLabel": "Number of licensed products related to milestone and royalties" } } }, "localname": "NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" ], "xbrltype": "integerItemType" }, "xoma_NumberOfMajorPartners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of major partners.", "label": "Number Of Major Partners", "terseLabel": "Number of major partners" } } }, "localname": "NumberOfMajorPartners", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "integerItemType" }, "xoma_NumberOfPerformanceObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of performance obligations.", "label": "Number Of Performance Obligations", "terseLabel": "Number of performance obligations" } } }, "localname": "NumberOfPerformanceObligations", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "integerItemType" }, "xoma_NumberOfRoyaltyInterestAcquisitionAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of royalty interest acquisition agreements.", "label": "Number Of Royalty Interest Acquisition Agreements", "terseLabel": "Number of agreements" } } }, "localname": "NumberOfRoyaltyInterestAcquisitionAgreements", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" ], "xbrltype": "integerItemType" }, "xoma_NumberOfSharesRightAndOptionToSellPostSplitSharesNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of counterparty's post-split shares held by entity that entity has right and option to sell if counterparty does not list common stock shares on national exchange by specified date.", "label": "Number Of Shares Right And Option To Sell, Post-Split Shares, Number", "terseLabel": "Number of Rezolute's post-split shares Company has right and option to sell" } } }, "localname": "NumberOfSharesRightAndOptionToSellPostSplitSharesNumber", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails" ], "xbrltype": "sharesItemType" }, "xoma_OperatingLeasePaymentsNonCash": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating lease payments, non cash.", "label": "Operating Lease Payments Non Cash", "negatedLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeasePaymentsNonCash", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_OperatingLeasesNumberOfLeasedFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, number of leased facilities.", "label": "Operating Leases Number Of Leased Facilities", "terseLabel": "Operating leases, number of leased facilities" } } }, "localname": "OperatingLeasesNumberOfLeasedFacilities", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" ], "xbrltype": "integerItemType" }, "xoma_OperatingLossCarryForwardSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carry forward that is subject to expiration.", "label": "Operating Loss Carry Forward Subject To Expiration", "terseLabel": "Net operating loss carry forward subject to expiration" } } }, "localname": "OperatingLossCarryForwardSubjectToExpiration", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" ], "xbrltype": "monetaryItemType" }, "xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards offset of taxable income percentage.", "label": "Operating Loss Carryforwards Offset Of Taxable Income Percentage", "terseLabel": "Operating loss carryforward offset (as a percent)" } } }, "localname": "OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "percentItemType" }, "xoma_OtherAntibodiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other antibody technologies. Excludes TAK-079 (mezagitamab).", "label": "Other antibodies" } } }, "localname": "OtherAntibodiesMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" ], "xbrltype": "domainItemType" }, "xoma_OtherFinancingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other debt obligations not specifically mentioned in the taxonomy.", "label": "Other" } } }, "localname": "OtherFinancingsMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "xoma_PalobiofarmaSLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Palobiofarma, S.L.", "label": "Palobiofarma, S.L {Member]", "terseLabel": "Palo" } } }, "localname": "PalobiofarmaSLMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails" ], "xbrltype": "domainItemType" }, "xoma_Partner1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.", "label": "Partner 1" } } }, "localname": "Partner1Member", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" ], "xbrltype": "domainItemType" }, "xoma_PaymentsOfContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of contingent consideration.", "label": "Payments Of Contingent Consideration", "terseLabel": "Payments of contingent consideration" } } }, "localname": "PaymentsOfContingentConsideration", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" ], "xbrltype": "monetaryItemType" }, "xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments related to purchase of royalty rights and other commercial payment rights.", "label": "Payments Related To Purchase Of Royalty Rights And Other Commercial Payment Rights", "negatedLabel": "Payments related to purchase of royalty rights and other commercial payment rights", "terseLabel": "Payments related to purchase of royalty rights and other commercial payment rights" } } }, "localname": "PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on second license agreement between counterparty and third-party licensees.", "label": "Payments To Be Made Upon Exercise Of Option, Second License Agreement", "terseLabel": "Obligation upon exercise of options per licensed product, second agreement" } } }, "localname": "PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" ], "xbrltype": "monetaryItemType" }, "xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on third license agreement between counterparty and third-party licensees.", "label": "Payments To Be Made Upon Exercise Of Option, Third License Agreement", "terseLabel": "Obligation upon exercise of options per licensed product, third agreement" } } }, "localname": "PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" ], "xbrltype": "monetaryItemType" }, "xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers the percentage of compensation deduction in eligible employees salary to purchase entity common stock.", "label": "Percentage Of Compensation Of Eligible Employees To Purchase Shares Of Entity Common Stock At Discount Through Payroll Deductions", "terseLabel": "Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions" } } }, "localname": "PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" ], "xbrltype": "percentItemType" }, "xoma_PercentageOfDecreaseInFutureRoyaltyObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.", "label": "Percentage Of Decrease In Future Royalty Obligations", "terseLabel": "Percentage of decrease in future royalty obligations" } } }, "localname": "PercentageOfDecreaseInFutureRoyaltyObligations", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" ], "xbrltype": "percentItemType" }, "xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.", "label": "Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares", "terseLabel": "Sales commission paid per transaction (as a percent)" } } }, "localname": "PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" ], "xbrltype": "percentItemType" }, "xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.", "label": "Percentage Of Gross Proceeds Paid To Agent For Sale Of Shares", "terseLabel": "Sales commission paid per transaction, preferred stock (as a percent)" } } }, "localname": "PercentageOfGrossProceedsPaidToAgentForSaleOfShares", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" ], "xbrltype": "percentItemType" }, "xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty rights entity has option to purchase in future license agreements.", "label": "Percentage Of Optional Royalty Rights Purchase On Future License Agreements", "terseLabel": "Percentage of option to purchase royalty right on future license agreements" } } }, "localname": "PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" ], "xbrltype": "percentItemType" }, "xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty on net sales upon commercialization.", "label": "Percentage Of Royalty On Net Sales Upon Commercialization", "terseLabel": "Percentage of royalty on worldwide net sales of each product upon commercialization" } } }, "localname": "PercentageOfRoyaltyOnNetSalesUponCommercialization", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" ], "xbrltype": "percentItemType" }, "xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of monthly payments of principal and interest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Period Of Monthly Payments Of Principal And Interest", "terseLabel": "Period of monthly payments of principal and interest" } } }, "localname": "PeriodOfMonthlyPaymentsOfPrincipalAndInterest", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "durationItemType" }, "xoma_PreferredStockConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock conversion price per share.", "label": "Preferred Stock Conversion Price Per Share", "terseLabel": "Preferred stock conversion price per share" } } }, "localname": "PreferredStockConversionPricePerShare", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible stock must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Preferred Stock, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Trading days" } } }, "localname": "PreferredStockConvertibleThresholdConsecutiveTradingDays", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "integerItemType" }, "xoma_PreferredStockDividendAmountPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The dividend amount per share based on the dividend rate on preferred stock.", "label": "Preferred Stock Dividend Amount Per Share", "terseLabel": "Preferred stock, dividend amount (in dollars per share)" } } }, "localname": "PreferredStockDividendAmountPerShare", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails" ], "xbrltype": "perShareItemType" }, "xoma_PreferredStockDividendPeriodMonth": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of days in month over which dividend will be prorated and computed for any period greater or less than a full dividend period.", "label": "Preferred Stock, Dividend Period, Month", "terseLabel": "Number of days in month over which dividend will be prorated and computed" } } }, "localname": "PreferredStockDividendPeriodMonth", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "integerItemType" }, "xoma_PreferredStockDividendPeriodProratedMonthsInYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of months in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.", "label": "Preferred Stock, Dividend Period, Prorated Months in Year", "terseLabel": "Number of months in year over which dividend will be prorated and compute" } } }, "localname": "PreferredStockDividendPeriodProratedMonthsInYear", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "integerItemType" }, "xoma_PreferredStockDividendPeriodYearProrated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of days in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.", "label": "Preferred Stock, Dividend Period, Year Prorated", "terseLabel": "Number of days in year over which dividend will be prorated and computed" } } }, "localname": "PreferredStockDividendPeriodYearProrated", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "integerItemType" }, "xoma_PreferredStockRedemptionPricePerShareOptionalRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The price per share the company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event.", "label": "Preferred Stock, Redemption Price Per Share, Optional Redemption", "terseLabel": "Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share)" } } }, "localname": "PreferredStockRedemptionPricePerShareOptionalRedemption", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "perShareItemType" }, "xoma_PreferredStockShareCap": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share cap for which holder of shares can convert preferred shares into common stock pursuant to redemption rights.", "label": "Preferred Stock, Share Cap", "terseLabel": "Share cap (in shares)" } } }, "localname": "PreferredStockShareCap", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "xoma_ProceedsFromIssuanceOfPreferredStockNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds From Issuance Of Preferred Stock, Net", "terseLabel": "Net proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockNet", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesBPreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ProceedsFromIssuanceOrSaleOfEquityNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of offering costs.", "label": "Proceeds from Issuance or Sale of Equity, Net", "terseLabel": "Net proceeds from issuance of stock" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquityNet", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ProceedsFromUpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.", "label": "Proceeds From Upfront Payment", "terseLabel": "Cash payment received" } } }, "localname": "ProceedsFromUpfrontPayment", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ProceedsRelatedToPurchaseOfRoyaltyRights": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds related to purchased royalty rights.", "label": "Proceeds Related to Purchase of Royalty Rights", "terseLabel": "Receipts related to purchased royalty rights" } } }, "localname": "ProceedsRelatedToPurchaseOfRoyaltyRights", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Purchase of Rights to Future Milestones and Royalties [Abstract]", "terseLabel": "Purchase of Rights to Future Milestones and Royalties" } } }, "localname": "PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsToFutureMilestonesAndRoyaltiesAndIncomeTaxesAndNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.", "label": "Purchased Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones", "terseLabel": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones" } } }, "localname": "PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" ], "xbrltype": "monetaryItemType" }, "xoma_PurchasedPercentageOfMilestones": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased percentage of milestones.", "label": "Purchased Percentage Of Milestones", "terseLabel": "Purchased percentage of milestones" } } }, "localname": "PurchasedPercentageOfMilestones", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" ], "xbrltype": "percentItemType" }, "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased percentage of non-royalties on net sales of products.", "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products", "terseLabel": "Non-royalties to be received (as a percent)" } } }, "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "percentItemType" }, "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.", "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage", "terseLabel": "Future non-royalty payments to be received (as a percent)" } } }, "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "percentItemType" }, "xoma_ReductionOfContingentRefundLiability": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reduction in contingent refund liability.", "label": "Reduction of Contingent Refund Liability", "negatedLabel": "Reduction of contingent NIH refund liability", "terseLabel": "Reduction of contingent refund liability" } } }, "localname": "ReductionOfContingentRefundLiability", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails", "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_RegulatoryAndCommercialMilestonesReceivableMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.", "label": "Regulatory and Commercial Milestones Receivable, Maximum", "terseLabel": "Maximum amount of potential regulatory and commercial milestones receivable" } } }, "localname": "RegulatoryAndCommercialMilestonesReceivableMaximum", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "xbrltype": "monetaryItemType" }, "xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer, excluding extinguishment of debt.", "label": "Repayments of Long-term Debt, Excluding Extinguishment of Debt", "negatedLabel": "Principal payments - debt" } } }, "localname": "RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt": { "auth_ref": [], "calculation": { "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer, considered extinguishment of debt.", "label": "Repayments of Long-term Debt, Extinguishment of Debt", "negatedLabel": "Payment for extinguishment of debt" } } }, "localname": "RepaymentsOfLongTermDebtExtinguishmentOfDebt", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for sale of future revenue streams.", "label": "Revenue Recognition Deferred Revenue Policy [Text Block]", "terseLabel": "Sale of Future Revenue Streams" } } }, "localname": "RevenueRecognitionDeferredRevenuePolicyTextBlock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "xoma_RezoluteIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rezolute, Inc.", "label": "Rezolute" } } }, "localname": "RezoluteIncMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEquitySecuritiesDetails", "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementDetailEquitySecuritiesDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfLevel3FinancialAssetsDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "xoma_RoyaltiesPeriodMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days", "label": "Royalties, Period, Minimum", "terseLabel": "Royalty payment period" } } }, "localname": "RoyaltiesPeriodMinimum", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails", "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" ], "xbrltype": "durationItemType" }, "xoma_RoyaltyAndCommercialRightsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty and commercial payment rights acquired.", "label": "Royalty And Commercial Rights Acquired", "terseLabel": "Acquisition of royalty and commercial payment rights" } } }, "localname": "RoyaltyAndCommercialRightsAcquired", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails" ], "xbrltype": "monetaryItemType" }, "xoma_RoyaltyInterestAcquisitionAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Interest Acquisition Agreements.", "label": "Royalty Sale Agreements" } } }, "localname": "RoyaltyInterestAcquisitionAgreementsMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" ], "xbrltype": "domainItemType" }, "xoma_RoyaltyPurchaseAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty purchase agreement.", "label": "Royalty and Commercial Payment Purchase Agreements" } } }, "localname": "RoyaltyPurchaseAgreementAbstract", "nsuri": "http://www.xoma.com/20211231", "xbrltype": "stringItemType" }, "xoma_RoyaltyPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty purchase agreement.", "label": "Royalty Purchase Agreement" } } }, "localname": "RoyaltyPurchaseAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "xbrltype": "domainItemType" }, "xoma_RoyaltyPurchaseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty purchase agreement.", "label": "Royalty Purchase Agreement [Text Block]", "terseLabel": "Royalty and Commercial Payment Purchase Agreements" } } }, "localname": "RoyaltyPurchaseAgreementTextBlock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" ], "xbrltype": "textBlockItemType" }, "xoma_RoyaltyPurchaseAgreementTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A second royalty purchase agreement.", "label": "Second Royalty Purchase Agreement" } } }, "localname": "RoyaltyPurchaseAgreementTwoMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" ], "xbrltype": "domainItemType" }, "xoma_RoyaltyReceivablePercentageOnNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties entity has the right to receive as a percentage.", "label": "Royalty Receivable Percentage On Net Sales", "terseLabel": "Royalties entity has right to receive (as a percent)" } } }, "localname": "RoyaltyReceivablePercentageOnNetSales", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" ], "xbrltype": "percentItemType" }, "xoma_RoyaltyRightsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty rights acquired.", "label": "Royalty Rights Acquired", "terseLabel": "Acquisition of royalty rights" } } }, "localname": "RoyaltyRightsAcquired", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ScheduleOfRoyaltyRightsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of royalty rights.", "label": "Schedule Of Royalty Rights Table [Text Block]", "terseLabel": "Summary of Acquisition of Royalty Rights" } } }, "localname": "ScheduleOfRoyaltyRightsTableTextBlock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" ], "xbrltype": "textBlockItemType" }, "xoma_SecondRoyaltyInterestAcquisitionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Royalty Interest Acquisition Agreement.", "label": "Second Royalty Sale Agreement" } } }, "localname": "SecondRoyaltyInterestAcquisitionAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" ], "xbrltype": "domainItemType" }, "xoma_SecondTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second term loan from Silicon Valley Bank credit facility.", "label": "Second Term Loan [Member]", "terseLabel": "SVB Loan, Second Term Loan" } } }, "localname": "SecondTermLoanMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "domainItemType" }, "xoma_SeriesXAndSeriesYConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series X and series Y convertible preferred stock.", "label": "Series X And Series Y Convertible Preferred Stock" } } }, "localname": "SeriesXAndSeriesYConvertiblePreferredStockMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "xoma_SeriesXConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series X convertible preferred stock.", "label": "Series X Convertible Preferred Stock" } } }, "localname": "SeriesXConvertiblePreferredStockMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "xoma_SeriesYConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series Y convertible preferred stock.", "label": "Series Y Convertible Preferred Stock" } } }, "localname": "SeriesYConvertiblePreferredStockMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails", "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum age required for employees to qualify for immediate vesting of award.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award", "terseLabel": "Minimum age required for employees to qualify for immediate vesting of award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The length of each offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Offering Period", "terseLabel": "Offering period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" ], "xbrltype": "durationItemType" }, "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age", "terseLabel": "Threshold years required for retirement age" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "xoma_SiliconValleyBankAndNovartisPharmaAgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Silicon Valley Bank And Novartis Pharma AG", "label": "Silicon Valley Bank And Novartis Pharma AG" } } }, "localname": "SiliconValleyBankAndNovartisPharmaAgMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureDescriptionOfBusinessRepaymentOfDebtDetails" ], "xbrltype": "domainItemType" }, "xoma_SiliconValleyBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Silicon Valley Bank credit facility effective May 7, 2018 and subsequent amendments.", "label": "SVB Loan", "terseLabel": "SVB Loan" } } }, "localname": "SiliconValleyBankMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" ], "xbrltype": "domainItemType" }, "xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a 401(K) and to an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan and Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock related to 401(k) contribution and ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "xoma_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period Shares, Warrants Exercised", "terseLabel": "Exercise of warrant" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as 401(K) plan, and to employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan and Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock related to 401(k) contribution and ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.", "label": "Stock Issued During Period Value New Issues, Common Stock", "verboseLabel": "Issuance of common stock, fair value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesCommonStock", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "monetaryItemType" }, "xoma_TakedaPharmaceuticalCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Takeda Pharmaceutical Company Limited.", "label": "Takeda" } } }, "localname": "TakedaPharmaceuticalCompanyLimitedMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" ], "xbrltype": "domainItemType" }, "xoma_TaxCreditCarryForwardExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carry forward expiration year", "label": "Tax Credit Carry Forward Expiration Year", "terseLabel": "Tax credit carry forward expiration year" } } }, "localname": "TaxCreditCarryForwardExpirationYear", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" ], "xbrltype": "gYearItemType" }, "xoma_TenYearWarrantsIssuedThirdRangeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018.", "label": "Ten Year Warrants Issued in May 2018" } } }, "localname": "TenYearWarrantsIssuedThirdRangeMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails", "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails", "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSvbLoanDetails" ], "xbrltype": "domainItemType" }, "xoma_ThirdPartyConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third-party consultant.", "label": "Third-Party Consultant" } } }, "localname": "ThirdPartyConsultantMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" ], "xbrltype": "domainItemType" }, "xoma_TockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period from exercise of warrants.", "label": "tock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Exercise of common stock warrants (in shares)" } } }, "localname": "TockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "xoma_TwoThousandEighteenAtMarketAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At the Market Agreement, 2018 in which the company may sell common shares.", "label": "2018 ATM Agreement [Member]", "terseLabel": "2018 Common Stock ATM Agreement" } } }, "localname": "TwoThousandEighteenAtMarketAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" ], "xbrltype": "domainItemType" }, "xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2015 Employee Stock Purchase Plan and subsequent amendments.", "label": "2015 ESPP [Member]" } } }, "localname": "TwoThousandFifteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" ], "xbrltype": "domainItemType" }, "xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2010 Long Term Incentive and Share Award Plan and subsequent amendments.", "label": "2010 Plan [Member]" } } }, "localname": "TwoThousandTenLongTermIncentiveAndStockAwardPlanMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized tax benefits increase (decrease) resulting from prior period tax positions.", "label": "Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions", "terseLabel": "Increase (decrease) related to prior year tax position" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "xoma_UpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for initial payment under agreement.", "label": "Upfront Payment", "terseLabel": "Upfront payment" } } }, "localname": "UpfrontPayment", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" ], "xbrltype": "monetaryItemType" }, "xoma_ViractaTherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Viracta Therapeutics, Inc. (\"Viracta\").", "label": "Viracta" } } }, "localname": "ViractaTherapeuticsInc.Member", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfAcquisitionOfRoyaltyRightsDetails", "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" ], "xbrltype": "domainItemType" }, "xoma_XOMA052LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gevokizumab License Agreement with Novartis.", "label": "Gevokizumab License Agreement" } } }, "localname": "XOMA052LicenseAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "domainItemType" }, "xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "XOMA-052 license agreement and IL1 target license agreement.", "label": "Gevokizumab License Agreement and IL-1 Target License Agreement" } } }, "localname": "Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" ], "xbrltype": "domainItemType" }, "xoma_XomaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xoma Corporation.", "label": "Xoma Corporation" } } }, "localname": "XomaCorporationMember", "nsuri": "http://www.xoma.com/20211231", "presentation": [ "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 15 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1828-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2740-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "65", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "66", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21564-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130611-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r325": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r385": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r424": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r512": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r635": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r636": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r637": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r638": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-3" }, "r639": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r640": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r641": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r642": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r643": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r644": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r645": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r646": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r647": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r648": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r649": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r650": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r651": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 123 0001558370-22-003022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-003022-xbrl.zip M4$L#!!0 ( .@\:%05$9T]G1Q8 MU+-]AWG+GP^BX) $-F,'__/W__R/G_[K\/#WB^F=Y?AVM*9>:-F<.4MJ6>^/OC_Z\>3=V='Y]S^>GEB'AS&E"Q) 2=^S M!,FSH],DY3*FZGL?K//C'X[/3L[.K-/3#^^^_W!R8DWNDXSWT,H%T^9\"9P/ M@;VB:V(!KU[P(>#ASP>K,-Q\.#Y>D.#QR.?+8_B(Y4\/3TX/ST\/XJPN\SXG M>9^?GX]>'KDK\I^=G)P?8_(C,**RVQ'GT'O;I(C('E#[:.D_':M448\J\E*J MXOE<5'#Z_OW[8Y&JL@;,KB8,"3F: %NXW="@S*5*J6 5.J"N5))448R^V*OJ M5F%*GE5(=<)\YK@KOSN6B4ECP@VOX152@%[=.DA9J.M9 @NO7+NP.8[RU+S/ALO?%Y:,F)_\ZWA< U((F_$N8.\=/A MZ1F@= 3$#BRO>H353 7'?9NAID&L_[NZFJOGS79U!BV&E?@=M.*[RT]PC:Z?>R\6T:TCQ5U'6A:$/EU'Y,W3!(B!VFQ/HUJ;1D M[- B_+);@XHZ4KO&J%*R(3@3]FE$P[+>V(RJ(NJ':$C/)F3TD%;U)_G%7]4U M$\_S0T%$?%-?-QOF+?SX$WQ$G? #RM<?'*$!Q8#&;R;D62IJG&.73!/"88 2T6=/%# M*Z4(/Q11"ZA:DJR%="U)V%*4?SHNDBO6%,$N8NS]7?P-RTL NI+H0%R7X])Q MEJ:2-G'MR.U1,&U9?;GXJP*L/X[0:Z'0!B]!=?)=YN"L=T%<7'1F*TH5>"WR M-2$&Z[U +"$#?U^.'V;CN]NKT?SZRKH8W8T>+J^MV:_7U_/9@%$=1@ZHO-3) M@I"D!N/%>*.T8!Q:_AIZ9H4Z\A.]\X/@%O;@:_K1(Y'#H. E,']61G?O-33+ MQ5F57%Q=/\Q *'(2,IO#_^ZO'^8S:WQCC2?7T]'\%C)8HP?,>3^97O\*Q6X_ M75O?W(UGLV^MVP?X#+\BU9YOK6\0<>OLVT' M)- .]0EX@US1"/ZSTTK0G7^9EC?=8'U.;*&J,F\Y =AL1@-$"O),:0#;>EM,W,'JBH:$N27=;=_D MFV3C'0SYLZ*>)QI@^0LKVP0+=#\KTP@K;86EFH&"!16+K&E;Y+=OXN8,"T.- M5&4'^0WS0.UCQ$W&K.P]Z',>4=3JQ^&*\CM&'ID+3:5!C2SMAVBS!)V7)2A; MK974FYF!)&7(&5*!%*K/SZ%FV']1!>X2'G4*GL3V% M_ZY?-KAUA)E:I%WZ0=AN9.L*Z\ ^UX]KK,**ZQ"SNZ]_X//.Y!N?V!9LQ?G]R6L18TK $$?B9D+<6/L\G#O"VAW=*;1^T M(9@2L147-'RFU$/%* I]OIV"@@0C]'JQH'8(NW;\K4>^/TV=4)1F^8)0Y&NV M'F755J#JMCA4)J8#JJJ7GP:1:2\R:,?Q/;GE?Z"@M2\HY]2!M%$0T-HEH <% MG3B\TXA#6@\N_E"3I:K"+):L;,!>ASUTG.S8">6S%>%T%'L#D$>@YD,OKWT8 MW[[]>>6[#N6%"0 PELX:/H=Q?T4]?PU;,/CU$5I^ZUVFO3%>7&_JQ.=M&M$H M@:>GY0D)A2R60FBH)5IJ99MJA;XE&VME6UN>O%!B59/%E)5IM(6MMIAG9=J- M!:XGLT&<:\0Y]C=4_\-V.&;+3X/67 M"(9&R_.&BH+-J)YW.7B8S<>7__QU?'=U/9W]MW7]OQ]OYW\,R+:Q#7,S]H@M"%52,&^7D%^9'K[8S::%NO/]'9(V6=#)66BEUD2#;"2ELQ"-$K M"-$DXO:*X(PQ9?$6\HQ]> _$1ZRX($%/[P_KSNX M[TZA603>E44@J2/C=I6M!LWJ<4WXY^T,*ANPWPOVGS;KDQ]_0-W%/;V #MU% M"NIHZ>2A[+K321X^3>ZA6JFNW!V>6ECU(!T[2<>GLCJ02UN9%B"K.@:8=X+Y'\0+H!\NF!]2N\Z_OP<% M'>2E/4$+R..:K+BJ ?F=D!\M%FQ-G3Z0%XKJL/Z^!]9Q%0/&N^EPC+!>".<* MZO#]H8]V=CNZO1K0W0G=&7'I>"&-=%/Z1+V(SD).R;K6Q7HW:CHY^+&''&"M M: F*38UQQ59<\R @.@&1QMBMO#N[IAPM(Q-Y.*ILNLE)>#!:0N?6"<<.E)H% MX[OR=CZN2XA%6IL55Y=:H],*<4D0=0XBL5>1 %T*C;'[D(D"*9U0E/;TO80B MKG20BOU.%&A9YW7;^UU(Z:2BM-_O-U7(2@>IV*M43(CK[T,DLG1T\E R#?22 M!ZQQ$(:]"L,GQHE=:PW>A91.)$JF@UXB$5I>*?$??WHDSD".DDHF1@ MZ"41HLI!'O:K2"P6K,&PN!,MG524S!+]5(FXUD$P]BH8LVB])GP[7HSL+Q$+ MF'0ACDE(#Z1]R$R':G3B5+)N]!*GN$%H\L@T2;A=Q>1B]ZM!W#3B=D,8_T3< MB-Y3@K]%#R?>(?+B)H8.2",Y7!+.&75&85)T[$W1580S;WG1L U^S:J:Q>[[ MLNT$*5J"I)5M#J8DKC'QM541U" 3R2)NE47"+!40OZ1IL6O6('Q]A"^9;"Y7 M:.(,;CWE8.ZD8K"XHT_4/2](3Q?!VT,U.J$KV6;JA2XSH<7ML6Z]Q+/>R0G: MPA*MLL[+HCI(7!^)JP*^Z'8''1RMQ2V:3E+6D[1.LDKVG7K)JI.ALI-?IAV# M(/42I$M?N-12>9.2.7%,SBX"HR&A$XR2H:=>,-*:K%Q5 _;=+F&*7S"^[2XA MU^H*->/[0X5+9RD@DR1M+1+: Z#= !TYCF@"<3.! UJAVEA2!VW9?:L$;4K? M8FD% [Y:?'UO.:?XGLICJ [M8]W)6P:SI\<[G]0BW*5L,\8_5@Q?H'Z(Y.4% MW/2 /ZT"M<-/%Q96,R"]&]*)&[U?[Y'9F8 .\[+7=2O,$\=KK&L ?C?@;[V0 M0E>H6(B]L*^AH8._['K="GY56Q):<9" #H'3",?[=G7Q%AIR-J/YOHQF,1#: M:'H]LX#@@%<'O!Y\5P]5)I,.I=+99@&EA_'=@$\'?."?2TY!]T33YQ84SV?" MZQQBVQ;385@ZC2Q@B'$%;4'=LC/D!UP[X/K1X]3VEQ[[4\2$O* >-*E-7$E- M01VVI3/% K99\@)H5<& KO[-,-_^+%[KQ9BGI0W M-8*D)9\,SA)%:^1L,AE [ >B"JDZ(T^H)$[AW5I-]1V.*N*!LS[8?X;12*"=+JC]"[DM& M)P&EO52#!*C:K+BZX5AX3X._K&,W&B-WH*03A]+V2S _9GF91U6T@9: MV,)#U<1!)K4QS,B&A1AJ#+IY1CETYN\8OD[\]0=T*TS](0-()ESM&3%G712S MG8@URU%%Q-JXNGC2@AE*5&3]+B/?R1]_6)EZK:3BN,P@'IW%HZ<@](.\_*QD M->2C =G=D;WH"6U-.1VV)=M"#;87 [:[8'L%&S>'>DYMY,FFO#H,2\:#(H8) MQ0&T+J!=/"W&SQZH/"M69ZW79==!5[(%%*&[^'1C)50'^+K -PK7Z26E%OA5 MYM^S=Z4&!+NLB,F=D'2']!O!4#MA=HO49HWL1DF'>FG'7EHU M,_=',ELH2]69VT(-,M%!)BH ;(%_0RD=UJ4;DD6LJP$>0-7&[5ZO62CO0..M MU_CV@RTL':Y+'GV\__"4N?::?7(@B=X?7TRM#^G]*K4T"TUEM.^D'?'5VDQ+ M1'JF,9D%XV^%APF2%JD;N8.D[29I76X(]2>DDY?R%ELK+\-MH=[O!=C J>PN M?.(D@!WT,G[O\A?J+SG9K)B=N3%24:)60/9(NUEF*L+)YVC)-T^"SW^SXA8( M,4K;D'V%LZ[L($S[%Z8X%N3%-DTE[I0NFV:=5ZA#)UQEN] .PJ7B7SYNK6R+ M+-FD04)R@&9OKT_MX7DI#:S[?/IQ +[_RU!]GH#20-O_K:^[^*TWT!M,]^C8/F.L/X)N.V35(Z;R'A^[O?(#9X8A2 T[70^L!K'T= M">U^X*.!=I]GA0/L[5+A9M M3HD&=/=Y]% -YQ'5$#=E;8:R0[S_ :]=[./5P+4JTXQ@ MSS"P YH=0E1605?.T(R3+L#K $@?2WHU-HUY&V'J%*)L@&S/YO5J-/N2:0;Z MM QT[S B@R"TM[G7[$7*.9KATU[W'S#9MVVW=A?9CTXSOGMUVQ]DH8?']R4) M5@#AE 8P =JPC\[ZW0DTH?^N@Z>X&/?!2J"?UB2_#9[^>Y\#XF3]ZT7[ M)-TH*S!35-PX['_!1V6Z_7_Z"A+^@S'YIG1AO8@OA-N8-R=1S^='/E\>G[Y_ M__Y8Y#K><'^#4;%H<*Q(',0$5IPN?CX(UX^'9R=GIZ=GYZ?_ @:/7M:NRE&B M__+(75'#&2CD4FP+?1*W45$(68@D+M-,%N8*_F81-ZDF!'9_/@C8>N-"XX[? MA'- J"OG>5"K&;]*\AC*MTL>N_(-1:A;S_(=)AO*+0S]KMP69XMJIG/G)VUY M_^GX)7 ^D,T&GW83W^(OGN=+4O(C?H.B/@\MCZQIL"%VVFS1Y(#:1TO_"422 M'2.S7]X=6(&]HFMRY]N"DLP?U!? /P_EGT=0H6JEJ)RZ\G0 UQ) M891(:1O+/N <<2Z<@;&E/Q^TR"C[!EO%/L 6#J9TOKT-Z1HG0> B>@R@CR/D MX1?N1QN5E4$6Z%[Q-T@ \YVY(,0\C'J"#6 8[P#!":$)!Q8!0IS8X<\'"^(* M*1%E'XE+/.Q/^;1(,]]B.%/A]")VGTS&6;\-@@B)Y(*_W/A\1OD3LVDPYIM ]1KIWFT$==GZEWK4:.0YT)9Y[--L2]D!2"K*E5=4^7 M$L;T1!OQ:7.T-XKK49W1K4RV.U#K]I:OW!GR=Q/3C;>EYO0EO'"%SY]DMVUN MR:@3\D/\*_@0JJ2_!OS>#!?A;9G90%SCL\72864)TA89#4:SKO5%(/7Y#,2P M^W:P8GKJ3<' #HGC2$SE8U1RMRMCDL8IP@%F6Y;Q[N4*K7S=(=#$<_%U>ME4 MQ5EMJC'M+SS3"7(W6H.NS/Z,91(5!:5:7?J!<%M&NP3Z-,E#B1*<>R5I\.1V MN]X0QO';>*'TJG@B U&F[ DI)YW2,G.E8+R"AM9=%9W2/WTW"O&0^)ZN'RE/ MAV\IH8B: P28]^83E-07TN4E%YI+PD"=O'*ASVPN8A/NVY0ZP0WWUQ\W"PX[ MIMAY2?'8F,-TW\?WHY/OSHJ359XG72:--M*1U6+S>ZLF=Z=SPIVDT%#_"HBB*EK"JS64 8$4YFG/B!2"L$@.;UDT@Y7S&6'];*$KW MY(6MHW5L#T!U5=C_,[:4IARFG)*T4FUEHR/BXNC*6(KRGU]M%.VT)5;-#&(8 M?N-^2,>+19&-BO0W4M);'EQEK5$9(_,#< 73!2QCV[/\XM:MC*F+&QZ?+,)G MHL*V9?GXC86K7_PG6+KQ%W%'>/&\V V[4#"T4]1>:@*BZX6P#1HY#HN5%_VN M:K:A-ELPZMQ$H?0#GA'81=5OV5ZOFC?=L;59K&/[6'*B:7^)6"#ZH%[-:EG& M@(5<'78XH&W@*0!9PK10E@-MMN(PV$.]SGHWZ9#--/LKB 1MD6FT+R:68R43I MU"JS,'E*T2@,&VUF#:N[KVDMUV11 M97V*>LW*V:#S&>1.Q(!3.IIK$0!; M UK#"IJQ7(FC:-!V>"1"!R2R&1L3TFWKZU=DR @H7-?.SU(UB88N'C<43VO= M,=^LB'! MU*V)AWZ/#,APBOZ@L20F8_[UZ!LBW[#FC#?B$-];WOEXH8OS[<+GSX0[ 8Q< M)HG\ >,Z69N[%,E.A$O\]/8[C?K&CQ>+ )A; ,Y(/;F1'$].R;#?@8 AL'_T MN/0N^Q.F9/)R03VZ8"%JP!PC90=7-/X#IO3(15[1@BP.->3B!X4FOC0D)"OD MGHD:8X]O8Q.=/_OSE1\%Q'-NV"*DU+M>;UQ_2V6@ K5/0L_\_*3;IZ"9DW&& MDSGUE%/7K7#I1#W!DT^]CW"D-/9#M])F=D;6.I5=',8+9650, =S7X$LHA' M)'(-+(?;C._.*%0.@;'^!$HU!R7LBJ+I)SL&__IZ7W,*VVF>K[D8 WO]*?T2 M,1C4-SZ_)*&]^KC)9KIG7E;9W9F,F4=3-6RA ^HTF<5AU$T(4TI[Z4J1$)OR M^O@JI(T5,]'44B":S*[H8IMFB3?#8A8#UFF X47DX@=2-*4ADZ&X1FEOOB)] M$S:M2>075*9&3X2Y=2%?,+ZD+7RCT;O6*5X>V .A; <8>[_K+ MK8C8AOOHNTE^\=3E,G1'.N'QJ7"\A_*> !WED*$B :6^N:TR5\P3(N7-SW^2 M 'ZY&YFC-:ZNUR_H=@RBZ+IXQ1;&L5+[D#DL@-R&XOPSUPW)UOUUB!NC@K?Q M[LYH/M":(%#.W&*9\='$'^+]5^(65IDJU:DK 4.V=1DE^IHM5[B;&(7WA'^F M8S"[JC<_/F*\2IF MVV8VE%5LJ/ ,PLLFD8NS<(&_AAR&+GH9U[74F?(:6K+&N;ET]ESA\=:RV-OX ML[2[NE[[ZL<=[!RP51F^6^5M8+:C)K)2?YN>!Z*6:BX:M2YE"$[[MAA15I:4K>NDCY> M:N)!NMEP_XFXZI6NW.6>OZY6<]U5LX*C!"7QI$/^4P?<..)&EUJ68RDVRB0[F H&Y494]IR&/L9:#+%1KN8+N3V'YRMG_%5"XZ2\)SO[(& MZY2I<[&&]3893>:SZM83C,KD>D^ZF6A0V8X=8':G'E.@\"KQ. M1X'I32 EEGB\!-M44&^I5.K$I?L8BT3KZUS,8(G.[6;$M42>WG&K2S17#:V9 M59+Y-8U=7UZ 6I0PUY9?#.F'<15@RSKV"B=1+?*9J4S4-'S^[+=B,)O/3 9O M& ]$Z)([O^B469UD)AOR!+>:CYHT,QE)C+>+V-3C2PVU^EYOT4[6N[1Y=K)6 M$0?Q)M&4;O+:0:^2YBXNPIPMS^ZO(H1">O2)9>*!/HN4(&/Y3L2^>SF#-8;? MX9^*J&UXF;!=9+1=")@Y563C>\LCO=005)%BP.E>&H] %"WX6M>FFN"I6I2- MZ9_GW_W8?""5SV*F#+6)$%)Y][]="3.9%HI-"SXJU*$NI>/_9LX=T_"@):G)!;Y#-4#BD'!377[MAX ME6>P13XS&4P-=1?TGC@B?E <2"+QW9'S:E$$BX;K7A3,-1NU84LX]^[2+W4$ M#-[D),V\XM'RDGB.<'0I*O>:3&\_3U]&:_%$XQ.M.&1(3=3)%35IO4Y,HWU+ M&PRLNG9;,!H6OYHYC:EF?O0S5=-'C,9 M*[I37Z\IWSY!6^DE<=G"YQXCA9UKEQ)F,IV/*83&WMA-2MU_=5W_643M(%[V M!9XKF#M5-^Q(PP0SA88%$6YC[@L[. GQK&*+C<^$2,6DEOW1FIAY'8.NHRIR M[ VMB/+2/KL9Y^2%D%I<6;9;,%>?V0S6,B;J^":;TO3$%=;3=T<_%.YH="KQ M-4QGRB>VY-%9CF?:IZ"Q[DZ]HQ^,,>96B\L7OW%3),]] M"A[#FJSF[A?Q[.;2YQM?]DOY8*![-E[F!%T"3U5C0^KX&>V&*[9) MY]\+-##B]+J0]\SCB_J94-#[H&3*%-_I>FOR,DG!U6UW,F^_=_X'\8* >G%, MCUO//LI+>T.ZF0)?8ZZX?K'=*(!-?FRAD3:;5I8.3=&WQ["7RZ6T1<>R6=;9 M]DS3C'&OMM?JZ208I)7;[XIT,X6]R:^\[-+9.K?!EJUDC):D[ ;ZTR^/Y?I\ M;S]PBUY\:H6(O?G2:-#Z?&_/3&]M-W:\R,>XNUVO01A@"'Z"112$=KP0>7=6 MK3M69H+B+:QEJ8-NZ=)F0[HQ]S3O*&@1-'^?>!9M-C(?<7$JNG']Y\QKZ]4W M5/=!Z*OIE9U[XZOHA1K'0;EY4,&$E$4EG0&ZEFIR.16%_G*?+E2GT&>K^AI< MZ]QFJB8CY]]1$,:GIMGGLYASZUV2#0/QA$EKZ?-E[JBU1SF#U149EAIO]28; M9>&\D[LNILMDAO*<>8>AUFM+D\=,2;VG?Y(E]/::/!8=0.4GRI4[2[+%3?3,GUN0R69?5.11I^9DH7&$:9D4?TBMAFW"VU&Y8SC M=DH=NA8J6RZ.>Q+5,$FN9KI+;6^!XMOS+ZJ$/70U>YG4U]19.UC&;[TG M&ML"\OKWK]1-II-V6=^$[MVTS)-W?\WK=7L^+FSJ+'O]-[7#N MIVU6K'4L8ZPS6IOG(-.'[RY]#FO0$^-1,&(.J,^,+E"2(;>_9G9\=K@=V>HD M-)D^7[T:0Z(8)OS%K)3EY(+@4R]M&D30RID#FTF&PJU MV4'9^TN7R4S61K8-Y9WJ'=]#D^[%GI[O3#&23[K%]N& M2N_X9V'ZD5(WC>>-#Y0 M6)OW]/^J#M?P7BAGEO&JT/7+Z@I1RQ8R:,J_):"VZF,P4IS/2?QK-2O M&YH+&]P?C;<=6UV)-)N_T6+!UD7G\N)',W7G?T;<#RZ8']B, K_!:"F^? SN M7'S%5OR(3^+PU5?Q/<_G3A3,[)09'+ M :-E(7Q5EQ)F,MW"&:ATS1-6I:I5N(-_40>2YJJP1==-G,9 $C+7$0+EJU'G M[=EL4 M-\.2!I^=G!7NS'?(;^;TF+_CW.HB]%]]!7K'PZ3/U"%RK;*%Z8^X>->&>-LX M_&#A<=SV^,OS9D^RM= M8C;.*EL[:84E:CO-<\4^;NJ4TD,IK5?H-+*+U#S5-=*Z9SYSX6/:%=E1./KU M@\S;@F$!6L[O7UT#3RY^5W+=JMRN9\ [R4 M\[A#QR@'4QI0 J"-@A*Z]5E, M1#-S'_8W%JY^P5L;GKP9.,)7O[=GF3<9,X^C5(5\[T3@J^^,S$V!?IV1(6!B M9\1O6BMQ+O%:DVXB*_$KE,*N!$I8+4N:?":R-J5XOPK*9!^2*[G_9\S,;;(; ML_@V[$+R47=UEP'P(A;Z7I267G57H!0(>&>*7T\G%A_D25^]B%E/."XQ&TQ\ ME]E;^6_FZGCZL,'^:1>'8?=KZ*^C&VAB_)V='WW_7IV[R>W]/=F>G9S^6*D@ M[D3)Q)FJ/% 2#1#/JYKTXV+.[-#J'&/C="7(S5K%QR&+=U(;,QNS6.BVNXDK:W8' M![NVHDLK!>;"[(W33(?L0..KZ:=L3#1H2A HORN,4H'/I.(AM1]?XI/&^JP2 MTJ>TF3OF-L[C8[Y9$4^$U!,C+W$,[^3I7DOEZ^T8^'C]@K&KU.V3BE'"MPMY M>>%C",5D^.]^';AS;69V=-$.F5V02DG&3##:-2CV7H4Y@*#E.7,G*48O2'R3 MBRZR;JEWY&+1X3*-DK;L5-*5#M&*F M_.JDYI;16WRO/,[:9#:%=(P49&IECX_7;D6T>JZ:&\=$_?OGK7[[^[?CX]YOI@S(GFKU"AJ5H%*D6 MFBMOV%HJSV2]5@WE$5&*=5VYH7C^BA3E^N3RY*ISWCLYN[SJ=I3C8[>D&]6$ MG,10>)&]D^[NEZ%;*C&^*&>G_=->I]=3NMTOYY=?.AUE\KA+^ A2+G!J2AT; M__G"_O<"52H US"_'2TM:_WE]/3M[>WD_87J)X2^0O;.V:F7\,A)^>7=Q('4 M;V=>VN[I[X\/,VV)5NHQ-DQ+-;1]+E9,5+[N]?7U*?\5DIKXB\GS/Q!-M;@! M4N528E.P3\=>LF/VU7&W=WS6/7DWYYY<(;%2P,.O."']#C;H65&^4J*C*5HH M'-\7:[M&WXY,O%KKK$#^W9*BQ;,X( M<*/JK.S9$B'+/%)8X=^G]T%IR$H]TK(8BZ^_2.U("N4( ME-G,#!P2#P."5(B[ MHVK9%%O;\8)_GQ>M=.$%XS)3JQ3NC;.67):EIO!G]+YFXP(0A?\V)*95A)U2 MBRX.D]-+/ZOOR)Q0LL',-;TCU/=U)CP2Q9:"98HT BU;Q[R[NT'6&T(&:^6V M1>AV"JT=%#M:+)!FP5#%/N>%F:/&4C3 QF)B.&/:$X*.;0&3!32'WP:FB3+2 M-$OYQ:&#:AP!)HC.EBI% PN&IQ?;4E]T]$Q HA4!E1/M/TNBSV&:%;0)R E3 M*?!6" 53W"*#K*#_AT_?P;.[-UAW8>MNRM$ZFX(J$M'5L;;__0$TZNJ5B9C3 MD_<;#;U;"-SA^>Y;;+'R88X&\\!C95<<_'LX?IJ-'^YO!\^C6^5F\#!X&HZ4 MV:^CT?/,F<6 S#K1 L7K;'I&:) 43'@3I.$7Y<6_V5-,6'C_;>C M7D5&8DYPC&W83W4U29+BP\:*1=(,&P6G+,D-*C)M.ZPH#LTU:Z_>9AW]UX;Z M9TAC+C^X^'>;)QQCU:BD[3"J,#+7IF?UMJF[[&!ZTVQPA1#>,$?)!#'ZM+@O-XT",ZA7&@Q9H],VPXSBT-SS7I1;[-.*%JK>+Y?QN#D%?%S M!7*VP^19@;H$N*PW 8(NR!/,]A[(EMO_%9FF1-:1S-<+O<'3OCE:\K3YEDX\5WZ'^8 M(F),FIBG23:5!U*R$Q5:[F2+HQ?_WQ=)\Z)"9G:H(M_7K/?CY=HG9 M&0C?1HQ#T1@[IF5C&NF>=_N7O<[E^?7Y1;]? X#I6.K'Q$R*#M,V#6,SUK)] M*))GS.&$0=0]0-VKCV4C39)HQ"14S;"EMXHW4;?,CQ%;W0PFKK5-DV2,7],4 M %BR>:/][_@#8 GN=VJF%A@P!]!FK'>XV/P'7=*::G3Z%A@[&T:159 BVNB0 M\".K[L$5/'?/(7\WX%\3FVI+_XFZC\Y0AA):8-"B4(NLB=1@; M53&5FE"W7^)K.K=X XZ',4^?327F:X$-\V%U+7I=[W8:'))2%\WCDM?:VH)K M6E+8FC%C]O<^J;:-3MP&RTH@:^(Y@9W;D+[GE98OJ)-S4.A5XZR=#60S#F1^ M7-03V^6,S- *4\NA:\:,F5U$PQ9?X>'W]MTE(2U^VS A1ZVMG&<;419S,P9L MX5WO:+VUTM*"4)LQ<@?G$3]4W8X[3Q^1LGXF%K1-V*BBZ)JQ@^R[.YQDTH_) M@H@O6&"HIMI3"%HS^N#!?(X=P28JYC>[U]AB4D9O,D:G;I%I91 VHQ.>LKOY M!IJ/5&J UV .-,U>,7N@^2U:8 W'7X1(R]@BNV<$FW$B]?7T0X2$@L(F%!\< MS&^UV( +O:B "[>CI]GH-AAZ8?8,?SV.GIYGROA.&4]&T\'S/210!D\LY>-D M.OH5LMW_&"D_/8QGLY^5^R?X&C[9GEP_*S\Q-2F]GRN)W! 16>P)6>/%L_H> M/P[&Y6"4.NN<=<_[Y_U^M]_OGU]4>O>1T> .VI,SP;"A'>PI?^X@EC&\8_:1*M/XY Q,E8Q!N]A.K#N( MX?J'-'\.*L7VDI?0=*J^Z1U)@TK&#%<;S1@S=CLFJ6TH(F7]6/#91D[8@DI1 M4S/H,44;9-BQNP_>S_4C@J@9HN:^"9@:936O"7P\<39ZUW2;1;=G-PCAOWG\ M="U#2?7C0J)%8PF0&W.CN/)$K#C R=1(R-@6)LA";,9:]ZZ'="=%J>.^EZY^ M9LW>V8N!RSHG_&2+_A.FM53584HXF*^P@4V+8=L@%UN,?5-RU=C:B38+VSH+ MT*;TX28"#2YY<.(-T@F/AY-L]L0\05WT01?]AAI='F8S>F]O5N(B8<<;8US7Y6[A_%OU;Q P:.QPQ]V2&:CZ@QP,&AHZ-4M7\H) LNPJT.4 M73JX1<[?\-E9)AJ]:TO5>.5ORS@/S<0=C?A4(?PG<"^N.U=G%U5=)6;AL@$, M?Y (B'2S=5Y5V7G\ _8T3U+H+/$"ZM>/U,#HX;XKIT*;,6D&=- ?)VQX[1/4 MCS8Y+10V>0K89IB4/^W$7]5E9R)@U.5JC+M&$9DXB/ZJ!K'W"C>U!/"2UT*B MKZ:S$Z8&/[?IO-$%5;)8S_>F:;/'K\ 3V1\XOR-TAN@&:S#SHD-=Q:O(D$(Y MBVPQ*4I3C]SLMBK?XQ:M*=*<5]Y@]K6F9&YK"9U&;/H64R0;]MH&HQJL"+7P M_SB,\<)]:]9XY2]YLE5B;#I!$.,N?0AF/P!"Y%)%R1=RHX>6*7(IR[HT+][: MAP \4>.'2+X6&SR?#E(#6AT7%'HP>/M_HF[YR@6+31]^(3 ]0]OM*0\^-?S4 M06U]M(H1^720&L$J)S&BF_LCUI%I$U M\.*C7F"<(E7'_T-SQNB$11Z1K$'57%]>=:[;0HS<:O 6ACHUITAXD33A *:\+@BNDM:GY[&?5#2"S(8 M^;"D,'5$"CM()F56C$>L^*7*NA+KPWL=[&2K$[(T_;FA;(4=)+$R*\8C5OU/ MZ(01?WA9PL4N0Z;H$@Z501+:\&A3O^<2P\B\WM:]*2/,CP_Y#I(5(CKPN%#6 M:P#1*RMA6076R%,S^0&"/0!@:TY1Y%" 9^&:!_4/@XN)M2ON_!9?!*8TLX3)Y(:<-C2LW?(8C1V[VQ06:>\Y\1!=2/-$TZ M_RFJT&;,X$4Q10=U%6WOM/AK)PI44VIYT[E3QN5Z^?L MSLUE]7,B"J@?@9KDYX@JM!D7>+T.FMUL]1K>':&\88ES3[*4^A$PIZTC/)X" M-")RK:9RTNRO 01?;H 6ZWR!X$?^C0!WQ L[, KE5(R<)U75%F8T8-_M$BD& M^?(=+%G2=-"0,QZG'(8=HEO,KB^9W M R" UP>X\8;MPT??9&0K#N;..>3J&7.T(KY-X74&C=$#8U3]<-,G]4QEZJ^B MRT/K7:/S/RNZ"P@J<-<@>T$MYE'!2A&Z;U3XGGF\_'E)\2<7I'4A>5.ILL%N MA])[53S=V]FE# +O _"J'^HHTYF<[WYRQ:KH.;,\B]0QK31GF=6\:1J^+^W_*=A*KBZO>A=- MWEV(ZD!B838C$%(0:XPI@XD.P*@"@#-N2)?3U?LC,;ICH:KO BHZ/:5[M-S; M*?4="9/KX,_"';R_>F57OR^BHU,#I'2%X#TZ%T/QR9&U3X^>9L7C'=J4A@_K MB&:J)A2-(Q>+O89,DS/M#L4A$!*Y;2/M,_;#/ MQ M4=C7!-UYE;*:L\U_U_+Y106Q_8.^7H9C+)]X:RFWLM3[Q[)6T95'QGL# MSV](WZ!'8EC+N(E\UN*"K>,:6D>WXHF5K-G]/4&A6FC&9%H4\K^02I_?2$[Z MN*4<)FN2P-=J:LX1F*D#R1!JZ>4<34SQ043YB<%2>JT>39RSO?W^U7GWZOJR M?W9YV:]CQ_#=F+OQ3UDL$@V2#E;L4Q;T<64UMY.(-*)DOR&EE68,-7)WJH5N M#;>0%3*XZS=J["8'T_U#A# ;X[_QXWNRDY"S]$D(JTIQZ^*KM$X2C557^1S$ MQ1W;,>Y^KT&33! TG+".#?$#AOAF%0N@&3WI#Y5B%F$GS6JA= TSFIC\M>H% M_6&0V(D/ML)_1ZCO:[D>\+K3_=@#.F4IO##XN*M&61 :_+':SJ^0Q_$J:F%W M:,Z>4XX1*NH-Q1A8\@4%.-[MU"!2VB:_*&U!R507AP1%-.300&U.EX0 M\L1POJJV+]CI9*=,IAR)=B130#5ANB,%#)IK8+GM8T>90&(IZ%(EUZ]/D2=$ M(*)W22HIV?V+WFD7 <,OC?@/BX?!6<43LO:K M.\0TARJE6Y@+OZET_MV";,XC;OFYF*?:0^1CX?H2N1E;6^=_R,/X[",C0R(G M;O\/5;<=T^LZ>6/WBW-,!"1J:0LE/U,]J==O/_/@EV]A@GFBQ'"N$T)#"\&3 M788X3UF&V-?'=NVA1L6KDB51G$HK7G,(*0'$C&E9T4DK>K3W@RC_I/$/?$4G M#C*W6X,7W9-,$7R%5QA/,W9J0H#84RZ$;>=/D8E A>R>SRW:()TD16.5+:8! M#(BWK MLL!O*&%B?2;A/B&^A+;31!)Y,T([AU#"/YREA$SLB,[==F9(H&Y& MD+$HA!]>"_NP6NG=3XH.%I!PJJ",J@Z ;Z6HJ.15FK+(Z7WAS"I$>1;,U7;* M"* M.5)8:2X-VR<1]EY8XK;;.AZDW()#;4PLO*8EO1#3 [V^W,Q28]@PT($F>G6ZS;UEZI MX8#\,VG@_NGX)-5D+_@ M^O5=FK;V7]V;$?YW"W81.WO: M4G8L*&GXSE]P4)%G-5C#+(!*):FEMJZ]$-ZAJNON Q_@S/RF,K3YB!5=XN$R M2D(?(MNW\:NG7T\=F\'_7H# O_P?4$L#!!0 ( .@\:%3R;!ZDIV4 #E M!P 4 =&UB+3(P,C$Q,C,Q7V1E9BYX;6SMO5ESXSC6(/I^(^Y_T*UYN#,1 MDYEV9M8:W3,A;]7^VFEI;&=6]WVIH$E(0A=%JD#2F:I??P$N$A< !+@>T8BH MR+)-+&<#<' V_.U_?]NZLQ=$ NQ[?__N_.W9=S/DV;Z#O?7?OXN"-U9@8_S= M__Y?__?_];?_Y\V;?UT\W,T?SL]F;]ZD(UU8 >WI>[-XR/=OSP]?+M-1 M?>^7V8=W/[Y[?_;^_>S\_)>//_QR=C9;?CHT_$2A7&%!R_-#2Q=[?_S"_GFF M4\XHNE[P]^\V8;C[Y=V[KU^_OOWV3-RW/EG3[FO3W:.]05OK#?:"T/+L8R\V#*_?^<\___PN_GIH2J=WPD/;/#3?OTL^ MTJ8!_B6(I[KS;2N,>56+PDS8@OWV)FOVAOWIS?G[-Q_.WWX+G RN"@8U=*)? ML:3]@4*4);/9WXCOH@>TFL6D^"7<[]#?OPOP=N>R >._;0A:_?V[Z_7:7"E_U_[CG77HC#_:VW\LDVILUW,S;\YX?;(CS^UGIK^]MW[.,[ MM7'>M83V,:2BS(:_]+W =['#)/O"5V8SSJAFV+RQ4.;-NLEI;:-44K41V1'!(?T]T;H=CGOJ-3(_87X M'OW13@1Q**K4SM\==?(K[@9[=.? EGM8>LF$G0A'JXFZP_<.V\BC"W%->;"@ M&R.9$V)YZX2^]_Z+14(G M<*:!,'ZR_D!.#_B5QAT(FP?TE^]&(>H>G\K( V'T7Y87T$WQ OLALC?=XR48 M?R#LYJL5WB*G>[3* P^U?V +]X!-<=B!<'FT7+18W40A;?B 7I 7H<>07HNW MS0ZWMG-UA_6#O[?<<$_AN/2W6T38*;M,],UE1.P-O5#.UP2E@K2FP#3#N,T\ M(V%+MP&FBO6/;GFBL;C+=$?2[/AK-=%(^"XMU^\?V<(L(V'Z!1/+;JBXM9IH M)'S_&1%_@'5;G&:L54L/]\;:4+N91L+X,=IN+;)?K.8VO?\%.#&7I$,\X/6F MX<6[-R"ZH].-A*9L\YPY;S]B-K\27%B$8.?/P MT'7A/; +,Z':QT7C\ZU70'JFUX%UEQNFZ<0#J&QQH1!%V]A@V2%MFD[<,STN_=C$EIJ=L8-(;)SK#N^Z"3J\ MZZ#\9A;_1HEMITNUV95&;<@.B_M 3S1#=QC>>A0H]&1]0Y2&;B,4 M!$/T B/]YY(@!X?L8-ZO?/+5(LVL-'ZAOT*K1"AI'NT7IBX+MV&>Y?^Z'UC%O]U$1_5;-YFIXOFT /BU!,^H^ R MMT/\0M6L?E"JC-XW9K\A=@^C=XX7JDFM45M=M?$D@W"PNGVU.$O;S-,=MO1@2_!R%UK.+GGQV2T^!2D,]%E'(8II8J-SQII#ITI1%5+V^ MPFY$Q; 9608!:$3ZT?NX[S&5W4K,&??1EMU!?$+UJ2OD^5NJ3M'?/E,)N/4N M+=>.W+3E]:[9FAH)Q [C(:P=#EE@ @7Q$1'*WG^Q:(WXIW]33M-=(<04ER7) MCF#6LEE$1+NI^L2Y%^Q&P..B%T1$H_:#R14]9!WD.0W#;J0C]0/QQ?I!UO. MY*TQDXW99;3==HO#Q/O"W!*I?=!.M(C.K)$MINDTLM"FTY#TN'[ =T^UVDD M^*_(7Q-KM\%V+AJ],?R\"B@PZ.(^#OVOSBCXQT*T.I=VO[=5[9Z MWGATM_"_(O)=+=Z\S V7D,-X;,(WZ2^40.<_O3D_?_,^(5%YKCPJ&1YZ%T*Z M4UO$8=M#%(3^=OX-!U>T,6:V)2MR6<:#\B56>:PB<7A(J! QR+)X5E;P'),Q M"MZL+6O'\I/.WR$Z(?L+&S*(@7YS=I[FWOPWA)QM59PJ R4,H6W?77\+66@7 MU<.OO>1N0D7_#@>A6*":"$(N&8FE"WT? VNY[G<\\3STPE[XSL';@PC%'?J& MBD[(*.)[;YR$O7HPZX':T+4L!__GGG\_.9F]FQY'I+]G@,SKZ+!E^QL;/\#G,$*.3 M(>3Z=F%&EZ5'^J3QKLS^4MZ4TS__?LP#]^+ M+W@*RX/7IWZ)B'J-1X021-*5PFTK1%K8NKOU4L,$7P&8\98-'_C\TA$"W=WJ M"9#]=NV_O',0CF7FSX_LQS?)CXGBA/#O=VAMN4FF.6=M<%I4A$+09ACPDSFY MHEW^S 6\W*"Q ,LIY?-G&TQ"N= Q>>1!!6(#CYX#[&"+[)-\H%K=1M1>O''+ M>HR(^!&8>VM+?WPBEA=8=FQVE.W@]1W%I%#JVGYO5^"1KPO5\)N\&(O\!J\& M/82EQB(&;[T@)$G=$?$:JS842A2_*10<&4.D:TG47!'?8H?6ZT9*=U\-B,&7 M"0_H_/J0 0MA520*VB<4;GSGUGM!0>P@NO<].U>9(?F D&31:(]3HW1KCG0B M!%2XFVB-U T1.US#;<2@KM2!O-'O:-@(0YD:>_E<6=_NGW M2U9^!I&=1<(]V\DXVX&H645090V'Q>H![C9>F DO\ M!O ,MM;$\+.EI TWA$.WX'!G[O:+_1.=5'*\2GJ(3;WR/H#09V#)#=SB'NKH M%_NT/NK46.(K S3XX25%H&#_E@,.=$5=(,_>;"TB,Z?4==-96Y6.D*B1P::W MRDK=-*A1[=C'>A/Q2K;H.*!!6'DE5*3+CX/"6"KA)^L_/DF\QHCPO$[\1EQU MB-]L6'P2&U8!$J'R)VS+Q4[:NI5R)R6OKS#[H*H<#]I,D9-"">&8F3O_B9)+ M6G#CDWOT55234W+F:(TAW'*U1QF/:$Q;6*SF3B)AG](8)"YM>$V%)! U;GW2 M-.607P_;X$>-)B[Y$PUAG#:OY[D3NH4Q(V6Y2_2M"$C-%F^&X.WS; 8>E MI@@:X7$G[\"E2'V75@=?1QST58$=])QLAUQVHM8C!>)8I?N1DV;('C-HK[_9 M;N0@YX8RG$601&&6XVD1+RYPD&:37NSY \@.X?YF%!_9_Z;IJ$ M[-@;.8R$^'I8#:\^]$F%O+*A@CV$K2I5BHZ%?"6;#+=MG3I;;3WBPLZ7E_:< M>]^SCG_)!7H$4J5>"NA8$O_ 3AV!E!^^\0,K\E]' )JK#I6^ MB@'O0'T1D['.U>V](7$' YJ60:/04:KB* M?0&0A0>>]+*OT+.>+/*^K95]/=;YV@ .KNXK(917_A41 ;9"#S_^ R-"R;79 MQQ75U1:II+/*.JWI#H ^A=K]%6BU%ZUP#*WE*QVERX6LQMZ:M2R%=LQ5+<6N M;F%+L8*PQ"^M8,-J'M#_,3_&B^76N-;%'<2A2](NX^'^@(*08#M$#A]"_E^E M=K@V0PKIUW;0]F%A*CSWNP-X^& Q"8+Y)=X6,0@K/K<[W7J[**R)BA8U%TJK MK ,LK*7GLKB#%N8=GK@*G/!5@1E\A8F!SZ\O.= 05L_A!2&E-%=!:[$:)VX_ MHCN..216+) PL]5B;[U8<6 -&+\"_B?I8NMR"K'SK^-)VJO0M=+A]P?]\"JU M"-M"/%S'6(YF5Z6*0FH-%EE7BRT$R6N5-J.A( M^F3I6+'48YVO#>#@1XT20OEC1Q$1""NT6.SB 3DH>21GB0CV'>62*[R.0D%4 MZPJ5)AKE6?A=&]*EM[(M-;P3EG$1 SAR21<^0N(2+V)$(*S0+Q;![-&=!WK" M2]9CN9E0RG@-86 G75G5ADH8=KAJ)!3VZR8??$54@%FY-G^Y8 MD/C%;IG_0-1>[#Z0]0"&N$H)85X//>2[S/A68$>UJ+ (G.$-]V+P.=6%16!# M6$=,]11DTO&:B"\-I4;C8R2_'Q4:U6+5Y:V'3TU?-NGP-YD"D(4K2P4X"%(\ M9\\4UU@*"FW$F0CE5B/648W3;,JO=>:#^"_VQS9+:Q\;?!C\1R0\1VDY]#&5 MD,1]3=8^+TP@(7[_L ^?_57$M5#WM2<0XPL7O28L!W7 MJBQL.3)BO^%P\X"2]U+9\XE/_K6XN'B#$=2(43]&*P-\'9O\QF -:J07H)&9 MZAN #^$@3MX"/J0DW+&I&&/%Q[*DA_ $J>D##GWIV2OMHTN"#D]#-<;X&B - M?LA)4<@?>;6@0UA;A]=\9=;V?!NQ ;G<"@!2=- HQNKRP(>PWDK/Y-:82P2MQ;=Z<7M0*,OM(*+V.FAWN);J MF> K@C+*(S-HG]#Y$6VI]?TDF<" MR?N-7;:I *(\Z%O47AS!+>O1@;ZDRI1*$5(!2"/H2C4H5&N/"D ?[?V3:!LQ MV]H+NEZMD!TF 3['$JF"HT"E&W=S5>T(BPK"\T2M8R-*='3Z:'+*UP5NV#=3 ME)#)CC!U)""<;/S"!A=6@&5VKYI>XLRG^GXC1C+X).9F>(#R\,/QG7=I7K#& M".(8"+TQ>BK5P6.EWQA((.4Z>'0G]*TX=/B C^7.J@%==.7R (:P4"MDE00X.+RU" M]BN?Q($3XL4B;"^^KLAZ $.\-C*III<>$3J.%U)AC:\%TO!58\4H%.YL]:"/ M7CSS5^2OB;7;8%L8X2-LR[V92%L/C"1:EP$1%](4M>4C*6O=32%-";%]!2#& M*:99!?I04%,&;'D5_.U=B71W]-?D2_%O*50%I+Y^_?KV&QWZ+3W1WL787/EV ME&3O)O]G.8-Q%-"M1Q?E-@Y:^*[ &O0M1)Z#G!+:9V=G/Y_-WLRR@?(_6IXS M2T:=Y8<]R,*0_IN,'4\L"T7DM"DU>CN^XE+_H+/28Q&:=V.PI4\5"HY,H6&/?$AMR.E$RDR0219 MG$29 AX@&.%OM[X7@R4U6'#:]<6&F#IOMNDL=^&.5(TNN-,@.RW:__EG8-PS)0_/[(? MWR0_QIR@O_X^=PB7YJ5O@U+W0Q/JE@ &(>&'*$[LH5OZ8^T1G&O8$\4MUU7> MYBM@<\_;]$0N*\<4 "?\Q?:]D"I^UV[;C+E^]KPQ&W;GG19;[@'8^"254+C:#L,.H4[L( M.PBJ)\ZT:\^YHDA(R%YJ-RC=/[:E>PEX$(2/8S)CPM6*?+7IH.3_OO4F4X%_ M5 XDMH$;[*+[2*##5)L,2O$?FE*\"C< 2C^@-0Y"5D& 65R%U"XW&Y3B/[:C M>!EV %1G?B1"5UML_(KQN&2/*Y/]I>^(F5#3:U">_-2.)S6H D_7MUJ&( MX!5.\K5J]B-A^T'9\G,[M@B1 ,"0N>,0% 3I_Q@BYT)F<-L.:^LY:\<)+@8@ MN?!>@POOA^9"H_MP#09PN'!)?UR0)_]KV?(L;3DL!QK?@H7PPZ%_C,2"+(G_ M@CU;?'"+F@_+B<8W9#D2<-BQ](/06NM0 ^ \I<1(8A5.6<^!K8[4EPB M,0-$S8?E0\N[JP@) .RX]4)$6-&1%W1EA58*J<3RS&\^+#M:7F!%2 !@1[Q0 M+RD::Y_LI2ZO7*MAB=_RREJ"'0#-'[>6ZUY$ 84[$&]$I5;#TKSQS94+.P": M7V\16=.=\%?B?PTWK *LY8GE7=!Z6!ZT=/<*P>+**1+T&,V$K'^+^TT;&!AR_NP')51 M&91NBC>8;&\=#B]*WX^-+< EJ"!06F-T*7X>E;N.K;0%F"+3-ZBF+Z7ML M,2R-&]]7*W!#V,8IP(2]2.R@;_]$8D6ETFY8FK>\IE:@']>IFI@H;G!@6^Z_ MD47$H>#BIL/2O[FS58@ B(CP(UPW]"\\>X&PY; ,:'Q?%<(/B/Y)KH :!PIM MA^5!XYNJ!(-QCUH*E!,#QC<2E+X/2^W&U],2U/44_MN[KFHM'/.N?2_P7>RP MLMX7EFMY-J+W910>@9576C@_8Y46#L/1GR\7]X^+N]NK^=/UU>QB?C>_O[R> M/?[C^OKIT919,&46CDO E%DP919>2W9_J](+ V7WM^7,A39G!#T@9$GK<$: M!@3.T./]!9$0TZU7@SNUO2!D5JN6+:E!!0*73%6'X:HZM'B'-PBH7CQ_9KF< M=MES(VH$82]3XU,9\IXN?&WIG]IIE-A0:0OAS.>+4943%>#!,>32"C:B$R3^ M!(?< JDIG!0QR."('+\E@6UZ/6< \@/E:MI"V(.4V2# 1Q?KO^,6&Q!$OM- ME<";EWLL8 N_*00=2IDK?!3 ,65NVRR-/YA[SB+<(/* ;(1?F-X1W*-0OG@4 M^T(H;J/,-D6

0!7P3M(50!4>93P(

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�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

GC0DX:?1SH40D1@GI8MB'[:I^GI$8 A(E28$ >" M[N@%#\(()OV*3[V,E!#XPA-(,$(9\L<.HHC0>420I)[I/,7PID5)AQ=E'UM5 M7EB/ICMT\")O2P5T=\O$: OL'!\+9.%DRAEV487]?21H]7-4?&FF^*K#UO*J MD-/GTGPXNXM/*X_Q;G?]Q8IO6RRNG*ODW5;2EK-QPKPIW,Q')RF^],$@T(_6 M^PZM]^%A9QI]8.AI+O*:\?1>PZFNV:(%H$]V) MW-+L$O-$$_$T\43KP?:&X)4!GU)X(/4JA65!VGTF*ZPKE;=ITJ(; 4R$RC=S M9HZW++W%"W,W1^/<]*HOH1"G6ATP-$]M=@+N,/XL-&%A.@B_\YH1_\(W&S7Q=]D/ M%Z<>RU'SAV5H1$.!L"/-P^ -XO;1:RG/4.N/X8VQ/X3X@HF0%^@B>#%#N?1 M+:A&/!KT!Q;!;\%[ +>/G+=@U'KF-=,S7K'KV:K3$*%>E[=H51QTR&(8,>3- M M!6PHKHF9".IZ6_+M +0X,B_M_Z7F2KM(']SX;[;HP+$GG.:^[;MN_XE480LL[^*=;&>!Q=^"7TK^4-IP M+#N8'"N"I])710L^XF+? L8P %=GQKU49MKMI4T;YB4_"B\P*D9!:7*232)C M7_1!._) #2QW J( =N69?HF A+_>W1_@4&8:* M7'B5:G]Q=3G'="S=?Q&&$@67N!IQ,6';X]F^XA[M>X,!T?MFR1F[8*V/)\M, MU!%:4!X*ON"[_+A7A2?[^'VYN>]%Q'=*:DR-PI)2"X!6-X9Y&! -/NA +^#7]T** H8G/;E M%HUKL>'@MI!;^ AR&ON)#/G7*?[7076V MK*H !XIUOJ*(83@OVL[Z/-L.ZBGI"JQ@VZ_0P>QG1PYA3/!O.+Q$EO:QZ.OQ MRZC22!-GFO8;L/IYB'+H8[B/.07>AF#+AKF@PZB QP*0TWSZJT)G[\%+_5YG MSZ@-MP##ELQ,/BQ+9?)GU[8Y:EGMH@N_8O-X]B\J$IL*_)%(^/O J'O2X8.E M04CAPMYO/CJ_'8[VAQ>>'E7X_>HK$C_U%3_U%;]87Y&2Y&%,R0T'Y)_2(!E+ MQ@?9S# YR Q'R?@HEXZ/))457M [NLJ@/Z_$5S?MRJBD&>.;_$NJ7]_&VA * MWKVRD8VJMYM>)B45FD9_G#-B5^W2FER9VKTR7IX-*D[\+BWU"[5YZL58-E;S M]B"^_\QDZ>&A.+N?/TCI]M/C4^TE.AF5XTS Q-XR6VW.)@9;J/E6;-_7U(+E_Y=R\-E>%QW%K&H_.!X6H M9E3J3GZ0VK\R+=6RRZ'R..B5MW9U>%5-/VYS^4%Z_\K,PR8UJ<0=NQ?/7$]; MO4*IIB_7@\S^E0NWJ5\]#-?Y4K.F&Z/42_=.K^7)E7N[='6?>.B\:*G[Z;:] M?JS?U+);YQJN% 9Y?&JE">E4_VE7TAH#MERJO$J724L\GJM.FFK_7 M^EEKGJI\:@>"&/,][&$3W5T0=: ?K.QX, =%"%+-SCE*?;XS:/,GX#WSWTH7 M(6-;>96NZA6!^*-)_=FQ0JY$[#D<1?[W9V/&P$C CC(A3OU,:X[H0=0Q&.E/ MZMO_K::]-CHPVZ\.E-OG=E2:JT8A5LC.TY7Y,2R:\,F!'IC$S@CFZ_M&M>$- ME AM0N\VMF7CL?UU M>+$FUY8O ZDCK]U1M]"WEX7U5^ZY<6]-2G6WMRW)]8Z4L==VHG8__N-O8O$< MW'.8+L>#O<2I\,M MI\R=5&NN;&NH#@OMV B%/RX% ::+J#25FY+4YZ MY;S6&5O==G]9R /?Y8[SG8QM8%]Q-KL3"S[K;%QI5I@HW59LFEXF&NY=Q[H= M/.<_^VQ"1&$K+M>F4G]2TBJW\6%^%J_5ULB6(<-J0]GR(J*ZFC>0Q&M;%<,6 M(P8C?;I^^[B1Y"=C&G]DW^5G](@!=II072:$[G#AGVT@^TS UB(L +V_?GB>M+]GAL1^0%;<4DIG8KPO8)PA*J$) *\0T/J3 M!LE=F]QI__6?#R2;PR&B$X-"-$W/ RH8_8@BZOK"UO[#_T-\*^P*BSV %ZY0 M[YT'D##8(;N.R7]!(QWXFT! 1,* C!@-\6-.61K$<"R^+O:^&/U*1_6^$6H+ MB81BITBC5SR>(UUFH)'S@A0BR*@R\(!Z\M><&^.7XI MI?]EGTR,P7_=)_]0]K_AD_^EE/V;?O/_=2S06+^A=LK^^W@X&Q87?>,>$-L( M?OG__1'_X[W4'K],I3YU0[+'4F[L)XX=O;TJ/?_N2<,/DPP,F^4]T\L-A$,UD1X MEO^,&06B)+^+E#QK,HC_[F0@O5B)0@G8.0U82;\CI M,#YM6>8(REZQ-H5P9V$GR9KX@Q?1U/I7R^:M[EY/.ZG4_'$SG(_KF_8@,4@0 MX95+AS[,QH"J%"YX.O(,YQ#G#;4T7\S, MK:;Q>6Z'99"ZRL7O&U5E62JO7=7L7R\6?O'K_GQ:W[B%^<2O[@R#=<^YLYL%I5R;*Z,VM.ENTYV!T[J-C<> M#U)@2J1^HA8_W/T3M3@C6^6MW#V]U6OWZWRS4M+T;.XN.LI<+Z4UX6YBFF1^ M\U@%K<26>3YEIR+[Q]LY52!]7T[P+#:!V1[?O MG(ZH^W!!!-MWO6C@LLQJM M0KQ:?DE/IO&7IZ@6'^K]L=,>I,$B2>[WQ?QP^P^WO]D6^>'V3S),WLSMW7&S M?Z^T;C,]V7:ESEA:SQYO /F 6"C9Y#\K=N*ALJ3Q^5W3D6<_#M7'.U1!]DX0 M]E9-%WJSOD7*_>]/C9!\^[>>C2S[E/1,WE!1I)TDR^Z[>:WPDJK-IOW4)-F[ M-9*N%@,<%8BEQ'^"*3^\_['QDV__UK/A_4])!KV)]_78XVC:;U;:TVU]'5M6 M$HO\8@VX3,2.22?CKQDR_Q>;A__>&^UWGEU:7[S($Y<5F *7S$JI["?#5R&Q MW.H*0!D88TXN>0O1W!'^8+\MO],TDRDG5:I/EZF;:5(ISS?W1GY_MF[X=9\_ M6_*OD9<3[;@$60?ST$=LD%'>0.RQT5D;5HS%2?#740LG@O_ M^R>R3;^:CL,#\D2P9OI*BB5M(WX+ %R IO8G-*VTF;G [68@*41: 6"<_N+/ MBZ!KX,.(R<>IKD+15@&7G/*B?XFE(WLBM#!= 7SL#&!HX4L9 BZ;2W3Q1II MG%N&YPV0W@AWB^-RY0CV,UCDL+=1]I_B>N'7[#\C0]G68=( ><\LXG,EHP)& M-!%S2#B%(Y3;WM%*#T=BH%E?&^H^_34.+3(A(!&&*&@CF2V[M7:N(43'@ M)P,\]MDH#Q$UFHYG0PQQ@*(&"MAQ*HUDK M'>;:N9[D?(.P]"'P4>2BC*>#\9A. ("K,4QW,:VM_R[$IA8NYBQ*I =9H@)" M#2Z9$D$?G9CK"Z:N\&-4C?(A1?6VM 61P,!E)_HD ',UR"XW^6NE/'1[<_UN M=3=W[.<.H89_#C/YCE*U<;W/6\1;"N.M!HXU;(X(]^ =AJ(U?6GM^4F2P%>% MJ\EBZ"1EMY2NF\65U;L:I,=YY*M]T#.*EP[5YOX+!'T0!$$7\ 1QT ^*P(B[ M(!J0G/9"WO)94I^,8T?/G;L1YW+P#]-&8?C2LS>ET%#AE,4GQ05<$"! Z+Z M)DJ]S_]4\%^#IEZ6GIN)C"/-5TKN93I9=>3<.M3#_@#/YQ@ ^!Z8 'ZYYQOC MO\Y3 ZW);FOD06@,T_D0&IR@N\ !#.0?Q.'[/,#=,Y/-V<5@4X_G-*.TC)8J MB?6B<-<>L1-R2O3'3"9/"7YJCH>R%W MG@[.&VK!\T:\IX4#6@[U8KQ>ON^62WWK.F-%%^:T !,ODUGI&*<35A41HC_ '.!KP]%K8QG!IY/I!@$,JC(C3A8,YA&]-6]%D85K MV:Y,!]"]T2C"/G!P(HAE0BROH!L/,^SP_9^MMC(!M94Y#YY8I(N/BM1RG5XZ M5AE=/PRW[4;\_5BM=U2C@.+BXW;ZQ+7CLW9*&V:=PKP>\G^U*V]"*5U.=WJ- M?ED=]^;E*SO1R?4V"P>@6X\2ND LS!IA9BKJ.A\-V?8") )\+KZ.P5B]3OG M+QUW.O:B'P+_[^T8G?E,]@% J55MH>$[P,!83@Y-D?V&?CRBR-_%V[8!.RYRSH<\KVT6VCHYV! MC@CEXW?!]1BS@P/!4)'GEC$ALR#>K,9"-/2]_E1H[W $07E))-UV9]@IGTL& M,^M"A?F?OEM(HSZZ9O_E#5,26&--J#H2FH7X_6;R)']F\F@_,WE"R?7DF3R0 M[4KD$ME8(C@ 9J E%"*A,IF!*B7505)*20,YF M<]H]B> ]L.140DI(FF.&)K,5;"\A RD'/R>CTL > MU1QT;AM$K8>:9IPB^HD\=U@\!?&X,2+N#R:FBBMHL:+I>( M<%JZ;W@3J^'79+TZ,DU0=>CVGKYB3\8UL0>H(2J+S@,D:YQMS]/YY?F#, ?8 MTX)@V3 :\4*D?NZ'QSE!N9.K(28]E.$"[ZX9& =L$CF.!\"3EHGR);0'FZ-% M5?)Z!PX2E!;1(N1".AB;>^$S<\U*2\*OO=RWO?R("CR"&#'"%^%T1F9&T!> M>Z$KQ&BQ^)>)>0Y*3YRMO9S9S"2?8W%+3F5DI&T6NC]B':^3;0>&(>B 6>%@ M1F@FZW/R0&*4<6^0OQ9-;=GAK[Z E,II^9/8N49\AW?WI:O.RW5;6KY4TO5\ M.^TXN?S)Z9,[?FXT0U(G-N?^6G['5*CB\?UE/B"L%L M8)P1LVNJ^<*&'QIB_.N6[8CF(="O,+0R['C.AZ^;PH39T&$W7^#%$Z(3QJCX M/YT%%=:MIIQ[KF8;O?XL+M6GA?O9IO#]?OQU[-[96L92D6J#IU1'?!YL*J)F;; \1,Q(W.)J[L"$AV 2L,(+M-'+ZX'V!R(+5%%*\M M.*CN+] CWS\5.U_EWD^)YLR$UT%9\\;3.%GG:GWRRK]Y7)5(?04>;( M-"Z@(46V)]Z07M_]'\HSFL3XS,36H5^5BWF]K@ M1:GG2LT[<_VPOG7EU8)(@LQEXO"I[ ?N((8+JHI9/H'JID2.6$8J6>^.><0W MZ4/'('V&YD9J_[#]>]H=WLZ85B_;Y57*J#^[>3V?>E!!/Q]N)J-9"2I;D6O7)7 MQ43U+@4IP>.9DO=D]\Y&>+YQ.BVMNP(7_BNFRGX[24^4N)VXE>[7O7G.KM9C MT9=IJW*,I \4(''1&28O04PZ5.7ODV3ON3U?QAV]5G('&3O7*:9SPW3[C[^_ M8K[LM^]^HMSL5=QOKHW>_GG+=6:%RI4_EN/DTFFC5 MO@P>EV&&-,GLUX/1MV%(T<&"5^]7X@1!(>'D3"#.YN_0Y0^7O>N^_R]3S?:T9O^9J3TY-[& ML2>%V\ICIPUM+R$EEOL\YDUTM6GW@CETGC$81B63$"93M,5BC^"@_6 M9'['9.=O)X7MMIH;EJ*U:*^YF#P/K7RA6-3>[^Q^E)N@QK?Z?:TS3/7BG8=$ MNS?JS M8Z&/=!%6;Z.QO3;"^U9=RF;^PF^%"R)7FB-_C\^2#@WXY-TQN8]^3CS)*R%/ M[R@L:RMSJK^X5P.4I2#:]KIUV32UK$TV?%..XS/N*[P:FEFCDQ4;Y4&(^S=_;5RV8>?6?<W/ MSJ:J-W)>&^>-]C3=?TH]WSC94K]!;.!8ZE@V%?)V"UE7 VG5G[/Z%,Z$!.V= MMCARALK:JN0ZSX-"J5F1D\[BX>$IY:[)&2:/Y5[_U):@<0@K$I642"?_>^+Q ME7IW@ZW9KZ7+3T_;4G]:M..+VVHOF3S4SOMS?,>/+[TPKYSDT!QGIH5"AIBN8\,) MTX:(H4.=V5MB+=S*0]."O!5861UH*"=*G9O[[&?/J!%M'W[MK2E[5L]EI$JL M)I4:5H*13HB&^K9P/]EZU](1& #JVXS0!>,B WI$C)MA8>CG%^G\$TF;1UE$ M15*UP6U0R+H@<6D:'0=!F4*(>31*E'JW4[@>>6+)QZ=3393LP?%1'/<3>O*>JIEXTXYU7A)36+C+SR]#@_PE)8N(6&@ M1], /Q:?P*\2=O&C3K]:+MSVRJO*LK>\[3FQN\1(6KT&/6644-?:!O5Z*6)39%*Y"YBB7W<_ @] MO!V)Y7&Z@IM%_!FR(.**0;\8\6,5+)"@I>JONP5%XH*I&C(XHY1Z_6$]E6?M M:,EU]';Y99&M%,?J6N5.J3X6P:C4[M3GDR*ZC#0*U>\BUT@=M' M":-E4>07_%TH*;02N?9RL\J\2(6Y-5OI)>/QKD5((7<9SX3 ^D%E/*4&*LY' MLFX1=6!--2Q!=S4_N^+31$3'Q02"#J 3\T3&:QHD M?K58CPUWD9[VMYUIYJ90VL:*:P#-RQ[4(!=^VP92QXQ67E'R^)$1'R$CWJ@] M8 -1/(2*!3/7FJ[JW6J]5RC>WZ:M]=R0[HC)F[W,A7@LGE" \PT/;-+&?SAS MB,K]7JS_W08?LJY 4RU+F^O0HA*&4)%);8J)Q75JJF=&I94=4Q.)%3'OI,L0 M8<[-NP5](/56@D6]W]I6?R7*C)WN=IC8ZS[^IJA)5.]/$DT-B(F9JYKD8=C;Q%S,8=S0\=".K+A@:_/,^C74%8:[&D:0T-D:Z((-4*@B&_)4-Y#J*=UAN#B0M"+" M65=8$82'2R$VK?^.R!2I'V2*'V2*7T2FR.9264E6AX.A&DL-DI*4'N2&Z>$@ MD\FF,NE4.IO5U"#^PREW[ )0G'1/XMUP$O$WP4DDO@=. HL--(RCAX6?O#J4 MSL1T9V(!SP94ODWCZ?N)?@8S=%P@8FN^SIKNN&V\BRU@GU-*_R@ ]O$2)J]R MZY#1\ 6PV,=1L4\T0;QZF<$X+\GU0K*?+[GW;OIV6KOO%)VOC#6(MOV:BW#XG"Y5;J:1,W?@@>6N^/!O=EZ/1@%- ;G=?%AX\7O>7+W']ZK$Y M+3S<5E^2[?1M:T!L%&>]W^#@%RYY]5C?CE)^G 60DD-(]I-@R7^+<,7GXI#? MOVR>HJ-9J]HK5#K/KGY[95;5\1]_V_H&ZA&=R4'H\04\/+*F3V= Y+OAB]/= MH<"4@U,(2?YPHL&F5#GTN\ZH>+'[$7H$.P(5W!% 9S(1'.K3 ,O_I8)=G%=# MA7RH1%^I-X7,>B!+TM(I5?IM2VI4J^T#B.5"IUEDJ"FR2^TK!NH5J)EFZ);!,D=>!%: MVW O(!'K-LH(KV:1H8;R"A58@F? H_CTC'Z6B-S_ICVDT2/(K4=VY"AD?^CZ M0N ^A5X50/ZD-*6/+O:=&!M5!3L$<G"]!/[OS\2H'9R?;TET6_=CU= MVHFG<6YUGW.KQX)UK[0BLM:E.P[1$#KX(1Q?I?X\*DX?JW9/RV8V$VMNQ*YK MX]"^7T+%%C5D#V'T.Y0$%Z9^5GW_E"D(@VH+$8$N(%J=5X1,&/8N%]:B0CSF64>0Z"XO% M;1#QC%)^#O0C#_2-V86&<==-:YU&K>UKM&MLSAP1WT4) 46!"$FWZ(^&[QB1:[89)7QQO"3R,= MR-*FD0Z_G,=U)B9VGU!D%C[T3!Q^1*L/0R8@!2:(9?9J8$+&Z^U+R2\8L/>^ M245?2?.UZY>7S3+]4):B:;7D^^&.A_7TLY-?%8Q2P>RNC$&FT\X\ MM5_Q5L0H#,:0&$T)'JZJS8CU1:B/8ZY[3"&@([Q"U*?0]/GX^L=CL9\STNBU MB4:_\32C?]T,(^=G!LB_=0;(;PX/^CN'K]^,5METY(>[VX6L]?1B=M%^EMK3 M>>ELL$*_\B@6,:T^63:>U6G9=ON' 3^" =]V$$ZY M7[Y?)!K97JVKK=+VU=751L/\W=>CBJKZAW/BQZ")?B4]##H=38VGZRFI7._U MC7BJMLE)QP:ZGY;:_64?F=ZRB]U)OX+\?3:C<#G H6)=NS/AUQP"\L1Z3SQQK$I:H7NG8DG.',@# M_!AY@:B\(NZA/"9ZP';\NC5:3&9#V)WXZ+2O@;[Z6YMM#Z!X'M^XX*[/9:^3 M4*R "@L(C$[Z;R\/3)6Y@;W>%ZF//K,RELIOV'F_SJNO?2U=< 8)<[UM,H-@)T\[6HE,E%_IS[NTMAAN$O ML72.I@N.]SJR )W7E"O/9CY6K.T.G]FP3I3F+-H4,,J\?B,O0Q)"USB=D[X0 MHU80$>:;+4^[8;=@\Z9[W-VPFWM2PF?R>ADTH2I"1@>W';"\);X!R[*7Q'9ODHX)*E/Z=J*49>,&!7@DOWV)H:S*77; MM\6G;J]3*"F=I=DNF\OP K(QD9/*?#DTI.73JOL8K]9'QE6;J/_$ M96J_L8NG[6T_67-P;C)-TNP YG/3?.N-5&9:,GQN-I&E44H) DH'':+])[DQ M%H\(JPE?B3YB&0S L1<2BV/-8!0T7VB.3JG4I!,&R?.C_H+^.I_43=6(7&M# MRY6MK>=:Y79F %'4R8& MT=UCY'H_U2@3XTRGV;.#8D6\E_76.-K80@==-R@9:0,5Y3_)^D&RI;=KI MS'(QO9Z6*]&)TNT865MZ9^7D">X+D4)%+@'8IQ8 -!>2J:'>B3W9+%+9A^JZ M5!C*_9=D;3A-(X+ZL6+9!1U%L"-H%/ZB=WHC'BO\X]V2?[I]\*_AXA,[PU\U M$NXV3V4KFVU5>^G'H7,_FPVZM20@;$M4_^X:"B=8!SBZX].L@_/1V&=:;/%: M?N)D MJ)8&FUE/6;4^/;_[6C[OR[9??U[/X@_QT7.I[R02TU+,T-3$%VY_;5 :&5H^ MJDOSFZF4OJYGDK'L/ZNHXA_+:J_G[P.0M;6V/KR[:R0D5V_'5ZW._4-)__2) MK/]81GO;YG?OWTMI';;*7"XS*_<%O/_7KW_3,K/BJEWU,V M[>(B6KN6"HWY>'573665:>I:K3>OR^;64)1U4A]#\^+^<(DC<\I\-_0R$LC[IP5SEKD Q"[7 M.6R :MH8^6$W>VY>"T=2Q(G5[JK8RB$D%+UN5R_.)5M8C/V)/$^H*NUSO?_3 MF:B48KO7'^43M[5>)S4=9ZKSZ&A5_'[BBNG&5271:=5+T:C<*3ZOM.+-=/W' MW\>F,>T'18+4M0/P'(KMS"%! @C2"SJID\[&^P0%\?N:&V=>EM!>QR?=]FCX MV&L^7264F[*:DR<0][^\P;*S5J^GVL=VXNZ]US'MHF8X?.<;@\/:+KQTT M?QFA";ES+A6]TU[,F>MH9Q,<)49CL/,['=;X'2@6E?VQN,'J4/YQ@1G=A\>] M!R9/CV?F4' JR8W>TZ"/=$?N,-<_0218B? MB4#5'EC_SKA%\FCOE71\1?"C _.ZO.EM_A;L?[3_.*\N%N=\[0#^(9L$VQUA MM=2JXAK2\[;)7_ 3892]HED8!3 0$ '81'>"P^;$P!O\C6751M [JF#RV,LG MG4_ _D"=[1[57?@[K-LH>6 3P2CEIWU@X D 31KNB'P[-4%VR8KEPOU4FVS; MID*1&"FEPPGPJ1*6MG1UB^[QG"@-[UC>.F[E("+DIV75/=LY?0J* M_MJJ&\ MWRV_>R%;QVZ?C=W,\R1UVY7\3B:R*I?B)7U:-DMZI[FHYIZ? M._DE.%J)HZX6TW:\Q%L+CGX[:8R3"-L)+KM M: M;G=97>I\Q,PN]>G83*>OC#4\4P_5+W:L>4F:R# M/;C2/"?0)P^*0L%>?0%![I-J#CTQ1LW\[Y%IF:O->/+8+(ZDM)*HMB;SU;1X MT_ZX0@ Y]K+,N4IQ)6F%^&U[N'ELIB")XZRUV4I[K1B ']'1PH CAQ%";,RD M"!M*P>0C\ M$$#6]Y$$NS-^KU;FTJ.C3+>F$WBJ MWA'#> ['*[FDU=T,)Q$Y6G@D_NSIE?<1.U,E>5G<@;5_9_=I-TSR\)E!]@<.#0I&04Z=];*_ MM'<._#E;G?VY0W[FT9>Z5*KG:Z7"X]W\<1&?5DLW4!]"_ ZR>:J\/3CEA\WU M8;P$0@IXR&@YB63(TRZ9RFQ;2WW[&[LI/N>7]?9O)-?9FI[^G+7(#,=EB MA45A@"IG\MH.1M4F\@X:\*OJT#?Q(\I$GLTTHI!L\6+5&]1Y-JY/P]S)3$#Q MD+8AZR>+5[UY0HHK&F-"<>]EI&J\)[=Q,'5B3V2+VFE[J0XDV[Y%M:,(B,VI8Q?QS+R\MUS?9Z][D M=G.K$2OS>$D/,,\>J^RD*<(XYY.K.O[-)%$U;,)R,_C/8*)+4T,/_FG^CR7;/QJ]]WD>*T;OZNG6-/WX,E6>MF9_E/[T M]J,ST@7Q=[O?)#LFA'M6%>TK\=,_EWYK6W[7\\NNZEI.?K M*TDS'RQ[-E[V[@MK\*?_D5#);ZNL_LA@_2S=J3>+C>1U:2Y9C_)V,+1Z_6 - M?.*K$'5%P^NANI*UR;)P6UK*"<64*]5%HGQN[71!MI]=-/"43LU+Z15(> MGLU"KU5??_]!E/O+DI6YFQG3='U8OXDV5-,TUO]0:../&V@$Y25T8]\RG >3 M_8%)2)@]/3S4Y?VC?.0C9C]N*[7Y?X.>@!OR:80!(E>Z"3!=9T,.@1R.GUG[ MS_\:X?]V" ;VG7\)ZB.L"M%HJ698U!(K4R!VZ07.><0R<\DR/Q \SKMCLG0, M80;#C^(+=TKU#;)#QPKS0[L1L-+&;T@0.A'X6XXV(GBUHI8[]H&N;*$?3JA_ M"HX]$VMY TN_\%X]EU4H)")<%H7\KM>B^9DAURP-K>3H<,D$^^&X1F'K9:1, M],KE+RL6H_782!>>:SDI'J\8J8S4OEY$OV8<]#I_?;UX*::)/*FYX\EUNCAL M9;"/]DC0C% )G/1E)._A>T,K%"0WL-XB2"![I=I0+N',^+BO'8 ]/P3W^4![ M_\#CK\L;J*[*(TB;WQ>PUS*PURA0H,Q=8)5S0M\ \4:$U@%6OUW"V7NA)'6S MS,O9WDW]7HJVKS9M^WF5NI/7@*;W6@">[>VA^#N7/UYUWQ&5[=69\R&!^1 H M>ALQ'H=$][-BO5W)1F4I &4!"7,D/L ,X-"5?J4A#GTD<5G#$=F9? OZ/6-8:Z -!N<=*ZB[W"/G=Q::OUYCZ\Q[1.IM$P22/DNN) MD;0A/\[)A8"Q:.@XS]*?7GIJK:18'$B][J#M@XQ@Q17GW# M9TCL:->!7I$UK1(3T2+96ZD]=4:1=]'\"QF &MP)>V*Z,Q7D"4QD=-'FPLI2 MC7P8V0/B!J"U#P];0+FDIOI0U;9WCYV,\?W]Z:V245%O MI7%IVD\4C/BT;,4?E/8KQIG0D/YK+>+OR99\ M G$UV_,G:UA7DZ5"/OG4V;@/J7KE^Q&<;MJ30F)^TUA/^P]/V;5]GW_.PSA( MZ3)^$GZ<$'!%@1J$B6'[>#YYCW\K>BDM(W'-O'A MMCXMY&\2\ZJDMA?&#^]\^#Y;6RNYC;42*TF?Q4=WX\$@GTI_87&/EZ_X2MSM M;[>55O%M2K4'E% MLX3[]6('RA.\1 =&UOBK<* IL \$REC28">IO.,CD?='JH52",OB)L7Q0R., M&>?F3%/<&:N\7) 'F3*H(D,F;R+/GQ+M13Y"T68SFR/%\.)4\I*(=_]NL=() M'RP+ 1^ONYI%#??&/4+JF]4 T/&$F)G 20%[X(=G%/U^)0-V',/U4,:+T<9[ M,UX[M?U"T@66=599L+#].9NL5_CB_O0!U+RTV%\GY<4X^7JYL9],%K=USX&5 M#\1XSRB:R^3"+[M=NJ)*TNIAV9O.3:,DO?3CI5XN_W7S!!^?MLE<-?\P[37; M2NUV,#3KR6YXPT58&#&@^6!M47T3G>@J.>3_5/!? WM1-^XVO6BI5TM4:ZK3 M[<[E_GBW8OVC;*5C5G)8S-,SE&D)^QE'0,^5XMXV6,_J=WN]?GQ3+47;E9>G MU)V64F"25F@T[M>#;V<59ONH$^SE6[U"T8C>3>0JJ^+ZW2?X4;U; ME9?[<:84GU2F3>.QFKMKJ+51/@]'NW^PW) Y$JDY%*CY2"WUX4Y6HYJO%L]& MC2*0(:_C$6MB=^>%#XEQHHVPS&<(@.Q0[TJ[>])!FX69OU!91"=U\Y89?U;, MR,5SP^3Q2%,1A1)^QYPMW"$1_QUO__CR 2I=[00&L]GIF6Y^V'L21':RTG*<_S]] "FTY>9H^4$;#F M 2S5]@7QG_Q5D8;)6OLJE4XCGHG#64B2%,\6_J)=-F+Q'0XA<'2(G+HSG7P: M_C@TU>V^ETJ]Z,^B&PY0%'M-IG\KX737II]N2?0;I5:YU[]6[E[Z5JZJ%M\) M7O1&PI&23U=&^>[ZMB2O"N-BMO(\7(V(V(]GC\XO/(%P(A[-Q&*$9A*QPE]A M)#.T3%G%H1N.Q4C&,3> LLO5B6-ILL,OG[A$\$8HB=GSR,+4;=- 8.UNP)8P MK2FJIZ'&'#@F^" AA!9)9#%S 8-N XI+T]C<"#@P4P8ND:]OQU>#&>;"'I\].X"?MRC/ WA4H M:G1OU09W=JS$@"B#?$V))@]"&WJ7Q]L"N#FAM],$!AI3KL0 M/(U&&V*#!T[D#_KRV'4E!H'PU"\C"/IF.U[95)B6I1#Q.U/5<.3"9>)WBO=9*#)1 Q-VDCQ0,/)#ZL)K M!\-!+6!HX+YX:-LLWDJ?0>?'!(O$X"/\]6/)('EPDM4JLDIZACF)!H"W)^1D M=&(- 5^:KF6SR!*A?5BTMED 1=H,L=]'EV0!&:^-[LB]$'D"64-X&.LB/W>@ M:2SY^_!O^C'_=/OX6!Y*\THF7W\I32ON]?MK9?.T44B8X'2H(B-3E?)+I=#9 M2GKIJC>X*4R*M[?K5W*ZEO?83\G'_QSCD0C2+8N7;$./LY@>Z\5.VUE,^WJY M-[J^[M5J-4S1'S$<5;:!GF@>RC.0IY#<" 3_1#"XW4&':\O$J"AU:CZ[M2L3 M:.UZ#>/^C"AD('4MQ5C;J9+VW.^V'_OR*'?SSL%MG#QL]EU].(+F:!1*&7+! M?5S'UM6J5-BT):=5JE; MJ>K'<6'$@74.>=3D)2[2-UJ*1+_.==O&[C0P2LF:$DC0259V$DM134Y?0R>] M@/Y6-&(]<3M Z$@+EN1+R#0R4W5?-GCYC:6%9\01O8&SGJ_FI?2TN2YD1^U> M78%.Z8^4F62'B!5V7'(VR[>NFHR^)'J=7%.]C67Z\3*QH/^.'>,/@/3V\CD6 MOB50Q&NNJ8U$*)[/* QT33)!&[$G,!=//BAL.4BL[*,-G%<1W!G14Z(:KR9: MZ]G3M%"LWJ^[/5U_,-\N87\M(JN/#?*>\"HZ>UFY&C_-'WJ%Y.!^$Q])DYF+ M%E?Z,*%QHMKN1FEE*FL@'L-L^J\;&WU*B%@*ZUD"=@BV]/JN!SJ$*,W)IP&E M\5_R=) 7%5!FIJU%3=>APMFV=Y2*R@HK#'\P+6P/=;[(RFD)8H@'AL$L3$IC M,Y7GX.UR^/8SJH??F(DZ(\:+-BIWH[MK5>F5:^.\]PKRIW2N M8<4RH_ZTWZWU:/>U-\9"[_CPJHY*F Q'\R:/>5@!U)GGSV7*K MUC?;_"L&&K?.+D+TYGDIRMAKS;T+60]HM%!])-J;GSM3Y$>@<8%6->A(67^T M[#XY'[$'D]9VHI-O?Y3FI8?QPU6T5%3'[>/Z"BGMQ_!XK^'QCL*MG2,MT/FQ MH0<0U7B )34Q L?\K]80_2/H3M M^J&5P1]>J-%AU1!T(G.$452D ZG"N?V=DT.;QHX['J>QSYU*C$!=_(ELZ65M M!N.\)-<+R7Z^Y-Z[Z=MI[;Y3= Y-;2'\&<>89YJ)7O[3<6ZM:/*,$+/L#;P& M]C2(?NNNS5M]#E/&^6].9UGVJ"I^O>WDE:6KTWX5KTJ*/TTKV[=776/>EN9U M5<[6ZF[VKKL^AM%W@$=1XC9<>*@'T'=T :'E42TU)EU=R_-8KV-?1[ME9QDK M7N-HX+#Z*(;-I[/7T.H=[_SLR)^..<8"84H5$'>,2_]EBXL@=?OKP;_&_OL7 MM3,JA;N6"&)+VP#";PW2'!$!S'7F8_2.8)XBDI('5F1ZE>D>SJ W(5O,/D:8 M(!:70*4.A1:F+$''I$G$;QYJSAI*M&F"D+RROR7; N@GY%05S74 ^X1L5W#D M&AP:FW?>&A%6M6AA@0S@G8@S2\?2?0ENW!DQUS50P@D$SD?OFH.Z>BT]*M/Y M8_5A%',G+XG8VS-/[\'Z;3=R67D\=Y]*\5)\.*EWND8)<.+31P!U+FC!AM_B M(T0VA6G3H%Z,\>?Y8K_/^4XFY5;]6GHP)3>QZ#DWU]U"H_/.HJ(2:TIJ\=WW M6YB"$]$@\;.'Z-OA;35477-L5*^U/AR]MR-OK>M*(7E?VCX7MX[5>'),A1!) M\EAA$O.]L'WG9!A;K#X91../]=ZRV.J5RNZH:%5:C[5MX]] !F_1HSY\,^U0 MHGHU5&-N!M/1.FJTM%Y?UJLQ1\H;M2JO PH9AN;U7OEPMD*S$*;0YIK#8>O1 MJ,KR_%ON,G*U4^Z"3[@0KKWP+C[P=&C$\AN:? U+ML,D=P94[#^FKSSWTU?^ MTU?^WK[RM_=C?UR']9M&37M",>AXZ7O.VIZC=MAHYM5KOI7,BN&-2'Y.(W8@ M<.XTC/VI^Z8QLXQ9L0-; HK*;UO&1>W\H:LREI<4F/WWVGC=E 6GZ[]TNYM MIYS/S^]*[E7!GJM/T\=Y^6L&6M2*C9?HIF>EI:61-!^'9D'=U"!*%SMBY9Y/ M$V>@'WLFV[9?9;-@&^$/G<6 .'BF$$YR#88JR<+E%\ UP8Y>(99.F09HU8Z: MHRC_-5'U$R@36C$E/--'7LQK;\ -E'DKLFL?[)"947KC6!"TG'1ESECK-[,: M!3H2W._+2 > YU][Q ZVP/X:\$,=>8J@ - 3S>I]?;<^:+V23X&:$ :DCBRO MZO8"!K7OO&E_/X@YQ#9DM]T9!Y@[%O'<78L7 \ P'@5B@K,9:@PPCX)24#4U MVNF.K=6!]O:C.SK6#-[CS..5(+5&,W-MXZP+\@64;'@'-[:L&V9D[,J(6 QD MA/EWK%,@BS;X/?N%4A;/X-,1Z1Z9_EN$XX=&U]Z4H=M/:.P$^\-Q=1>3^U6Z M>?OM6UWWH_F#P1H#T1:_9X)KWP(++V1K%L10%Y&_0*M M"0H0C1!U O6&8\.X//-;5<*$,Q#A'@WKO%DI7$^&:D)\S6P+=X4H17\1_V?I MFLY_=YF"_M9C#>[QDH707Q&/>0Y=,ZP4BIJ=NZ@8"%XASV!*#!NN OELE\+, M1)#$O2(MC]^.61!,J7F[Z^VWL,W#K;BW=/ =WNSM$D"U\/>&Z_4+KG0,*-VB MFXAUPW3-?!GXD?Y<=L'HOHP4_?F39-LL-;(D6LOQ"I>S5$5U)KKE#[(1C@S^ M*)CU(7/[0#VSLC)ON9[X&FICV?"HA5+.;J/4(;N*Z5XOFH_'PPO8^/2@L[1% M/[$B^M?P ;Y;'B>31O>E&E^72_/K5FJ9U8?]IZM?!L]OF,ZA0M;P[J#8L%&> MVHK>B_8WZUG*2D\?G['FYDBMZOE!='[W80[6K4=ENZYW>UI&LZO#L7937/XR MGN=;#[/X4BPYF_MHN92.Y3J)A[K=NNVL7Z]P/\VW\Z24K07G3_EC?6E0) SY M,U#K'H2/#Y;![P""'NE/8GCS$856:N ST35B/[,.4K^Z>,X@WMYMCJ* _^:R MP>^F=/UVV4,H-X//I<2;V_!IC['54LHSM6=&/=/#U72HWZM-1< MI1^BL4S>?IQA%=6QF5:?WKSX[SZPAFDH1\ZLT[Y6Y%5"MDO1^OW+U:/92]85 MT"Z)HYGCDR7 3@&E$/?ZYJ+][S[TK%I>UN^RRKQ77MSV7SK;M+OX!7SIT[E4 MWM[WM/JVLI5J3]A@7]T*B\4'8]>2/X(H ZT3O,_%&J/7 [^I93XKY>? M6_Q]"@+) 3=%C6\SS9O\O">5'T>#S/VXJ4W;XV!'!:-)UU)@T)1'/5WRCBOB MI$__X+D\TZP/4E+R9C*MZ?.8/LEM%B]N>Q]5.?PZS/G%_HAHA$H6Y.6.Y6H? MB[$LUI >=B!3EU[(!VC+G\@;81F<"-\*(4!PS@6P_&OVETW3"5#N['Y?(>SN M_C>-2$=;.+Q1X4*(CH16Q&+4!C\A M(B#HVY7&'J_SOH;X6LZV:E?I4GKI/,CS\>UR60V8<_&3^[3HF_Q*,&$TMC<1 M.WSX=7;Z(-UFLO=1::D5NXO[K4@-5*F>>MATQP?/ MTTX^5GA6J[VMJQ2?[?6JTJT>BM/_6\[[/6%[5MR@LD^S[VB&LFOZ17YYGKSR\B?K*::_MDKH=9Q:Z,FVUN&A7O!+8\9U&R+"&47/%+*I!&&J=DK_X1" M-<"QV"L$6TH]SLFCBJ(F_*6DVHK8]JST7F[WX M.#\?WCQ5[K79^%VBR",P002-0@I. T)HF;L:WU>C>JLT5WJ+S^! $8R,[*^8:$.)W4O"ZZF?@95_- M8<$ 3Y& G1S%U(=?TD^>:I)7.QS5D\*<.Q;VHE<;A7RY$4_DI,B?"-[8K=:C MB;]8>91CLT&DL9U!I#2%M2> #_,*9/6]Y-K,7$=@_BD=K$E5I-L?OO]'G.]@['-.1'=$60^#HNX^;TDK$K.DFTVY/M#'STOJX2E*K1&-)$H/Q.]_UL\=%]5X_^Z/VUCV$2/%P%\D7 M,%"AN2(9)C:3:0H?&F5V;(W,^>=TVD]=)(7-4)_RZXX8_UU;($%D M2_CBFX41?XIH_4 ^K'LTW.J@0W'(VS5!^THB#R!R>T]I8"LV^]O= U-[R/D)C,IRJ&N!>N(^^>.5PVIC2#A_#/;9^O/#,9N#XUC* M=P4F6RDEB+JG(]S9U-Y;-1FX M%[_1@UH*BRWJ&$84Y7'-5"?6NO1)?JMJZA0"<=MLXT'QU=1+X35R*B^VX]U, M9*SQLK>+TFEK1+;>8"48JE' ^VQ+TRUV/R!_GH? .<:="! [ B.NKJT.<)Q/ MKLH.;+L5G++CE+9-8>((P![U.K2EHQ.BNCY&]2'>1&N-9A.YGU\/NA.#QW4&9;M= MNE6A"P@UX4/";>]A0\#!\.9:B+I M8/&&A3%<"527:"Y)3*Q8R<1DH+7H!!;6HH>UZ%?I<4X1,2QQN6GXY825#Z2W M$+O_=\M:1VU,J)B]CI7!'4!-M&P/1X-;T=C8]PJ3SS=%L52^I* M=#K@S%#_)U'=MT!&_09$P>EIYMVP0[\@J-4Y93S0'0_^+.FVJG]H\&OGIWG_ M"$@$]$53TQTL$0E2#&6./D?2AQZ]3P%K:7EUDU:JSRB^-(S6&"N]4]3,HF D MAY\ 5K1A,O?[VYCL[=O3@,[9&SN:CW?;EE$MR@4]7QG&1*F8EEKG 14]5#R] MH!\/&/&MO+",I*$^9X$QOAMJ)"^.=7#@MA$B_N3T^[B8&.:NX2.988?8@N/4 M]<3']Q)E:T=JG;"(^QI8]GBF?Z'=ZAT&35#1IF,HPE=Y9L2=,1#=PF+W^?#] M0(>&A8@<_-#@)1&VTHDX:<*VB7$VR@SY=8K*Y(6(MK 1A6&7$Y?XW(T"@P1+ MQ*'++/6&?'&6V!7YF0IM!2"RKRELHLNQG"3;VQ4SW_+RNK(J8/S+]%(JTR6' MK2>^UUC8V&9'GMJ] U>U8C#5*)JH8LW>0%PI"QR"RY\) M!1ZQH1N/4,'>W[@"_4!/<'L$A+BI'K7(FL/I@.:,=&O>)J,REKI6GMJ!:&_1 M\JC$O#-JBK%%?L1$,=G0L[4N)]"O88">J<<^DF3GQ !*$(NBO?;4-GL -MU4 MLR.83HB((SEPXE#]4!2GQX?-11,'(E05IQJ0@+:9:;/67E! <(UC$0A#77O0 MS?TDSRS*\7BXF6T2C 3#:!]0[V \XX#)8@NH4^P2!US-+R;!UWG+J2AW7O_D M"[D!554;*Q CQ7XBV)<;Q8$?3/!]/%#5U3)BC1-0I)9V2.=*0AMUZ?20G'>B M9=/Q!358I>A&\85G\_$2WH0P#-@E;'*@?;L<<*@^_P@7V?P7>"9Z<(%[7:;J M0IJ]BZ<2HC*?5$>9&D-$ 6NE]?JFW7NKX^1YG@J,WOM*&/Y(M_7%X4-^_$-^ MO$4T7EB5^&:T8,T847N9*4:Z5F\1ZSOU/6D@T)WZ>AK(D]-YST5#.K3&/,;<\EZ-KW'[[5KK M?4,V.6SBT1XBK<3W_O,2D6Q;PYZ>&F7I"IDQFI* +7.C-YJK/;L=6\ +P-OW MB4*7Z.ZY'/DC>J/[\QA7U'FU#F9HA=EAEXRJE7"8D;5>GF%W':Z MMQ.V0U;6 7[JC>Y[[XVX_N!(Z]$>_E!B[C^<;3RD"KLQ8Q[-5AINTYO$;/4CK(XGFXU)=N;9W1FR^+,9+D2S$H"=<>^X/FP%BB+ M6H-%A*[BY#\*^RZW;B!*<#@W..52KSDLSIWK+_1-,:JV(4JC H\UHCUV MQAN5M+KY)!M_TGFQ% ;;+*Z+%>>G3-C)']L-15>Z#9 0-D"6BA! M/3G-]P["R/.ECR"B^$JMX<'GO)#+3FO7IX-DLE5>)R%@+YJ\ 1)P;T3WF%-[ M#"B/E'NGC(#N0C:YW*3S?&%L,7.IO6K/3>.EHYY-CXNQB?>XBYVMNJ8QF&MT M2D-E)6ER=B',$]4!WURF/YTTM7]Z3K>FV;W)<*'GXXC%:G2\@&WE;;S;RIO1 M:&W=!3?Q!-#XC.L% @Z9,V"DC#53XB,S$#D5X8%;),OQ)?R[$^WA;T M-*P[.-O/TV-BHGO:D\7F;.>AJ<:126GG*<,M/ YVHD_<774/LS> %++(E[ ( MO0$;#D,@3NZ.G%EMJF-F]AVS>8++V+_93X&*@$0X7ZVL2\:U*7, MTU<:YDH-G1SN*T];P!5\)'X)%_.$:+!I--,OY@5 M:8O,E3:UBWQR&XBM;2.I-1+C"<9DZW%S+)8S\U81NA:P5X"2SJH)M\EQ?R1Z M?OST7J0-7&Q%W*>?IV*A5EL)AD9O)\U!9IHF .2JWIZSA8#GF/ MU+8(-(:UN<0[[DP;*O'X-K#/OFVC/M(M !9Z&X:(KC@VGJ#:%8:(S8:5NMR= MX9N+E1'7U17B_7X^EN+X#D;$1P2>S&.5Q&3Z2J:\1U. _A%+7=C ^$!%]RH M$!#^O!* W(A^1_K1'? &HMFAY_BC290 \=#7")5JK!CK6A9;HK,U!D]-)ZPU MX"^@M!Y)DR-4/+=YLH<5("<=BQ_$1=^EW3N!AR7V88G]GY?8$QA!I@@\[I38 MG]3>QPG<]P?TC3C^^:)\XD-%^>1]^LPC?SZ076Y#RV!=)/?P+WW-G9!M* )9 MI4<->FO,92,]W:R3YFN J^_W^X5T>3==[+Q.)YI\^.(K=E^UF-GB:=EDLB7& MTB:Q#=VDP17NQ^O\7SN2? X^%FEV"Y2H&2R=/[!N7!]U\F"_M/,:?&W:PJ2> MD,TR5JJ JWI/6BG4;?B-C^"D*+R&Z/I:),:&='7^>D.XPFMXQ_[\+.%XJ3Y= M];*27" R8R$WG$4Y_9/Y"8P=@W+.T?FL^+*.5XQ$K4 7VFN]^#)NI9XQ1%W&8X5;Z>'2L6*BFV6H_+6;RISWM978J//EDV\0X&6+=H+#H;S.OT MMA$UYCC?X)@!;!MPB0'<=NXG?(!"(9S=RUS1.-4#/%F%OT*1UA%Y2Y?,[6F\ MN=/+1/ZJ:Z882?Y]XAM'L78W&JO9)8C<&T6(MZBN^0%^].M4)#;W#8_O7Q=V.JLY8R@<1#O,EC)FF"&ED&IWEBEF_1U2L++&4"Q03 M6U*3B;$ O9?(GX1MAHV#SJ87D=]*PX!#@B,X9A 3_YX"?)@'70#B(7B:2 & MG@;_<"A$V*=='6PW. NHFTS!5D-,%8\)>&-4E>_'4@=@X@.B2MK=6)M_&I,W MM(-:-IMOQ?*%&!VMD835KU=3DQ30#I(7(?X]7'(4A7/3' \SVPN8 ZJF?Y"= M^8QL?I3FC[PZ*TZ7-,O89U]#[@+\"3[4[=Q H)[ Q)Z08>XA@V2FIF5C946G M&[MF'!BRXU1?:5U=!CEL3E/0HD_,)4^Z.;'MV4#OFYU\?EV93)2O:WA ML4&5;O7?9@-XWG41(IF(IWZ^ -7S!0N.),@.YYL7\403TV52(AHZ(W)]?3:? M;E_P8OK7OZD_;41S/022MU3MX)E3P>*,*X".Q*H5@\,JS07=D(EY:=VK5 UV M?=E<0L$$;_OYT\H'I)?I/RPY_1@R@]!C4[/4NAC%.*ECJ:GIKE,9OV'NOHZXX0T8I8WS!NQ! T$1 M>?<,0_<7=\$..M3'V;!=W%A2H)<5?L]QCY[1=1N-@IJ,YKG,*G[$JNF=]7=)GLI-'.;FD4C MJ?2$>K)?9OI18Y.@F'AGQE\)N\*V;AZY<+')*=I8TB8+3DIDM$;/NQJ)I\N37:\% M%$9#VO@/]TG5(:2KZZ,ZVQ'00.0%; ?X5#1=$X(## R!+Z##RYRMN:U-W0/_ M..VS;60Y\ YDFD1,:PYNA">4:E+4A*DLJ?M<)V4[7\S !CP!GC%G<^X__ Q( M8XF/:&,82K<#/@M+F6LJ;*0A2(8(:/$4L10>Z4HK>,T"_07"7TN"I,&)@6\? MOC&1QKJ&T+$52T5[ +X(#HJAZ=(>PD6%/1%X;0:>Q(.UB^ *FXG@4?"Y'I0 MYWI#J_.Z#M'YJ[H J+XD_E>!:,9;='2?(?0.1)A'W;ZY(T(X%0/0R50OM?%$ M\BD"O=..W7;^Q7;YL#TME<4Z]4( ^SWWM[UMH8YM!PPUV4WZRG(%WC]] MJX?I.Y.)G M0XWGHG!' )3:W%$!>$4@]96L[ZIW&#HXX@C>KOO7?J\<1YP,X M0&!.0["\?8&_F&_N\DLNNFVKFV];LC5MJ9WUL-UJK-[LS1M8X)[[(C>&)NZ? MF[@W.FJBU-BHZZ50Q++9S*I:3O4:Y?+70S12YK:3R[+-"E,H=2IR:S9+TK&P M*=XLTI/@NKG[752V05M#^(H$X0&0?MV8=>?\*7OV$O*.!V#'49%/L+]N#I]# ML@3QGM/J; $06SJW$"U3XB&FUO/5CJVJ#;%JO41A=+3 %&@YUNI7B2_,!Z3Z MNWJESE-CAIKG"M4H3=9VR=?:C;GV:139I#Y+%CJF;Z;3'P@&A&U0J%>K#\UX M)XK5L>PTTS;ZTKA7:@407O-E9U9*1B(^H2FR)AMQ;9D98;").4F?26 *7,83+\1NZP+[.<=M( M0T4]%A8S>/OQB")@FYZG:!J@Z?YG:0I,,H)+H\(6ETGO> M*:K:2CN\\E@!N2RT_I+^OFE'G* P\=LBZ#.Y9 <] 6'Y0%7L*'+7=O(VG 8^ M9]FV9&X-61PLMYBU2W&T6<]VQTF@3,1C;R0''=Q@WGOFU+GJ9 PA/RE*3N46 M0/T&2NU;5Y)]!)YLO" 4U0_YY(-\8E/]+$><906++2QP 1]-Z4YW(U2W16[( M2C!9]:(9=QS)]:8*.9ME4_HO*3SJ'R9A6YS"]"]-WX(;Z7 9G9, E\YXMZ7Q MB"9;J) M?KE\%-%J,I)F\)((1+61GJ)/&*.J\,":0K\X],P#N8P^O]HY59K53,LLUJKT M]B7+CRB)[:.8O'%%Z7?DH/?K4S00(!+T M$;B7_<$/[K(4L]#4-#^3Q)5H7PA-73SG<#A['2Q61JG930E9N8!)\ZVQ*DQ& MI30L+;ND>$�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end

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